



# SABAH CANCER REGISTRY REPORT 2012-2016







# **SABAH CANCER REGISTRY REPORT 2012-2016**

Non-Communicable Diseases Unit,  
Public Health Division, Sabah State Health Department  
Level 1, Federal House, Jalan Mat Salleh,  
88590 Kota Kinabalu,  
SABAH  
Tel: 088 - 265960 / 088 - 512555  
Fax: 088 - 217740

This book is also available in electronic format at

[http:// http://jknsabah.moh.gov.my/](http://http://jknsabah.moh.gov.my/)

**Disclaimer:**

Copyright © Ministry of Health Malaysia

All rights reserved. This report may not be produced, in whole or in part, in any form or means, electronic or mechanical, including photocopying, without written permission from publisher

## **EDITORIAL TEAM**

### **Editors**

**Dr. Nirmal Kaur**, Public Health Medicine Specialist

**Dr. Sahrol Nizam Bin Abu Bakar**, Public Health Medicine Specialist

**Dr. Lim Jyh Hann**, Public Health Medicine Specialist

**Dr. Nur Hasanah Sanudin**, Medical Officer

**Dr. Abraham Chiu En Loong**, Medical Officer

**Maslinda Mat Said**

**Dinie Najiy Awang Amdan**

### **Advisors**

**Dr. Christina Rundi**, State Director

**Dr. Asits Sanna**, Deputy Director of Health (Public Health)

**Dr. Prabakaran Dhanaraj**, Public Health Medicine Specialist

**Any enquiries about of comments on this report should be directed to:**

Non-Communicable Diseases Unit, Public Health Division, Sabah State Health Department

# TABLE OF CONTENTS

EDITORIAL TEAM .....	iv
TABLE OF CONTENTS .....	v
PREFACE .....	vii
FOREWORD .....	viii
ACKNOWLEDGEMENT .....	ix
LIST OF TABLES .....	x
LIST OF FIGURES .....	xi
LIST OF APPENDICES .....	xiii
LIST OF ABBREVIATIONS .....	xv
EXECUTIVE SUMMARY .....	16
1.0. INTRODUCTION .....	17
1.1 Geographical Background .....	17
1.2 Sabah Population and Health Status .....	19
1.2.1 Health Status, Socioeconomic and Health Facilities .....	20
1.2.2 Cancer Death Certification (NCR PREPARE & DISTRIBUTE IN APRIL) .....	22
2.0. METHODOLOGY .....	23
2.1 Sources of data .....	23
2.2 Registration procedure .....	23
2.3 Quality control .....	24
2.4 Data Analysis .....	26
Description of statistical methods .....	26
3.0 RESULTS .....	28
3.1 Overall Cancer Incidence .....	28
Cancer Trends .....	30
3.2 Age-specific Incidence Rates .....	31
3.2 Incidence of Ten Most Common Cancers .....	33
3.4 Ethnic Variations .....	35
3.5 Staging .....	41
3.6 Validity .....	41
3.7 Age Groups and Cancers .....	42
3.8 National Comparisons .....	44
4.0 SUMMARY TABLES .....	45
4.1 Incidence Summary Table .....	45
4.2 Staging by Cancer Sites .....	47
4.3 Quality Indicators .....	48
5.0 COMMENTARY ON 10 SELECTED CANCER SITES .....	49
5.1 Female Breast (ICD-10: C50) .....	49
5.2 Colorectal (ICD10: C18-C21) .....	51
5.3 Trachea, Bronchus and Lung (ICD-10: C33-C34) .....	54

5.4	Lymphoma (ICD10: C81-C85, C96).....	57
5.5	Cervix Uteri (ICD10:C53).....	60
5.6	Nasopharynx (ICD-10: C11).....	62
5.7	Leukaemia (ICD10: C91-95).....	65
5.8	Stomach (ICD-10:C16).....	68
5.9	Other Skin (ICD-10:C44).....	71
5.10	Prostate (ICD10: C61).....	74
	REFERENCES.....	76
	APPENDICES.....	77

## **PREFACE**

This is the third five-year report of the Sabah Cancer Registry. The first five-year report for the incidence period of 2001-2005 was published in 2009 and the second cancer report which covered the period from 2006-2010 was published in 2015. The following report should covers the third five year period from 2011 to 2015, however to give equivalent data to that of the Malaysian National Cancer Registry (MNCR) 2012-2016, Sabah Cancer Registry decided to published the same incident period as the MNCR for this third Sabah Cancer Registry Report. The summary of the 2011 cancer report is attached as an appendix.

This report is based on new cancers diagnosed in Sabah for the period of 1st January 2012 through to 31st December 2016 and only captured for Malaysian citizens and residents. The data reported in this report were as they stood on the 31st June 2019.

The data from this registry provide an epidemiological profile of cancer, the distribution of the cancer burden and incidence trends. It is a prelude to a more specialised reports that will focus on special topics of interest, such as survival. Information from this registry can provide an insight on cancer incidence in Sabah and it is useful in the State Cancer Control Programme especially in developing strategies in health care planning and also to stimulate further research.

The cancer registry needs to be strengthen especially in utilizing man power to function at maximum level. All hospitals have to establish a cancer registry unit to improve the hospital cancer notification. Multisectoral collaboration with private agencies, hospitals, clinics and all medical laboratories needs to be improved further in making cancer notification compulsory.

We wish to record our thanks to all participating hospitals for their cooperation and regular notifications to the Sabah Cancer Registry. We also wish to extend our appreciation to Cancer Registry Unit, National Cancer Institute for their assistance. A very big thank you for their continued support and contributions, without which this report will not be possible.

### **Editorial Team**



## FOREWORD



I wish to congratulate the Non Communicable Disease Unit for being instrumental in developing this Sabah Cancer Registry Report. I appreciate their concerted efforts, persistence and endurance in the gathering and processing of data for the Sabah Cancer Registry for the incidence year of 2012-2016.

Cancer is a chronic disease, hence the retrieval of cancer is a complex process. The information on new cancer cases comes from voluntary notification as well as from active finding in all hospitals in Sabah by Cancer Registry team. Cancer Registries are crucial in any Cancer Control Programme as the data in the Cancer Registries are needed in developing strategies in primary, secondary and tertiary prevention, as well as health care planning

and planning for patient care and research.

This report provide a wide range of descriptive data on cancer trend amongst the Sabah residents which can be used by the health authorities, service providers and researchers. Hopefully this five years report will provide valuable information on cancer situation in Sabah and stimulate further research on cancer.

Finally I would like to record my appreciation to the excellent teamwork of Sabah Cancer Registry editorial committee members for this publication. I would like to acknowledge the participation from government and private hospitals for their commendable efforts and cooperation in notifying cancer cases to the Sabah Cancer Registry. I would also like to extend my sincere appreciation and gratitude to all the public health physicians, pathologists and medical record team members in the hospitals for their contribution to this report.

Thank you.

A handwritten signature in black ink, appearing to read 'C. Rundi', with a large, sweeping flourish on the left side.

**DATUK DR. CHRISTINA RUNDI**  
Pengarah Kesihatan Negeri  
Jabatan Kesihatan Negeri Sabah

## ACKNOWLEDGEMENT

The Sabah State Health Department wishes to express our gratitude to individuals and organisations for their contributions to the development of Sabah Cancer Registry Report 2012-2016. All staff members of the medical and health profession in Sabah, both in the public and the private sectors for the cancer notifications. The following hospitals and institutions have contributed data or provide continuous support to the Sabah Cancer Registry:

1. Hospital Queen Elizabeth
2. Hospital Queen Elizabeth II
3. Hospital Wanita dan Kanak-Kanak Sabah
4. Hospital Duchess of Kent, Sandakan
5. Hospital Lahad Datu
6. Hospital Tawau
7. Hospital Keningau
8. Hospital Beaufort
9. Hospital Beluran
10. Hospital Kinabatangan
11. Hospital Kota Belud
12. Hospital Kota Marudu
13. Hospital Kuala Penyu
14. Hospital Kudat
15. Hospital Kunak
16. Hospital Papar
17. Hospital Pitas
18. Hospital Ranau
19. Hospital Semporna
20. Hospital Sipitang
21. Hospital Tambunan
22. Hospital Tenom
23. Hospital Tuaran
24. Damai Specialist Centre
25. Gleneagles Kota Kinabalu
26. Jesselton Medical Centre Sdn Bhd
27. KPJ Sabah Specialist Hospital
28. Rafflesia Medical Centre
29. KK Specialist Centre

Special thanks to Dr. Nabihah Ali, Medical Officer, Cancer Registry Unit, National Cancer Institute

Lastly, we wish to record our appreciation to all individuals and organisations that have directly or indirectly contributed to this report.

**Thank you all for the valuable contributions.**

## LIST OF TABLES

Table 1. Population by sex, ethnic groups and citizenship, Sabah, 2014.....	19
Table 2. Health facilities and number of doctors in Sabah, 2014-2016 .....	21
Table 3. Incidence summary of new cancer cases by sex, Sabah, 2012-2016.....	28
Table 4. Incidence summary by major ethnic groups and sex, Sabah, 2012-2016 .....	28
Table 5. Ten most common cancers, all residents, Sabah, 2012-2016.....	33
Table 6. Ten most common cancers by sex, all residents, Sabah, 2012-2016 .....	34
Table 7. Age-standardised incidence rates for ten most common cancers in males by major ethnic groups, Sabah, 2012-2016.....	35
Table 8. Age-standardised incidence rates for ten most common cancers in females by major ethnic groups, Sabah, 2012-2016.....	35
Table 9. Ten most common cancers in Kadazan/Dusun by sex, Sabah, 2012-2016 .....	36
Table 10. Ten most common cancers in Chinese by sex, Sabah, 2012-2016 .....	37
Table 11. Ten most common cancers in Bajau by sex, Sabah, 2012-2016 .....	38
Table 12. Ten most common cancers in Malay by sex, Sabah, 2012-2016 .....	39
Table 13. Ten most common cancers in Murut by sex, Sabah, 2012-2016 .....	40
Table 14. Incidence summary of all cancer sites by year and ethnic group, Sabah .....	45
Table 15. Incidence summary of all cancer sites by district, Sabah .....	46
Table 16. Staging for all cancer types, Sabah, 2012-2016.....	47
Table 17. Quality indicators for all cancer types, Sabah, 2012-2016 .....	48
Table 18. Female Breast: Cancer incidence summary by year, Sabah.....	49
Table 19. Female Breast: Incidence summary by year and ethnicity, Sabah.....	49
Table 20. Colorectal: Cancer incidence summary by year, Sabah .....	51
Table 21. Colorectal: Incidence summary by sex, year and ethnicity, Sabah .....	51
Table 22. Trachea, bronchus and lung: Cancer incidence summary by year, Sabah .....	54
Table 23. Trachea, bronchus and lung: Incidence summary by sex, year and ethnicity, Sabah .....	54
Table 24. Lymphoma: Cancer incidence summary by year, Sabah .....	57
Table 25. Lymphoma: Incidence summary by sex, year and ethnicity, Sabah.....	57
Table 26. Cervix Uteri: Cancer incidence summary by year, Sabah .....	60
Table 27. Cervix Uteri: Incidence summary by sex, year and ethnicity, Sabah.....	60
Table 28. Nasopharynx: Cancer incidence summary by year, Sabah.....	62
Table 29. Nasopharynx: Incidence summary by sex, year and ethnicity, Sabah .....	62
Table 30. Leukaemia: Cancer incidence summary by year, Sabah .....	65
Table 31. Leukaemia: Incidence summary by year and ethnicity, Sabah.....	65
Table 32. Stomach: Cancer incidence summary by year, Sabah.....	68
Table 33. Stomach: Incidence summary by sex, year and ethnicity, Sabah .....	68
Table 34. Other Skin: Cancer incidence summary by year, Sabah .....	71
Table 35. Other Skin: Incidence summary by year and ethnicity, Sabah .....	71
Table 36. Prostate: Cancer incidence summary by year, Sabah.....	74
Table 37. Prostate: Incidence summary by year and ethnicity, Sabah.....	74

## LIST OF FIGURES

Figure 1. Map of Sabah .....	18
Figure 2. Population pyramid, all residents, Sabah, 2014 .....	19
Figure 3. Perinatal, neonatal, infant and maternal mortality rates in MOH Hospitals, Sabah, 2012-2016 .....	20
Figure 4. Number of medically certified and non-medically certified cancer death, Sabah, 2012-2016 .....	22
Figure 5. Certified and uncertified cancer death, Sabah, 2012-2016 .....	22
Figure 6. Outline of registration procedure .....	25
Figure 7. Comparison of incidence summary by ethnicity, 2012-2016 .....	29
Figure 8. Number of cases by age group and sex, Sabah, 2012-2016 .....	29
Figure 9. Annual age-standardised rate (ASR) by sex, Sabah, 2006-2016 .....	30
Figure 10. Age-specific incidence rate by sex, all sites, Sabah, 2012-2016 .....	31
Figure 11. Age-specific incidence rate for five common sites, males, Sabah, 2012-2016 .....	32
Figure 12. Age-specific incidence rate for five common sites, females, Sabah, 2012-2016 .....	32
Figure 13. Comparison of ten most common cancers, all residents, Sabah .....	33
Figure 14. Age-standardised incidence rate for ten common cancers by sex, Sabah, 2012-2016 .....	34
Figure 15. Age-standardised incidence rate for ten common cancers in Kadazan/Dusun by sex, Sabah, 2012-2016 .....	36
Figure 16. Age-standardised incidence rate for ten common cancers in Chinese by sex, Sabah, 2012-2016 .....	37
Figure 17. Age-standardised incidence rate for ten common cancers in Bajau by sex, Sabah, 2012-2016 .....	38
Figure 18. Age-standardised incidence rate for ten common cancers in Malay by sex, Sabah, 2012-2016 .....	39
Figure 19. Age-standardised incidence rate for ten common cancers in Murut by sex, Sabah, 2012-2016 .....	40
Figure 20. Common cancers among 0-14 years age group by sex, Sabah, 2012-2016 .....	42
Figure 21. Common cancers among 15-24 years age group by sex, Sabah, 2012-2016 .....	42
Figure 22. Common cancers among 25-59 years age group by sex, Sabah, 2012-2016 .....	43
Figure 23. Common cancers among 60-74 years age group by sex, Sabah, 2012-2016 .....	43
Figure 24. Common cancers in 75 years and above age group by sex, Sabah, 2012-2016 .....	43
Figure 25. All Sites: National comparisons – Age-standardised rates .....	44
Figure 26. Female Breast: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah .....	50
Figure 27. Female Breast: Comparison of age-specific incidence rate by year, Sabah .....	50
Figure 28. Female Breast: Staging percentage, Sabah .....	50
Figure 29. Colorectal: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah .....	52
Figure 30. Colorectal: Comparison of age-specific incidence rate by year in males .....	52
Figure 31. Colorectal: Comparison of age-specific incidence rate by year in females .....	52
Figure 32. Colorectal: Staging percentage by sex, Sabah .....	53
Figure 33. Trachea, Bronchus and Lung: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah .....	55
Figure 34. Trachea, Bronchus and Lung: Comparison of age-specific incidence rate by year in males .....	56
Figure 35. Trachea, Bronchus and Lung: Comparison of age-specific incidence rate by year in females .....	56
Figure 36. Trachea, Bronchus and Lung: Staging percentage by sex, Sabah, 2012-2016 .....	56
Figure 37. Lymphoma: Comparison of age-standardised rate by year, major ethnic group and sex, Sabah .....	58
Figure 38. Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016 .....	58
Figure 39. Lymphoma: Staging percentage by sex, Sabah, 2012-2016 .....	59
Figure 40. Hodgkin Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016 .....	59
Figure 41. Non-Hodgkin Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016 .....	59
Figure 42. Cervix Uteri: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah .....	61
Figure 43. Cervix Uteri: Comparison of age-specific incidence rate by year, Sabah .....	61
Figure 44. Cervix Uteri: Staging percentage, Sabah, 2012-2016 .....	61
Figure 45. Nasopharynx: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah .....	63
Figure 46. Nasopharynx: Age-specific incidence rate by sex, Sabah, 2012-2016 .....	63
Figure 47. Nasopharynx: Staging percentage by sex, Sabah, 2012-2016 .....	64
Figure 48. Leukaemia: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah .....	66

Figure 49. Leukaemia: Comparison of age-specific incidence rate by year, Sabah .....	66
Figure 50. Leukaemia types: Age-specific incidence rate, males, Sabah, 2012-2016 .....	67
Figure 51. Leukaemia types: Age-specific incidence rate, females, Sabah, 2012-2016 .....	67
Figure 52. Stomach: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah .....	69
Figure 53. Stomach: Age-specific incidence rate by sex, Sabah, 2012-2016 .....	69
Figure 54. Stomach: Staging percentage by sex, Sabah, 2012-2016 .....	70
Figure 55. Other Skin: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah .....	72
Figure 56. Other Skin: Age-specific incidence rate by sex, Sabah, 2012-2016.....	72
Figure 57. Other Skin: Staging percentage by sex, Sabah.....	73
Figure 58. Prostate: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah ....	75
Figure 59. Prostate: Comparison of age-specific incidence rate by year, Sabah .....	75
Figure 60. Prostate: Staging percentage, Sabah, 2012-2016 .....	75

## LIST OF APPENDICES

Appendix 1: Person-years at risk, all Sabah, 2012-2016.....	77
Appendix 2: Population table by sex, ethnicity and age group, Sabah residents, 2012-2016 .....	78
Appendix 3: Population table by sex, district and age group, Sabah residents, 2012-2016 .....	79
Appendix 4: Population table by sex, district and age group, Sabah residents, 2012-2016 (continue) .....	80
Appendix 5: Population table by sex, district and age group, Sabah residents, 2012-2016 (continue) .....	81
Appendix 6: Population table by sex, district and age group, Sabah residents, 2012-2016 (continue) .....	82
Appendix 7: Population table by sex, district and age group, Sabah residents, 2012-2016 (continue) .....	83
Appendix 8: Incidence summary table, all residents, males, Sabah, 2012-2016 .....	84
Appendix 9: Incidence summary table, all residents, females, Sabah, 2012-2016.....	85
Appendix 10: Incidence summary table, Kadazan Dusun males, Sabah, 2012-2016 .....	86
Appendix 11: Incidence summary table, Kadazan Dusun females, Sabah, 2012-2016 .....	87
Appendix 12: Incidence summary table, Chinese males, Sabah, 2012-2016 .....	88
Appendix 13: Incidence summary table, Chinese females, Sabah, 2012-2016 .....	89
Appendix 14: Incidence summary table, Bajau males, Sabah, 2012-2016 .....	90
Appendix 15: Incidence summary table, Bajau females, Sabah, 2012-2016 .....	91
Appendix 16: Incidence summary table, Malay males, Sabah, 2012-2016 .....	92
Appendix 17: Incidence summary table, Malay females, Sabah, 2012-2016 .....	93
Appendix 18: Incidence summary table, Murut males, Sabah, 2012-2016 .....	94
Appendix 19: Incidence summary table, Murut females, Sabah, 2012-2016 .....	95
Appendix 20: Incidence summary table, Other Bumiputra males, Sabah, 2012-2016 .....	96
Appendix 21: Incidence summary table, Other Bumiputra females, Sabah, 2012-2016 .....	97
Appendix 22: Incidence summary table, Others males, Sabah, 2012-2016.....	98
Appendix 23: Incidence summary table, Others females, Sabah, 2012-2016.....	99
Appendix 24: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016.....	100
Appendix 25: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue) .....	101
Appendix 26: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue) .....	102
Appendix 27: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue) .....	103
Appendix 28: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue) .....	104
Appendix 29: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016.....	105
Appendix 30: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016 (continue)..	106
Appendix 31: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016 (continue)..	107
Appendix 32: Number of new cancer cases by site and age group, all residents, Male, Sabah, 2012-2016 .....	108
Appendix 33: Cancer Incidence by site and age group, all residents, male, Sabah, 2012-2016.....	109
Appendix 34: Number of new cancer cases by site and age group, all residents, female, Sabah, 2012-2016 ..	110
Appendix 35: Cancer Incidence by site and age group, all residents, female, Sabah, 2012-2016.....	111
Appendix 36: Number of new cancer cases by site and age group, Kadazan Dusun male, Sabah, 2012-2016.	112
Appendix 37: Cancer Incidence by site and age group, Kadazan Dusun male, Sabah, 2012-2016 .....	113
Appendix 38: Number of new cancer cases by site and age group, Kadazan Dusun female, Sabah, 2012-2016 .....	114
Appendix 39: Cancer Incidence by site and age group, Kadazan Dusun female, Sabah, 2012-2016 .....	115
Appendix 40: Number of new cancer cases by site and age group, Chinese male, Sabah, 2012-2016 .....	116
Appendix 41: Cancer Incidence by site and age group, Chinese male, Sabah, 2012-2016.....	117
Appendix 42: Number of new cancer cases by site and age group, Chinese female, Sabah, 2012-2016 .....	118
Appendix 43: Cancer Incidence by site and age group, Chinese female, Sabah, 2012-2016.....	119
Appendix 44: Number of new cancer cases by site and age group, Bajau male, Sabah, 2012-2016 .....	120
Appendix 45: Cancer Incidence by site and age group, Bajau male, Sabah, 2012-2016.....	121
Appendix 46: Number of new cancer cases by site and age group, Bajau female, Sabah, 2012-2016 .....	122
Appendix 47: Cancer Incidence by site and age group, Bajau female, Sabah, 2012-2016.....	123
Appendix 48: Number of new cancer cases by site and age group, Malay male, Sabah, 2012-2016.....	124
Appendix 49: Cancer Incidence by site and age group, Malay male, Sabah, 2012-2016 .....	125

Appendix 50: Number of new cancer cases by site and age group, Malay female, Sabah, 2012-2016 .....	126
Appendix 51: Cancer Incidence by site and age group, Malay female, Sabah, 2012-2016 .....	127
Appendix 52: Number of new cancer cases by site and age group, Murut male, Sabah, 2012-2016 .....	128
Appendix 53: Cancer Incidence by site and age group, Murut male, Sabah, 2012-2016.....	129
Appendix 54: Number of new cancer cases by site and age group, Murut female, Sabah, 2012-2016 .....	130
Appendix 55: Cancer Incidence by site and age group, Murut female, Sabah, 2012-2016.....	131
Appendix 56: Number of new cancer cases by site and age group, Other Bumiputra male, Sabah, 2012-2016	132
Appendix 57: Cancer Incidence by site and age group, Other Bumiputra male, Sabah, 2012-2016.....	133
Appendix 58: Number of new cancer cases by site and age group, Other Bumiputra female, Sabah, 2012-2016 .....	134
Appendix 59: Cancer Incidence by site and age group, Other Bumiputra female, Sabah, 2012-2016.....	135
Appendix 60: Number of new cancer cases by site and age group, Others male, Sabah, 2012-2016.....	136
Appendix 61: Cancer Incidence by site and age group, Others male, Sabah, 2012-2016 .....	137
Appendix 62: Number of new cancer cases by site and age group, Others female, Sabah, 2012-2016.....	138
Appendix 63: Cancer Incidence by site and age group, Others female, Sabah, 2012-2016 .....	139
Appendix 64: Number of new cancer cases by site and age group, all residents, Male, Sabah, 2011 .....	140
Appendix 65: Cancer Incidence by site and age group, all residents, male, Sabah, 2011 .....	141
Appendix 66: Number of new cancer cases by site and age group, all residents, female, Sabah, 2011 .....	142
Appendix 67: Cancer Incidence by site and age group, all residents, female, Sabah, 2011 .....	143
Appendix 68: Cancer notification form.....	144
Appendix 69: Explanatory notes for completing cancer notification form .....	145

## LIST OF ABBREVIATIONS

95% CL	95% Confidence Limit
AR	Age-specific rate
ASR	Age-standardised incidence rate
CI5	Cancer Incidence in Five Continents
CR	Crude incidence rate
CR74	Cumulative Rate
CumR	Cumulative Risk
DCO	Death Certificate Only
DOSM	Department of Statistic Malaysia
ENCR	European Network of Cancer Registries
IARC	International Agency for Research on Cancer
IACR	International Association of Cancer Registries
ICD-10	International Classification of Diseases, Tenth Revision
ICD-O-3	International Classification of Diseases for Oncology, Third Edition
KKom	Klinik Komuniti
MNCR	Malaysian National Cancer Registry
MOH	Ministry of Health
MV	Morphological Verified
NRD	National Registration Department
NRIC	Number Registration Identification Card
Other skin	Non-Melanoma skin malignancy
SE	Standard Error
TNM	Tumour, Node, Metastasis
WHO	World Health Organisation



## EXECUTIVE SUMMARY

Sabah Cancer Registry Report is a population-based registry that was first published in 2009. It has covered the period from 2001-2005. The second cancer report covered the period from 2006-2010 which was published in 2015. This report covers the third five year period from 2012 to 2016 with summary of the 2011 cancer report is attached as appendix. It applies only to Malaysian citizens and residents living in Malaysia at the time of diagnosis. The population denominator in this report is based on the midyear population of 2014 interpolated from the census of the year 2010.

A total of 8,818 new cases were registered for the period of 2012-2016. Males comprised of 4,006 (45.4%) and females were 4,812 (54.6%). The age-standardised incidence rates (ASR) were 94.8 for males and 111.1 for females per 100,000. The incidence rates for all sites combined were increased by 7.8 in females and slightly reduced by 0.3 in males 100,000 populations when comparing the last five-year period (2012-2016) with the previous one (2006-2010).

The cumulative rate percent to age 74 (CR74) was 11.4 for males and 12.5 for females. The cumulative risk (CumR) that represents the risk of developing cancer before the age of 75 in the absence of other causes of death was 10.8 for males and 11.7 for females. Thus the life time risk was 1 in 9 for males and 1 in 8 for females. As expected, cancer incidence increased exponentially with age. The incidence of cancer increased for both males and females after the age of 30 years. The incidence rate in males markedly increased and exceeds the incidence rate in females after the age of 60. The median age at diagnosis for males was 60 years and for females was 50 years.

The majority of cases 2,047 (23.2%) were amongst the Kadazan/Dusun. This corresponds to the population structure of Sabah where 23.6% were Kadazan/Dusun [Table 1]. This is followed by Chinese 1,983 (22.5%), Bajau 1,173 cases (13.3%), Malay with 357 cases (4.0%) and Murut 250 cases (2.8%) [Table 5].

The 10 leading cancers among males were Colorectal, Lung, Prostate, Lymphoma, Nasopharynx, Stomach, Liver, Leukaemia, Skin (Non-Melanoma) and Bladder, whereas Breast, Cervix Uteri, Colorectal, Lung, Lymphoma, Ovary, Skin (Non-Melanoma), Thyroid, Corpus Uterus and Stomach were the 10 most common cancer sites in females.

The relative impact of cancers, however, varies considerably by age. Among children (0–14 years of age), Leukaemia is the most common for both sexes. Among children and adolescents (15-24 years of age), Lymphoma is the most common cancer in boys and Ovarian Cancer in girls. In men (25 years of age and above), Colorectal Cancer is the most common cancer. Among women (25-74 years of age), Breast is the most common cancer site and Colorectal Cancer is the most common cancer for those 75 years of age and above.

The incidence rates for all most common cancer in males were reduced except for Prostate Cancer, which was increased by 1.3 per 100,000 populations. For the most common cancers in females, the largest increase in incidence rate occurred for Breast, followed by Corpus Uteri, Thyroid and slightly increased in Cervix Uteri and Skin (Non-Melanoma). A reduction in rates were seen for cancer in Colorectal, Lung, Lymphoma and Ovary.

Only 46.5% of the cancer cases, staging was done. However, this variable input was improved from previous report which only 16% were reported in second Sabah Cancer Registry. Of these, 14.5% were reported as stage I, 18.9% as stage II, 20.5% as stage III and 46.1% as stage IV. Most of the cancer cases were detected at late stage. National policies and programmes should be strengthened to raise awareness, to reduce exposure to cancer risk factors and to ensure that people are provided with the information and support they need to adopt healthy lifestyles. If cancer were detected early, the cure rate or survival rates are much higher.

## 1.0. INTRODUCTION

Sabah State Health Department first started collecting data on cancer way back in 1993. However, it was not fully established until 1999 when Sabah state was included as one of the six states (Sabah, Sarawak, Penang, Kelantan, Pahang and Johor) that were chosen to participate in Regional Cancer Registry (RCR) Programme using the Canreg3 computer programme supplied by World Health Organisation (WHO).

In 2002, the National Cancer Registry (NCR) was operating under the Clinical Research Centre (CRC) while in 2007, the NCR and the RCR were merged and called as National Cancer Registry managed by Public Health Division MOH involved all states using the Canreg4 computer programme. In January 2015, its secretariat had been transferred to the National Cancer Institute in Putrajaya.

This is the third five-year report for the period of 2012-2016. The data from this registry will provide an epidemiological profile of cancer, cancer burden and trends, high risk groups for specific cancers and variations of incidence which may suggest clues to the causes of cancer, guides for control measures and further research. Sabah is a unique state with multicultural, multi-ethnic and geographical differences as compared to other states in Malaysia.

### 1.1 Geographical Background

Sabah is the second largest state in Malaysia and well known as The Land Below The Wind. Before admission into the Federation of Malaysia, Sabah was a British Crown Colony known as North Borneo. It is one of the three Malaysian states on the island of Borneo. The southern part of the island, called Kalimantan, belongs to Indonesia. Sabah covers an area about 73,700 square kilometres. The western part of Sabah is generally mountainous, containing the three highest mountains in Malaysia. The most prominent range is the Crocker Range which houses several mountains of varying height from about 1,000 metres to 4,000 metres. At the height of 4,095 metres, Mount Kinabalu is the highest mountain in Malaysia. Lying nearby Mount Kinabalu is Mount Tambuyukon with a height of 2,579 metres, it is the third highest peak in the country. Adjacent to the Crocker Range is the Trus Madi Range which houses the second highest peak in the country, Mount Trus Madi, at a height of 2,642 metres. There are lower ranges of hills extending towards the western coasts, southern plains, and the interior or central part of Sabah. These mountains and hills are traversed by an extensive network of river valleys and are in most cases covered with dense rainforest.

The central and eastern portions of Sabah are generally lower mountain ranges and plains with occasional hills. Kinabatangan River begins from the western ranges and snakes its way through the central region towards the east coast out into the Sulu Sea. It is the second longest river in Malaysia. The forests surrounding the river valley also contains an array of wildlife habitats, and is the largest forest-covered floodplain in Malaysia. Over three quarters of the human population inhabit the coastal plains. Major towns and urban centres have sprouted along the coasts of Sabah. The interior region remains sparsely populated with only villages, and the occasional small towns or townships. Beyond the coasts of Sabah lie a number of islands and coral reefs, including the largest island in Malaysia, Pulau Banggi. Other popular islands mainly for tourism are Pulau Sipadan, Pulau Selingan, Pulau Gaya, Pulau Tiga, and Pulau Layang-Layang. Sabah consists of five administrative divisions namely West Coast, Interior, Kudat, Sandakan and Tawau Divisions which are in turn divided into 24 districts. The capital City of Sabah located in Kota Kinabalu and other three big towns are Sandakan, Tawau and Keningau.




Figure 1. Map of Sabah


## 1.2 Sabah Population and Health Status

The Sabah population in 2014 was 3.7 million including the non-citizens. The population pyramid and its distribution by sex and age group is shown in Figure 2. Among Malaysian citizens, there were 50.7% males and 49.3% females. The people of Sabah are divided into 36 officially recognised ethnic groups. Majority were Kadazan/Dusun (23.6%), followed by Bajau (18.7%), Chinese (11.8%), Malays (10.2%) and Murut (4.3%). Other Bumiputera (26.5%) in this report comprises of the many smaller ethnic groups in Sabah such as the Banjar, Bisaya, Brunei, Bugis, Irranun, Jawa, Kedayan, Kokos, Orang Sungai, Paitan, Rungus, Sino Kadazan, Suluk, Tidong and Ubian. While the term 'Others' ethnic (4.9%) are Indians, Bidayuh, Iban, Lun Bawang, Melanau etc.

*Table 1. Population by sex, ethnic groups and citizenship, Sabah, 2014*

Variables	Characteristics	NO.	%
<b>Sex</b>	Male	1,308,700	50.7
	Female	1,275,100	49.3
<b>Ethnic groups</b>	Kadazan/Dusun	610,600	23.6
	Chinese	483,700	18.7
	Bajau	303,600	11.8
	Malay	262,600	10.2
	Murut	111,200	4.3
	Other Bumiputera	685,800	26.5
	Others	126,300	4.9
	<b>Total</b>	<b>2,583,800</b>	<b>100.0</b>
<b>Citizenship</b>	Malaysian	2,583,800	70.4
	Non-Malaysian	1,086,100	29.6
	<b>Total</b>	<b>3,669,900</b>	<b>100.0</b>


Source: Department of Statistics Malaysia, 2014



*Figure 2. Population pyramid, all residents, Sabah, 2014*

### 1.2.1 Health Status, Socioeconomic and Health Facilities

**Health status:** The health status in Sabah improved tremendously with life expectancy at birth of male from 69.9 in 1999 increased to 72.7 in 2016. The female life expectancy at birth was 74.9 in 1999 to 76.2 in 2016. Cancer was reported to be one of the leading causes of death in government hospitals. The health status of Sabah has been enhanced with the improvement of economic status, health infrastructure and health services, as indicated by the decline in the Infant Mortality Rate from 19.26 in 1990 to 10.8 per 1,000 live births in 2016 [Figure 3].



\* Source: Health Fact Sabah, JKNS 2012-2016

**Figure 3.** Perinatal, neonatal, infant and maternal mortality rates in MOH Hospitals, Sabah, 2012-2016

**Socioeconomic:** Sabah's economy was traditionally dependent on the timber industry, based on export of tropical timber, but with increasing depletion of the natural forests, palm oil has emerged as a more sustainable resource. Other agricultural products contribute to Sabah economy growth include rubber and cocoa. Presently tourism is one of the largest contributors to the state economy.

**Health facilities:** The doctor-population ratio has also improved from 1:1,334 in 2014 to 1:1,151 in 2016 [Table 3]. In 2016, there were 24 government hospitals and 7 private hospitals providing services to the population of Sabah with the bed-population ratio of 1:745. Other government health facilities include 104 health clinics, 23 maternal and child health clinics, 168 rural clinics and 39 Gov. Community Clinics (1Msia Clinic).


**Table 2.** Health facilities and number of doctors in Sabah, 2014-2016

	2014	2015	2016
<b>No. of Medical Officer</b>			
Government	2,197	2,362	2,683
Private	416	460	446
<b>Total</b>	<b>2,613</b>	<b>2,822</b>	<b>3,129</b>
<b>Doctor: Population ratio</b>	<b>1:1,334</b>	<b>1:1,261</b>	<b>1:1,151</b>
<b>Hospitals</b>			
Government	24	24	24
Private	5	7	7
<b>Total</b>	<b>29</b>	<b>31</b>	<b>31</b>
<b>Hospitals Beds</b>			
Government	4,555	4,817	4,795
Private	130	333	309
<b>Total</b>	<b>4,685</b>	<b>5,150</b>	<b>5,104</b>
<b>Other facilities</b>			
Gov. Community Clinics (1Msia Clinic)	36	36	39
Government	292	294	295
Private	NA	NA	NA
<b>Total</b>	<b>328</b>	<b>330</b>	<b>334</b>

*Private Hospitals: Private Hospitals, Private Maternity Home, Private Nursing Home And Hospice  
 Government Health Clinics: Health Clinic, Rural Community Clinic, Maternal and Child Health Clinic  
 Gov. Community Clinics (1Msia Clinic) currently known as KKom  
 Source: Health Facts Sabah, JKNS 2014-2016*


## 1.2.2 Cancer Death Certification

A total of 5,638 medically certified and non-medically certified cancer deaths were reported by the National Registration Department of the period 2012 to 2016 (Figure 4). Over the years, the numbers of medically certified cancer deaths have gradually increased. The overall percentage of medically certified cancer death was 69.9% and 30.1% are non-medically certified cancer death (Figure 5).



Source: National Registration Department (Death registry 2012-2016)

**Figure 4.** Number of medically certified and non-medically certified cancer death, Sabah, 2012-2016



Source: National Registration Department (Death registry 2012-2016)

**Figure 5.** Certified and uncertified cancer death, Sabah, 2012-2016

## 2.0. METHODOLOGY

### 2.1 Sources of data

As cancer is not a notifiable disease, case registration is based primarily on voluntary notifications. The registry sought to obtain basic epidemiological and clinical data on cases of cancer diagnosed in Malaysia which only captured for Malaysian citizens and residents.

The registry received the notifications from all data source providers in government and private health facilities using a standardised format (Refer Appendix 30). Comprehensive cancer registration was achieved through data obtained from a combination of sources using both passive and active case finding methods, (a) notifications by the medical profession (b) pathology records, (c) hospital discharges records, (d) mortality data from the National Registration Department (NRD) and hospital death notification, and (e) Hospital based cancer registry. For cancer cases obtained from sources other than physician notification, the data was checked against known registered cases in the registry. If the cases are not in the system, the registry staff will continue with active case findings with the respective facilities. Patient confidentiality was maintained at all times. Passive notification and active case finding are defined as below;

**i. Passive notification** – registry relies on medical profession or other healthcare workers to complete notification forms and forward them to the registry.

**ii. Active case finding** – collecting at source, whereby registry staff would visit the sources of data to extract the required information and record it onto forms, or to obtain copies of the relevant information. To ensure completeness of the data, active case finding and routine checks were done using government and private hospital discharge records, as well as pathology records from the public and private laboratories. These were supplemented by case detection from death records supplied by the National Registration Department. Any cancer case detected from pathology and death records were then checked with previously registered cases. If they were not yet notified, reminders were sent to the person in-charge for more information. Additional missing data for these cases were also sought by registry staff by searching the relevant hospital records.

### 2.2 Registration procedure

All updated information collected on hardcopies, either passively or actively, were entered into the Canreg5 software a computer database provided by IARC, Lyon, France. As this is a population-based cancer registry, all respective states registries will only register the cases by residential address in their geographical area. Cases from other states will be transferred to the respective state for further action. The outline of the registration process is shown in Figure 6.

Every item relating to the patient was collated and updated which subject to data quality check. All 15 registries registered all new cases of cancer diagnosed in Malaysia by their geographical area. The National Cancer Registry team consolidated information from all 13 states and 2 federal territories cancer registries for final data quality check and analysis.

Multiple sources of data had assisted in optimising completeness of collection; however, this could create problem of multiple notification of a patient. This issue was addressed by cross checking names, age, date of birth and National Registration Identity Card numbers (NRIC) using CanReg5 software prior to the case registration. Identification card number is a unique number given to each Malaysian citizen.

The CanReg5 program accommodates comparison of essential variables across cases. 80% conformity is the standard used to trigger a further check of duplication. If the patient has been registered before, a check will be done along with the previous notifications to ascertain if it was a new primary. If the cancer is a new primary, the case is registered with a new registration number and if it is not, the records are updated. Data from hospital discharges and reports from laboratories and death list from National Registration Department (NRD) were also sent to the registry and the same procedures were followed as described above. The same procedures were followed in NCR in the process of consolidating the data from 15 cancer registries.



Every effort was made to ensure that all the variables were completed. In the event if there was incomplete information, the notification forms with incomplete information were sent back to the respective data providers for further clarification and returned back to the registry upon completion. If there were no clarification, or incomplete forms returned, registries staff would visit the source providers to obtain the required information and to decide whether the case can be registered or not. For most cases the staging used was TNM Classification System. However, for cases with other staging classifications the registry staff assisted in converting it to TNM Classification System too.

Death certificate list were obtained from the National Registration Department, government and private hospitals in the same procedures as explained earlier. Those with mention of cancer on death certificate were identified, and transcripts of associated reports or certificates were used by the registry. If no information was available, then the case would be registered as Death Certificate Only (DCO).

## 2.3 Quality control

In order to achieve a high validity and accuracy of data the Sabah Cancer Registry has used the same five common indices as indicated in the Cancer Incidence in Five Continents (CI5), Volume XI (Bray et al., 2017) which are (a) Internal consistency; (b) Histological verification; (c) Death certificate only (DCO); (d) Other and unspecified cases (ill-defined cases), and (e) Age unknown.

To ensure data comparability and accuracy, all cases notified to the registry must follow the IARC rules as follows;

**Definition of Incidence Date:** We use the standard recommendation for the definitions of incidence given by the European Network of Cancer Registries (ENCR) (Tyczynski et al., 2003).

**Coding:** Topography and morphology were coded to the International Classification of Diseases for Oncology (ICD-O-3) (Fritz et al., 2013).

**Multiple Primaries:** Registration of multiple primary cancers is in accordance with the IARC/IACR rules (IARC, IACR & ENCR, 2004).

**Consistency Check:** The logical inconsistencies between the variables in each cancer record were checked using IARC tools. The variables in each record were checked for eligibility (e.g. age and cancer behaviour), definite errors (e.g. sex site errors, invalid dates, impossible date sequence, and missing vital status), and possible errors, including a wide range of inconsistencies between age, cancer site, and morphology.

**Morphology verification:** The proportion of cancer records with morphological verification of the diagnosis were examined, whether from histology of a biopsy or surgical specimen, cytology of a smear or bone marrow aspirate, or from imaging or biomarkers, including tumours with a specific morphology code.

All data supplied for this report were coded to ICD-O-3, and then were converted to ICD-10 by the system for analysis and report writing.




Figure 6. Outline of registration procedure

## 2.4 Data Analysis

All the results refer only to the Malaysian citizen and resident. Population denominators for the respective years obtained from the Department of Statistics Malaysia (DOSM) were used to compute the rates. Segi's World Population (1960) was used for direct standardisation to calculate age-standardised incidence rates (ASR).

Analysis by ethnicity was done for 5 major ethnic groups which are Kadazan/Dusun, Chinese, Bajau, Malay and Murut using respective year's population denominators provided by DOSM. Data were analysed using R statistic built in Canreg5 software provided by IARC, Lyon, France.

### Description of statistical methods

#### *i. Crude incidence rate (CR)*

The number of new cancer cases (incidence cases) observed in the population during a defined period, divided by the number of population at risk in the same period. It is usually expressed per 100,000.

$$CR = N / P \times 100,000$$

N – Total number of new cancer cases

P – Person-years at risk

#### *ii. Age-specific incidence rate (AR)*

Incidence rate in a specified five-year age group; calculated by dividing the number of cancer cases in the five-year age group by the Malaysian population in the particular age group and multiply by 100,000.

$$AR = N_i / P_i \times 100,000$$

$N_i$  - Number of new cancer occurring in the  $i^{\text{th}}$  age group

$P_i$  – Person-years at risk in the  $i^{\text{th}}$  age group

#### *iii. Age-standardised incidence rate (ASR)*

Since the incidence of cancer depends heavily on the age structure of the population, there is a need for age adjustment for comparative analysis. The age-standardised incidence rate is a summary measure, indicating the rate that a population would have if it had a standard age structure.

It is calculated by summing the age-specific rates weighting to the world standard population; the calculated incidence rate is then called the World Standardised incidence rate. It is also expressed per 100,000.

$$ASR = \sum (AR_i \times P_{i.std}) / \text{total world standard population}$$

$AR_i$  - Age specific rate in the  $i^{\text{th}}$  age class

$P_{i.std}$  - The number in the  $i^{\text{th}}$  age class of world standard population

**iv. Standard error (SE)**

As with any measurement of a population, incidence rates have a certain amount of chance variation. The index measure of this variability is known as the standard error and is computed as follows:

$$SE = \sqrt{\sum_i d_i(w_i/y_i)^2}$$

$d_i$  - Number of cases of the cancer of interest in the age class  $i$

$w_i$  - Standard world population for age class  $i$

$y_i$  - Person-years at risk for age class  $i$

**v. 95% Confidence Limit of ASR (95% CL)**

ASRs are subject to random variation around the true underlying rate. 95% confidence limits are endpoints of a range in which the true rate would be expected to fall 95% of the time. 95%CLs are computed from the standard error (SE) of the ASR using the following formula:

$$95\% \text{ CL} = \text{ASR} \pm (1.96 \times \text{SE})$$

**vi. Cumulative rate (CR74)**

Cumulative rate is the weighted sum of age-specific incidence rates until completion of 74 years of age. The weighting used in this calculation is based simply on the widths of the age groups, i.e. multiplying the five-year age-sex specific rates per person by 5 and summing over age groups from 0-4 to 70-74. CR74 is necessary in order to ascertain the cumulative risk and is expressed in percentages.

$$CR74 = 5 \times \sum_i (d_i / y_i) \times 100$$

$i$  - 5-year age groups

$d_i$  - Number of cases in age class  $i$

$y_i$  - Person-years at risk of age class  $i$

**vii. Cumulative risk (CumR)**

Cumulative risk is defined as a probability that an individual would develop cancer during a certain age period, in the absence of any competing cause of death. The age period over which the risk is accumulated in this report is 0-74 years. The precise mathematical relationship between the cumulative rate and the cumulative risk is:

$$\text{CumR} = 100 \times [1 - \exp(-\text{CR74}/100)]$$

exp - exponential

**viii. Lifetime risk**

Lifetime risk is defined as the likelihood that a person who is free of a certain type of cancer will develop or die from that type of cancer during his or her lifetime. Lifetime risk estimates are usually expressed as the odds of developing cancer ('1 in x') or as a percentage.

$$\text{Lifetime risk} = \frac{100}{\text{CumR}}$$

## 3.0 RESULTS

### 3.1 Overall Cancer Incidence

A total of 8,818 new cancer cases were diagnosed in Sabah for the period of 2012- 2016.

The Age-standardised incidence rates (ASR) were 94.8 for males and 111.1 for females per 100,000 populations. When comparing with the previous report (2006-2010), the ASR were increased by 7.8 in females and slightly reduced by 0.3 per 100,000 populations in males.

The cumulative risk (CumR) was 10.8 for male and 11.7 for female, representing the probability of being diagnosed with a cancer before the age of 75, in the absence of other causes of death. The lifetime risk for males is 1 in 9, whereas lifetime risk for females is 1 in 8 (Table 4).

*Table 3. Incidence summary of new cancer cases by sex, Sabah, 2012-2016*

Sex	No.	%	CR	ASR	CR74	CumR	Lifetime risk
Males	4,006	45.4	63.5	94.8	11.4	10.8	1 in 9
Females	4,812	54.6	78.5	111.1	12.5	11.7	1 in 8
<b>Total</b>	<b>8,818</b>	<b>100.0</b>					

*Table 4. Incidence summary by major ethnic groups and sex, Sabah, 2012-2016*

Ethnicity	No.	Male			Female			
		CR	ASR	CumR	No.	CR	ASR	CumR
Kadazan/Dusun	927	60.2	85.1	9.5	1,120	74.2	94.9	10.2
Chinese	974	124.0	110.4	12.5	1,009	137.9	124.1	13.4
Bajau	489	40.0	64.2	7.4	684	57.1	81.0	8.6
Malay	157	23.6	57.6	6.0	200	31.0	54.0	5.5
Murut	108	38.5	64.1	8.1	142	51.4	75.9	8.7

By ethnicity, Chinese had the highest incidence in both males and females. The overall incidence rates among Kadazan/Dusun, Bajau and Murut were reduced slightly, whereas the overall incidence rates among Malays and Chinese were observed to be increase compared to previous report in both sexes.




Figure 7. Comparison of incidence summary by ethnicity, 2012-2016




Figure 8. Number of cases by age group and sex, Sabah, 2012-2016

Number of cancer cases increased exponentially with age with the highest age at diagnosis was within age group of 60-64 years old in males and 50-54 years old in females.

## Cancer Trends

Cancer incidence by Age Standardised Rate (ASR) in Sabah was noted to be higher in females than males.




Figure 9. Annual age-standardised rate (ASR) by sex, Sabah, 2006-2016

### 3.2 Age-specific Incidence Rates

The incidence of cancer increased for both males and females after the age of 30 years (Figure 10). The incidence rate in males exceeded the incidence rate in females after the age of 60 years. This results are due to increased incidence of Colorectal and Prostate Cancers in males while decrease incidence of Breast Cancer in females after the age of 60.




Figure 10. Age-specific incidence rate by sex, all sites, Sabah, 2012-2016






Figure 11. Age-specific incidence rate for five common sites, males, Sabah, 2012-2016





Figure 12. Age-specific incidence rate for five common sites, females, Sabah, 2012-2016

### 3.2 Incidence of Ten Most Common Cancers

The ten most common cancers were Breast, Colorectal, Lung, Lymphoma, Cervix Uteri, Nasopharynx, Leukaemia, Stomach, Skin (Non-Melanoma) and Prostate (Table 6 and Figure 13).

*Table 5. Ten most common cancers, all residents, Sabah, 2012-2016*

ICD-10	Sites	No.	%
C50	Breast	1,218	13.8
C18-21	Colorectal	1,053	11.9
C33-34	Trachea, Bronchus and Lung	774	8.8
C81-85,C96	Lymphoma	585	6.6
C53	Cervix Uteri	570	6.5
C11	Nasopharynx	493	5.6
C91-95	Leukemia	402	4.6
C16	Stomach	377	4.3
C44	Other Skin	336	3.8
C61	Prostate	265	3.0
	Others	2745	31.1
	<b>Total</b>	<b>8,818</b>	<b>100.0</b>



*Figure 13. Comparison of ten most common cancers, all residents, Sabah*

Table 6. Ten most common cancers by sex, all residents, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C18-21	Colorectal	622	15.5	9.5	14.2	1.9	1.7
C33-34	Trachea, Bronchus and Lung	483	12.1	7.4	11.3	1.6	1.5
C61	Prostate	265	6.6	4.1	7.2	1.1	1.0
C81-85,C96	Lymphoma	345	8.6	5.3	6.9	0.8	0.8
C11	Nasopharynx	353	8.8	5.4	6.7	0.8	0.8
C16	Stomach	232	5.8	3.6	5.5	0.7	0.6
C22	Liver	183	4.6	2.8	4.2	0.5	0.5
C91-95	Leukaemia	222	5.5	3.4	3.9	0.4	0.3
C44	Other Skin	163	4.1	2.5	3.9	0.5	0.5
C67	Bladder	97	2.4	1.5	2.3	0.3	0.3
	Others	1,041	26.0				
	<b>Total</b>	<b>4,006</b>	<b>100.0</b>	<b>63.5</b>	<b>94.8</b>	<b>10.8</b>	<b>11.4</b>
<b>Female</b>							
C50	Breast	1,206	25.1	18.9	24.5	2.9	2.7
C53	Cervix Uteri	570	11.8	8.9	11.5	1.4	1.3
C18-21	Colorectal	431	9.0	6.8	9.9	1.3	1.2
C33-34	Trachea, Bronchus and Lung	291	6.0	4.6	7.2	1.0	0.9
C81-85,C96	Lymphoma	240	5.0	3.8	4.7	0.6	0.5
C56	Ovary	229	4.8	3.6	4.5	0.5	0.5
C44	Other Skin	173	3.6	2.7	4.3	0.5	0.5
C73	Thyroid	210	4.4	3.3	4.0	0.5	0.4
C54	Corpus Uteri	190	3.9	3.0	3.8	0.5	0.4
C16	Stomach	145	3.0	2.3	3.5	0.4	0.4
	Others	1,127	23.4				
	<b>Total</b>	<b>4,812</b>	<b>100.0</b>	<b>78.5</b>	<b>111.1</b>	<b>11.7</b>	<b>12.5</b>




Figure 14. Age-standardised incidence rate for ten common cancers by sex, Sabah, 2012-2016

### 3.4 Ethnic Variations

The ASR per 100,000 population of cancer among the ethnic groups for ten common cancers are shown in Table 8 and Table 9. In males, the incidence rates of Colorectal, Lung, Prostate, Leukaemia, Skin (Non-Melanoma) and Bladder cancers were more common in Chinese whereas Stomach and Liver cancers were more common in Murut, Nasopharynx cancer was more common in Kadazan/Dusun and Lymphoma was more common in Malay. In females, the incidence of Breast, Colorectal, Lung, Ovary and Corpus Uteri cancers were more common in Chinese whereas Skin (Non-Melanoma) and Stomach cancers were more common in Kadazan/Dusun, Thyroid cancer was more common in Bajau, Lymphoma was more common in Malay and Cervix Uteri cancer was more common in Murut.

**Table 7.** Age-standardised incidence rates for ten most common cancers in males by major ethnic groups, Sabah, 2012-2016

Sites	ASR per 100,000 population by Ethnicity				
	Kadazan/ Dusun	Chinese	Bajau	Malay	Murut
Colorectal	10.2	21.6	12.5	7.1	6.4
Trachea, Bronchus and Lung	9.6	14.0	9.7	8.5	6.1
Prostate	5.4	10.4	3.0	3.9	5.8
Lymphoma	5.5	7.0	5.5	8.5	3.6
Nasopharynx	11.8	9.0	2.2	3.8	5.9
Stomach	8.9	5.9	2.5	0.7	8.9
Liver	4.0	4.9	5.0	1.7	5.8
Leukaemia	4.1	4.3	3.9	3.1	1.7
Other skin	3.5	5.1	2.7	1.1	1.7
Bladder	1.3	3.1	2.2	2.4	2.0


**Table 8.** Age-standardised incidence rates for ten most common cancers in females by major ethnic groups, Sabah, 2012-2016

Sites	ASR per 100,000 population by Ethnicity				
	Kadazan/ Dusun	Chinese	Bajau	Malay	Murut
Breast	18.1	34.8	15.3	17.0	11.6
Cervix uteri	11.5	8.5	11.6	3.1	17.4
Colorectal	7.4	15.7	8.4	5.8	10.3
Trachea, Bronchus and Lung	6.7	11.4	6.0	3.3	4.4
Lymphoma	4.0	4.5	3.8	4.8	2.6
Ovary	3.6	5.8	4.5	1.3	5.0
Other skin	5.6	3.8	2.2	2.2	1.1
Thyroid	3.4	2.6	5.4	1.6	3.4
Corpus uteri	2.5	6.2	3.0	2.6	0.4
Stomach	5.6	3.7	1.8	1.8	2.3

Among Kadazan/Dusun males, the most common cancers were Nasopharynx, Colorectal, Lung, Stomach and Lymphoma, whereas among females were Breast, Cervix Uteri, Colorectal, Lung and Skin (Non-Melanoma).

**Table 9.** Ten most common cancers in Kadazan/Dusun by sex, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C11	Nasopharynx	151	16.3	9.8	11.8	1.3	1.3
C18-21	Colorectal	104	11.2	6.8	10.2	1.2	1.2
C33-34	Trachea, Bronchus and Lung	97	10.5	6.3	9.6	1.2	1.2
C16	Stomach	89	9.6	5.8	8.9	0.9	1.0
C81-85,C96	Lymphoma	64	6.9	4.2	5.5	0.6	0.6
C61	Prostate	47	5.1	3.1	5.4	0.8	0.8
C91-95	Leukaemia	56	6.0	3.6	4.1	0.3	0.3
C22	Liver	41	4.4	2.7	4.0	0.4	0.4
C44	Other Skin	34	3.7	2.2	3.5	0.5	0.5
C90	Multiple Myeloma	17	1.8	1.1	1.6	0.2	0.2
	Others	227	24.5				
	<b>Total</b>	<b>927</b>	<b>100.0</b>	<b>60.2</b>	<b>85.1</b>	<b>9.5</b>	<b>10.0</b>
<b>Female</b>							
C50	Breast	226	20.2	15.0	18.1	2.0	2.0
C53	Cervix Uteri	140	12.5	9.3	11.5	1.3	1.3
C18-21	Colorectal	83	7.4	5.5	7.4	0.9	0.9
C33-34	Trachea, Bronchus and Lung	69	6.2	4.6	6.7	1.0	1.0
C44	Other Skin	61	5.4	4.0	5.6	0.5	0.5
C16	Stomach	57	5.1	3.8	5.6	0.7	0.7
C11	Nasopharynx	53	4.7	3.5	4.4	0.5	0.5
C81-85,C96	Lymphoma	52	4.6	3.4	4.0	0.4	0.4
C56	Ovary	46	4.1	3.0	3.6	0.4	0.4
C73	Thyroid	44	3.9	2.9	3.4	0.4	0.4
	Others	289	25.8				
	<b>Total</b>	<b>1,120</b>	<b>100.0</b>	<b>74.2</b>	<b>94.9</b>	<b>10.2</b>	<b>10.7</b>




**Figure 15.** Age-standardised incidence rate for ten common cancers in Kadazan/Dusun by sex, Sabah, 2012-2016

Among Chinese males, the most common cancers were Colorectal, Lung, Prostate, Nasopharynx and Lymphoma, whereas among Chinese females were Breast, Colorectal, Lung, Cervix Uteri and Corpus Uteri.

**Table 10.** Ten most common cancers in Chinese by sex, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C18-21	Colorectal	192	19.7	24.5	21.6	2.7	2.7
C33-34	Trachea, Bronchus and Lung	124	12.7	15.8	14.0	1.8	1.8
C61	Prostate	87	8.9	11.1	10.4	1.5	1.5
C11	Nasopharynx	85	8.7	10.8	9.0	1.0	1.0
C81-85,C96	Lymphoma	62	6.4	7.9	7.0	0.8	0.8
C16	Stomach	51	5.2	6.5	5.9	0.6	0.6
C44	Other Skin	45	4.6	5.7	5.1	0.6	0.6
C22	Liver	46	4.7	5.9	4.9	0.7	0.7
C91-95	Leukaemia	35	3.6	4.5	4.3	0.4	0.4
C67	Bladder	28	2.9	3.6	3.1	0.3	0.3
	Others	219	22.5				
	<b>Total</b>	<b>974</b>	<b>100.0</b>	<b>124.0</b>	<b>110.4</b>	<b>12.5</b>	<b>13.1</b>
<b>Female</b>							
C50	Breast	287	28.4	39.3	34.8	3.9	3.9
C18-21	Colorectal	129	12.8	17.6	15.7	1.8	1.8
C33-34	Trachea, Bronchus and Lung	93	9.2	12.7	11.4	1.3	1.3
C53	Cervix Uteri	70	6.9	9.6	8.5	1.1	1.1
C54	Corpus Uteri	52	5.2	7.1	6.2	0.7	0.7
C56	Ovary	45	4.5	6.2	5.8	0.7	0.7
C81-85,C96	Lymphoma	36	3.6	4.9	4.5	0.6	0.6
C11	Nasopharynx	33	3.3	4.5	4.0	0.4	0.4
C44	Other Skin	30	3.0	4.1	3.8	0.5	0.5
C16	Stomach	31	3.1	4.2	3.7	0.3	0.3
	Others	203	20.1				
	<b>Total</b>	<b>1,009</b>	<b>100.0</b>	<b>137.9</b>	<b>124.1</b>	<b>13.4</b>	<b>14.2</b>




**Figure 16.** Age-standardised incidence rate for ten common cancers in Chinese by sex, Sabah, 2012-2016

Among Bajau males, the most common cancers were Colorectal, Lung, Lymphoma, Liver and Leukaemia, whereas among Bajau females were Breast, Cervix Uteri, Colorectal, Lung and Thyroid.

**Table 11.** Ten most common cancers in Bajau by sex, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C18-21	Colorectal	96	19.6	7.9	12.5	1.5	1.5
C33-34	Trachea, Bronchus and Lung	68	13.9	5.6	9.7	1.4	1.4
C81-85,C96	Lymphoma	44	9.0	3.6	5.5	0.6	0.6
C22	Liver	33	6.7	2.7	5.0	0.7	0.6
C91-95	Leukaemia	40	8.2	3.3	3.9	0.4	0.4
C61	Prostate	17	3.5	1.4	3.0	0.4	0.4
C44	Other Skin	18	3.7	1.5	2.7	0.3	0.3
C16	Stomach	19	3.9	1.6	2.5	0.3	0.3
C11	Nasopharynx	20	4.1	1.6	2.2	0.2	0.2
C67	Bladder	13	2.7	1.1	2.2	0.4	0.4
	Others	121	24.7				
	<b>Total</b>	<b>489</b>	<b>100.0</b>	<b>40.0</b>	<b>64.2</b>	<b>7.4</b>	<b>7.6</b>
<b>Female</b>							
C50	Breast	134	19.6	11.2	15.3	1.6	1.6
C53	Cervix Uteri	101	14.8	8.4	11.6	1.2	1.2
C18-21	Colorectal	66	9.6	5.5	8.4	0.9	0.9
C33-34	Trachea, Bronchus and Lung	39	5.7	3.3	6.0	0.8	0.8
C73	Thyroid	46	6.7	3.8	5.4	0.6	0.6
C56	Ovary	45	6.6	3.8	4.5	0.4	0.4
C81-85,C96	Lymphoma	34	5.0	2.8	3.8	0.5	0.5
C54	Corpus Uteri	26	3.8	2.2	3.0	0.3	0.4
C91-95	Leukaemia	27	3.9	2.3	2.6	0.2	0.2
C44	Other Skin	16	2.3	1.3	2.2	0.2	0.2
	Others	150	21.9				
	<b>Total</b>	<b>684</b>	<b>100.0</b>	<b>57.1</b>	<b>81.0</b>	<b>8.6</b>	<b>8.9</b>




**Figure 17.** Age-standardised incidence rate for ten common cancers in Bajau by sex, Sabah, 2012-2016

Among Malay males, the most common cancers were Lymphoma, Lung, Colorectal, Nasopharynx and Prostate, whereas among Malay females were Breast, Colorectal, Lymphoma, Lung and Leukaemia.

**Table 12.** Ten most common cancers in Malay by sex, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C81-85,C96	Lymphoma	25	15.9	3.8	8.5	0.6	0.7
C33-34	Trachea, Bronchus and Lung	20	12.7	3.0	8.5	1.2	1.2
C18-21	Colorectal	17	10.8	2.6	7.1	0.8	0.8
C61	Prostate	7	4.5	1.1	3.9	0.5	0.6
C11	Nasopharynx	14	8.9	2.1	3.8	0.4	0.4
C91-95	Leukaemia	14	8.9	2.1	3.1	0.2	0.2
C67	Bladder	6	3.8	0.9	2.4	0.4	0.5
C25	Pancreas	3	1.9	0.5	2.0	0.2	0.2
C22	Liver	4	2.5	0.6	1.7	0.2	0.2
C23-24	Gallbladder etc.	4	2.5	0.6	1.7	0.1	0.1
	Others	43	27.4				
	<b>Total</b>	<b>157</b>	<b>100.0</b>	<b>23.6</b>	<b>57.6</b>	<b>6.0</b>	<b>6.3</b>
<b>Female</b>							
C50	Breast	62	31.0	9.6	17.0	1.9	1.9
C18-21	Colorectal	16	8.0	2.5	5.8	0.8	0.8
C81-85,C96	Lymphoma	24	12.0	3.7	4.8	0.4	0.4
C33-34	Trachea, Bronchus and Lung	9	4.5	1.4	3.3	0.4	0.4
C91-95	Leukaemia	16	8.0	2.5	3.1	0.3	0.3
C53	Cervix Uteri	10	5.0	1.6	3.1	0.2	0.2
C54	Corpus Uteri	9	4.5	1.4	2.6	0.3	0.3
C44	Other Skin	5	2.5	0.8	2.2	0.4	0.4
C16	Stomach	3	1.5	0.5	1.8	0.1	0.1
C73	Thyroid	8	4.0	1.2	1.6	0.1	0.1
	Others	38	19.0				
	<b>Total</b>	<b>200</b>	<b>100.0</b>	<b>31.0</b>	<b>54.0</b>	<b>5.5</b>	<b>5.7</b>




**Figure 18.** Age-standardised incidence rate for ten common cancers in Malay by sex, Sabah, 2012-2016



Among Murut males, the most common cancers were Stomach, Colorectal, Lung, Nasopharynx and Liver, whereas among Murut females were Cervix Uteri, Breast, Colorectal, Ovary and Lung.

**Table 13.** Ten most common cancers in Murut by sex, Sabah, 2012-2016

ICD-10	Sites	No.	%	CR	ASR	CumR	CR74
<b>Male</b>							
C16	Stomach	12	11.1	4.3	8.9	1.6	1.6
C18-21	Colorectal	12	11.1	4.3	6.4	0.6	0.6
C33-34	Trachea, Bronchus and Lung	10	9.3	3.6	6.1	0.8	0.8
C11	Nasopharynx	10	9.3	3.6	5.9	0.8	0.8
C22	Liver	9	8.3	3.2	5.8	0.7	0.7
C61	Prostate	7	6.5	2.5	5.8	1.0	1.0
C81-85,C96	Lymphoma	7	6.5	2.5	3.6	0.4	0.4
C43	Melanoma of Skin	3	2.8	1.1	3.2	0.6	0.6
C67	Bladder	2	1.9	0.7	2.0	0.4	0.4
C91-95	Leukaemia	5	4.6	1.8	1.7	0.1	0.1
	Others	31	28.7				
	<b>Total</b>	<b>108</b>	<b>100.0</b>	<b>38.5</b>	<b>64.1</b>	<b>8.1</b>	<b>8.5</b>
<b>Female</b>							
C53	Cervix Uteri	33	23.2	12.0	17.4	2.0	2.0
C50	Breast	22	15.5	8.0	11.6	1.2	1.2
C18-21	Colorectal	18	12.7	6.5	10.3	1.4	1.4
C56	Ovary	11	7.7	4.0	5.0	0.5	0.5
C33-34	Trachea, Bronchus and Lung	6	4.2	2.2	4.4	0.6	0.5
C73	Thyroid	6	4.2	2.2	3.4	0.5	0.5
C81-85,C96	Lymphoma	7	4.9	2.5	2.6	0.2	0.2
C16	Stomach	3	2.1	1.1	2.3	0.4	0.4
C91-95	Leukaemia	5	3.5	1.8	2.0	0.3	0.3
C23-24	Gallbladder	3	2.1	1.1	2.0	0.2	0.3
	Others	28	19.7				
	<b>Total</b>	<b>142</b>	<b>100.0</b>	<b>51.4</b>	<b>75.9</b>	<b>8.7</b>	<b>8.9</b>



**Figure 19.** Age-standardised incidence rate for ten common cancers in Murut by sex, Sabah, 2012-2016

### 3.5 Staging

Staging was reported for 3,914 cases (46.5%). This variable input was improved from previous report which only 16% were reported in second Sabah Cancer Registry. Of these 568 (14.5%) were in stage I, 740 (18.9%) in stage II, 801 (20.5%) in stage III and 1,805 (46.1%) in stage IV. Thus at the time of diagnosis, 2,606 (66.6%) had advanced cancers (stage III and IV). Most of the cancer cases were detected at late stage.

### 3.6 Validity

The Data Quality in this report was measured through data completeness, comparability and validity. Validity can be defined as the proportion of cases in a data-set which truly have the reported attribute. The Sabah Cancer Registry Report has used the same five common indices as indicated in the Cancer Incidence in Five Continents (CI5), Vol XI, as below:

- a) **Internal consistency:** The IARC/IACR CHECK program used to perform consistency checks. All cases queried are checked by the registry staff, using the software program, before incorporating relevant items into the database.
- b) **Histological verification:** The accuracy of the stated diagnosis is likely to be higher if there is histological confirmation by a pathologist or cytology/haematology confirmation. Sabah Cancer Registry used morphologically verification (MV) instead of histological verification. For cancers with specified sites, the morphologically verified proportion was **96.5%** of all cases for both sexes.
- c) **Death Certificate Only (DCO):** All the death notified by the public, private health facilities to the registry was traced and checked with the National Registry Departments. There were **2 cases classified as DCO**.
- d) **Other and unspecified cases (ill-defined cases):** For this category, the percentage was **1.0% (0.5% for males and 0.5% for females)** A low proportion of cases that are assigned to this category generally imply a better diagnostic precision in determining the site of primary cancer.
- e) **Age unknown:** If there are a large number of cases with age unknown, several of the figures and graphs from the data-set would not be accurate. In this report, **all the ages were known**.

### 3.7 Age Groups and Cancers

The five most common cancers by sex in each of the five broad age groups are shown in Figures 22-23.

In children below age of 15 years, main cancers in both sexes were leukaemia (40.6% in males, 39.5% in females) followed by Lymphoma, Brain/Nervous System, Eye and Nasopharynx cancers in males, whereas Brain/Nervous System, Lymphoma, Bone and Kidney cancers in females. Childhood cancer age 0 to 18 years old comprised of 455 cases, 252 (55.4%) cases were males and 203 (44.6%) cases were females.

In the 15-24 year age group, the most common cancers in males were Lymphoma (20.1%) followed by Leukaemia (15.8%) and Nasopharynx (11.5%). While in females, the most common cancers were Ovary (17.5%) followed by Thyroid (16.8%) and Leukaemia (16.1%).

In the group aged 25-59 years, Colorectal cancer was the most common cancer in males (15.6%), followed by Nasopharynx cancer (13.9%), and Lung cancer (11.8%). The most common cancers seen in females were Breast (31.8%), Cervix Uteri (15.2%) and Colorectal (7.5%).

In the 60-74 year age group, the most common cancers in males were Colorectal (17.5%), Lung (15.3%) and Prostate cancers (11.5%). In females the most common cancers were Breast (18.8%), Colorectal (12.1%) and Lung cancers (11.0%).

In the group aged 75 years and above, cancer of the Colorectal remained the most common cancer among males (18.8%) followed by Prostate (13.8%) and Lung cancers (11.5%). In females, Colorectal cancer (15.7%) was followed by cancer of the Skin (Non-Melanoma) (14.0%) and Breast (11.8%).




Figure 20. Common cancers among 0-14 years age group by sex, Sabah, 2012-2016




Figure 21. Common cancers among 15-24 years age group by sex, Sabah, 2012-2016




Figure 22. Common cancers among 25-59 years age group by sex, Sabah, 2012-2016




Figure 23. Common cancers among 60-74 years age group by sex, Sabah, 2012-2016



Figure 24. Common cancers in 75 years and above age group by sex, Sabah, 2012-2016

### 3.8 National Comparisons




Figure 25. All Sites: National comparisons – Age-standardised rates

## 4.0 SUMMARY TABLES

### 4.1 Incidence Summary Table

*Table 14.* Incidence summary of all cancer sites by year and ethnic group, Sabah

Year	Total	Male					Female				
		NO.	CR	ASR	(95% CL)	CumR	NO.	CR	ASR	(95% CL)	CumR
2006	1,419	683	68.8	106.7	(97.5,116.0)	11.6	736	68.9	103.2	(95.2,111.1)	11.1
2007	1,484	728	65.2	99.8	(92.2,107.4)	11.3	756	69.8	99.5	(91.9,107.0)	10.2
2008	1,462	704	62.2	90.8	(83.8,97.9)	10.0	758	69.2	98.0	(90.6,105.4)	10.7
2009	1,486	713	62.4	88.5	(81.7,95.3)	9.9	773	69.6	96.4	(89.2,103.5)	10.7
2010	1,812	798	68.4	97.9	(90.8,105.0)	11.1	1,014	90.1	117.7	(110.0,125.4)	12.3
2011	1,696	774	62.3	97.7	(90.5,104.9)	11.4	922	76.6	112.3	(104.8,119.9)	12.1
2012	1,493	656	52.0	77.4	(71.2,83.6)	8.7	837	68.2	93.9	(87.3,100.6)	9.8
2013	1,784	813	63.1	92.6	(86.0,99.3)	10.7	971	77.5	106.5	(99.5,113.5)	11.1
2014	1,816	801	61.2	86.3	(80.1,92.6)	9.8	1,015	79.6	108.8	(101.9,115.8)	11.7
2015	1,853	861	64.8	90.2	(83.9,96.4)	10.1	992	76.5	100.7	(94.2,107.2)	10.7
2016	1,872	875	64.6	88.7	(82.6,94.7)	10.1	997	75.6	98.1	(91.8,104.4)	10.5
<b>Ethnic group (2012-2016)</b>											
Kadazan/Dusun	2,047	927	60.1	85.1	(79.4,90.9)	9.5	1,120	73.9	95.0	(89.3,100.8)	10.2
Chinese	1,983	974	123.8	111.5	(104.4,118.6)	12.5	1,009	138.0	124.6	(116.8,132.3)	13.4
Bajau	1,173	489	40.0	64.3	(58.2,70.5)	7.4	684	57.1	81.2	(74.7,87.7)	8.6
Malay	357	157	23.5	57.3	(46.5,68.1)	6.0	200	30.9	54.1	(45.6,62.5)	5.5
Murut	250	108	38.4	63.7	(50.2,77.3)	8.1	142	51.5	77.0	(63.1,90.9)	8.7
<b>Ethnic group (2006-2010)</b>											
Kadazan/Dusun	2,091	975	74.1	145.7	(134.5,156.9)	20.0	1,116	83.2	115.4	(108.2,122.5)	12.3
Chinese	1,769	876	121.8	106.5	(99.3,113.7)	11.6	893	133.2	112.9	(105.4,120.4)	11.9
Bajau	904	404	41.3	70.4	(63.0,77.8)	8.2	500	52.3	80.9	(73.1,88.6)	8.9
Malay	140	85	9.4	16.2	(12.1,20.2)	1.8	55	6.4	11.2	(7.5,14.8)	1.1
Murut	241	109	45.8	75.6	(60.4,90.8)	8.1	132	55.6	87.2	(71.3,103.1)	10.2

**Table 15.** Incidence summary of all cancer sites by district, Sabah

State (2012-2016)	Total	Male					Female				
		NO.	CR	ASR	(95% CL)	CumR	NO.	CR	ASR	(95% CL)	CumR
Kota Kinabalu	3,204	1,479	150.2	192.6	(182.4,202.5)	20.5	1,725	175.7	217.4	(208.2,229.4)	21.6
Sandakan	972	431	57.6	73.5	(67.4,81.9)	8.5	541	74.4	94.5	(86.3,102.7)	9.3
Tawau	803	342	50.4	66.6	(60.0,74.8)	7.6	461	68.7	89.8	(81.7,98.8)	9.1
Penampang	471	225	77.2	101.9	(87.3,114.2)	11.9	246	84.9	106.5	(92.7,119.9)	11.5
Keningau	411	185	47.0	65.8	(56.9,77.0)	7.6	226	60.3	78.6	(68.4,89.7)	8.1
Tuaran	355	137	48.7	72.7	(58.8,83.8)	8.0	218	80.1	109.7	(93.4,123.4)	11.8
Papar	324	160	50.4	78.1	(66.1,91.7)	9.4	164	53.5	78.5	(67.1,92.7)	9.1
Lahad Datu	257	105	28.1	39.7	(32.2,48.4)	4.6	152	42.2	55.7	(46.7,65.5)	5.9
Ranau	256	126	50.1	70.7	(57.1,82.6)	8.2	130	54.6	70.0	(56.9,81.9)	7.4
Beaufort	237	105	58.4	95.3	(80.0,119.9)	10.2	132	75.6	119.5	(100.7,144.8)	13.9
Kota Belud	232	92	38.6	58.8	(45.9,71.0)	7.4	140	58.7	83.2	(69.2,98.1)	9.5
Kudat	213	99	46.5	64.7	(50.3,76.0)	7.2	114	55.4	81.6	(65.9,97.4)	9.0
Kota Marudu	176	89	48.5	64.9	(51.3,80.0)	7.1	87	49.2	65.7	(50.7,79.4)	6.9
Tenom	135	58	39.4	59.4	(43.7,75.4)	6.6	77	55.3	78.1	(60.3,97.2)	8.8
Semporna	128	54	20.2	29.1	(21.5,38.6)	3.2	74	27.3	37.6	(28.7,47.0)	4.5
Beluran	109	61	34.3	48.1	(36.5,62.2)	4.3	48	30.0	40.0	(27.6,50.7)	4.1
Sipitang	101	50	54.2	87.1	(65.1,119.4)	10.5	51	56.7	82.8	(59.4,108.7)	9.5
Tambunan	97	39	41.8	54.8	(36.7,73.1)	5.0	58	62.7	80.9	(61.4,106.0)	9.8
Kuala Penyu	95	53	99.1	166.2	(118.4,216.5)	19.2	42	80.9	118.6	(86.3,170.8)	13.3
Pitas	68	34	33.2	46.8	(31.4,65.9)	3.9	34	33.8	47.3	(31.0,65.1)	6.7
Putatan	58	27	17.1	25.2	(15.3,35.6)	2.8	31	22.0	29.7	(18.7,39.9)	2.2
Kinabatangan	49	23	12.8	18.4	(10.4,25.3)	2.5	26	15.6	20.4	(12.3,29.1)	1.8
Nabawan	34	16	20.1	26.3	(12.3,38.3)	2.6	18	24.3	29.8	(15.1,42.9)	3.0
Kunak	33	16	17.3	25.7	(12.4,40.2)	3.1	17	18.4	30.8	(15.2,45.0)	3.8

## 4.2 Staging by Cancer Sites

Table 16. Staging for all cancer types, Sabah, 2012-2016

ICD10	SITES	SEX	TOTAL	NO. WITH RECORDED STAGE	% RECORDED STAGE	STAGE							
						I	%	II	%	III	%	IV	%
C00	Lip	M	2	1	50.0	-	-	-	-	1	100.0	-	-
		F	16	12	75.0	3	25.0	4	33.3	2	16.7	3	25.0
C01-02	Tongue	M	48	33	68.8	1	3.0	5	15.2	6	18.2	21	63.6
		F	42	35	83.3	5	14.3	7	20.0	4	11.4	19	54.3
C03-06	Mouth	M	31	26	83.9	1	3.8	2	7.7	2	7.7	21	80.8
		F	46	42	91.3	4	9.5	4	9.5	7	16.7	27	64.3
C07-08	Salivary Glands	M	20	10	50.0	1	10.0	2	20.0	4	40.0	3	30.0
		F	17	8	47.1	1	12.5	1	12.5	-	-	6	75.0
C09	Tonsil	M	8	5	62.5	-	-	1	20.0	1	20.0	3	60.0
		F	2	0	0	-	-	-	-	-	-	-	-
C10	Other Oropharynx	M	11	4	36.4	-	-	1	25.0	1	25.0	2	50.0
		F	3	3	100.0	-	-	1	33.3	1	33.3	1	33.3
C11	Nasopharynx	M	353	245	69.4	16	6.5	40	16.3	69	28.2	120	49.0
		F	140	95	67.9	12	12.6	14	14.7	23	24.2	46	48.4
C12-13	Hypopharynx	M	12	7	58.3	-	-	-	-	-	-	7	100.0
		F	7	7	100.0	1	14.3	1	14.3	-	-	5	71.4
C14	Pharynx Unspec.	M	4	4	100.0	-	-	2	50.0	1	25.0	1	25.0
		F	1	1	100.0	-	-	-	-	-	-	1	100.0
C15	Oesophagus	M	60	25	41.7	2	8.0	3	12.0	1	4.0	19	76.0
		F	25	11	44.0	1	9.1	1	9.1	2	18.2	7	63.6
C16	Stomach	M	232	68	29.3	4	5.9	5	7.4	17	25.0	42	61.8
		F	145	52	35.9	4	7.7	4	7.7	8	15.4	36	69.2
C17	Small Intestine	M	17	3	17.6	-	-	-	-	1	33.3	2	66.7
		F	9	3	33.3	-	-	-	-	1	33.3	2	66.7
C18-21	Colorectal	M	622	297	47.7	18	6.1	62	20.9	71	23.9	146	49.2
		F	431	202	46.9	6	3.0	37	18.3	65	32.2	94	46.5
C22	Liver	M	183	67	36.6	7	10.4	-	-	5	7.5	55	82.1
		F	68	33	48.5	1	3.0	1	3.0	5	15.2	26	78.8
C23-24	Gallbladder etc.	M	44	12	27.3	-	-	-	-	2	16.7	10	83.3
		F	36	12	33.3	1	8.3	-	-	1	8.3	10	83.3
C25	Pancreas	M	67	31	46.3	-	-	2	6.5	2	6.5	27	87.1
		F	42	22	52.4	-	-	-	-	3	13.6	19	86.4
C30-31	Nose, Sinuses etc.	M	30	14	46.7	1	7.1	2	14.3	4	28.6	7	50.0
		F	15	8	53.3	-	-	-	-	1	12.5	7	87.5
C32	Larynx	M	60	41	68.3	4	9.8	6	14.6	12	29.3	19	46.3
		F	7	3	42.9	1	33.3	1	33.3	1	33.3	-	-
C33-34	Trachea, Bronchus, Lung	M	483	245	50.7	5	2.0	3	1.2	20	8.2	217	88.6
		F	291	151	51.9	5	3.3	5	3.3	7	4.6	134	88.7
C37-38	Other Thoracic Organs	M	22	6	27.3	-	-	-	-	1	16.7	5	83.3
		F	24	9	37.5	-	-	-	-	1	11.1	8	88.9
C40-41	Bone	M	35	11	31.4	2	18.2	1	9.1	1	9.1	7	63.6
		F	32	9	28.1	1	11.1	2	22.2	1	11.1	5	55.6
C43	Melanoma of Skin	M	34	13	38.2	2	15.4	1	7.7	2	15.4	8	61.5
		F	22	7	31.8	1	14.3	-	-	1	14.3	5	71.4
C44	Other Skin	M	163	20	12.3	8	40.0	7	35.0	-	-	5	25.0
		F	173	23	13.3	10	43.5	4	17.4	1	4.3	8	34.8
C45	Mesothelioma	M	3	0	0	-	-	-	-	-	-	-	
C46	Kaposi Sarcoma	M	7	0	0	-	-	-	-	-	-	-	
C47,C49	Connective, Soft Tissue	M	58	15	25.9	1	6.7	3	20.0	3	20.0	8	53.3
		F	42	10	23.8	3	30.0	-	-	1	10.0	6	60.0
C50	Breast	M	12	10	83.3	3	30.0	2	20.0	3	30.0	2	20.0
		F	1,206	704	58.4	91	12.9	223	31.7	179	25.4	211	30.0
C51	Vulva	F	13	4	30.8	-	-	1	25.0	3	75.0	-	-
		F	6	1	16.7	-	-	-	-	-	-	1	100.0
C53	Cervix Uteri	F	570	440	77.2	121	27.5	171	38.9	86	19.5	62	14.1
		F	190	121	63.7	56	46.3	14	11.6	32	26.4	19	15.7
C55	Uterus Unspec.	F	74	33	44.6	14	42.4	4	12.1	9	27.3	6	18.2
		F	229	172	75.1	57	33.1	27	15.7	52	30.2	36	20.9
C57	Other Female Genital	F	2	1	50.0	-	-	-	-	-	1	100.0	
C58	Placenta	F	4	0	0	-	-	-	-	-	-	-	
C60	Penis	M	17	3	17.6	-	-	-	-	-	3	100.0	
C61	Prostate	M	265	46	17.4	3	6.5	3	6.5	4	8.7	36	78.3
		M	42	8	19.0	2	25.0	3	37.5	1	12.5	2	25.0
C62	Testis	M	3	1	33.3	-	-	-	-	-	1	100.0	
C63	Other Male Genital	M	3	1	33.3	-	-	-	-	-	-	-	
C64	Kidney	M	53	18	34.0	-	-	2	11.1	3	16.7	13	72.2
		F	30	12	40.0	3	25.0	1	8.3	2	16.7	6	50.0
C65	Renal Pelvis	M	1	0	0	-	-	-	-	-	-	-	
C67	Bladder	M	97	22	22.7	3	13.6	3	13.6	2	9.1	14	63.6
		F	13	2	15.4	-	-	1	50.0	-	-	1	50.0
C69	Eye	M	19	5	26.3	1	20.0	2	40.0	1	20.0	1	20.0
		F	9	2	22.2	1	50.0	-	-	1	50.0	-	-
C70-72	Brain, Nervous System	M	65	10	15.4	2	20.0	2	20.0	3	30.0	3	30.0
		F	47	7	14.9	-	-	-	-	2	28.6	5	71.4
C73	Thyroid	M	54	20	37.0	7	35.0	-	-	4	20.0	9	45.0
		F	210	57	27.1	30	52.6	7	12.3	10	17.5	10	17.5
C74	Adrenal Gland	M	5	0	0	-	-	-	-	-	-	-	
		F	1	1	100.0	-	-	1	100.0	-	-	-	
C75	Other Endocrine	M	8	0	0	-	-	-	-	-	-	-	
		F	3	0	0	-	-	-	-	-	-	-	
C81-85; C96	Lymphoma	M	345	101	29.3	12	11.9	19	18.8	18	17.8	52	51.5
		F	240	83	34.6	22	26.5	14	16.9	16	19.3	31	37.3
C88	Immunoproliferative Dis.	M	18	2	11.1	-	-	-	-	-	-	2	100.0
		F	11	1	9.1	1	100.0	-	-	-	-	-	
C90	Multiple Myeloma	M	48	2	4.2	1	50.0	-	-	1	50.0	-	
		F	40	2	5.0	-	-	-	-	2	100.0	-	
C90	Others	M	123	28	22.8	1	3.6	3	10.7	-	-	24	85.7
		F	98	34	34.7	4	11.8	2	5.9	4	11.8	24	70.6
	<b>All Sites</b>		<b>8,416</b>	<b>3,914</b>	<b>46.5</b>	<b>568</b>	<b>14.5</b>	<b>740</b>	<b>18.9</b>	<b>801</b>	<b>20.5</b>	<b>1,805</b>	<b>46.1</b>

\* Leukemia (402 cases) is not included in the table due to absence of staging



### 4.3 Quality Indicators

Table 17. Quality indicators for all cancer types, Sabah, 2012-2016

ICD10	SITES	NO. CASES	% TOTAL	QUALITY INDICATOR		
				% DCO	% CLINICAL	% M.V
C00	Lip	18	0.2	-	-	100.0
C01-02	Tongue	90	1.0	-	1.1	98.9
C03-06	Mouth	77	0.9	-	1.3	98.7
C07-08	Salivary Glands	37	0.4	-	-	100.0
C09	Tonsil	10	0.1	-	-	100.0
C10	Other Oropharynx	14	0.2	-	-	100.0
C11	Nasopharynx	493	5.6	-	1.0	99.0
C12-13	Hypopharynx	19	0.2	-	-	100.0
C14	Pharynx Unspecified	5	0.1	-	-	100.0
C15	Oesophagus	85	1.0	-	3.5	96.5
C16	Stomach	377	4.3	-	1.6	98.4
C17	Small Intestine	26	0.3	-	7.7	92.3
C18-21	Colon, Rectum, Anus	1,053	11.9	-	0.9	99.0
C22	Liver	251	2.8	-	29.9	69.3
C23-C24	Gallbladder etc.	80	0.9	-	3.8	96.3
C25	Pancreas	109	1.2	-	19.3	80.7
C30-C31	Nose, Sinuses etc.	45	0.5	-	-	100.0
C32	Larynx	67	0.8	-	1.5	98.5
C33-34	Lung, Trachea, Bronchus	774	8.8	-	13.0	87.0
C37-C38	Other Thoracic Organs	46	0.5	-	-	100.0
C40-C41	Bone	67	0.8	-	3.0	97.0
C43	Melanoma of Skin	56	0.6	-	-	100.0
C44	Non-Melanoma Skin	336	3.8	-	-	100.0
C45	Mesothelioma	3	0	-	-	100.0
C46	Kaposi Sarcoma	7	0.1	-	-	100.0
C47;C49	Connective, Soft Tissue	100	1.1	-	-	100.0
C50	Breast	1,218	13.8	-	0.2	99.8
C51-C52	Vulva & Vagina	19	0.2	-	-	100.0
C53	Cervix	570	6.5	0.2	0.7	99.1
C54-55	Corpus & Uterus NOS	268	3.0	-	1.1	98.9
C56	Ovary & Adnexa	229	2.6	-	3.9	96.1
C57	Other Female Genital	2	0	-	-	100.0
C60	Penis	17	0.2	-	5.9	94.1
C61	Prostate	265	3.0	-	-	100.0
C62	Testis	42	0.5	-	4.8	95.2
C63	Other Male Genital	3	0	-	-	100.0
C64-66	Kidney & Urinary NOS	84	1.0	-	6.0	94.0
C67	Bladder	110	1.2	-	3.6	96.4
C69	Eye	28	0.3	-	17.9	82.1
C70-72	Brain & Nervous System	112	1.3	-	6.3	93.8
C73	Thyroid	264	3.0	-	1.5	98.5
C74	Adrenal Gland	6	0.1	-	33.3	66.7
C75	Other Endocrine	11	0.1	-	-	100.0
C81-C85;C96	Lymphoma	603	6.8	0.2	-	99.8
C88	Immunoproliferative Dis.	29	0.3	-	-	100.0
C90	Multiple Myeloma	88	1.0	-	-	100.0
C91-95	Leukaemia	402	4.6	-	-	100.0
	Other & Unspecified	203	2.3	-	6.9	93.1
	<b>All Sites</b>	<b>8818</b>	<b>100.0</b>	<b>0.0</b>	<b>3.4</b>	<b>96.5</b>

\* Percentage of cases registered on the basis of information from a death certificate only (DCO) and morphological verification (MV) which is based on cytology or histology (of the primary tumor, or a metastasis).

## 5.0 COMMENTARY ON 10 SELECTED CANCER SITES

Commentary is made on fifteen leading cancers by site, focussing to the ethnic variation and gender.

### 5.1 Female Breast (ICD-10: C50)

A total of 1,206 cases of female Breast cancer were diagnosed for the period of 2012-2016 compared with 799 cases in 2006-2010 report. Breast cancer is the most common cancer and accounted for 25.1% of all cancer among females in Malaysia. The ASR was increased from 18.7 in previous report to 24.5 per 100,000 populations in this report. The incidence was highest among Chinese followed by Kadazan/Dusun, Malay, Bajau and Murut.

The overall cumulative risk (CumR) was 2.9, highest among Chinese (3.9) and lowest among Murut (1.2). The overall lifetime risk was 1 in 35 compared to 1 in 49 in previous report. In Chinese it was 1 in 26, Kadazan/Dusun 1 in 51, Malays 1 in 53, Bajau 1 in 64 and Murut 1 in 81. The incidence increased after the age of 25 years and the peaked age was 60-64 years then reduced after 65 years of aged.

Staging was reported for 704 cases (58.4%). Of these 55.4% were detected at late stage (III & IV).

**Table 18. Female Breast: Cancer incidence summary by year, Sabah**

All residents	No.	CR	ASR	CumR
2006-2010	799	14.6	18.7	2.0
2012-2016	1,206	18.9	24.5	2.9
2012	243	19.8	26.2	2.9
2013	232	18.5	24.3	2.6
2014	235	18.4	24.1	2.6
2015	254	19.6	24.2	2.5
2016	242	18.3	23.4	2.5

**Table 19. Female Breast: Incidence summary by year and ethnicity, Sabah**

Female	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
Kadazan/Dusun	133	9.9	12.5	1.3	226	15.0	18.1	2.0
Chinese	249	37.1	31.1	3.4	287	39.2	34.8	3.9
Bajau	93	9.7	13.4	1.4	134	11.2	15.3	1.6
Malay	12	1.4	1.6	0.2	62	9.6	17.0	1.9
Murut	16	6.7	8.8	0.9	22	8.0	11.6	1.2




Figure 26. Female Breast: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah




Figure 27. Female Breast: Comparison of age-specific incidence rate by year, Sabah




Figure 28. Female Breast: Staging percentage, Sabah

## 5.2 Colorectal (ICD10: C18-C21)

A total of 1,053 cases of Colorectal cancer were registered for the period of 2012-2016 compared with 920 cases in 2006-2010 report. 59.1% were among males and 40.9% were among females. Colorectal cancer was the most common cancer in males and third in females. The incidence of Colorectal cancer was highest among Chinese for both sexes followed by Bajau and Kadazan/Dusun for males; Murut and Bajau for females. The lifetime risk for males was 1 in 54. It was 1 in 37 for Chinese, 1 in 69 for Bajau and 1 in 83 for Kadazan/Dusun. The lifetime risk for females was 1 in 77; for Chinese 1 in 55, Murut 1 in 70 and Bajau 1 in 108. The incidence increased with age and peak at the age of 70 and above for both sexes.

Staging was reported for 297 (47.7%) and 202 (46.9%) respectively for both males and females. Of these 73.1% in males and 78.7% in females were detected at late stage (III & IV).

**Table 20.** Colorectal: Cancer incidence summary by year, Sabah

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	528	9.3	14.3	1.7	392	7.1	11.2	1.3
2012-2016	622	9.5	14.2	1.9	431	6.8	9.9	1.3
2012	111	8.8	13.2	1.5	71	5.8	9.0	1.2
2013	120	9.3	14.7	1.8	74	5.9	8.7	1.0
2014	116	8.9	12.8	1.5	100	7.8	11.8	1.5
2015	142	10.7	15.5	2.0	92	7.1	9.9	1.2
2016	133	9.8	14.1	1.6	94	7.1	9.9	1.1

**Table 21.** Colorectal: Incidence summary by sex, year and ethnicity, Sabah

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	82	6.2	11.3	1.6	104	6.8	10.2	1.2
Chinese	187	26.0	22.6	2.6	192	24.5	21.6	2.7
Bajau	69	7.0	12.5	1.5	96	7.9	12.5	1.5
Malay	12	1.3	2.4	0.3	17	2.6	7.1	0.8
Murut	20	8.4	13.9	1.6	12	4.3	6.4	0.6
<b>Female</b>								
Kadazan/Dusun	82	6.1	8.7	1.1	83	5.5	7.4	0.9
Chinese	118	17.6	15.3	1.7	129	17.6	15.7	1.8
Bajau	45	4.7	8.5	1.1	66	5.5	8.4	0.9
Malay	10	1.2	2.8	0.3	16	2.5	5.8	0.8
Murut	12	5.1	9.6	1.3	18	6.5	10.3	1.4




Figure 29. Colorectal: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah




Figure 30. Colorectal: Comparison of age-specific incidence rate by year in males




Figure 31. Colorectal: Comparison of age-specific incidence rate by year in females




Figure 32. Colorectal: Staging percentage by sex, Sabah

### 5.3 Trachea, Bronchus and Lung (ICD-10: C33-C34)

A total of 774 cases of Trachea, Bronchus and Lung cancers were registered for the period of 2012-2016 compared with 714 cases in 2006-2010 report. 62.4% were among males and 37.6% were among females. It was the second most common cancer in males and fourth in females. The lifetime risk for males was 1 in 62. For Chinese, Bajau and Kadazan/Dusun, it was 1 in 57, 1 in 71 and 1 in 84 respectively. The lifetime risk for females was 1 in 100; for Chinese was 1 in 77, 1 in 103 for Kadazan/Dusun and 1 in 125 for Bajau.


The ASR was highest among Chinese for both sexes and the trend is increasing compared to previous report as in Figures 34. The incidence increased with age and peak at the age of 70 for males and 65 for females. Most of the lung cancer cases were detected at very late stage (III & IV) which were above 90% for both sexes (figure 37).

**Table 22.** Trachea, bronchus and lung: Cancer incidence summary by year, Sabah

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	441	7.8	12.6	1.6	273	5.0	8.6	1.1
2012-2016	483	7.4	11.3	1.6	291	4.6	7.2	1.0
2012	63	5.0	7.9	1.0	45	3.7	6.0	0.6
2013	102	7.9	12.4	1.7	64	5.1	8.1	1.0
2014	96	7.3	11.0	1.3	53	4.2	6.9	1.0
2015	109	8.2	12.2	1.6	64	4.9	7.6	1.0
2016	113	8.3	11.9	1.6	65	4.9	7.0	0.9

**Table 23.** Trachea, bronchus and lung: Incidence summary by sex, year and ethnicity, Sabah

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	115	8.7	19.0	3.0	97	6.3	9.6	1.2
Chinese	109	15.2	13.1	1.6	124	15.8	14.0	1.8
Bajau	62	6.3	12.4	1.6	68	5.6	9.7	1.4
Malay	8	0.9	1.8	0.2	20	3.0	8.5	1.2
Murut	11	4.6	8.9	1.1	10	3.6	6.1	0.8
<b>Female</b>								
Kadazan/Dusun	77	5.7	9.4	1.3	69	4.6	6.7	1.0
Chinese	67	10.0	8.8	1.0	93	12.7	11.4	1.3
Bajau	30	3.1	6.5	0.9	39	3.3	6.0	0.8
Malay	4	0.5	1.6	0.1	9	1.4	3.3	0.4
Murut	15	6.3	10.4	1.4	6	2.2	4.4	0.6



*Figure 33. Trachea, Bronchus and Lung: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah*






Figure 34. Trachea, Bronchus and Lung: Comparison of age-specific incidence rate by year in males




Figure 35. Trachea, Bronchus and Lung: Comparison of age-specific incidence rate by year in females




Figure 36. Trachea, Bronchus and Lung: Staging percentage by sex, Sabah, 2012-2016

## 5.4 Lymphoma (ICD10: C81-C85, C96)

A total of 585 cases of Lymphoma were registered for the period of 2012-2016 compared with 556 cases in 2006-2010 report. 59.0% were among males and 41.0% were among females. Lymphoma ranked fourth in males and fifth in females. The incidence was highest among Malay for both sexes followed by Chinese, Kadazan/Dusun and Bajau in males; Chinese and Kadazan/Dusun in females. The lifetime risk for males was 1 in 123; 1 in 155 for Malays, 1 in 131 for Chinese, 1 in 173 for Kadazan/Dusun and 1 in 175 for Bajau. The lifetime risk for females was 1 in 179; 1 in 239 for Malays, 1 in 181 for Chinese and 1 in 236 for Kadazan/Dusun.

Staging was reported for 101 (29.3%) and 83 (34.6%) cases respectively for males and females (figure 41). Of these 69.3% in males and 56.6% in females were detected at late stage (III & IV).

**Table 24. Lymphoma: Cancer incidence summary by year, Sabah**

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	339	6.0	8.0	0.9	217	4.0	5.4	0.6
2012-2016	345	5.3	6.9	0.8	240	3.8	4.7	0.6
2012	41	3.3	4.4	0.5	41	3.3	4.7	0.6
2013	77	6.0	8.1	0.9	64	5.1	6.8	0.8
2014	76	5.8	7.5	0.7	48	3.8	4.6	0.5
2015	83	6.2	8.0	0.9	34	2.6	3.3	0.4
2016	68	5.0	6.2	0.7	53	4.0	4.5	0.4

**Table 25. Lymphoma: Incidence summary by sex, year and ethnicity, Sabah**

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	97	7.4	13.7	2.1	64	4.2	5.5	0.6
Chinese	42	5.8	4.8	0.5	62	7.9	7.0	0.8
Bajau	45	4.6	6.6	0.7	44	3.6	5.5	0.6
Malay	14	1.5	2.7	0.3	25	3.8	8.5	0.6
Murut	5	2.1	4.2	0.6	7	2.5	2.6	0.2
<b>Female</b>								
Kadazan/Dusun	57	4.2	5.8	0.6	52	3.4	4.0	0.4
Chinese	40	6.0	5.0	0.5	36	4.9	4.5	0.6
Bajau	29	3.0	4.1	0.4	34	2.8	3.8	0.5
Malay	7	0.8	1.2	0.1	24	3.7	4.8	0.4
Murut	17	7.1	12.3	1.3	7	2.5	3.6	0.4





Figure 37. Lymphoma: Comparison of age-standardised rate by year, major ethnic group and sex, Sabah




Figure 38. Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016




Figure 39. Lymphoma: Staging percentage by sex, Sabah, 2012-2016

Age-specific incidence rate for Hodgkin and Non-Hodgkin Lymphoma as in Figure 40 and 41.




Figure 40. Hodgkin Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016




Figure 41. Non-Hodgkin Lymphoma: Age-specific incidence rate by sex, Sabah, 2012-2016

## 5.5 Cervix Uteri (ICD10:C53)

A total of 570 cases of Cervix Uteri cancer were registered for the period of 2012-2016 compared with 473 cases in 2006-2010 report. Cancer of the Cervix Uteri was the second most common cancer in females and ranked fifth in Sabah. The incidence rate was almost the same as in previous report. The lifetime risk was 1 in 73. Murut had higher incidence rate followed by Bajau and Kadazan/Dusun. The lifetime risk for Murut was 1 in 50, Bajau 1 in 82 and Kadazan/Dusun 1 in 78.

Staging was reported for 440 cases (77.2%). Of these 33.6% were detected at late stage (III & IV) and 66.4% were detected at stage I and II.

**Table 26. Cervix Uteri: Cancer incidence summary by year, Sabah**

All residents	No.	CR	ASR	CumR
2006-2010	473	8.6	11.1	1.2
2012-2016	570	8.9	11.5	1.4
2012	106	8.6	11.5	1.3
2013	126	10.1	13.3	1.5
2014	132	10.4	13.5	1.4
2015	117	9.0	11.8	1.3
2016	89	6.7	7.9	0.8

**Table 27. Cervix Uteri: Incidence summary by sex, year and ethnicity, Sabah**

Female	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
Kadazan/Dusun	141	10.5	12.8	1.4	140	9.3	11.5	1.3
Chinese	78	11.6	9.6	1.0	70	9.6	8.5	1.1
Bajau	77	8.1	12.1	1.4	101	8.4	11.6	1.2
Malay	3	0.4	0.3	0.0	10	1.6	3.1	0.2
Murut	13	5.5	8.6	1.0	33	12.0	17.4	2.0




Figure 42. Cervix Uteri: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah




Figure 43. Cervix Uteri: Comparison of age-specific incidence rate by year, Sabah




Figure 44. Cervix Uteri: Staging percentage, Sabah, 2012-2016

## 5.6 Nasopharynx (ICD-10: C11)

A total of 493 cases of Nasopharynx cancer were registered for the period of 2012-2016 compared with 506 cases in 2006-2010 report. 71.6% were among males and 28.4% were among females. Nasopharynx was the fifth most common cancer in males. The lifetime risk for males was 1 in 123, in Kadazan/Dusun it was 1 in 79 and 1 in 100 in Chinese. The lifetime risk for females was 1 in 309. The incidence in males increased after the age of 25 and peaked at 65 years old.

Staging was reported for 245 (69.4%) and 95 (67.9%) respectively for both males and females. Of these 77.2% in males and 72.6% in females were detected at late stage (III & IV).

**Table 28. Nasopharynx: Cancer incidence summary by year, Sabah**

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	370	6.6	8.2	0.9	136	2.5	3.2	0.4
2012-2016	353	5.4	6.7	0.8	140	2.2	2.8	0.3
2012	49	3.9	4.7	0.5	21	1.7	2.2	0.2
2013	63	4.9	6.2	0.6	39	3.1	4.1	0.4
2014	67	5.1	6.5	0.7	21	1.7	2.1	0.2
2015	85	6.4	7.7	0.8	29	2.2	2.8	0.3
2016	89	6.6	8.3	1.0	30	2.3	2.8	0.3

**Table 29. Nasopharynx: Incidence summary by sex, year and ethnicity, Sabah**

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	147	11.2	16.8	2.3	151	9.8	11.8	1.3
Chinese	100	13.9	11.2	1.2	85	10.8	9.0	1.0
Bajau	12	1.2	1.9	0.3	20	1.6	2.2	0.2
Malay	15	1.7	2.0	0.2	14	2.1	3.8	0.4
Murut	2	0.8	1.3	0.1	10	3.6	5.9	0.8
<b>Female</b>								
Kadazan/Dusun	55	4.1	5.3	0.6	53	3.5	4.4	0.5
Chinese	29	4.3	3.5	0.4	33	4.5	4.0	0.4
Bajau	8	0.8	1.3	0.2	10	0.8	1.0	0.1
Malay	2	0.2	0.6	0.1	1	0.2	0.3	0.0
Murut	2	0.8	1.6	0.2	4	1.5	1.7	0.1




Figure 45. Nasopharynx: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah





Figure 46. Nasopharynx: Age-specific incidence rate by sex, Sabah, 2012-2016





*Figure 47.* Nasopharynx: Staging percentage by sex, Sabah, 2012-2016

## 5.7 Leukaemia (ICD10: C91-95)

A total of 402 cases of Leukaemia were registered for the period of 2012-2016 compared with 385 cases in 2006-2010 report. 55.2% were among males and 44.8% were among females and majority of the cases were 0-14 years of age. Leukaemia is the eighth most common cancer in males. Chinese had the highest incidence rates in males followed by Kadazan/Dusun and Bajau. The lifetime risk for males was 1 in 279 and for females was 1 in 315.

**Table 30.** Leukaemia: Cancer incidence summary by year, Sabah

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	228	4.0	4.6	0.4	157	2.9	3.2	0.2
2012-2016	222	3.4	3.9	0.4	180	2.8	3.4	0.3
2012	28	2.2	2.3	0.2	24	2.0	2.1	0.1
2013	50	3.9	4.8	0.5	38	3.0	3.5	0.3
2014	43	3.3	3.7	0.4	45	3.5	4.2	0.4
2015	52	3.9	4.1	0.3	35	2.7	3.3	0.3
2016	49	3.6	4.3	0.4	38	2.9	3.5	0.3

**Table 31.** Leukaemia: Incidence summary by year and ethnicity, Sabah

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	58	4.4	5.7	0.5	56	3.6	4.1	0.3
Chinese	40	5.6	5.2	0.4	35	4.5	4.3	0.4
Bajau	26	2.7	3.1	0.3	40	3.3	3.9	0.4
Malay	1	0.1	0.1	0.0	14	2.1	3.1	0.2
Murut	11	4.6	5.1	0.5	5	1.8	1.7	0.1
<b>Female</b>								
Kadazan/Dusun	45	3.4	3.3	0.2	46	3.1	3.4	0.2
Chinese	18	2.7	2.5	0.2	23	3.1	3.2	0.3
Bajau	25	2.6	3.4	0.3	27	2.3	2.6	0.2
Malay	2	0.2	0.2	0.0	16	2.5	3.1	0.3
Murut	7	2.9	2.7	0.2	5	1.8	2.0	0.3




Figure 48. Leukaemia: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah




Figure 49. Leukaemia: Comparison of age-specific incidence rate by year, Sabah

Leukaemia in this report include lymphoid, myeloid and other unspecified types. The age specific incidence rates by type as shown in figure 50 for males and in figure 51 for female.




Figure 50. Leukaemia types: Age-specific incidence rate, males, Sabah, 2012-2016




Figure 51. Leukaemia types: Age-specific incidence rate, females, Sabah, 2012-2016

## 5.8 Stomach (ICD-10:C16)

A total of 377 cases of Stomach cancer were diagnosed for the period of 2012-2016 compared with 449 cases in 2006-2010 report. 61.5% were among males and 38.5% were among females. Stomach cancer is the sixth most common cancer in males and tenth in females. Kadazan/Dusun and Murut had higher incidence rates in males followed by Chinese, Bajau and Murut. The incidence rate in females were noted to be higher in Kadazan/Dusun followed by Chinese and Murut. The overall lifetime risk was 1 in 144 for males and 1 in 228 for females. The incidence of Stomach cancer increased with age and higher in males compared to females.

Staging was reported for 68 (29.3%) and 52 (35.9%) cases respectively for both males and females. Of these 86.8% in males and 84.6% in females were detected at late stage (III & IV).

**Table 32. Stomach: Cancer incidence summary by year, Sabah**

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	264	4.7	7.6	1.0	185	3.4	5.6	0.7
2012-2016	232	3.6	5.5	0.7	145	2.3	3.5	0.4
2012	44	3.5	5.7	0.5	27	2.2	3.4	0.3
2013	44	3.4	5.3	0.6	24	1.9	3.1	0.3
2014	47	3.6	5.5	0.7	38	3.0	4.7	0.6
2015	47	3.5	5.1	0.6	23	1.8	2.7	0.4
2016	50	3.7	5.7	0.7	33	2.5	3.6	0.3

**Table 33. Stomach: Incidence summary by sex, year and ethnicity, Sabah**

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	108	8.2	19.8	3.3	89	5.8	8.9	0.9
Chinese	46	6.4	5.9	0.7	51	6.5	5.9	0.6
Bajau	19	1.9	3.6	0.4	19	1.6	2.5	0.3
Malay	3	0.3	0.9	0.2	3	0.5	0.7	0.1
Murut	10	4.2	7.7	0.9	12	4.3	8.9	1.6
<b>Female</b>								
Kadazan/Dusun	82	6.1	10.0	1.2	57	3.8	5.6	0.7
Chinese	32	4.8	3.9	0.4	31	4.2	3.7	0.3
Bajau	18	1.9	3.5	0.5	13	1.1	1.8	0.2
Malay	2	0.2	0.2	0.0	3	0.5	1.8	0.1
Murut	11	4.6	7.6	1.0	3	1.1	2.3	0.4




Figure 52. Stomach: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah





Figure 53. Stomach: Age-specific incidence rate by sex, Sabah, 2012-2016



*Figure 54.* Stomach: Staging percentage by sex, Sabah, 2012-2016

## 5.9 Other Skin (ICD-10:C44)

A total of 336 cases of Skin cancer (Non-Melanoma) were diagnosed for the period of 2012-2016 compared with 275 cases in 2006-2010 report. Cancer of the Skin (Non-Melanoma) was the ninth most common cancer in males and seventh in females. The lifetime risk was 1 in 199 in males and 1 in 190 in females. Chinese had higher incidence rate in males and Kadazan/Dusun in females. The incidence of Skin cancer (Non-Melanoma) increased with age.

Staging was reported for 20 cases (12.3%) and 23 cases (13.3%) respectively for both males and females. Of these 75.0% in males and 60.9% in females were detected at early stage (I & II).

**Table 34. Other Skin: Cancer incidence summary by year, Sabah**

All residents	Male				Female			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
2006-2010	135	2.4	4.0	0.5	140	2.6	4.2	0.5
2012-2016	163	2.5	3.9	0.5	173	2.7	4.3	0.5
2012	26	2.1	3.4	0.5	17	1.4	2.3	0.2
2013	34	2.6	4.5	0.6	35	2.8	4.5	0.5
2014	36	2.8	4.0	0.5	32	2.5	4.2	0.5
2015	34	2.6	3.7	0.4	51	3.9	5.7	0.6
2016	33	2.4	3.6	0.3	38	2.9	4.4	0.6

**Table 35. Other Skin: Incidence summary by year and ethnicity, Sabah**

	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
<b>Male</b>								
Kadazan/Dusun	33	2.5	6.5	1.0	34	2.2	3.5	0.5
Chinese	38	5.3	4.7	0.6	45	5.7	5.1	0.6
Bajau	10	1.0	1.8	0.2	18	1.5	2.7	0.3
Malay	2	0.2	0.5	0.1	2	0.3	1.1	0.0
Murut	4	1.7	2.9	0.3	2	0.7	1.7	0.3
<b>Female</b>								
Kadazan/Dusun	42	3.1	5.1	0.5	61	4.0	5.6	0.5
Chinese	25	3.7	3.2	0.4	30	4.1	3.8	0.5
Bajau	15	1.6	3.3	0.5	16	1.3	2.2	0.2
Malay	2	0.2	1.0	0.1	5	0.8	2.2	0.4
Murut	5	2.1	2.9	0.3	2	0.7	1.1	0.1






Figure 55. Other Skin: Comparison of age-standardised incidence rate by year, major ethnic group and sex, Sabah




Figure 56. Other Skin: Age-specific incidence rate by sex, Sabah, 2012-2016




Figure 57. Other Skin: Staging percentage by sex, Sabah

## 5.10 Prostate (ICD10: C61)

A total of 265 cases of Prostate cancer were registered for the period of 2012-2016 compared with 175 cases in 2006-2010 report. Cancer of Prostate ranked fourth in males. The highest incidence was at the age of 70-74. The lifetime risk was 1 in 92. It was 1 in 66 for Chinese, 1 in 101 for Murut and 1 in 122 for Kadazan/Dusun.

Staging was reported for 46 cases (17.4%). Of these 87.0% were detected at late stage (III & IV).

**Table 36.** Prostate: Cancer incidence summary by year, Sabah

All residents	No.	CR	ASR	CumR
2006-2010	175	3.1	5.7	0.7
2012-2016	265	4.1	7.2	1.1
2012	58	4.6	8.4	1.0
2013	42	3.3	5.8	0.8
2014	45	3.4	6.2	0.9
2015	58	4.4	7.4	1.1
2016	62	4.6	7.8	1.2

**Table 37.** Prostate: Incidence summary by year and ethnicity, Sabah

Male	2006-2010				2012-2016			
	No.	CR	ASR	CumR	No.	CR	ASR	CumR
Kadazan/Dusun	35	2.7	7.0	1.2	47	3.4	5.4	0.8
Chinese	54	7.5	7.0	0.8	87	11.1	10.4	1.5
Bajau	12	1.2	2.9	0.3	17	1.4	3.0	0.4
Malay	6	0.7	2.0	0.2	7	1.1	3.9	0.5
Murut	1	0.4	0.8	0.2	7	2.5	5.8	1.0




Figure 58. Prostate: Comparison of age-standardised incidence rate by year and major ethnic group, Sabah




Figure 59. Prostate: Comparison of age-specific incidence rate by year, Sabah





Figure 60. Prostate: Staging percentage, Sabah, 2012-2016

## REFERENCES

1. Maria, S, Nirmal, K, Nafisah, A & Maslinda,MS (2015), *Sabah Cancer Registry Report 2006-2010*, Sabah State Health Department, Malaysia.
2. Azizah, AM, Hashimah, B, Nirmal, K, Siti Zubaidah, AR, Puteri NA, Nabihah, A, Sukumaran, R, Balqis, B, Nadia, SMR, Sharifah, SSS, Rahayu, O, Nur Alham, O & Azlina, AA (2019), *Malaysian National Cancer Registry Report (MNCR) 2012-2016*, National Cancer Registry Department, National Cancer Institute, Malaysia, <<http://www.nci.moh.gov.my/>>
3. Department of Statistic, Malaysia (2012-2016), *Population Distribution and Basic Demographic Characteristic, Population and Housing Census of Malaysia 2010*, Malaysia, <<https://www.dosm.gov.my/v1/>>
4. Fritz, A.G. ed., 2013. *International classification of diseases for oncology: ICD-O*. World Health Organization.
5. *Health Facts Sabah 2014-2016*, Sabah State Health Department.

## APPENDICES

### Appendix 1: Person-years at risk, all Sabah, 2012-2016



Age Group	SABAH POPULATION		WORLD STANDARD POPULATION
	Male	Female	
0-4	664,400	625,500	12,000
5-9	712,200	679,400	10,000
10-14	717,700	682,900	9,000
15-19	691,900	672,100	9,000
20-24	663,800	663,000	8,000
25-29	571,500	604,500	8,000
30-34	522,400	533,600	6,000
35-39	389,600	392,700	6,000
40-44	349,100	351,300	6,000
45-49	325,900	312,000	6,000
50-54	298,100	267,800	5,000
55-59	236,500	206,200	4,000
60-64	153,500	135,300	4,000
65-69	95,500	93,000	3,000
70-74	69,300	68,000	2,000
75+	81,400	83,700	2,000
<b>TOTAL</b>	<b>6,542,800</b>	<b>6,371,000</b>	<b>100,000</b>

Appendix 2: Population table by sex, ethnicity and age group, Sabah residents, 2012-2016

Age Group	ETHNIC GROUPS						
	Malay	Chinese	Kadazan Dusun	Bajau	Murut	Other Bumiputra	Others
<b>Male</b>							
0-4	163,300	39,100	126,200	120,600	30,900	141,500	41,800
5-9	162,800	56,600	136,700	103,700	30,100	183,000	39,500
10-14	164,600	61,400	141,400	90,100	31,800	192,300	36,400
15-19	171,400	67,900	143,700	49,400	33,600	191,900	35,400
20-24	163,600	71,400	134,900	49,200	28,700	184,700	32,000
25-29	133,200	67,100	106,200	53,700	24,700	159,900	25,900
30-34	117,200	67,500	91,900	49,700	22,400	150,800	23,000
35-39	86,900	57,200	68,500	36,300	17,700	106,800	17,500
40-44	82,500	53,000	60,400	29,800	15,700	93,800	15,200
45-49	80,000	51,200	58,600	25,500	12,600	84,400	14,700
50-54	69,900	53,500	56,000	22,000	11,800	71,800	13,200
55-59	51,500	46,700	40,500	15,700	8,000	62,200	11,500
60-64	35,700	35,300	22,800	9,200	3,600	40,000	6,900
65-69	21,200	24,500	14,200	5,200	2,500	23,600	3,800
70-74	16,300	15,600	10,400	3,200	2,500	17,900	2,500
75+	20,300	17,200	11,200	2,000	4,100	21,800	4,500
<b>Total</b>	<b>1,540,400</b>	<b>785,200</b>	<b>1,223,600</b>	<b>665,300</b>	<b>280,700</b>	<b>1,726,400</b>	<b>323,800</b>
<b>Female</b>							
0-4	153,300	36,400	117,600	112,700	29,300	138,000	39,500
5-9	152,700	50,100	130,500	100,200	30,000	175,600	40,000
10-14	156,300	56,100	136,000	85,400	31,600	182,000	36,300
15-19	164,800	65,700	139,200	46,800	32,200	191,600	32,600
20-24	156,100	70,100	134,600	51,100	29,700	191,300	31,200
25-29	134,900	70,400	112,700	60,200	26,100	171,600	27,800
30-34	118,800	67,300	97,400	49,900	21,800	153,800	24,100
35-39	91,800	53,900	70,600	34,900	15,400	109,900	17,500
40-44	85,000	48,100	64,900	28,100	14,700	97,600	13,800
45-49	78,700	47,200	55,200	22,800	12,600	82,800	11,800
50-54	68,400	44,800	44,800	19,300	10,800	68,600	10,100
55-59	50,200	39,000	35,400	13,300	7,200	53,400	7,800
60-64	32,500	29,800	21,000	9,000	4,300	33,600	5,000
65-69	23,100	20,700	14,700	5,300	2,500	22,300	2,700
70-74	19,100	14,000	10,000	3,800	2,500	16,100	2,500
75+	24,400	17,900	12,500	3,100	5,400	18,700	1,100
<b>Total</b>	<b>1,510,100</b>	<b>731,500</b>	<b>1,197,100</b>	<b>645,900</b>	<b>276,100</b>	<b>1,706,900</b>	<b>303,800</b>
<b>Both sexes</b>							
0-4	316,600	75,500	243,800	233,300	60,200	279,500	81,300
5-9	315,500	106,700	267,200	203,900	60,100	358,600	79,500
10-14	320,900	117,500	277,400	175,500	63,400	374,300	72,700
15-19	336,200	133,600	282,900	96,200	65,800	383,500	68,000
20-24	319,700	141,500	269,500	100,300	58,400	376,000	63,200
25-29	268,100	137,500	218,900	113,900	50,800	331,500	53,700
30-34	236,000	134,800	189,300	99,600	44,200	304,600	47,100
35-39	178,700	111,100	139,100	71,200	33,100	216,700	35,000
40-44	167,500	101,100	125,300	57,900	30,400	191,400	29,000
45-49	158,700	98,400	113,800	48,300	25,200	167,200	26,500
50-54	138,300	98,300	100,800	41,300	22,600	140,400	23,300
55-59	101,700	85,700	75,900	29,000	15,200	115,600	19,300
60-64	68,200	65,100	43,800	18,200	7,900	73,600	11,900
65-69	44,300	45,200	28,900	10,500	5,000	45,900	6,500
70-74	35,400	29,600	20,400	7,000	5,000	34,000	5,000
75+	44,700	35,100	23,700	5,100	9,500	40,500	5,600
<b>TOTAL</b>	<b>3,050,500</b>	<b>1,516,700</b>	<b>2,420,700</b>	<b>1,311,200</b>	<b>556,800</b>	<b>3,433,300</b>	<b>627,600</b>

Appendix 3: Population table by sex, district and age group, Sabah residents, 2012-2016

Age Group	DISTRICT				
	Tawau	Lahad Datu	Semporna	Sandakan	Kinabatangan
<b>Male</b>					
0-4	66,500	37,300	27,300	61,500	15,900
5-9	72,400	40,100	30,100	79,700	19,300
10-14	71,400	41,700	30,800	81,500	21,100
15-19	70,800	41,500	30,900	78,600	20,300
20-24	69,500	37,700	28,500	73,600	18,400
25-29	58,700	33,100	23,100	66,800	16,100
30-34	57,300	29,400	19,800	61,500	15,300
35-39	40,600	22,400	15,000	45,600	10,700
40-44	36,400	19,500	13,600	41,600	9,300
45-49	33,500	18,400	13,100	38,300	9,200
50-54	31,000	16,400	12,700	36,300	7,700
55-59	26,500	13,500	8,900	30,700	6,100
60-64	17,100	8,800	5,300	20,500	4,400
65-69	10,900	5,100	3,500	13,000	2,500
70-74	7,800	4,000	2,600	9,300	1,900
75+	8,800	4,200	2,800	10,300	1,900
<b>Total</b>	<b>679,200</b>	<b>373,100</b>	<b>268,000</b>	<b>748,800</b>	<b>180,100</b>
<b>Female</b>					
0-4	61,900	33,200	27,900	64,000	13,300
5-9	69,600	38,600	30,100	76,800	18,700
10-14	70,400	39,700	30,100	77,300	18,300
15-19	71,700	39,700	30,900	75,700	18,200
20-24	70,800	37,600	29,900	73,000	18,600
25-29	63,300	34,600	25,200	69,300	16,000
30-34	59,900	31,000	21,400	63,500	14,800
35-39	42,100	22,300	15,800	45,800	10,400
40-44	37,500	19,500	14,800	40,900	9,400
45-49	33,000	17,900	12,400	36,400	7,700
50-54	28,300	14,800	10,000	32,000	6,800
55-59	22,700	11,300	8,400	24,800	5,200
60-64	14,600	7,700	4,900	17,400	3,300
65-69	10,000	4,200	3,800	11,200	2,400
70-74	7,300	3,800	2,500	8,400	1,600
75+	8,400	4,500	3,000	10,400	1,900
<b>Total</b>	<b>671,500</b>	<b>360,400</b>	<b>271,100</b>	<b>726,900</b>	<b>166,600</b>
<b>Both sexes</b>					
0-4	128,400	70,500	55,200	125,500	29,200
5-9	142,000	78,700	60,200	156,500	38,000
10-14	141,800	81,400	60,900	158,800	39,400
15-19	142,500	81,200	61,800	154,300	38,500
20-24	140,300	75,300	58,400	146,600	37,000
25-29	122,000	67,700	48,300	136,100	32,100
30-34	117,200	60,400	41,200	125,000	30,100
35-39	82,700	44,700	30,800	91,400	21,100
40-44	73,900	39,000	28,400	82,500	18,700
45-49	66,500	36,300	25,500	74,700	16,900
50-54	59,300	31,200	22,700	68,300	14,500
55-59	49,200	24,800	17,300	55,500	11,300
60-64	31,700	16,500	10,200	37,900	7,700
65-69	20,900	9,300	7,300	24,200	4,900
70-74	15,100	7,800	5,100	17,700	3,500
75+	17,200	8,700	5,800	20,700	3,800
<b>TOTAL</b>	<b>1,350,700</b>	<b>733,500</b>	<b>539,100</b>	<b>1,475,700</b>	<b>346,700</b>



*Appendix 4: Population table by sex, district and age group, Sabah residents, 2012-2016  
(continue)*

Age Group	DISTRICT				
	Beluran	Kota Kinabalu	Ranau	Kota Belud	Tuaran
<b>Male</b>					
0-4	16,300	93,000	26,200	28,100	34,700
5-9	20,900	105,200	26,600	25,300	30,100
10-14	18,900	102,400	27,200	26,100	30,300
15-19	19,600	95,000	27,900	26,900	29,800
20-24	18,800	100,300	26,000	24,500	29,600
25-29	16,400	85,600	22,600	20,400	23,900
30-34	13,100	78,200	18,900	18,200	20,900
35-39	10,800	60,500	14,200	13,100	15,500
40-44	9,800	53,300	13,200	11,900	14,500
45-49	8,600	51,800	12,800	11,700	13,500
50-54	7,600	48,800	11,700	10,800	12,800
55-59	6,300	40,600	8,800	7,900	9,300
60-64	4,200	26,500	5,800	5,100	6,200
65-69	2,600	17,300	3,600	3,100	3,700
70-74	2,000	12,600	2,800	2,400	2,800
75+	2,100	13,700	3,100	2,800	3,600
<b>Total</b>	<b>178,000</b>	<b>984,800</b>	<b>251,400</b>	<b>238,300</b>	<b>281,200</b>
<b>Female</b>					
0-4	14,100	98,100	25,400	27,600	29,500
5-9	17,200	101,200	23,600	24,300	29,100
10-14	17,100	101,400	24,300	25,300	28,700
15-19	17,900	92,400	25,200	26,900	29,200
20-24	17,900	102,700	25,100	24,400	28,800
25-29	15,700	92,500	21,900	21,400	25,100
30-34	12,300	81,200	19,600	19,300	21,400
35-39	10,400	61,700	13,900	13,800	16,400
40-44	8,700	55,700	13,300	13,000	14,600
45-49	7,800	48,700	12,000	12,000	13,700
50-54	6,900	43,500	10,600	9,500	10,900
55-59	4,900	34,800	7,800	7,400	8,800
60-64	3,200	23,900	5,000	4,700	5,600
65-69	2,500	16,900	3,800	3,300	3,800
70-74	1,800	11,900	3,000	2,600	2,800
75+	1,700	15,200	3,600	3,000	3,800
<b>Total</b>	<b>160,100</b>	<b>981,800</b>	<b>238,100</b>	<b>238,500</b>	<b>272,200</b>
<b>Both sexes</b>					
0-4	30,400	191,100	51,600	55,700	64,200
5-9	38,100	206,400	50,200	49,600	59,200
10-14	36,000	203,800	51,500	51,400	59,000
15-19	37,500	187,400	53,100	53,800	59,000
20-24	36,700	203,000	51,100	48,900	58,400
25-29	32,100	178,100	44,500	41,800	49,000
30-34	25,400	159,400	38,500	37,500	42,300
35-39	21,200	122,200	28,100	26,900	31,900
40-44	18,500	109,000	26,500	24,900	29,100
45-49	16,400	100,500	24,800	23,700	27,200
50-54	14,500	92,300	22,300	20,300	23,700
55-59	11,200	75,400	16,600	15,300	18,100
60-64	7,400	50,400	10,800	9,800	11,800
65-69	5,100	34,200	7,400	6,400	7,500
70-74	3,800	24,500	5,800	5,000	5,600
75+	3,800	28,900	6,700	5,800	7,400
<b>TOTAL</b>	<b>338,100</b>	<b>1,966,600</b>	<b>489,500</b>	<b>476,800</b>	<b>553,400</b>

*Appendix 5: Population table by sex, district and age group, Sabah residents, 2012-2016  
(continue)*

Age Group	DISTRICT				
	Penampang	Papar	Kudat	Kota Marudu	Pitas
<b>Male</b>					
0-4	31,800	41,900	22,300	19,500	9,400
5-9	29,600	39,000	22,700	19,600	11,000
10-14	29,700	37,700	22,500	19,600	11,500
15-19	28,800	30,300	23,400	20,700	11,500
20-24	28,400	29,700	22,000	19,700	10,000
25-29	24,900	25,900	18,800	15,600	9,600
30-34	23,300	24,800	17,300	14,200	8,500
35-39	17,600	17,600	12,200	10,600	6,000
40-44	15,700	16,000	11,200	9,700	5,500
45-49	15,800	14,400	10,500	9,300	5,100
50-54	13,600	13,400	9,300	8,600	4,400
55-59	11,200	9,700	7,500	6,200	3,700
60-64	8,000	6,600	5,000	4,200	2,400
65-69	5,300	4,100	3,100	2,600	1,600
70-74	3,700	2,900	2,300	2,000	1,000
75+	4,000	3,500	2,800	2,300	1,100
<b>Total</b>	<b>291,400</b>	<b>317,500</b>	<b>212,900</b>	<b>184,400</b>	<b>102,300</b>
<b>Female</b>					
0-4	28,300	40,900	22,300	18,000	9,000
5-9	28,600	36,900	21,000	18,200	10,200
10-14	28,500	35,200	21,600	18,500	11,000
15-19	29,000	29,200	22,500	19,600	11,200
20-24	29,800	28,600	21,400	18,600	10,500
25-29	27,000	27,100	19,300	16,600	10,300
30-34	24,500	24,700	17,500	14,100	8,800
35-39	18,600	18,000	12,800	10,700	6,100
40-44	16,100	15,000	11,500	9,800	5,800
45-49	14,800	13,600	9,700	8,900	4,900
50-54	13,500	11,900	8,100	7,700	4,000
55-59	10,600	8,800	6,600	5,400	3,100
60-64	7,100	5,600	4,100	3,800	2,000
65-69	5,200	4,100	3,000	2,600	1,500
70-74	3,600	3,100	2,100	2,000	1,100
75+	4,600	3,800	2,400	2,500	1,100
<b>Total</b>	<b>289,800</b>	<b>306,500</b>	<b>205,900</b>	<b>177,000</b>	<b>100,600</b>
<b>Both sexes</b>					
0-4	60,100	82,800	44,600	37,500	18,400
5-9	58,200	75,900	43,700	37,800	21,200
10-14	58,200	72,900	44,100	38,100	22,500
15-19	57,800	59,500	45,900	40,300	22,700
20-24	58,200	58,300	43,400	38,300	20,500
25-29	51,900	53,000	38,100	32,200	19,900
30-34	47,800	49,500	34,800	28,300	17,300
35-39	36,200	35,600	25,000	21,300	12,100
40-44	31,800	31,000	22,700	19,500	11,300
45-49	30,600	28,000	20,200	18,200	10,000
50-54	27,100	25,300	17,400	16,300	8,400
55-59	21,800	18,500	14,100	11,600	6,800
60-64	15,100	12,200	9,100	8,000	4,400
65-69	10,500	8,200	6,100	5,200	3,100
70-74	7,300	6,000	4,400	4,000	2,100
75+	8,600	7,300	5,200	4,800	2,200
<b>TOTAL</b>	<b>581,200</b>	<b>624,000</b>	<b>418,800</b>	<b>361,400</b>	<b>202,900</b>

*Appendix 6: Population table by sex, district and age group, Sabah residents, 2012-2016  
(continue)*

Age Group	DISTRICT				
	Beaufort	Kuala Penyu	Sipitang	Tenom	Nabawan
<b>Male</b>					
0-4	31,000	7,800	11,100	16,500	9,300
5-9	19,400	6,100	10,700	15,500	8,500
10-14	18,600	5,900	10,800	16,200	9,100
15-19	17,200	5,100	9,600	16,700	9,300
20-24	15,900	5,000	8,900	14,700	7,900
25-29	14,600	4,500	7,900	12,700	6,600
30-34	13,400	4,200	7,700	11,300	6,500
35-39	10,100	3,100	5,300	9,000	4,500
40-44	8,700	2,500	4,600	8,200	4,300
45-49	8,000	2,500	4,100	6,700	3,600
50-54	7,100	2,100	3,700	6,400	3,400
55-59	5,800	1,700	3,000	5,000	2,400
60-64	3,700	1,100	1,800	2,900	1,200
65-69	2,400	500	1,100	2,000	1,000
70-74	1,800	500	1,000	1,600	800
75+	2,000	900	1,000	2,000	1,100
<b>Total</b>	<b>179,700</b>	<b>53,500</b>	<b>92,300</b>	<b>147,400</b>	<b>79,500</b>
<b>Female</b>					
0-4	33,000	6,900	10,000	15,600	7,300
5-9	18,000	5,700	10,300	14,600	8,200
10-14	17,700	5,800	10,300	15,200	8,500
15-19	16,200	5,200	9,400	15,500	8,800
20-24	15,700	5,000	9,200	13,900	8,000
25-29	15,100	4,500	8,200	12,800	7,000
30-34	13,200	4,300	7,700	11,300	5,900
35-39	9,600	3,100	5,300	7,900	4,000
40-44	8,600	2,600	4,800	7,100	4,000
45-49	7,500	2,500	4,100	6,900	3,300
50-54	6,200	2,000	3,400	6,000	2,800
55-59	4,900	1,500	2,500	4,300	1,900
60-64	3,200	1,000	1,700	2,500	1,300
65-69	2,100	600	1,000	2,000	1,000
70-74	1,600	500	1,000	1,600	900
75+	2,000	700	1,000	2,100	1,200
<b>Total</b>	<b>174,600</b>	<b>51,900</b>	<b>89,900</b>	<b>139,300</b>	<b>74,100</b>
<b>Both sexes</b>					
0-4	64,000	14,700	21,100	32,100	16,600
5-9	37,400	11,800	21,000	30,100	16,700
10-14	36,300	11,700	21,100	31,400	17,600
15-19	33,400	10,300	19,000	32,200	18,100
20-24	31,600	10,000	18,100	28,600	15,900
25-29	29,700	9,000	16,100	25,500	13,600
30-34	26,600	8,500	15,400	22,600	12,400
35-39	19,700	6,200	10,600	16,900	8,500
40-44	17,300	5,100	9,400	15,300	8,300
45-49	15,500	5,000	8,200	13,600	6,900
50-54	13,300	4,100	7,100	12,400	6,200
55-59	10,700	3,200	5,500	9,300	4,300
60-64	6,900	2,100	3,500	5,400	2,500
65-69	4,500	1,100	2,100	4,000	2,000
70-74	3,400	1,000	2,000	3,200	1,700
75+	4,000	1,600	2,000	4,100	2,300
<b>TOTAL</b>	<b>354,300</b>	<b>105,400</b>	<b>182,200</b>	<b>286,700</b>	<b>153,600</b>

*Appendix 7: Population table by sex, district and age group, Sabah residents, 2012-2016  
(continue)*

Age Group	DISTRICT			
	Keningau	Tambunan	Kunak	Putatan
<b>Male</b>				
0-4	39,800	9,000	10,500	22,500
5-9	41,800	10,100	10,400	18,500
10-14	42,600	10,200	10,300	17,900
15-19	43,200	10,500	10,200	15,400
20-24	41,200	10,100	9,600	14,600
25-29	34,400	8,000	7,900	13,300
30-34	30,800	6,900	7,500	11,900
35-39	22,900	5,400	4,900	9,100
40-44	21,200	5,000	4,400	7,900
45-49	19,900	4,900	4,500	7,300
50-54	17,900	4,400	4,100	6,200
55-59	13,700	3,100	3,100	5,000
60-64	8,800	2,200	1,900	3,300
65-69	5,700	1,200	1,200	2,000
70-74	4,300	1,000	900	1,500
75+	5,100	1,300	1,000	1,700
<b>Total</b>	<b>393,300</b>	<b>93,300</b>	<b>92,400</b>	<b>158,100</b>
<b>Female</b>				
0-4	37,100	8,300	10,800	18,800
5-9	39,500	9,400	10,000	16,200
10-14	40,100	9,700	10,100	16,000
15-19	41,200	10,500	10,500	13,600
20-24	38,800	10,100	9,700	13,500
25-29	35,000	8,200	8,400	12,800
30-34	30,000	7,000	7,500	11,200
35-39	22,600	5,600	5,300	8,500
40-44	20,400	5,300	5,000	7,200
45-49	18,800	4,900	4,000	6,300
50-54	16,100	4,300	3,500	5,300
55-59	11,800	3,100	2,700	4,100
60-64	7,800	1,800	1,800	2,700
65-69	5,400	1,500	1,100	1,700
70-74	4,500	1,100	800	1,400
75+	5,500	1,700	1,000	1,400
<b>Total</b>	<b>374,600</b>	<b>92,500</b>	<b>92,200</b>	<b>140,700</b>
<b>Both sexes</b>				
0-4	76,900	17,300	21,300	41,300
5-9	81,300	19,500	20,400	34,700
10-14	82,700	19,900	20,400	33,900
15-19	84,400	21,000	20,700	29,000
20-24	80,000	20,200	19,300	28,100
25-29	69,400	16,200	16,300	26,100
30-34	60,800	13,900	15,000	23,100
35-39	45,500	11,000	10,200	17,600
40-44	41,600	10,300	9,400	15,100
45-49	38,700	9,800	8,500	13,600
50-54	34,000	8,700	7,600	11,500
55-59	25,500	6,200	5,800	9,100
60-64	16,600	4,000	3,700	6,000
65-69	11,100	2,700	2,300	3,700
70-74	8,800	2,100	1,700	2,900
75+	10,600	3,000	2,000	3,100
<b>TOTAL</b>	<b>767,900</b>	<b>185,800</b>	<b>184,600</b>	<b>298,800</b>

Appendix 8: Incidence summary table, all residents, males, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C18-C21	Colorectal	622	15.5	9.5	1.7	14.2	(14.2,16.8)	1.9
C33-C34	Trachea, Bronchus, Lung	483	12.1	7.4	1.5	11.3	(11.2,13.4)	1.6
C61	Prostate	265	6.6	4.1	1	7.2	(6.8,8.7)	1.1
C81-C85;C96	Lymphoma	345	8.6	5.3	0.8	6.9	(6.6,8.2)	0.8
C11	Nasopharynx	353	8.8	5.4	0.8	6.7	(6.5,8.0)	0.8
C16	Stomach	232	5.8	3.6	0.6	5.5	(5.2,6.7)	0.7
C22	Liver	183	4.6	2.8	0.5	4.2	(3.9,5.2)	0.5
C91-C95	Leukaemia	222	5.5	3.4	0.3	3.9	(3.5,4.6)	0.4
C44	Other Skin	163	4.1	2.5	0.5	3.9	(3.5,4.8)	0.5
Others	Other & Unspecified	123	3.1	1.9	0.3	2.6	(2.3,3.4)	0.3
C67	Bladder	97	2.4	1.5	0.3	2.3	(2.0,3.0)	0.3
C25	Pancreas	67	1.7	1	0.2	1.6	(1.3,2.2)	0.2
C15	Oesophagus	60	1.5	0.9	0.2	1.5	(1.2,2.0)	0.2
C32	Larynx	60	1.5	0.9	0.2	1.5	(1.2,2.0)	0.2
C64	Kidney	53	1.3	0.8	0.2	1.2	(0.9,1.6)	0.2
C70-C72	Brain, Nervous System	65	1.6	1	0.1	1.1	(0.8,1.4)	0.1
C47; C49	Connective, Soft Tissue	58	1.4	0.9	0.1	1.1	(0.8,1.4)	0.1
C73	Thyroid	54	1.3	0.8	0.1	1.1	(0.8,1.5)	0.1
C01-C02	Tongue	48	1.2	0.7	0.1	1	(0.8,1.4)	0.1
C90	Multiple Myeloma	48	1.2	0.7	0.1	1	(0.8,1.4)	0.1
C23-C24	Gallbladder Etc.	44	1.1	0.7	0.1	0.9	(0.7,1.3)	0.1
C43	Melanoma Of Skin	34	0.8	0.5	0.1	0.8	(0.5,1.1)	0.1
C03-C06	Mouth	31	0.8	0.5	0.1	0.7	(0.5,1.1)	0.1
C62	Testis	42	1.0	0.6	0	0.6	(0.4,0.8)	0
C30-C31	Nose, Sinuses Etc.	30	0.7	0.5	0.1	0.6	(0.4,0.9)	0.1
C40-C41	Bone	35	0.9	0.5	0	0.5	(0.4,0.7)	0
C37-C38	Other Thoracic Organs	22	0.5	0.3	0.1	0.5	(0.3,0.8)	0.1
C07-C08	Salivary Glands	20	0.5	0.3	0.1	0.4	(0.2,0.6)	0.1
C88	Immunoproliferative Dis.	18	0.4	0.3	0	0.4	(0.2,0.6)	0
C69	Eye	19	0.5	0.3	0	0.3	(0.2,0.5)	0
C17	Small Intestine	17	0.4	0.3	0	0.3	(0.2,0.6)	0
C60	Penis	17	0.4	0.3	0	0.3	(0.2,0.5)	0
C12-C13	Hypopharynx	12	0.3	0.2	0	0.3	(0.1,0.5)	0
C50	Breast	12	0.3	0.2	0	0.3	(0.1,0.5)	0
C10	Other Oropharynx	11	0.3	0.2	0	0.3	(0.1,0.5)	0
C09	Tonsil	8	0.2	0.1	0	0.2	(0.1,0.3)	0
C75	Other Endocrine	8	0.2	0.1	0	0.1	(0.0,0.2)	0
C46	Kaposi Sarcoma	7	0.2	0.1	0	0.1	(0.0,0.2)	0
C74	Adrenal Gland	5	0.1	0.1	0	0.1	(0.0,0.2)	0
C14	Pharynx Unspec.	4	0.1	0.1	0	0.1	(0.0,0.2)	0
C45	Mesothelioma	3	0.1	0.1	0	0.1	(0.0,0.2)	0
C63	Other Male Genital	3	0.1	0.1	0	0.1	(0.0,0.2)	0
C00	Lip	2	0.0	0	0	0.1	(0.0,0.1)	0
C65	Renal Pelvis	1	0.0	0	0	0	(0.0,0.1)	0
C66	Ureter	0	0.0	0	0	0	(0.0,0.0)	0
C68	Other Urinary Organs	0	0.0	0	0	0	(0.0,0.0)	0
<b>All</b>	<b>All sites total</b>	<b>4,006</b>	<b>100.0</b>	<b>63.5</b>	<b>11.4</b>	<b>94.8</b>	<b>(91.8,97.9)</b>	<b>10.8</b>

*Appendix 9: Incidence summary table, all residents, females, Sabah, 2012-2016*

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	1,206	25.1	18.9	2.7	24.5	(25.1,28.3)	2.9
C53	Cervix Uteri	570	11.8	8.9	1.3	11.5	(11.5,13.6)	1.4
C18-C21	Colorectal	431	9.0	6.8	1.2	9.9	(9.8,11.9)	1.3
C33-C34	Trachea, Bronchus, Lung	291	6.0	4.6	0.9	7.2	(6.9,8.8)	1
C81-C85;C96	Lymphoma	240	5.0	3.8	0.5	4.7	(4.4,5.8)	0.6
C56	Ovary	229	4.8	3.6	0.5	4.5	(4.2,5.6)	0.5
C44	Other Skin	173	3.6	2.7	0.5	4.3	(4.0,5.4)	0.5
C73	Thyroid	210	4.4	3.3	0.4	4	(3.8,5.0)	0.5
C54	Corpus Uteri	190	3.9	3	0.4	3.8	(3.6,4.9)	0.5
C16	Stomach	145	3.0	2.3	0.4	3.5	(3.2,4.5)	0.4
C91-C95	Leukaemia	180	3.7	2.8	0.3	3.4	(3.0,4.1)	0.3
C11	Nasopharynx	140	2.9	2.2	0.3	2.8	(2.5,3.6)	0.3
Others	Other & Unspecified	98	2.0	1.5	0.2	2.2	(1.9,2.9)	0.3
C22	Liver	68	1.4	1.1	0.2	1.6	(1.3,2.2)	0.2
C55	Uterus Unspec.	74	1.5	1.2	0.2	1.5	(1.3,2.1)	0.2
C03-C06	Mouth	46	1.0	0.7	0.1	1.1	(0.8,1.6)	0.2
C01-C02	Tongue	42	0.9	0.7	0.1	1	(0.7,1.4)	0.1
C25	Pancreas	42	0.9	0.7	0.1	1	(0.8,1.5)	0.1
C70-C72	Brain, Nervous System	47	1.0	0.7	0.1	0.9	(0.6,1.2)	0.1
C90	Multiple Myeloma	40	0.8	0.6	0.1	0.9	(0.7,1.4)	0.1
C23-C24	Gallbladder Etc.	36	0.7	0.6	0.1	0.9	(0.6,1.3)	0.1
C47; C49	Connective, Soft Tissue	42	0.9	0.7	0.1	0.8	(0.6,1.2)	0.1
C64	Kidney	30	0.6	0.5	0.1	0.6	(0.4,0.9)	0.1
C15	Oesophagus	25	0.5	0.4	0.1	0.6	(0.4,0.9)	0.1
C37-C38	Other Thoracic Organs	24	0.5	0.4	0.1	0.6	(0.4,1.0)	0.1
C40-C41	Bone	32	0.7	0.5	0	0.5	(0.3,0.7)	0
C43	Melanoma Of Skin	22	0.5	0.4	0.1	0.5	(0.3,0.8)	0.1
C00	Lip	16	0.3	0.3	0	0.4	(0.2,0.6)	0
C07-C08	Salivary Glands	17	0.4	0.3	0	0.3	(0.2,0.5)	0
C30-C31	Nose, Sinuses Etc.	15	0.3	0.2	0	0.3	(0.2,0.6)	0
C51	Vulva	13	0.3	0.2	0	0.3	(0.1,0.5)	0
C67	Bladder	13	0.3	0.2	0	0.3	(0.1,0.5)	0
C88	Immunoproliferative Dis.	11	0.2	0.2	0	0.2	(0.1,0.4)	0
C17	Small Intestine	9	0.2	0.1	0	0.2	(0.1,0.4)	0
C69	Eye	9	0.2	0.1	0	0.2	(0.1,0.3)	0
C32	Larynx	7	0.1	0.1	0	0.2	(0.0,0.3)	0
C12-C13	Hypopharynx	7	0.1	0.1	0	0.1	(0.0,0.3)	0
C52	Vagina	6	0.1	0.1	0	0.1	(0.0,0.3)	0
C58	Placenta	4	0.1	0.1	0	0.1	(0.,0.1)	0
C10	Other Oropharynx	3	0.1	0.1	0	0.1	(0.0,0.1)	0
C57	Other Female Genital	2	0.0	0	0	0.1	(0.0,0.2)	0
C75	Other Endocrine	3	0.1	0.1	0	0	(0.0,0.1)	0
C09	Tonsil	2	0.0	0	0	0	(0.0,0.1)	0
C14	Pharynx Unspec.	1	0.0	0	0	0	(0.0,0.1)	0
C74	Adrenal Gland	1	0.0	0	0	0	(0.0,0.0)	0
C45	Mesothelioma	0	0.0	0	0	0	(0.0,0.0)	0
C46	Kaposi Sarcoma	0	0.0	0	0	0	(0.0,0.0)	0
C65	Renal Pelvis	0	0.0	0	0	0	(0.0,0.0)	0
C66	Ureter	0	0.0	0	0	0	(0.0,0.0)	0
C68	Other Urinary Organs	0	0.0	0	0	0	(0.0,0.0)	0
<b>All</b>	<b>All sites total</b>	<b>4,812</b>	<b>100.0</b>	<b>78.5</b>	<b>12.5</b>	<b>111.1</b>	<b>(107.8,114.4)</b>	<b>11.7</b>

*Appendix 10: Incidence summary table, Kadazan Dusun males, Sabah, 2012-2016*

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C11	Nasopharynx	151	16.3	9.8	1.3	11.8	(9.9,13.8)	1.3
C18-C21	Colorectal	104	11.2	6.8	1.2	10.2	(8.2,12.2)	1.2
C33-C34	Trachea, Bronchus, Lung	97	10.5	6.3	1.2	9.6	(7.6,11.5)	1.2
C16	Stomach	89	9.6	5.8	1.0	8.9	(7.0,10.8)	0.9
C81-C85;C96	Lymphoma	64	6.9	4.2	0.6	5.5	(4.1,6.9)	0.6
C61	Prostate	47	5.1	3.1	0.8	5.4	(3.9,7.0)	0.8
C91-C95	Leukaemia	56	6.0	3.6	0.3	4.1	(3.0,5.2)	0.3
C22	Liver	41	4.4	2.7	0.4	4.0	(2.7,5.3)	0.4
C44	Other Skin	34	3.7	2.2	0.5	3.5	(2.3,4.7)	0.5
Others	Other & Unspecified	21	2.3	1.4	0.2	1.9	(1.1,2.7)	0.2
C90	Multiple Myeloma	17	1.8	1.1	0.2	1.6	(0.8,2.4)	0.2
C15	Oesophagus	15	1.6	1.0	0.2	1.6	(0.8,2.4)	0.2
C32	Larynx	15	1.6	1.0	0.2	1.6	(0.8,2.4)	0.2
C01-C02	Tongue	15	1.6	1.0	0.2	1.4	(0.7,2.2)	0.2
C67	Bladder	13	1.4	0.8	0.2	1.3	(0.6,2.0)	0.2
C03-C06	Mouth	12	1.3	0.8	0.2	1.2	(0.5,1.9)	0.2
C73	Thyroid	13	1.4	0.8	0.1	1.1	(0.5,1.8)	0.1
C23-C24	Gallbladder Etc.	12	1.3	0.8	0.1	1.0	(0.4,1.7)	0.1
C25	Pancreas	10	1.1	0.6	0.2	1.0	(0.4,1.6)	0.2
C64	Kidney	9	1.0	0.6	0.1	0.8	(0.2,1.3)	0.1
C43	Melanoma Of Skin	8	0.9	0.5	0.1	0.8	(0.2,1.4)	0.1
C47; C49	Connective, Soft Tissue	9	1.0	0.6	0.1	0.7	(0.2,1.1)	0.1
C40-C41	Bone	11	1.2	0.7	0.0	0.6	(0.3,1.0)	0.0
C30-C31	Nose, Sinuses Etc.	7	0.8	0.5	0.1	0.6	(0.1,1.1)	0.1
C12-C13	Hypopharynx	6	0.6	0.4	0.1	0.6	(0.1,1.1)	0.1
C70-C72	Brain, Nervous System	6	0.6	0.4	0.1	0.6	(0.1,1.1)	0.1
C62	Testis	8	0.9	0.5	0.0	0.5	(0.2,0.9)	0.0
C07-C08	Salivary Glands	5	0.5	0.3	0.1	0.4	(0.0,0.8)	0.1
C17	Small Intestine	4	0.4	0.3	0.0	0.4	(0.0,0.7)	0.0
C37-C38	Other Thoracic Organs	4	0.4	0.3	0.1	0.4	(0.0,0.8)	0.0
C60	Penis	4	0.4	0.3	0.0	0.3	(0.0,0.6)	0.0
C69	Eye	4	0.4	0.3	0.0	0.3	(0.0,0.7)	0.0
C10	Other Oropharynx	3	0.3	0.2	0.0	0.3	(0.0,0.6)	0.0
C88	Immunoproliferative Dis.	3	0.3	0.2	0.1	0.3	(0.0,0.7)	0.1
C09	Tonsil	2	0.2	0.1	0.0	0.2	(-0.1,0.5)	0.0
C46	Kaposi Sarcoma	2	0.2	0.1	0.0	0.1	(-0.1,0.3)	0.0
C75	Other Endocrine	2	0.2	0.1	0.0	0.1	(-0.1,0.3)	0.0
C00	Lip	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C14	Pharynx Unspec.	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C45	Mesothelioma	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C74	Adrenal Gland	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C50	Breast	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C63	Other Male Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>927</b>	<b>100.0</b>	<b>60.2</b>	<b>10.0</b>	<b>85.1</b>	<b>(79.4,90.8)</b>	<b>9.5</b>

*Appendix 11: Incidence summary table, Kadazan Dusun females, Sabah, 2012-2016*

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	226	20.2	15.0	2.0	18.1	(15.7,20.6)	2.0
C53	Cervix Uteri	140	12.5	9.3	1.3	11.5	(9.5,13.5)	1.3
C18-C21	Colorectal	83	7.4	5.5	0.9	7.4	(5.8,9.1)	0.9
C33-C34	Trachea, Bronchus, Lung	69	6.2	4.6	1.0	6.7	(5.1,8.3)	1.0
C44	Other Skin	61	5.4	4.0	0.5	5.6	(4.2,7.1)	0.5
C16	Stomach	57	5.1	3.8	0.7	5.6	(4.1,7.1)	0.7
C11	Nasopharynx	53	4.7	3.5	0.5	4.4	(3.2,5.6)	0.5
C81-C85;C96	Lymphoma	52	4.6	3.4	0.4	4.0	(2.9,5.1)	0.4
C56	Ovary	46	4.1	3.1	0.4	3.6	(2.5,4.7)	0.4
C91-C95	Leukaemia	46	4.1	3.0	0.2	3.4	(2.4,4.4)	0.2
C73	Thyroid	44	3.9	2.9	0.4	3.4	(2.4,4.5)	0.4
C54	Corpus Uteri	33	2.9	2.2	0.3	2.5	(1.6,3.3)	0.3
Others	Other & Unspecified	23	2.1	1.5	0.2	2.1	(1.3,3.0)	0.2
C03-C06	Mouth	17	1.5	1.1	0.2	1.5	(0.8,2.3)	0.2
C22	Liver	15	1.3	1.0	0.2	1.5	(0.7,2.3)	0.2
C90	Multiple Myeloma	14	1.3	0.9	0.2	1.4	(0.6,2.1)	0.2
C01-C02	Tongue	13	1.2	0.9	0.1	1.3	(0.6,2.0)	0.1
C55	Uterus Unspec.	14	1.3	0.9	0.1	1.1	(0.5,1.7)	0.1
C15	Oesophagus	11	1.0	0.7	0.2	1.1	(0.4,1.7)	0.2
C47; C49	Connective, Soft Tissue	12	1.1	0.8	0.1	0.9	(0.4,1.4)	0.1
C70-C72	Brain, Nervous System	11	1.0	0.7	0.1	0.9	(0.4,1.4)	0.1
C23-C24	Gallbladder Etc.	9	0.8	0.6	0.1	0.9	(0.3,1.6)	0.1
C00	Lip	8	0.7	0.5	0.1	0.8	(0.2,1.4)	0.1
C25	Pancreas	8	0.7	0.5	0.1	0.7	(0.2,1.2)	0.1
C43	Melanoma Of Skin	7	0.6	0.5	0.1	0.6	(0.1,1.1)	0.1
C40-C41	Bone	8	0.7	0.5	0.0	0.5	(0.1,0.8)	0.0
C30-C31	Nose, Sinuses Etc.	5	0.4	0.3	0.1	0.5	(0.0,1.0)	0.1
C37-C38	Other Thoracic Organs	4	0.4	0.3	0.1	0.5	(0.0,0.9)	0.1
C07-C08	Salivary Glands	6	0.5	0.4	0.1	0.4	(0.1,0.7)	0.0
C64	Kidney	5	0.4	0.3	0.0	0.4	(0.0,0.7)	0.0
C12-C13	Hypopharynx	3	0.3	0.2	0.0	0.3	(0.0,0.6)	0.0
C51	Vulva	3	0.3	0.2	0.0	0.3	(0.0,0.6)	0.0
C67	Bladder	3	0.3	0.2	0.0	0.2	(0.0,0.5)	0.0
C17	Small Intestine	2	0.2	0.1	0.0	0.2	(-0.1,0.4)	0.0
C57	Other Female Genital	2	0.2	0.1	0.0	0.2	(-0.1,0.6)	0.0
C09	Tonsil	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C32	Larynx	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C58	Placenta	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C69	Eye	1	0.1	0.1	0.0	0.1	(0.0,0.1)	0.0
C74	Adrenal Gland	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C75	Other Endocrine	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C88	Immunoproliferative Dis.	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C52	Vagina	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>1,120</b>	<b>100.0</b>	<b>74.2</b>	<b>10.7</b>	<b>94.9</b>	<b>(89.3,100.8)</b>	<b>10.2</b>



Appendix 12: Incidence summary table, Chinese males, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C18-C21	Colorectal	192	19.7	24.5	2.7	21.6	(18.8,25.0)	2.7
C33-C34	Trachea, Bronchus, Lung	124	12.7	15.8	1.8	14.0	(11.6,16.6)	1.8
C61	Prostate	87	8.9	11.1	1.5	10.4	(8.4,12.8)	1.5
C11	Nasopharynx	85	8.7	10.8	1.0	9.0	(7.1,10.9)	1.0
C81-C85;C96	Lymphoma	62	6.4	7.9	0.8	7.0	(5.3,8.9)	0.8
C16	Stomach	51	5.2	6.5	0.6	5.9	(4.3,7.6)	0.6
C44	Other Skin	45	4.6	5.7	0.6	5.1	(3.6,6.6)	0.6
C22	Liver	46	4.7	5.9	0.7	4.9	(3.5,6.4)	0.7
C91-C95	Leukaemia	35	3.6	4.5	0.4	4.3	(2.8,5.8)	0.4
C67	Bladder	28	2.9	3.6	0.3	3.1	(2.0,4.4)	0.3
Others	Other & Unspecified	22	2.3	2.8	0.3	2.4	(1.4,3.4)	0.3
C15	Oesophagus	20	2.1	2.6	0.4	2.3	(1.3,3.4)	0.4
C25	Pancreas	20	2.1	2.6	0.3	2.2	(1.2,3.2)	0.3
C64	Kidney	17	1.7	2.2	0.3	1.9	(1.0,2.8)	0.3
C32	Larynx	16	1.6	2.0	0.2	1.8	(0.9,2.7)	0.2
C70-C72	Brain, Nervous System	10	1.0	1.3	0.1	1.7	(0.5,2.9)	0.1
C01-C02	Tongue	12	1.2	1.5	0.2	1.3	(0.6,2.0)	0.2
C30-C31	Nose, Sinuses Etc.	10	1.0	1.3	0.1	1.1	(0.4,1.7)	0.1
C90	Multiple Myeloma	10	1.0	1.3	0.1	1.1	(0.4,1.7)	0.1
C23-C24	Gallbladder Etc.	9	0.9	1.1	0.2	1.1	(0.4,1.8)	0.2
C47; C49	Connective, Soft Tissue	8	0.8	1.0	0.1	1.1	(0.2,1.9)	0.1
C03-C06	Mouth	8	0.8	1.0	0.1	0.9	(0.3,1.6)	0.1
C50	Breast	7	0.7	0.9	0.1	0.8	(0.2,1.4)	0.1
C88	Immunoproliferative Dis.	7	0.7	0.9	0.1	0.8	(0.2,1.4)	0.1
C43	Melanoma Of Skin	6	0.6	0.8	0.0	0.6	(0.1,1.2)	0.0
C62	Testis	5	0.5	0.6	0.0	0.5	(0.1,1.0)	0.0
C60	Penis	4	0.4	0.5	0.1	0.4	(0.0,0.9)	0.1
C73	Thyroid	4	0.4	0.5	0.0	0.4	(0.0,0.8)	0.0
C10	Other Oropharynx	3	0.3	0.4	0.0	0.4	(0.0,0.8)	0.0
C40-C41	Bone	3	0.3	0.4	0.0	0.3	(0.0,0.7)	0.0
C75	Other Endocrine	2	0.2	0.3	0.0	0.3	(-0.1,0.7)	0.0
C07-C08	Salivary Glands	2	0.2	0.3	0.1	0.2	(-0.1,0.6)	0.0
C09	Tonsil	2	0.2	0.3	0.0	0.2	(-0.1,0.5)	0.0
C17	Small Intestine	2	0.2	0.3	0.0	0.2	(-0.1,0.5)	0.0
C37-C38	Other Thoracic Organs	2	0.2	0.3	0.0	0.2	(-0.1,0.5)	0.0
C46	Kaposi Sarcoma	2	0.2	0.3	0.0	0.2	(-0.1,0.5)	0.0
C63	Other Male Genital	2	0.2	0.3	0.0	0.2	(-0.1,0.6)	0.0
C12-C13	Hypopharynx	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C14	Pharynx Unspec.	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C45	Mesothelioma	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C69	Eye	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>974</b>	<b>100.0</b>	<b>124.0</b>	<b>13.1</b>	<b>110.4</b>	<b>(99.4,113.4)</b>	<b>12.5</b>

Appendix 13: Incidence summary table, Chinese females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	287	28.4	39.2	3.9	34.8	(30.8,39.0)	3.9
C18-C21	Colorectal	129	12.8	17.6	1.8	15.7	(13.0,18.5)	1.8
C33-C34	Trachea, Bronchus, Lung	93	9.2	12.7	1.3	11.4	(9.1,13.8)	1.3
C53	Cervix Uteri	70	6.9	9.6	1.1	8.5	(6.6,10.6)	1.1
C54	Corpus Uteri	52	5.2	7.1	0.7	6.2	(4.5,7.9)	0.7
C56	Ovary	45	4.5	6.2	0.7	5.8	(4.1,7.5)	0.7
C81-C85;C96	Lymphoma	36	3.6	4.9	0.6	4.5	(3.0,6.0)	0.6
C11	Nasopharynx	33	3.3	4.5	0.4	4.0	(2.7,5.4)	0.4
C44	Other Skin	30	3.0	4.1	0.5	3.8	(2.5,5.3)	0.5
C16	Stomach	31	3.1	4.2	0.3	3.7	(2.4,5.0)	0.3
C91-C95	Leukaemia	23	2.3	3.1	0.3	3.2	(1.8,4.6)	0.3
C73	Thyroid	21	2.1	2.9	0.4	2.6	(1.5,3.7)	0.4
C22	Liver	21	2.1	2.9	0.3	2.5	(1.4,3.6)	0.3
Others	Other & Unspecified	21	2.1	2.9	0.2	2.5	(1.4,3.6)	0.2
C55	Uterus Unspec.	18	1.8	2.5	0.3	2.2	(1.2,3.2)	0.3
C25	Pancreas	14	1.4	1.9	0.2	1.8	(0.8,2.7)	0.2
C23-C24	Gallbladder Etc.	11	1.1	1.5	0.2	1.3	(0.5,2.1)	0.2
C70-C72	Brain, Nervous System	8	0.8	1.1	0.1	1.3	(0.3,2.3)	0.1
C01-C02	Tongue	9	0.9	1.2	0.1	1.1	(0.4,1.8)	0.1
C37-C38	Other Thoracic Organs	7	0.7	1.0	0.1	0.9	(0.2,1.6)	0.1
C64	Kidney	7	0.7	1.0	0.1	0.9	(0.2,1.5)	0.1
C51	Vulva	6	0.6	0.8	0.1	0.8	(0.2,1.4)	0.1
C90	Multiple Myeloma	5	0.5	0.7	0.1	0.6	(0.1,1.2)	0.1
C17	Small Intestine	4	0.4	0.5	0.1	0.6	(0.0,1.1)	0.1
C88	Immunoproliferative Dis.	4	0.4	0.6	0.1	0.5	(0.0,1.0)	0.1
C03-C06	Mouth	4	0.4	0.6	0.0	0.4	(0.0,0.9)	0.0
C07-C08	Salivary Glands	3	0.3	0.4	0.0	0.4	(0.0,0.8)	0.0
C40-C41	Bone	3	0.3	0.4	0.1	0.4	(-0.1,0.7)	0.0
C15	Oesophagus	2	0.2	0.3	0.0	0.3	(-0.1,0.6)	0.0
C52	Vagina	2	0.2	0.3	0.0	0.3	(-0.1,0.7)	0.0
C67	Bladder	2	0.2	0.3	0.1	0.3	(-0.1,0.7)	0.1
C00	Lip	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C12-C13	Hypopharynx	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C14	Pharynx Unspec.	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C30-C31	Nose, Sinuses Etc.	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C32	Larynx	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C43	Melanoma Of Skin	1	0.1	0.1	0.0	0.1	(-0.1,0.4)	0.0
C47; C49	Connective, Soft Tissue	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C75	Other Endocrine	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C58	Placenta	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C69	Eye	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>1,009</b>	<b>100.0</b>	<b>137.9</b>	<b>14.2</b>	<b>124.1</b>	<b>(116.8,132.3)</b>	<b>13.4</b>

Appendix 14: Incidence summary table, Bajau males, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C18-C21	Colorectal	96	19.6	7.9	1.5	12.5	(9.8,15.2)	1.5
C33-C34	Trachea, Bronchus, Lung	68	13.9	5.6	1.4	9.7	(7.3,12.2)	1.4
C81-C85;C96	Lymphoma	44	9.0	3.6	0.6	5.5	(3.8,7.3)	0.6
C22	Liver	33	6.7	2.7	0.6	5.0	(3.2,6.9)	0.7
C91-C95	Leukaemia	40	8.2	3.3	0.4	3.9	(2.6,5.2)	0.4
C61	Prostate	17	3.5	1.4	0.4	3.0	(1.5,4.5)	0.4
C44	Other Skin	18	3.7	1.5	0.3	2.7	(1.4,4.1)	0.3
C16	Stomach	19	3.9	1.6	0.3	2.5	(1.3,3.7)	0.3
C11	Nasopharynx	20	4.1	1.6	0.2	2.2	(1.2,3.1)	0.2
C67	Bladder	13	2.7	1.1	0.4	2.2	(1.0,3.4)	0.4
Others	Other & Unspecified	11	2.2	0.9	0.1	1.5	(0.6,2.4)	0.1
C32	Larynx	9	1.8	0.7	0.2	1.5	(0.5,2.5)	0.2
C25	Pancreas	10	2.0	0.8	0.2	1.3	(0.5,2.2)	0.2
C73	Thyroid	9	1.8	0.7	0.1	0.9	(0.3,1.6)	0.1
C64	Kidney	7	1.4	0.6	0.1	0.9	(0.2,1.6)	0.1
C37-C38	Other Thoracic Organs	5	1.0	0.4	0.1	0.8	(0.1,1.6)	0.1
C62	Testis	7	1.4	0.6	0.1	0.7	(0.2,1.3)	0.1
C23-C24	Gallbladder Etc.	6	1.2	0.5	0.1	0.7	(0.1,1.2)	0.1
C15	Oesophagus	5	1.0	0.4	0.1	0.7	(0.1,1.4)	0.1
C90	Multiple Myeloma	6	1.2	0.5	0.1	0.6	(0.1,1.2)	0.1
C43	Melanoma Of Skin	5	1.0	0.4	0.1	0.6	(0.0,1.1)	0.1
C70-C72	Brain, Nervous System	6	1.2	0.5	0.0	0.5	(1.0,1.0)	0.0
C40-C41	Bone	5	1.0	0.4	0.1	0.5	(0.0,0.9)	0.1
C47; C49	Connective, Soft Tissue	5	1.0	0.4	0.0	0.5	(0.0,1.0)	0.0
C01-C02	Tongue	4	0.8	0.3	0.1	0.5	(0.0,0.9)	0.1
C03-C06	Mouth	3	0.6	0.3	0.0	0.5	(-0.1,1.0)	0.0
C17	Small Intestine	4	0.8	0.3	0.0	0.4	(0.0,0.8)	0.0
C10	Other Oropharynx	2	0.4	0.2	0.1	0.4	(-0.2,1.1)	0.1
C69	Eye	3	0.6	0.3	0.0	0.3	(0.0,0.6)	0.0
C09	Tonsil	2	0.4	0.2	0.0	0.3	(-0.1,0.7)	0.0
C30-C31	Nose, Sinuses Etc.	2	0.4	0.2	0.1	0.3	(-0.1,0.7)	0.1
C50	Breast	1	0.2	0.1	0.1	0.2	(-0.2,0.6)	0.0
C74	Adrenal Gland	1	0.2	0.1	0.0	0.2	(-0.2,0.5)	0.0
C07-C08	Salivary Glands	2	0.4	0.2	0.0	0.1	(0.0,0.3)	0.0
C88	Immunoproliferative Dis.	1	0.2	0.1	0.0	0.1	(-0.1,0.3)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C12-C13	Hypopharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C60	Penis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C63	Other Male Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>489</b>	<b>100.0</b>	<b>40.0</b>	<b>7.6</b>	<b>64.2</b>	<b>(58.2,70.4)</b>	<b>7.4</b>

Appendix 15: Incidence summary table, Bajau females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	134	19.6	11.2	1.6	15.3	(12.7,18.1)	1.6
C53	Cervix Uteri	101	14.8	8.4	1.2	11.6	(9.2,14.0)	1.2
C18-C21	Colorectal	66	9.6	5.5	0.9	8.4	(6.3,10.6)	0.9
C33-C34	Trachea, Bronchus, Lung	39	5.7	3.3	0.8	6.0	(4.0,7.9)	0.8
C73	Thyroid	46	6.7	3.8	0.6	5.4	(3.7,7.2)	0.6
C56	Ovary	45	6.6	3.8	0.4	4.5	(3.1,5.9)	0.4
C81-C85;C96	Lymphoma	34	5.0	2.8	0.5	3.8	(2.4,5.2)	0.5
C54	Corpus Uteri	26	3.8	2.2	0.4	3.0	(1.8,4.2)	0.3
C91-C95	Leukaemia	27	3.9	2.3	0.2	2.6	(1.6,3.6)	0.2
C44	Other Skin	16	2.3	1.3	0.2	2.2	(1.1,3.3)	0.2
C03-C06	Mouth	13	1.9	1.1	0.3	2.2	(1.0,3.4)	0.3
Others	Other & Unspecified	16	2.3	1.3	0.3	2.0	(1.0,3.1)	0.3
C16	Stomach	13	1.9	1.1	0.2	1.8	(0.8,2.8)	0.2
C55	Uterus Unspec.	13	1.9	1.1	0.2	1.5	(0.6,2.3)	0.2
C22	Liver	9	1.3	0.8	0.1	1.1	(0.3,1.8)	0.1
C11	Nasopharynx	10	1.5	0.8	0.1	1.0	(0.4,1.7)	0.1
C01-C02	Tongue	9	1.3	0.8	0.1	1.0	(0.3,1.8)	0.1
C15	Oesophagus	6	0.9	0.5	0.1	0.9	(0.1,1.7)	0.1
C47; C49	Connective, Soft Tissue	7	1.0	0.6	0.1	0.8	(0.2,1.5)	0.1
C70-C72	Brain, Nervous System	7	1.0	0.6	0.0	0.6	(0.1,1.0)	0.0
C40-C41	Bone	6	0.9	0.5	0.0	0.5	(0.1,0.9)	0.0
C07-C08	Salivary Glands	4	0.6	0.3	0.1	0.5	(0.0,1.0)	0.1
C25	Pancreas	4	0.6	0.3	0.1	0.5	(0.0,1.0)	0.1
C43	Melanoma Of Skin	4	0.6	0.3	0.1	0.5	(0.0,1.0)	0.1
C64	Kidney	4	0.6	0.3	0.0	0.5	(0.0,0.9)	0.0
C23-C24	Gallbladder Etc.	3	0.4	0.3	0.1	0.5	(-0.1,1.1)	0.1
C30-C31	Nose, Sinuses Etc.	3	0.4	0.3	0.0	0.3	(0.0,0.6)	0.0
C67	Bladder	3	0.4	0.3	0.0	0.3	(0.0,0.6)	0.0
C90	Multiple Myeloma	3	0.4	0.3	0.0	0.3	(0.0,0.7)	0.0
C00	Lip	2	0.3	0.2	0.0	0.3	(-0.1,0.6)	0.0
C12-C13	Hypopharynx	2	0.3	0.2	0.0	0.2	(-0.1,0.4)	0.0
C69	Eye	2	0.3	0.2	0.0	0.2	(-0.1,0.5)	0.0
C88	Immunoproliferative Dis.	2	0.3	0.2	0.0	0.2	(-0.1,0.5)	0.0
C17	Small Intestine	1	0.1	0.1	0.0	0.2	(-0.1,0.5)	0.0
C32	Larynx	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C37-C38	Other Thoracic Organs	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C51	Vulva	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C58	Placenta	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C52	Vagina	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>684</b>	<b>100.0</b>	<b>57.1</b>	<b>8.9</b>	<b>81.0</b>	<b>(74.7,87.7)</b>	<b>8.6</b>

Appendix 16: Incidence summary table, Malay males, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C81-C85;C96	Lymphoma	25	15.9	3.8	0.7	8.5	(4.3,12.8)	0.6
C33-C34	Trachea, Bronchus, Lung	20	12.7	3.0	1.2	8.5	(4.2,12.4)	1.2
C18-C21	Colorectal	17	10.8	2.6	0.8	7.1	(3.4,10.9)	0.8
C11	Nasopharynx	14	8.9	2.1	0.4	3.8	(1.5,6.2)	0.4
C91-C95	Leukaemia	14	8.9	2.1	0.2	3.1	(0.8,5.4)	0.2
C61	Prostate	7	4.5	1.1	0.6	3.9	(0.7,6.9)	0.5
C47; C49	Connective, Soft Tissue	6	3.8	0.9	0.2	1.5	(0.2,2.8)	0.2
C67	Bladder	6	3.8	0.9	0.5	2.4	(0.2,4.4)	0.4
C22	Liver	4	2.5	0.6	0.2	1.7	(0.0,3.5)	0.2
C23-C24	Gallbladder Etc.	4	2.5	0.6	0.1	1.7	(-0.4,3.8)	0.1
C70-C72	Brain, Nervous System	4	2.5	0.6	0.2	1.1	(-0.2,2.3)	0.2
C01-C02	Tongue	3	1.9	0.5	0.1	1.7	(-0.5,3.9)	0.1
C16	Stomach	3	1.9	0.5	0.1	0.7	(-0.1,1.6)	0.1
C25	Pancreas	3	1.9	0.5	0.2	2.0	(-0.4,4.5)	0.2
C88	Immunoproliferative Dis.	3	1.9	0.5	0.1	1.5	(-0.6,3.6)	0.1
Others	Other & Unspecified	3	1.9	0.5	0.1	0.6	(0.1,1.4)	0.1
C07-C08	Salivary Glands	2	1.3	0.3	0.0	0.3	(-0.2,0.8)	0.0
C15	Oesophagus	2	1.3	0.3	0.2	0.8	(-0.4,1.9)	0.2
C32	Larynx	2	1.3	0.3	0.1	0.8	(-0.4,2.1)	0.1
C40-C41	Bone	2	1.3	0.3	0.1	0.5	(-0.2,1.1)	0.0
C44	Other Skin	2	1.3	0.3	0.0	1.1	(-0.9,3.1)	0.0
C62	Testis	2	1.3	0.3	0.0	0.3	(-0.1,0.8)	0.0
C73	Thyroid	2	1.3	0.3	0.0	0.4	(-0.2,0.9)	0.0
C12-C13	Hypopharynx	1	0.6	0.2	0.1	0.4	(-0.4,1.3)	0.1
C37-C38	Other Thoracic Organs	1	0.6	0.2	0.1	0.6	(-0.6,1.8)	0.1
C43	Melanoma Of Skin	1	0.6	0.2	0.1	0.4	(-0.4,1.3)	0.1
C50	Breast	1	0.6	0.2	0.0	1.0	(-0.1,3.0)	0.0
C60	Penis	1	0.6	0.2	0.2	0.6	(-0.5,1.7)	0.1
C64	Kidney	1	0.6	0.2	0.0	0.2	(-0.2,0.5)	0.0
C90	Multiple Myeloma	1	0.6	0.2	0.0	0.3	(-0.2,0.7)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C03-C06	Mouth	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C17	Small Intestine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C30-C31	Nose, Sinuses Etc.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C63	Other Male Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C69	Eye	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>157</b>	<b>100.0</b>	<b>23.6</b>	<b>6.3</b>	<b>57.6</b>	<b>(46.5,68.1)</b>	<b>6.0</b>

Appendix 17: Incidence summary table, Malay females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	62	31.0	9.6	1.9	17.0	(12.4,21.7)	1.9
C18-C21	Colorectal	16	8.0	2.5	0.8	5.8	(2.8,8.7)	0.8
C81-C85;C96	Lymphoma	24	12.0	3.7	0.4	4.8	(2.7,6.8)	0.4
C33-C34	Trachea, Bronchus, Lung	9	4.5	1.4	0.4	3.3	(0.9,5.8)	0.4
C91-C95	Leukaemia	16	8.0	2.5	0.3	3.1	(1.4,4.8)	0.3
C53	Cervix Uteri	10	5.0	1.6	0.2	3.1	(0.9,5.4)	0.2
C54	Corpus Uteri	9	4.5	1.4	0.3	2.6	(0.8,4.3)	0.3
C44	Other Skin	5	2.5	0.8	0.4	2.2	(0.1,4.3)	0.4
C16	Stomach	3	1.5	0.5	0.1	1.8	(-0.3,3.9)	0.1
C73	Thyroid	8	4.0	1.2	0.1	1.6	(0.4,2.7)	0.1
C56	Ovary	7	3.5	1.1	0.1	1.3	(0.3,2.4)	0.1
C40-C41	Bone	5	2.5	0.8	0.1	1.2	(-0.1,2.5)	0.1
C90	Multiple Myeloma	3	1.5	0.5	0.1	0.9	(-0.2,1.9)	0.1
C22	Liver	2	1.0	0.3	0.0	0.9	(-0.5,2.4)	0.0
C52	Vagina	2	1.0	0.3	0.2	0.7	(-0.4,1.7)	0.1
C55	Uterus Unspec.	3	1.5	0.5	0.1	0.6	(-0.1,1.2)	0.0
C64	Kidney	3	1.5	0.5	0.0	0.5	(-0.1,1.1)	0.0
C88	Immunoproliferative Dis.	2	1.0	0.3	0.1	0.5	(-0.2,1.2)	0.1
C47; C49	Connective, Soft Tissue	2	1.0	0.3	0.0	0.4	(-0.2,1.1)	0.0
C70-C72	Brain, Nervous System	2	1.0	0.3	0.0	0.3	(-0.1,0.6)	0.0
C03-C06	Mouth	1	0.5	0.2	0.0	0.3	(-0.3,0.8)	0.0
C07-C08	Salivary Glands	1	0.5	0.2	0.0	0.3	(-0.3,0.8)	0.0
C11	Nasopharynx	1	0.5	0.2	0.0	0.3	(-0.3,0.9)	0.0
C67	Bladder	1	0.5	0.2	0.0	0.3	(-0.3,0.8)	0.0
C69	Eye	2	1.0	0.3	0.0	0.2	(-0.1,0.5)	0.0
C37-C38	Other Thoracic Organs	1	0.5	0.2	0.0	0.1	(-0.1,0.3)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C01-C02	Tongue	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C12-C13	Hypopharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C15	Oesophagus	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C17	Small Intestine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C23-C24	Gallbladder Etc.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C25	Pancreas	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C30-C31	Nose, Sinuses Etc.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C32	Larynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C43	Melanoma Of Skin	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C51	Vulva	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C58	Placenta	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
Others	Other & Unspecified	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>200</b>	<b>100.0</b>	<b>31.0</b>	<b>5.7</b>	<b>54.0</b>	<b>(45.6,62.5)</b>	<b>5.5</b>

*Appendix 18: Incidence summary table, Murut males, Sabah, 2012-2016*

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C16	Stomach	12	11.1	4.3	1.6	8.9	(3.5,14.4)	1.6
C18-C21	Colorectal	12	11.1	4.3	0.6	6.4	(2.3,10.4)	0.6
C33-C34	Trachea, Bronchus, Lung	10	9.3	3.6	0.8	6.1	(2.0,10.0)	0.8
C11	Nasopharynx	10	9.3	3.6	0.8	5.9	(1.7,10.1)	0.8
C22	Liver	9	8.3	3.2	0.7	5.8	(1.6,10.0)	0.7
C61	Prostate	7	6.5	2.5	1.0	5.8	(1.2,10.2)	1.0
C81-C85;C96	Lymphoma	7	6.5	2.5	0.4	3.6	(0.5,6.6)	0.4
C43	Melanoma Of Skin	3	2.8	1.1	0.6	3.2	(-0.5,6.9)	0.6
Others	Other & Unspecified	5	4.6	1.8	0.3	2.8	(0.0,5.6)	0.3
C67	Bladder	2	1.9	0.7	0.4	2.0	(-0.8,4.8)	0.4
C91-C95	Leukaemia	5	4.6	1.8	0.1	1.7	(0.2,3.2)	0.1
C44	Other Skin	2	1.9	0.7	0.3	1.7	(-0.8,4.2)	0.3
C01-C02	Tongue	2	1.9	0.7	0.2	1.5	(-0.9,3.8)	0.2
C15	Oesophagus	3	2.8	1.1	0.2	1.3	(-0.2,2.9)	0.2
C60	Penis	2	1.9	0.7	0.1	0.8	(-0.3,2.0)	0.1
C69	Eye	2	1.9	0.7	0.0	0.8	(-0.3,1.8)	0.0
C70-C72	Brain, Nervous System	2	1.9	0.7	0.0	0.8	(-0.3,1.8)	0.0
C62	Testis	2	1.9	0.7	0.0	0.6	(-0.2,1.4)	0.0
C14	Pharynx Unspec.	1	0.9	0.4	0.1	0.5	(-0.5,1.5)	0.1
C37-C38	Other Thoracic Organs	1	0.9	0.4	0.1	0.5	(-0.5,1.5)	0.1
C46	Kaposi Sarcoma	1	0.9	0.4	0.0	0.5	(-0.4,1.3)	0.0
C47; C49	Connective, Soft Tissue	1	0.9	0.4	0.1	0.5	(-0.5,1.5)	0.1
C25	Pancreas	1	0.9	0.4	0.0	0.4	(-0.4,1.2)	0.0
C50	Breast	1	0.9	0.4	0.0	0.4	(-0.4,1.2)	0.0
C74	Adrenal Gland	1	0.9	0.4	0.0	0.4	(-0.4,1.1)	0.0
C12-C13	Hypopharynx	1	0.9	0.4	0.0	0.3	(-0.3,0.9)	0.0
C40-C41	Bone	1	0.9	0.4	0.0	0.3	(-0.3,0.8)	0.0
C75	Other Endocrine	1	0.9	0.4	0.0	0.3	(-0.3,0.8)	0.0
C88	Immunoproliferative Dis.	1	0.9	0.4	0.0	0.3	(-0.3,0.9)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C03-C06	Mouth	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C07-C08	Salivary Glands	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C17	Small Intestine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C23-C24	Gallbladder Etc.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C30-C31	Nose, Sinuses Etc.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C32	Larynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C63	Other Male Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C64	Kidney	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C73	Thyroid	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C90	Multiple Myeloma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
All	All sites total	108	100.0	38.5	8.5	64.1	(50.2,77.3)	8.1

Appendix 19: Incidence summary table, Murut females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C53	Cervix Uteri	33	23.2	12.0	2.0	17.4	(11.1,24.2)	2.0
C50	Breast	22	15.5	8.0	1.2	11.6	(6.5,17.2)	1.2
C18-C21	Colorectal	18	12.7	6.5	1.4	10.3	(5.3,15.6)	1.4
C56	Ovary	11	7.7	4.0	0.5	5.0	(1.9,8.4)	0.5
C33-C34	Trachea, Bronchus, Lung	6	4.2	2.2	0.5	4.4	(0.6,8.4)	0.6
C73	Thyroid	6	4.2	2.2	0.5	3.4	(0.5,6.5)	0.5
Others	Other & Unspecified	4	2.8	1.5	0.5	2.8	(-0.2,5.9)	0.5
C81-C85;C96	Lymphoma	7	4.9	2.5	0.2	2.6	(0.6,4.6)	0.2
C16	Stomach	3	2.1	1.1	0.4	2.3	(-0.6,5.1)	0.4
C91-C95	Leukaemia	5	3.5	1.8	0.3	2.0	(0.0,4.0)	0.3
C23-C24	Gallbladder Etc.	3	2.1	1.1	0.3	2.0	(-0.6,4.6)	0.2
C11	Nasopharynx	4	2.8	1.5	0.1	1.7	(0.0,3.4)	0.1
C01-C02	Tongue	2	1.4	0.7	0.2	1.6	(-0.9,4.0)	0.2
C22	Liver	2	1.4	0.7	0.1	1.1	(-0.4,2.7)	0.1
C44	Other Skin	2	1.4	0.7	0.1	1.1	(-0.4,2.7)	0.1
C37-C38	Other Thoracic Organs	1	0.7	0.4	0.1	0.9	(-1.0,3.0)	0.1
C69	Eye	2	1.4	0.7	0.0	0.8	(-0.3,1.9)	0.0
C03-C06	Mouth	1	0.7	0.4	0.1	0.6	(-0.5,1.7)	0.1
C25	Pancreas	1	0.7	0.4	0.1	0.6	(-0.5,1.7)	0.1
C30-C31	Nose, Sinuses Etc.	1	0.7	0.4	0.1	0.6	(-0.5,1.7)	0.1
C90	Multiple Myeloma	1	0.7	0.4	0.1	0.6	(-0.5,1.7)	0.1
C55	Uterus Unspec.	1	0.7	0.4	0.0	0.5	(-0.5,1.4)	0.0
C64	Kidney	1	0.7	0.4	0.0	0.5	(0.4,1.3)	0.0
C51	Vulva	1	0.7	0.4	0.0	0.4	(-0.4,1.2)	0.0
C54	Corpus Uteri	1	0.7	0.4	0.0	0.4	(-0.4,1.2)	0.0
C47; C49	Connective, Soft Tissue	1	0.7	0.4	0.0	0.3	(-0.3,0.8)	0.0
C58	Placenta	1	0.7	0.4	0.0	0.3	(0.3,0.8)	0.0
C70-C72	Brain, Nervous System	1	0.7	0.4	0.0	0.3	(-0.3,1.0)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C07-C08	Salivary Glands	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C12-C13	Hypopharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C15	Oesophagus	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C17	Small Intestine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C32	Larynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C40-C41	Bone	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C43	Melanoma Of Skin	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C52	Vagina	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C67	Bladder	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C88	Immunoproliferative Dis.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>142</b>	<b>100.0</b>	<b>51.4</b>	<b>8.9</b>	<b>75.9</b>	<b>(63.1,90.9)</b>	<b>8.7</b>



*Appendix 20: Incidence summary table, Other Bumiputra males, Sabah, 2012-2016*

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C18-C21	Colorectal	153	14.4	8.9	1.6	13.1	(11.0,15.4)	1.6
C33-C34	Trachea, Bronchus, Lung	136	12.8	7.9	1.6	12.2	(10.2,14.4)	1.6
C81-C85;C96	Lymphoma	113	10.6	6.6	0.9	8.2	(6.6,9.9)	0.9
C61	Prostate	79	7.4	4.6	1.1	8.1	(6.4,10.1)	1.1
C11	Nasopharynx	60	5.6	3.5	0.6	4.8	(3.6,6.1)	0.6
Others	Other & Unspecified	52	4.9	3.0	0.6	4.4	(3.2,5.8)	0.6
C91-C95	Leukaemia	58	5.4	3.4	0.3	4.0	(2.9,5.1)	0.3
C44	Other Skin	44	4.1	2.6	0.5	4.0	(2.8,5.3)	0.5
C22	Liver	47	4.4	2.7	0.5	3.9	(2.8,5.1)	0.5
C16	Stomach	41	3.8	2.4	0.5	3.6	(2.5,4.8)	0.5
C67	Bladder	28	2.6	1.6	0.3	2.5	(1.5,3.5)	0.3
C73	Thyroid	21	2.0	1.2	0.2	1.7	(1.0,2.5)	0.2
C25	Pancreas	17	1.6	1.0	0.3	1.6	(0.8,2.5)	0.3
C70-C72	Brain, Nervous System	24	2.3	1.4	0.1	1.5	(0.9,2.2)	0.1
C47; C49	Connective, Soft Tissue	19	1.8	1.1	0.1	1.4	(0.7,2.0)	0.1
C64	Kidney	16	1.5	0.9	0.2	1.4	(0.7,2.1)	0.2
C32	Larynx	15	1.4	0.9	0.2	1.3	(0.6,2.1)	0.2
C15	Oesophagus	12	1.1	0.7	0.2	1.1	(0.5,1.8)	0.2
C90	Multiple Myeloma	12	1.1	0.7	0.1	1.0	(0.4,0.7)	0.1
C01-C02	Tongue	12	1.1	0.7	0.1	0.9	(0.4,1.4)	0.1
C43	Melanoma Of Skin	10	0.9	0.6	0.1	0.8	(0.3,1.4)	0.1
C62	Testis	14	1.3	0.8	0.1	0.7	(0.3,1.0)	0.0
C30-C31	Nose, Sinuses Etc.	9	0.8	0.5	0.1	0.7	(0.2,1.2)	0.1
C07-C08	Salivary Glands	8	0.8	0.5	0.1	0.6	(0.2,1.1)	0.1
C69	Eye	7	0.7	0.4	0.0	0.6	(0.2,1.0)	0.0
C40-C41	Bone	10	0.9	0.6	0.0	0.5	(0.2,0.8)	0.0
C23-C24	Gallbladder Etc.	7	0.7	0.4	0.1	0.5	(0.1,0.9)	0.0
C37-C38	Other Thoracic Organs	6	0.6	0.4	0.1	0.4	(0.1,0.8)	0.1
C03-C06	Mouth	5	0.5	0.3	0.1	0.4	(0.0,0.8)	0.1
C17	Small Intestine	5	0.5	0.3	0.1	0.4	(0.0,0.8)	0.1
C60	Penis	5	0.5	0.3	0.0	0.4	(0.0,0.7)	0.0
C12-C13	Hypopharynx	3	0.3	0.2	0.1	0.3	(0.0,0.6)	0.0
C88	Immunoproliferative Dis.	3	0.3	0.2	0.0	0.2	(0.0,0.5)	0.0
C09	Tonsil	2	0.2	0.1	0.0	0.2	(-0.1,0.4)	0.0
C10	Other Oropharynx	2	0.2	0.1	0.0	0.2	(-0.1,0.5)	0.0
C74	Adrenal Gland	2	0.2	0.1	0.0	0.2	(-0.1,0.4)	0.0
C46	Kaposi Sarcoma	2	0.2	0.1	0.0	0.1	(0.0,0.2)	0.0
C75	Other Endocrine	2	0.2	0.1	0.0	0.1	(0.0,0.3)	0.0
C00	Lip	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C14	Pharynx Unspec.	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C45	Mesothelioma	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C50	Breast	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C63	Other Male Genital	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>1,066</b>	<b>100.0</b>	<b>61.8</b>	<b>10.7</b>	<b>88.6</b>	<b>(83.8,95.1)</b>	<b>10.3</b>

Appendix 21: Incidence summary table, Other Bumiputra females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	374	28.2	21.9	2.8	27.6	(24.8,30.6)	2.8
C53	Cervix Uteri	182	13.7	10.7	1.5	13.7	(11.6,15.8)	1.4
C18-C21	Colorectal	100	7.5	5.9	1.1	8.9	(7.1,10.7)	1.1
C33-C34	Trachea, Bronchus, Lung	66	5.0	3.9	0.9	6.5	(4.9,8.2)	0.8
C81-C85;C96	Lymphoma	68	5.1	4.0	0.7	5.6	(4.1,7.0)	0.6
C54	Corpus Uteri	57	4.3	3.3	0.6	4.6	(3.4,5.9)	0.6
C73	Thyroid	64	4.8	3.8	0.4	4.5	(3.3,5.7)	0.4
C56	Ovary	59	4.4	3.5	0.5	4.4	(3.2,5.6)	0.5
C44	Other Skin	38	2.9	2.2	0.5	3.9	(2.6,5.1)	0.5
C91-C95	Leukaemia	48	3.6	2.8	0.4	3.6	(2.5,4.7)	0.4
C16	Stomach	30	2.3	1.8	0.3	2.7	(1.7,3.7)	0.3
C11	Nasopharynx	33	2.5	1.9	0.2	2.4	(1.6,3.3)	0.2
Others	Other & Unspecified	26	2.0	1.5	0.3	2.2	(1.3,3.0)	0.3
C55	Uterus Unspec.	21	1.6	1.2	0.2	1.6	(0.9,2.3)	0.2
C22	Liver	17	1.3	1.0	0.2	1.6	(0.8,2.5)	0.2
C47; C49	Connective, Soft Tissue	15	1.1	0.9	0.2	1.3	(0.6,2.0)	0.2
C25	Pancreas	14	1.1	0.8	0.2	1.3	(0.6,1.9)	0.2
C70-C72	Brain, Nervous System	15	1.1	0.9	0.1	1.0	(0.5,1.6)	0.1
C37-C38	Other Thoracic Organs	9	0.7	0.5	0.2	1.0	(0.3,1.6)	0.2
C01-C02	Tongue	9	0.7	0.5	0.1	0.9	(0.3,1.5)	0.1
C03-C06	Mouth	9	0.7	0.5	0.1	0.8	(0.3,1.4)	0.1
C23-C24	Gallbladder Etc.	9	0.7	0.5	0.1	0.8	(0.3,1.4)	0.1
C43	Melanoma Of Skin	8	0.6	0.5	0.1	0.8	(0.2,1.3)	0.1
C90	Multiple Myeloma	8	0.6	0.5	0.1	0.7	(0.2,1.1)	0.0
C15	Oesophagus	6	0.5	0.4	0.1	0.5	(0.1,1.0)	0.1
C00	Lip	5	0.4	0.3	0.1	0.5	(0.1,0.9)	0.1
C64	Kidney	6	0.5	0.4	0.0	0.4	(0.1,0.8)	0.0
C32	Larynx	4	0.3	0.2	0.1	0.4	(0.0,0.8)	0.0
C40-C41	Bone	7	0.5	0.4	0.0	0.3	(0.1,0.6)	0.0
C30-C31	Nose, Sinuses Etc.	4	0.3	0.2	0.0	0.3	(0.0,0.6)	0.0
C67	Bladder	3	0.2	0.2	0.0	0.3	(0.0,0.7)	0.0
C10	Other Oropharynx	3	0.2	0.2	0.0	0.2	(0.0,0.5)	0.0
C07-C08	Salivary Glands	2	0.2	0.1	0.0	0.2	(-0.1,0.4)	0.0
C09	Tonsil	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C12-C13	Hypopharynx	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C17	Small Intestine	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C51	Vulva	1	0.1	0.1	0.0	0.1	(-0.1,0.3)	0.0
C52	Vagina	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C88	Immunoproliferative Dis.	1	0.1	0.1	0.0	0.1	(-0.1,0.2)	0.0
C58	Placenta	1	0.1	0.1	0.0	0.0	(0.0,0.1)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C69	Eye	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C75	Other Endocrine	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>1,326</b>	<b>100.0</b>	<b>77.7</b>	<b>11.8</b>	<b>106.1</b>	<b>(100.3,112.4)</b>	<b>11.1</b>

Appendix 22: Incidence summary table, Others males, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C18-C21	Colorectal	48	16.8	14.8	3.0	23.8	(16.7,31.1)	3.0
C33-C34	Trachea, Bronchus, Lung	28	9.8	8.7	2.1	14.2	(8.6,20.1)	2.1
C81-C85;C96	Lymphoma	30	10.5	9.3	1.8	14.0	(8.8,20.0)	1.8
C61	Prostate	21	7.4	6.5	1.9	12.8	(7.0,18.8)	1.9
C16	Stomach	17	6.0	5.3	1.4	9.6	(4.7,14.4)	1.4
C44	Other Skin	18	6.3	5.6	0.8	8.0	(4.0,11.7)	0.8
C11	Nasopharynx	13	4.6	4.0	0.6	4.9	(2.1,7.7)	0.6
C91-C95	Leukaemia	14	4.9	4.3	0.3	4.3	(2.0,6.7)	0.3
Others	Other & Unspecified	9	3.2	2.8	0.4	3.9	(1.2,6.5)	0.4
C70-C72	Brain, Nervous System	13	4.6	4.0	0.3	3.8	(1.7,5.9)	0.3
C47; C49	Connective, Soft Tissue	10	3.5	3.1	0.2	3.6	(1.3,5.8)	0.2
C25	Pancreas	6	2.1	1.9	0.4	3.5	(0.8,6.9)	0.4
C67	Bladder	7	2.5	2.2	0.2	2.7	(0.6,4.7)	0.2
C23-C24	Gallbladder Etc.	6	2.1	1.9	0.4	2.7	(0.4,5.0)	0.4
C73	Thyroid	5	1.8	1.5	0.5	2.7	(0.1,5.2)	0.5
C03-C06	Mouth	3	1.1	0.9	0.3	1.7	(-0.4,4.0)	0.3
C32	Larynx	3	1.1	0.9	0.2	1.6	(-0.3,3.4)	0.2
C15	Oesophagus	3	1.1	0.9	0.2	1.4	(-0.4,3.4)	0.2
C90	Multiple Myeloma	2	0.7	0.6	0.3	1.4	(-0.6,3.4)	0.3
C22	Liver	3	1.1	0.9	0.0	1.3	(-0.2,2.6)	0.0
C64	Kidney	3	1.1	0.9	0.1	1.2	(-0.2,2.4)	0.1
C62	Testis	4	1.4	1.2	0.1	1.1	(0.0,2.1)	0.1
C37-C38	Other Thoracic Organs	3	1.1	0.9	0.1	1.1	(-0.1,2.3)	0.1
C40-C41	Bone	3	1.1	0.9	0.1	0.9	(-0.1,2.1)	0.1
C07-C08	Salivary Glands	1	0.4	0.3	0.2	0.8	(-0.8,2.4)	0.2
C10	Other Oropharynx	1	0.4	0.3	0.2	0.8	(-0.8,2.4)	0.2
C50	Breast	1	0.4	0.3	0.1	0.8	(-0.8,2.5)	0.1
C65	Renal Pelvis	1	0.4	0.3	0.2	0.8	(-0.8,2.4)	0.2
C17	Small Intestine	2	0.7	0.6	0.1	0.7	(-0.3,1.8)	0.1
C30-C31	Nose, Sinuses Etc.	2	0.7	0.6	0.1	0.6	(-0.3,1.6)	0.1
C69	Eye	2	0.7	0.6	0.0	0.5	(-0.2,1.3)	0.0
C43	Melanoma Of Skin	1	0.4	0.3	0.0	0.3	(-0.3,1.0)	0.0
C60	Penis	1	0.4	0.3	0.0	0.3	(-0.3,1.0)	0.0
C75	Other Endocrine	1	0.4	0.3	0.0	0.3	(-0.2,0.7)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C01-C02	Tongue	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C12-C13	Hypopharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C63	Other Male Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C88	Immunoproliferative Dis.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>285</b>	<b>100.0</b>	<b>88.0</b>	<b>16.4</b>	<b>132.3</b>	<b>(116.0,149.5)</b>	<b>15.4</b>

Appendix 23: Incidence summary table, Others females, Sabah, 2012-2016

ICD-10	SITE	NO.	%	CR	CR74	ASR	(ASR 95%CL)	CumR
C50	Breast	101	30.5	33.3	5.9	55.9	(43.9,69.3)	5.7
C53	Cervix Uteri	34	10.3	11.2	2.1	20.9	(12.9,29.9)	2.1
C44	Other Skin	21	6.3	6.9	1.9	17.9	(9.4,27.9)	1.9
C18-C21	Colorectal	19	5.7	6.3	1.6	15.7	(7.7,24.9)	1.6
C81-C85;C96	Lymphoma	19	5.7	6.3	0.8	11.5	(5.0,18.7)	0.8
C73	Thyroid	21	6.3	6.9	0.8	9.9	(4.6,15.4)	0.8
C56	Ovary	16	4.8	5.3	0.6	9.8	(3.6,16.7)	0.6
C91-C95	Leukaemia	15	4.5	4.9	0.8	7.2	(3.2,11.4)	0.8
C16	Stomach	8	2.4	2.6	0.6	6.6	(1.3,12.5)	0.7
C54	Corpus Uteri	12	3.6	4.0	0.7	6.2	(2.4,9.8)	0.7
C33-C34	Trachea, Bronchus, Lung	9	2.7	3.0	0.8	5.6	(1.7,9.7)	0.8
C90	Multiple Myeloma	6	1.8	2.0	0.4	5.2	(0.4,10.4)	0.4
Others	Other & Unspecified	8	2.4	2.6	0.5	4.4	(1.0,8.0)	0.5
C11	Nasopharynx	6	1.8	2.0	0.2	4.0	(-0.2,8.7)	0.2
C47; C49	Connective, Soft Tissue	4	1.2	1.3	0.3	3.4	(-0.8,7.9)	0.3
C64	Kidney	4	1.2	1.3	0.4	2.9	(-0.1,6.1)	0.4
C55	Uterus Unspec.	4	1.2	1.3	0.2	2.2	(-0.1,4.3)	0.2
C22	Liver	2	0.6	0.7	0.0	2.1	(-1.7,6.2)	0.0
C69	Eye	2	0.6	0.7	0.0	2.1	(-1.7,6.3)	0.0
C17	Small Intestine	1	0.3	0.3	0.0	1.8	(-1.9,5.9)	0.0
C43	Melanoma Of Skin	2	0.6	0.7	0.3	1.3	(-0.5,3.1)	0.3
C03-C06	Mouth	1	0.3	0.3	0.2	1.1	(-1.2,3.6)	0.2
C30-C31	Nose, Sinuses Etc.	1	0.3	0.3	0.2	1.1	(-1.2,3.6)	0.2
C40-C41	Bone	3	0.9	1.0	0.0	0.9	(-0.1,1.8)	0.0
C70-C72	Brain, Nervous System	3	0.9	1.0	0.0	0.9	(-0.1,1.8)	0.0
C25	Pancreas	1	0.3	0.3	0.1	0.8	(-0.8,2.4)	0.1
C37-C38	Other Thoracic Organs	1	0.3	0.3	0.1	0.8	(-0.8,2.4)	0.1
C67	Bladder	1	0.3	0.3	0.1	0.8	(-0.8,2.4)	0.1
C23-C24	Gallbladder Etc.	1	0.3	0.3	0.1	0.5	(-0.5,1.5)	0.0
C51	Vulva	1	0.3	0.3	0.1	0.5	(-0.5,1.5)	0.0
C52	Vagina	1	0.3	0.3	0.1	0.5	(-0.5,1.5)	0.1
C75	Other Endocrine	1	0.3	0.3	0.1	0.5	(-0.5,1.5)	0.0
C88	Immunoproliferative Dis.	1	0.3	0.3	0.0	0.4	(-0.4,1.3)	0.0
C07-C08	Salivary Glands	1	0.3	0.3	0.0	0.2	(0.2,0.7)	0.0
C00	Lip	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C01-C02	Tongue	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C09	Tonsil	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C10	Other Oropharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C12-C13	Hypopharynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C14	Pharynx Unspec.	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C15	Oesophagus	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C32	Larynx	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C45	Mesothelioma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C46	Kaposi Sarcoma	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C57	Other Female Genital	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C58	Placenta	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C65	Renal Pelvis	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C66	Ureter	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C68	Other Urinary Organs	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
C74	Adrenal Gland	0	0.0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>All</b>	<b>All sites total</b>	<b>331</b>	<b>100.0</b>	<b>109.0</b>	<b>19.9</b>	<b>205.6</b>	<b>(183.4,238.4)</b>	<b>18.2</b>

**Appendix 24: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016**

District	Total	MALE						FEMALE					
		No.	CR	CR74	ASR	(95% CL)	CumR	No.	CR	CR74	ASR	(95% CL)	CumR
<b>1. Breast</b>													
Kota Kinabalu	428	3	0.3	0.1	0.4	(-0.1,0.7)	0.1	425	43.3	5.6	52.0	(47.1,57.2)	5.5
Sandakan	157	0	0.0	0.0	0.0	(0.0,0.0)	0.0	157	21.6	2.8	26.8	(22.6,31.2)	2.7
Tawau	128	4	0.6	0.1	0.8	(0.0,1.6)	0.1	124	18.5	2.5	23.3	(19.2,27.8)	2.5
Penampang	70	3	1.0	0.2	1.5	(-0.2,3.4)	0.2	67	23.1	3.4	29.0	(21.9,36.0)	3.3
Keningau	62	1	0.3	0.0	0.3	(-0.3,0.8)	0.0	61	16.3	1.9	19.8	(14.8,25.0)	1.9
Tuaran	55	0	0.0	0.0	0.0	(0.0,0.0)	0.0	55	20.2	3.2	26.2	(18.6,32.7)	3.0
Papar	51	0	0.0	0.0	0.0	(0.0,0.0)	0.0	51	16.6	2.5	23.9	(17.3,31.2)	2.5
Lahad Datu	51	0	0.0	0.0	0.0	(0.0,0.0)	0.0	51	14.2	1.8	17.3	(12.4,22.5)	1.8
Beaufort	28	0	0.0	0.0	0.0	(0.0,0.0)	0.0	28	16.0	2.5	23.0	(1.4,32.5)	2.5
Kota Belud	27	0	0.0	0.0	0.0	(0.0,0.0)	0.0	27	11.3	2.1	16.2	(1.0,22.9)	2.1
Ranau	23	0	0.0	0.0	0.0	(0.0,0.0)	0.0	23	9.7	1.0	10.4	(6.1,14.8)	1.0
Semporna	19	0	0.0	0.0	0.0	(0.0,0.0)	0.0	19	7.0	1.0	9.7	(5.1,14.6)	1.0
Tambunan	17	0	0.0	0.0	0.0	(0.0,0.0)	0.0	17	18.4	2.8	22.2	(11.9,34.6)	2.9
Sipitang	16	0	0.0	0.0	0.0	(0.0,0.0)	0.0	16	17.8	3.0	25.6	(12.5,38.9)	3.0
Tenom	16	0	0.0	0.0	0.0	(0.0,0.0)	0.0	16	11.5	1.5	15.0	(7.4,22.6)	1.5
Kudat	15	1	0.5	0.1	0.6	(-0.8,2.4)	0.0	14	6.8	1.0	8.9	(4.1,13.9)	1.0
Beluran	13	0	0.0	0.0	0.0	(0.0,0.0)	0.0	13	8.1	0.8	9.8	(4.1,14.9)	0.8
Kota Marudu	12	0	0.0	0.0	0.0	(0.0,0.0)	0.0	12	6.8	0.9	8.6	(3.5,13.4)	0.9
Kuala Penyu	8	0	0.0	0.0	0.0	(0.0,0.0)	0.0	8	15.4	2.9	24.1	(6.6,43.9)	3.1
Pitas	6	0	0.0	0.0	0.0	(0.0,0.0)	0.0	6	6.0	0.7	7.1	(1.0,13.0)	0.7
Putatan	6	0	0.0	0.0	0.0	(0.0,0.0)	0.0	6	4.3	0.4	5.9	(1.1,10.4)	0.4
Kinabatangan	6	0	0.0	0.0	0.0	(0.0,0.0)	0.0	6	3.6	0.4	4.3	(0.8,7.7)	0.4
Kunak	3	0	0.0	0.0	0.0	(0.0,0.0)	0.0	3	3.3	0.9	5.4	(-0.7,10.6)	0.8
Nabawan	1	0	0.0	0.0	0.0	(0.0,0.0)	0.0	1	1.4	0.1	1.5	(-1.4,4.4)	0.1
<b>2. Colorectal</b>													
Kota Kinabalu	372	222	22.5	3.6	29.6	(25.6,33.6)	3.6	150	15.3	2.6	20.8	(17.6,24.5)	2.6
Sandakan	136	84	11.2	1.8	14.8	(11.8,18.5)	1.8	52	7.2	0.9	9.1	(6.7,12.0)	0.9
Tawau	111	67	9.9	1.9	13.6	(10.3,17.0)	1.8	44	6.6	0.9	8.9	(6.2,11.7)	0.9
Penampang	56	32	11.0	2.0	15.2	(9.8,20.4)	1.9	24	8.3	1.5	11.0	(6.5,15.5)	1.5
Keningau	47	26	6.6	1.4	9.9	(6.1,14.2)	1.4	21	5.6	0.9	7.6	(4.3,11.1)	0.9
Tuaran	44	21	7.5	1.4	10.7	(5.9,15.5)	1.4	23	8.5	1.5	12.8	(7.4,18.1)	1.5
Papar	38	26	8.2	2.2	14.6	(8.8,20.2)	2.2	12	3.9	1.2	6.8	(3.0,11.1)	1.3
Kudat	30	19	8.9	0.9	12.7	(6.7,18.0)	0.9	11	5.3	1.4	9.4	(3.8,15.3)	1.4
Lahad Datu	29	20	5.4	0.8	8.2	(4.6,12.2)	0.8	9	2.5	0.3	3.7	(1.2,6.1)	0.3
Tenom	25	13	8.8	1.2	12.8	(5.5,19.7)	1.2	12	8.6	1.7	12.3	(5.1,19.6)	1.7
Beaufort	25	13	7.2	1.5	14.1	(7.1,24.1)	1.5	12	6.9	1.1	11.0	(4.7,17.6)	1.2
Ranau	22	9	3.6	0.6	5.1	(1.6,8.4)	0.6	13	5.5	0.9	7.0	(3.1,11.0)	0.9
Kota Belud	21	14	5.9	1.5	9.5	(4.3,14.4)	1.5	7	2.9	0.6	5.0	(1.2,8.6)	0.6
Semporna	19	12	4.5	0.7	6.6	(2.7,11.0)	0.7	7	2.6	0.2	2.9	(0.7,5.0)	0.2
Kota Marudu	16	9	4.9	0.8	7.2	(2.4,12.3)	0.8	7	4.0	0.7	5.7	(1.2,9.9)	0.7
Kuala Penyu	14	10	18.7	2.6	29.3	(9.7,49.5)	2.7	4	7.7	0.5	10.7	(-0.1,26.2)	0.5
Tambunan	11	6	6.4	0.1	8.9	(1.6,14.2)	0.1	5	5.4	0.8	6.8	(0.7,12.1)	0.8
Beluran	8	5	2.8	0.4	3.5	(0.4,6.7)	0.4	3	1.9	0.4	2.5	(-0.4,5.0)	0.4
Putatan	8	5	3.2	0.5	5.1	(0.5,10.0)	0.5	3	2.1	0.3	2.8	(-0.4,5.8)	0.3
Sipitang	6	3	3.3	0.7	6.9	(-1.1,16.5)	0.8	3	3.3	0.9	6.1	(-1.2,13.3)	0.8
Kunak	5	3	3.2	0.3	3.3	(-0.5,7.1)	0.3	2	2.2	0.6	4.5	(-1.5,9.5)	0.5
Pitas	4	1	1.0	0.0	1.8	(-1.9,5.9)	0.0	3	3.0	0.5	4.2	(-0.8,9.3)	0.5
Nabawan	3	1	1.3	0.2	1.5	(-1.4,4.2)	0.1	2	2.7	0.7	4.0	(-1.4,8.8)	0.7
Kinabatangan	3	1	0.6	0.1	0.6	(-0.6,2.0)	0.1	2	1.2	0.1	1.6	(-0.9,2.8)	0.0

**Appendix 25: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue)**

District	Total	MALE						FEMALE					
		No.	CR	CR74	ASR	(95% CL)	CumR	No.	CR	CR74	ASR	(95% CL)	CumR
<b>3. Trachea, Bronchus and Lung</b>													
Kota Kinabalu	269	152	15.4	2.9	21.2	(17.8,24.7)	2.8	117	11.9	2.1	16.3	(13.4,19.5)	2.1
Sandakan	100	66	8.8	1.6	11.9	(9.1,15.0)	1.6	34	4.7	0.8	6.9	(4.6,9.5)	0.8
Tawau	93	63	9.3	1.5	12.3	(9.3,15.6)	1.5	30	4.5	0.9	6.8	(4.3,9.3)	0.8
Penampang	44	29	10.0	1.7	13.6	(8.3,18.2)	1.6	15	5.2	0.6	6.4	(3.1,9.8)	0.6
Keningau	35	17	4.3	0.8	6.8	(3.5,10.3)	0.9	18	4.8	0.9	7.3	(3.9,10.9)	0.9
Beaufort	26	15	8.4	1.6	13.6	(6.7,21.7)	1.5	11	6.3	2.3	12.2	(5.0,20.6)	2.4
Tuaran	24	15	5.3	1.0	8.1	(3.8,12.4)	1.0	9	3.3	0.9	5.9	(1.9,9.6)	0.9
Kota Belud	23	14	5.9	1.4	9.5	(4.3,14.7)	1.4	9	3.8	0.9	6.4	(2.2,10.9)	0.9
Papar	23	20	6.3	1.4	10.7	(5.9,15.7)	1.4	3	1.0	0.1	1.4	(-0.2,3.2)	0.1
Kota Marudu	17	9	4.9	0.7	6.8	(2.2,11.3)	0.7	8	4.5	0.9	7.2	(2.1,12.1)	0.9
Ranau	16	13	5.2	1.0	7.5	(3.2,11.6)	1.0	3	1.3	0.2	1.6	(-0.4,3.7)	0.2
Semporna	15	7	2.6	0.6	4.2	(1.0,7.8)	0.6	8	3.0	1.1	5.8	(1.7,9.8)	1.1
Kudat	14	10	4.7	1.1	6.9	(2.4,11.1)	1.0	4	1.9	0.3	3.3	(0.0,6.7)	0.3
Lahad Datu	14	10	2.7	0.7	3.9	(1.4,6.4)	0.7	4	1.1	0.1	1.7	(0.0,3.3)	0.1
Sipitang	12	11	11.9	2.5	20.2	(8.4,35.6)	2.7	1	1.1	0.0	2.0	(-1.9,5.9)	0.0
Beluran	11	7	3.9	0.5	6.1	(1.6,11.0)	0.5	4	2.5	0.9	4.7	(0.1,9.3)	0.8
Tenom	10	7	4.7	0.7	7.1	(1.7,12.5)	0.7	3	2.2	0.5	4.0	(-0.7,8.8)	0.5
Tambunan	7	2	2.1	0.4	4.0	(-2.1,10.8)	0.5	5	5.4	1.1	7.4	(0.7,14.4)	1.2
Pitas	6	4	3.9	0.6	6.5	(0.0,13.6)	0.6	2	2.0	0.6	3.0	(-1.4,7.8)	0.6
Kuala Penyu	5	4	7.5	2.9	17.3	(0.0,36.0)	3.0	1	1.9	0.8	5.0	(-5.8,17.8)	1.0
Kinabatangan	4	3	1.7	0.4	2.4	(-0.4,5.0)	0.4	1	0.6	0.0	0.0	(-0.1,2.8)	0.0
Kunak	3	2	2.2	1.0	4.7	(-2.1,12.1)	1.0	1	1.1	0.1	1.4	(-1.4,4.2)	0.1
Putatan	2	2	1.3	0.2	2.0	(-0.8,4.7)	0.2	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Nabawan	1	1	1.3	0.2	1.5	(-1.4,4.2)	0.1	0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>4. Lymphoma</b>													
Kota Kinabalu	235	147	14.9	1.9	17.8	(14.8,20.8)	1.9	88	9.0	1.0	10.4	(8.2,12.7)	1.0
Sandakan	54	30	4.0	0.6	4.9	(3.1,6.7)	0.6	24	3.3	0.4	3.9	(2.3,5.5)	0.4
Tawau	45	26	3.8	0.5	4.5	(2.7,6.5)	0.5	19	2.8	0.5	3.8	(2.0,5.6)	0.4
Penampang	30	20	6.9	1.0	8.5	(4.7,12.3)	0.9	10	3.5	0.6	4.2	(1.5,6.8)	0.6
Papar	30	17	5.4	0.8	7.3	(3.7,11.3)	0.8	13	4.2	0.7	5.8	(2.5,9.3)	0.7
Tuaran	25	11	3.9	0.7	6.2	(2.3,9.6)	0.7	14	5.1	0.7	6.4	(2.8,9.7)	0.7
Beaufort	21	11	6.1	0.7	9.4	(3.8,16.7)	0.7	10	5.7	1.0	8.9	(3.1,15.0)	1.0
Keningau	19	12	3.1	0.4	3.9	(1.6,6.2)	0.4	7	1.9	0.2	2.2	(0.6,3.7)	0.2
Lahad Datu	18	12	3.2	0.4	4.1	(1.7,6.6)	0.4	6	1.7	0.2	2.0	(0.3,3.6)	0.2
Kota Belud	16	10	4.2	0.6	5.6	(2.0,9.4)	0.6	6	2.5	0.5	3.2	(0.5,6.1)	0.5
Kudat	16	6	2.8	0.3	3.3	(0.7,6.0)	0.3	10	4.9	1.2	7.5	(2.6,12.7)	1.2
Kota Marudu	14	7	3.8	0.7	5.5	(1.2,9.8)	0.7	7	4.0	0.6	5.0	(1.0,8.9)	0.6
Ranau	10	8	3.2	0.5	4.1	(1.0,7.0)	0.5	2	0.8	0.1	0.6	(-0.2,1.4)	0.0
Sipitang	8	5	5.4	0.6	6.1	(0.7,11.7)	0.6	3	3.3	0.6	3.9	(-0.8,8.8)	0.6
Semporna	7	2	0.8	0.1	0.7	(-0.3,1.7)	0.1	5	1.8	0.2	1.9	(0.2,3.6)	0.2
Tenom	7	4	2.7	0.4	4.7	(0.0,9.1)	0.4	3	2.2	0.3	3.5	(-0.6,7.4)	0.3
Beluran	6	5	2.8	0.3	3.0	(0.4,5.7)	0.3	1	0.6	0.1	0.7	(-0.7,2.3)	0.1
Pitas	5	3	2.9	0.7	4.0	(-0.8,8.9)	0.7	2	2.0	0.2	2.6	(-1.0,6.2)	0.2
Tambunan	5	2	2.1	0.3	3.2	(-1.4,8.0)	0.3	3	3.2	0.5	4.2	(-0.8,9.3)	0.5
Kuala Penyu	4	1	1.9	0.0	2.2	(-1.9,5.9)	0.0	3	5.8	1.1	8.6	(-3.2,22.3)	1.2
Putatan	4	3	1.9	0.4	2.7	(-0.5,6.0)	0.4	1	0.7	0.0	0.7	(-0.7,2.1)	0.0
Nabawan	3	1	1.3	0.1	1.0	(-0.9,2.8)	0.1	2	2.7	0.2	2.6	(-1.1,6.3)	0.2
Kinabatangan	3	2	1.1	0.1	1.3	(-0.5,3.2)	0.1	1	0.6	0.0	0.0	(-0.4,1.3)	0.0
Kunak	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0

*Appendix 26: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue)*

District	FEMALE					
	NO.	CR	CR74	ASR	(95% CL)	CumR
<b>5. Cervix Uteri</b>						
Kota Kinabalu	197	20.1	2.4	23.5	(20.2,27.0)	2.4
Sandakan	73	10.0	1.3	12.3	(9.5,15.4)	1.3
Tawau	58	8.6	1.3	11.3	(8.3,14.3)	1.2
Keningau	36	9.6	1.4	11.9	(7.9,16.0)	1.4
Lahad Datu	21	5.8	1.0	8.2	(4.6,12.5)	1.0
Tuaran	21	7.7	1.2	10.2	(5.6,14.5)	1.2
Penampang	20	6.9	0.9	8.3	(4.5,11.8)	0.9
Papar	18	5.9	1.2	9.6	(5.0,14.5)	1.2
Kota Belud	14	5.9	0.8	7.7	(3.5,11.8)	0.8
Semporna	12	4.4	0.5	5.5	(2.4,8.6)	0.5
Kudat	12	5.8	0.7	7.2	(3.0,11.4)	0.7
Beaufort	12	6.9	1.4	11.0	(4.5,18.0)	1.5
Tambunan	12	13.0	2.1	16.4	(6.7,26.0)	2.0
Tenom	10	7.2	1.0	9.4	(3.5,15.6)	1.0
Kota Marudu	8	4.5	0.8	6.1	(1.7,10.7)	0.8
Beluran	7	4.4	0.6	5.7	(1.3,10.0)	0.6
Ranau	7	2.9	0.4	3.5	(0.9,6.1)	0.4
Nabawan	7	9.5	1.4	12.9	(2.9,22.5)	1.4
Sipitang	6	6.7	1.4	11.5	(1.9,21.8)	1.5
Putatan	5	3.6	0.4	4.5	(1.1,6.3)	0.3
Kinabatangan	5	3.0	0.7	0.7	(0.5,10.4)	0.8
Pitas	4	4.0	0.5	5.1	(-0.2,10.3)	0.5
Kunak	3	3.3	0.3	3.8	(-0.5,8.2)	0.3
Kuala Penyu	2	3.9	0.4	4.8	(-1.9,11.5)	0.4

DISTRICT	TOTAL	MALE						FEMALE					
		NO.	CR	CR74	ASR	(95% CL)	CumR	NO.	CR	CR74	ASR	(95% CL)	CumR
<b>6. Nasopharynx</b>													
Kota Kinabalu	174	127	12.9	1.5	14.6	(12.0,17.2)	1.5	47	4.8	0.5	5.6	(4.0,7.3)	0.5
Sandakan	44	31	4.1	0.6	5.0	(3.2,6.9)	0.6	13	1.8	0.2	2.1	(1.0,3.4)	0.2
Penampang	41	30	10.3	1.4	12.2	(7.8,16.9)	1.4	11	3.8	0.4	4.1	(1.6,6.5)	0.4
Keningau	35	26	6.6	1.1	8.5	(5.3,12.1)	1.1	9	2.4	0.4	3.4	(1.1,5.8)	0.4
Tawau	22	11	1.6	0.2	1.8	(0.7,2.9)	0.2	11	1.6	0.2	1.8	(0.7,3.0)	0.2
Ranau	22	16	6.4	0.8	7.3	(3.5,10.8)	0.7	6	2.5	0.3	3.1	(0.4,5.9)	0.3
Beaufort	22	14	7.8	1.4	11.5	(5.2,17.7)	1.4	8	4.6	0.9	7.5	(2.1,13.2)	0.9
Papar	22	18	5.7	1.0	8.1	(4.3,12.1)	1.0	4	1.3	0.2	2.0	(0.0,4.4)	0.2
Tuaran	19	12	4.3	0.6	5.6	(2.3,8.7)	0.6	7	2.6	0.5	4.1	(1.0,7.1)	0.5
Kota Marudu	12	9	4.9	0.6	6.0	(1.8,10.2)	0.6	3	1.7	0.2	2.2	(-0.4,4.7)	0.2
Kota Belud	11	10	4.2	0.4	4.8	(1.6,8.0)	0.4	1	0.4	0.1	0.5	(-0.5,1.6)	0.1
Tambunan	10	7	7.5	1.1	9.5	(1.9,18.3)	1.2	3	3.2	0.7	4.6	(-0.7,10.1)	0.7
Beluran	8	7	3.9	0.4	4.3	(1.0,7.6)	0.4	1	0.6	0.1	0.7	(-0.7,2.3)	0.1
Lahad Datu	8	4	1.1	0.1	1.2	(0.0,2.5)	0.1	4	1.1	0.1	1.2	(0.0,2.3)	0.1
Kudat	7	3	1.4	0.3	2.0	(-0.3,4.1)	0.3	4	1.9	0.6	4.0	(0.1,7.9)	0.6
Tenom	7	5	3.4	0.5	4.0	(0.2,8.0)	0.5	2	1.4	0.1	1.4	(-0.6,3.3)	0.1
Pitas	6	3	2.9	0.3	2.9	(-0.5,6.4)	0.3	3	3.0	0.3	2.7	(-0.5,6.0)	0.3
Putatan	6	5	3.2	0.4	4.2	(0.4,7.7)	0.4	1	0.7	0.0	0.5	(-0.5,1.5)	0.0
Sipitang	6	6	6.5	1.4	11.1	(1.8,22.0)	1.5	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Kinabatangan	5	4	2.2	0.2	2.6	(0.1,5.1)	0.2	1	0.6	0.1	0.1	(-0.6,1.7)	0.0
Kuala Penyu	4	4	7.5	1.9	11.1	(0.0,24.0)	2.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Nabawan	2	1	1.3	0.2	1.5	(-1.4,4.2)	0.1	1	1.4	0.1	1.0	(-1.0,3.0)	0.1
Kunak	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Semporna	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0

*Appendix 27: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue)*

District	Total	MALE						FEMALE					
		No.	CR	CR74	ASR	(95% CL)	CumR	No.	CR	CR74	ASR	(95% CL)	CumR
<b>7. Leukemia</b>													
Kota Kinabalu	130	75	7.6	0.7	8.6	(6.6,10.6)	0.7	55	5.6	0.7	6.7	(4.9,8.6)	0.7
Sandakan	43	21	2.8	0.3	3.1	(1.8,4.6)	0.3	22	3.0	0.3	3.6	(2.1,5.3)	0.3
Tawau	33	17	2.5	0.2	2.7	(1.4,4.1)	0.2	16	2.4	0.3	3.1	(1.5,4.8)	0.3
Tuaran	23	9	3.2	0.4	3.8	(1.1,6.6)	0.4	14	5.1	0.5	5.2	(2.4,7.9)	0.5
Ranau	21	11	4.4	0.4	4.6	(1.9,7.4)	0.4	10	4.2	0.6	5.5	(2.0,9.2)	0.6
Kota Marudu	18	13	7.1	0.8	8.0	(3.4,12.8)	0.8	5	2.8	0.1	2.8	(0.3,5.2)	0.1
Papar	17	10	3.2	0.3	3.1	(1.0,5.1)	0.3	7	2.3	0.2	2.3	(0.6,4.1)	0.2
Lahad Datu	16	9	2.4	0.2	2.4	(0.8,4.0)	0.2	7	1.9	0.2	2.2	(0.6,3.8)	0.2
Penampang	15	10	3.4	0.5	3.9	(1.4,6.4)	0.5	5	1.7	0.1	1.9	(0.2,3.5)	0.1
Kota Belud	14	4	1.7	0.2	2.1	(0.0,4.2)	0.2	10	4.2	0.3	3.7	(1.4,6.1)	0.3
Kudat	11	7	3.3	0.2	3.2	(0.8,5.7)	0.2	4	1.9	0.3	2.6	(-0.1,5.3)	0.3
Keningau	7	4	1.0	0.1	0.9	(0.0,1.7)	0.0	3	0.8	0.0	0.8	(-0.1,1.7)	0.0
Kuala Penyu	7	6	11.2	1.7	14.5	(2.4,27.1)	1.8	1	1.9	0.2	1.9	(-1.9,5.9)	0.2
Tambunan	7	5	5.4	0.5	6.2	(0.5,12.3)	0.5	2	2.2	0.1	2.9	(-1.2,7.2)	0.1
Semporna	7	6	2.2	0.3	3.0	(0.4,5.7)	0.3	1	0.4	0.0	0.4	(-0.4,1.1)	0.0
Beaufort	6	2	1.1	0.1	1.0	(-0.4,2.5)	0.1	4	2.3	0.5	3.1	(-0.2,6.6)	0.5
Beluran	6	2	1.1	0.2	1.7	(-0.7,4.2)	0.2	4	2.5	0.3	3.8	(0.0,8.0)	0.3
Pitas	6	5	4.9	0.3	4.7	(0.5,8.8)	0.2	1	1.0	0.1	0.8	(-0.7,2.3)	0.0
Sipitang	5	1	1.1	0.1	0.8	(-0.7,2.2)	0.1	4	4.5	0.2	4.2	(0.0,8.5)	0.2
Tenom	5	2	1.4	0.0	1.6	(-0.7,4.0)	0.0	3	2.2	0.1	1.9	(-0.3,4.1)	0.1
Putatan	2	1	0.6	0.0	0.5	(-0.5,1.6)	0.0	1	0.7	0.1	0.9	(-0.9,2.7)	0.1
Kinabatangan	1	0	0.0	0.0	0.0	(0.0,0.0)	0.0	1	0.6	0.0	0.0	(-0.5,1.5)	0.0
Nabawan	1	1	1.3	0.1	1.3	(-1.2,3.7)	0.1	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Kunak	1	1	1.1	0.1	1.3	(-1.3,3.9)	0.1	0	0.0	0.0	0.0	(0.0,0.0)	0.0
<b>8. Stomach</b>													
Beluran	128	78	7.9	1.2	10.7	(8.2,13.0)	1.2	50	5.1	0.8	6.8	(4.9,8.8)	0.8
Kuala Penyu	35	19	7.6	1.3	12.0	(6.5,17.6)	1.2	16	6.7	1.0	10.5	(4.9,14.9)	1.1
Sipitang	32	21	2.8	0.5	3.8	(2.2,5.5)	0.5	11	1.5	0.2	2.1	(0.8,3.4)	0.2
Semporna	30	24	6.1	0.7	8.4	(5.2,12.0)	0.7	6	1.6	0.3	2.5	(0.5,4.5)	0.3
Kota Marudu	26	15	5.2	1.1	7.4	(3.6,11.2)	1.1	11	3.8	0.6	5.2	(2.1,8.2)	0.6
Tambunan	20	13	1.9	0.3	2.7	(1.3,4.4)	0.3	7	1.0	0.1	1.4	(0.3,2.5)	0.1
Putatan	15	9	3.2	0.7	5.4	(1.7,8.9)	0.7	6	2.2	0.3	3.3	(0.6,6.1)	0.3
Tawau	10	5	2.8	0.4	5.2	(0.7,11.6)	0.4	5	2.9	0.8	5.4	(0.6,10.7)	0.8
Kudat	10	7	2.2	0.5	3.7	(0.9,6.7)	0.6	3	1.0	0.2	1.3	(-0.3,2.9)	0.2
Nabawan	9	6	6.5	2.5	12.7	(2.4,23.6)	2.5	3	3.3	0.8	5.9	(-1.2,13.3)	0.8
Keningau	8	4	4.3	0.8	6.0	(0.0,11.6)	0.8	4	4.3	0.8	6.2	(0.0,13.3)	0.8
Kunak	8	6	4.1	0.6	6.3	(1.1,11.5)	0.6	2	1.4	0.3	2.5	(-1.1,6.3)	0.3
Ranau	8	3	5.6	0.7	8.3	(-1.6,18.4)	0.7	5	9.6	2.6	18.4	(1.9,39.1)	2.7
Kota Belud	7	4	1.9	0.7	3.1	(0.0,5.8)	0.7	3	1.5	0.2	2.0	(-0.3,4.2)	0.1
Kinabatangan	7	3	1.3	0.3	2.0	(-0.4,4.5)	0.3	4	1.7	0.5	3.1	(0.1,6.3)	0.5
Kota Kinabalu	6	5	2.7	0.2	3.7	(0.4,7.3)	0.2	1	0.6	0.0	0.8	(-0.8,2.4)	0.0
Penampang	5	2	0.5	0.0	0.8	(-0.3,2.0)	0.0	3	0.8	0.1	1.2	(-0.2,2.5)	0.1
Lahad Datu	4	1	0.6	0.1	0.6	(-0.6,1.8)	0.1	3	1.9	0.2	2.2	(-0.3,4.4)	0.2
Sandakan	2	2	1.1	0.5	2.1	(-0.8,4.8)	0.5	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Beaufort	2	1	0.6	0.1	0.8	(-0.8,2.4)	0.1	1	0.7	0.1	1.0	(-1.0,3.0)	0.1
Tenom	1	1	0.4	0.0	0.7	(-0.8,2.4)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Tuaran	1	0	0.0	0.0	0.0	(0.0,0.0)	0.0	1	1.1	0.2	1.5	(-1.5,9.5)	0.5
Papar	1	1	1.3	0.6	2.5	(-1.9,5.9)	0.5	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Pitas	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0




*Appendix 28: Incidence summary table for 10 selected cancer sites by district and sex, Sabah, 2012-2016 (continue)*





District	Total	MALE						FEMALE					
		No.	CR	CR74	ASR	(95% CL)	CumR	No.	CR	CR74	ASR	(95% CL)	CumR
<b>9. Other Skin</b>													
Kota Kinabalu	168	77	7.8	1.3	10.7	(8.2,13.1)	1.3	91	9.3	1.4	12.5	(10.1,15.4)	1.4
Sandakan	28	18	2.4	0.4	3.2	(1.7,4.9)	0.4	10	1.4	0.2	1.9	(0.7,3.1)	0.2
Tawau	25	10	1.5	0.3	2.1	(0.8,3.6)	0.3	15	2.2	0.4	3.8	(1.9,5.8)	0.4
Kudat	15	8	3.8	0.4	5.2	(1.5,8.5)	0.4	7	3.4	0.6	5.2	(1.2,9.2)	0.6
Ranau	14	7	2.8	0.5	4.5	(1.1,7.8)	0.5	7	2.9	0.5	4.4	(1.0,7.4)	0.5
Keningau	13	5	1.3	0.2	1.7	(0.2,3.3)	0.2	8	2.1	0.3	3.3	(1.0,5.6)	0.3
Beaufort	9	5	2.8	0.1	4.4	(0.4,10.2)	0.1	4	2.3	0.5	4.5	(0.0,9.4)	0.5
Papar	8	5	1.6	0.2	2.4	(0.1,5.0)	0.2	3	1.0	0.3	1.5	(-0.2,3.3)	0.2
Tuaran	8	2	0.7	0.0	0.9	(-0.4,2.1)	0.0	6	2.2	0.5	3.8	(0.7,6.8)	0.5
Lahad Datu	7	5	1.3	0.4	2.6	(0.3,5.0)	0.4	2	0.6	0.1	1.0	(-0.4,2.3)	0.1
Kota Belud	7	1	0.4	0.1	0.5	(-0.5,1.6)	0.1	6	2.5	0.2	4.1	(0.8,7.3)	0.2
Kota Marudu	6	4	2.2	0.7	3.6	(0.0,7.1)	0.7	2	1.1	0.2	2.0	(-0.8,4.8)	0.2
Beluran	6	3	1.7	0.3	2.8	(-0.5,6.2)	0.3	3	1.9	0.3	3.2	(-0.5,6.6)	0.3
Kuala Penyu	5	4	7.5	2.3	12.2	(-0.4,24.7)	2.3	1	1.9	0.8	5.0	(-5.8,17.8)	1.0
Penampang	5	1	0.3	0.1	0.5	(-0.5,1.5)	0.1	4	1.4	0.2	1.8	(0.0,3.6)	0.2
Kinabatangan	3	3	1.7	0.2	2.1	(-0.3,4.5)	0.2	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Tenom	3	2	1.4	0.4	2.0	(-0.9,5.1)	0.4	1	0.7	0.1	0.9	(-1.0,3.0)	0.1
Sipitang	2	1	1.1	0.1	1.5	(-1.4,4.4)	0.1	1	1.1	0.5	2.0	(-1.9,5.9)	0.5
Pitas	1	0	0.0	0.0	0.0	(0.0,0.0)	0.0	1	1.0	0.5	1.8	(-1.9,5.9)	0.5
Semporna	1	0	0.0	0.0	0.0	(0.0,0.0)	0.0	1	0.4	0.2	0.8	(-0.8,2.4)	0.2
Tambunan	1	1	1.1	0.2	1.8	(-1.9,5.9)	0.2	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Kunak	1	1	1.1	0.0	2.0	(-1.9,5.9)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Putatan	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0
Nabawan	0	0	0.0	0.0	0.0	(0.0,0.0)	0.0	0	0.0	0.0	0.0	(0.0,0.0)	0.0

District	MALE					
	NO.	CR	CR74	ASR	(95% CL)	CumR
<b>10. Prostate</b>						
Kota Kinabalu	118	12.0	2.5	18.1	(14.7,21.3)	2.5
Tawau	23	3.4	0.7	5.3	(3.2,7.7)	0.7
Sandakan	20	2.7	0.5	3.9	(2.3,5.9)	0.5
Penampang	16	5.5	1.3	8.2	(4.0,11.7)	1.3
Tuaran	12	4.3	1.0	7.7	(3.1,11.3)	1.0
Papar	9	2.8	0.6	5.4	(1.9,9.4)	0.6
Keningau	9	2.3	0.6	4.1	(1.5,7.0)	0.6
Lahad Datu	8	2.1	0.7	4.1	(1.2,7.2)	0.7
Beaufort	7	3.9	1.5	7.9	(2.0,13.5)	1.4
Kudat	7	3.3	1.0	5.9	(1.4,10.2)	1.0
Ranau	6	2.4	0.9	4.2	(0.7,7.5)	0.8
Semporna	5	1.9	0.5	3.1	(0.3,6.2)	0.5
Pitas	4	3.9	0.6	7.4	(0.2,15.8)	0.7
Beluran	4	2.3	0.4	4.0	(0.1,8.3)	0.4
Kuala Penyu	3	5.6	2.0	14.2	(-3.1,31.1)	2.0
Tenom	3	2.0	0.6	3.5	(-0.5,7.9)	0.7
Nabawan	2	2.5	1.1	5.5	(-2.1,12.1)	1.0
Sipitang	2	2.2	0.3	4.2	(-1.9,11.2)	0.3
Kota Belud	2	0.8	0.1	1.0	(-0.4,1.25)	0.0
Kunak	1	1.1	0.4	2.5	(-2.9,8.9)	0.5
Putatan	1	0.6	0.3	1.5	(-1.4,4.4)	0.2
Kinabatangan	1	0.6	0.0	1.1	(-0.8,2.4)	0.0
Kota Marudu	1	0.5	0.0	0.9	(-1.0,3.0)	0.0
Tambunan	1	1.1	0.0	1.5	(-1.3,3.9)	0.0



**Appendix 29: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016**



**Appendix 30: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016 (continue)**



**Appendix 31: Age-standardised incidence rate (ASR) for 10 selected cancers, Sabah, 2012-2016 (continue)**



**Appendix 32: Number of new cancer cases by site and age group, all residents, Male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	2	0	0	0	0	0	0	1	2	0	6	3	2	8	5	8	5	1	0	0.1	C00
Tongue	48	0	0	0	0	0	0	1	2	0	6	3	2	8	5	8	5	4	4	1.2	C01-02
Mouth	31	0	0	0	0	0	0	1	0	0	1	2	3	5	5	3	4	7	0.8	C03-06	
Salivary glands	20	0	0	1	0	2	2	0	1	0	1	2	2	2	2	1	4	0	0.5	C07-08	
Tonsil	8	0	0	0	0	0	0	0	0	0	1	0	2	2	0	1	1	1	0.2	C09	
Other oropharynx	11	0	0	0	0	0	0	0	0	0	0	3	0	0	3	1	1	4	0.3	C10	
Nasopharynx	353	0	0	0	14	12	4	10	11	16	34	49	64	54	34	23	16	12	9.2	C11	
Hypopharynx	12	0	0	0	0	0	0	1	0	0	1	0	1	2	2	1	2	2	0.3	C12-13	
Pharynx unspecified	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0.1	C14	
Oesophagus	60	0	0	0	0	0	0	1	0	2	0	4	7	6	14	7	13	6	1.6	C15	
Stomach	232	0	0	0	0	0	2	5	1	3	10	18	17	25	36	27	34	54	6	C16	
Small intestine	17	0	0	0	0	0	0	0	0	0	4	2	3	2	3	0	1	2	0.4	C17	
Colon	285	0	0	0	0	0	1	3	5	11	13	17	29	40	58	34	31	43	7.4	C18	
Rectum	318	0	0	0	0	0	4	1	3	12	8	26	36	51	53	34	38	52	8.3	C19-20	
Anus	19	0	0	0	0	0	0	0	0	0	1	4	3	3	1	1	4	2	0.5	C21	
Liver	183	0	2	1	0	0	1	1	3	5	5	11	22	32	35	27	14	24	4.8	C22	
Gallbladder etc.	44	0	0	0	0	0	0	1	1	1	1	8	8	7	5	5	4	3	1.1	C23-24	
Pancreas	67	0	0	0	0	0	0	0	1	2	1	6	8	9	13	13	8	6	1.7	C25	
Nose, sinuses etc.	30	0	0	0	0	1	1	0	1	1	2	2	10	2	5	3	1	1	0.8	C30-31	
Larynx	60	0	0	0	0	0	0	0	0	1	1	4	7	6	12	11	12	1.6	C32		
Trachea, bronchus and lung	483	0	0	0	0	0	1	1	5	10	20	37	47	81	89	66	67	59	12.6	C33-34	
Other thoracic organs	22	0	0	0	0	2	1	0	0	0	1	0	2	5	4	4	2	1	0.6	C37-38	
Bone	35	0	0	0	6	9	6	2	1	0	4	1	3	1	0	1	1	0	0.9	C40-41	
Melanoma of skin	34	0	0	0	0	0	0	0	0	2	2	3	3	5	5	3	3	8	0.9	C43	
Other skin	163	0	0	0	1	1	2	3	5	2	3	10	13	15	25	20	26	37	4.2	C44	
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.1	C45	
Kaposi sarcoma	7	0	0	0	0	0	0	1	2	0	0	0	1	1	0	0	0	2	0.2	C46	
Connective and soft tissue	58	0	2	0	2	2	3	4	3	4	6	6	6	6	8	1	0	5	1.5	C47-C49	
Breast	12	0	0	0	0	0	0	0	0	0	2	0	3	0	1	2	2	2	0.3	C50	
Penis	17	0	0	0	0	0	0	0	1	1	1	2	6	2	1	1	1	1	0.4	C60	
Prostate	265	0	0	0	0	0	0	0	1	0	1	0	6	19	29	65	73	71	6.9	C61	
Testis	42	0	5	1	0	5	5	7	10	4	2	1	0	1	1	0	0	0	1.1	C62	
Other male genital organs	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0.1	C63	
Kidney	53	0	0	0	0	0	1	3	1	4	2	0	7	9	7	11	4	4	1.4	C64	
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	97	0	0	1	0	0	0	1	3	0	5	1	8	13	15	14	16	20	2.5	C67	
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	19	0	15	0	0	0	1	0	0	0	0	1	0	1	1	0	0	0	0.5	C69	
Brain, nervous system	65	0	11	10	4	5	1	7	3	5	3	3	3	3	1	3	2	1	1.7	C70-72	
Thyroid	54	0	0	0	1	1	3	2	3	4	2	6	7	5	9	3	4	4	1.4	C73	
Adrenal gland	5	0	2	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0.1	C74	
Other endocrine	8	0	0	0	3	3	0	0	0	0	0	1	1	0	0	0	0	0	0.2	C75	
Hodgkin disease	48	0	0	1	2	4	7	5	3	4	3	3	5	1	2	2	0	6	1.2	C81	
Non-Hodgkin lymphoma	297	0	9	8	7	8	9	9	12	11	18	22	38	32	33	30	24	27	7.7	C82-85,C96	
Immunoproliferative diseases	18	0	0	0	0	1	0	1	1	1	1	2	1	2	3	1	2	2	0.5	C88	
Multiple myeloma	48	0	0	0	0	1	1	0	2	1	1	9	4	9	7	6	3	4	1.2	C90	
Lymphoid leukaemia	82	0	25	17	8	5	3	2	5	2	3	3	1	2	1	3	1	1	2.1	C91	
Myeloid leukaemia	127	0	12	6	6	8	5	10	7	11	4	4	12	12	10	6	7	7	3.3	C92-94	
Leukaemia unspecified	13	0	3	1	0	1	0	1	0	1	1	1	2	0	1	0	1	0.3	C95		
Myeloproliferative disorders	8	0	1	0	0	0	0	0	0	1	2	0	0	1	2	1	0	0	0.2	MPD	
Myelodysplastic syndromes	16	0	0	0	0	0	0	2	0	0	0	1	0	0	4	3	2	4	0.4	MDS	
Other and unspecified	99	0	3	1	0	1	2	1	4	1	5	10	14	20	7	11	9	10	2.6	O&U	
<b>All sites</b>	<b>4006</b>	<b>0</b>	<b>90</b>	<b>48</b>	<b>54</b>	<b>72</b>	<b>67</b>	<b>89</b>	<b>99</b>	<b>129</b>	<b>179</b>	<b>288</b>	<b>424</b>	<b>500</b>	<b>550</b>	<b>459</b>	<b>443</b>	<b>515</b>	<b>104.2</b>	<b>ALL</b>	

### Appendix 33: Cancer Incidence by site and age group, all residents, male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	1.4	0	0.03	0.1	0	0.01	0.1	C00
Tongue	48	0	0	0	0	0	0.1	0.4	0	1.6	0.9	0.6	2.7	2.1	5.2	5.4	5.8	5	0.73	1.2	0.07	0.12	1	C01-02
Mouth	31	0	0	0	0	0	0	0.2	0	0	0.3	0.6	1	2.1	3.3	3.2	5.8	8.8	0.47	0.8	0.04	0.08	0.7	C03-06
Salivary glands	20	0	0	0.1	0	0.3	0.3	0	0.2	0	0.3	0.6	0.7	0.8	1.3	1.1	5.8	0	0.31	0.5	0.02	0.06	0.4	C07-08
Tonsil	8	0	0	0	0	0	0	0	0	0	0.3	0	0.7	0.8	0	1.1	1.4	1.2	0.12	0.2	0.01	0.02	0.2	C09
Other oropharynx	11	0	0	0	0	0	0	0	0	0	0	0.9	0	0	0	3.2	1.4	5	0.17	0.3	0	0.03	0.3	C10
Nasopharynx	353	0	0	0	1.9	1.7	0.6	1.8	2.1	4.2	9.8	15	21.3	22.6	22.2	24.9	23	15	5.39	9.2	0.52	0.76	6.7	C11
Hypopharynx	12	0	0	0	0	0	0	0.2	0	0	0.3	0	0.3	0.8	1.3	1.1	2.9	2.5	0.18	0.3	0.01	0.03	0.3	C12-13
Pharynx unspecified	4	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0	1.1	0	1.2	0.06	0.1	0	0.01	0.1	C14
Oesophagus	60	0	0	0	0	0	0	0.2	0	0.5	0	1.2	2.3	2.5	9.2	7.6	18.7	7.5	0.92	1.6	0.08	0.21	1.5	C15
Stomach	232	0	0	0	0	0.3	0.9	0.2	0.8	2.9	5.5	5.7	10.5	23.5	29.2	48.9	67.5	3.55	6	0.25	0.64	5.5	C16	
Small intestine	17	0	0	0	0	0	0	0	0	0	1.1	0.6	1	0.8	2	0	1.4	2.5	0.26	0.4	0.03	0.03	0.3	C17
Colon	285	0	0	0	0	0.1	0.5	0.9	2.9	3.7	5.2	9.7	16.8	37.9	36.8	44.6	53.8	4.36	7.4	0.39	0.8	6.6	C18	
Rectum	318	0	0	0	0	0.6	0.2	0.6	3.1	2.3	8	12	21.4	34.6	36.8	54.7	65	4.86	8.3	0.41	0.87	7.2	C19-20	
Anus	19	0	0	0	0	0	0	0	0	0	0.3	1.2	1	1.3	0.7	1.1	5.8	2.5	0.29	0.5	0.02	0.06	0.4	C21
Liver	183	0	0.3	0.1	0	0	0.1	0.2	0.6	1.3	1.4	3.4	7.3	13.4	22.9	29.2	20.1	30	2.8	4.8	0.26	0.5	4.2	C22
Gallbladder etc.	44	0	0	0	0	0	0	0.2	0.2	0.3	0.3	2.5	2.7	2.9	3.3	5.4	5.8	3.8	0.67	1.1	0.06	0.12	0.9	C23-24
Pancreas	67	0	0	0	0	0	0	0	0.2	0.5	0.3	1.8	2.7	3.8	8.5	14.1	11.5	7.5	1.02	1.7	0.09	0.22	1.6	C25
Nose, sinuses etc.	30	0	0	0	0	0.1	0.1	0	0.2	0.3	0.6	0.6	3.3	0.8	3.3	3.2	1.4	1.2	0.46	0.8	0.05	0.07	0.6	C30-31
Larynx	60	0	0	0	0	0	0	0	0	0.3	0.3	1.2	2.3	2.5	3.9	13	15.8	15	0.92	1.6	0.05	0.2	1.5	C32
Trachea, bronchus and lung	483	0	0	0	0	0.1	0.2	0.9	2.6	5.7	11.3	15.7	34	58.2	71.4	96.4	73.8	7.38	12.6	0.64	1.48	11.3	C33-34	
Other thoracic organs	22	0	0	0	0	0.3	0.1	0	0	0	0.3	0	0.7	2.1	2.6	4.3	2.9	1.2	0.34	0.6	0.03	0.07	0.5	C37-38
Bone	35	0	0	0	0.8	1.3	0.9	0.4	0.2	0	1.1	0.3	1	0.4	0	1.1	1.4	0	0.53	0.9	0.03	0.04	0.5	C40-41
Melanoma of skin	34	0	0	0	0	0	0	0	0.5	0.6	0.9	1	2.1	3.3	3.2	4.3	10	0.52	0.9	0.04	0.08	0.8	C43	
Other skin	163	0	0	0	0.1	0.1	0.3	0.5	0.9	0.5	0.9	3.1	4.3	6.3	16.3	21.6	37.4	46.2	2.49	4.2	0.17	0.46	3.9	C44
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	0	1.2	0.05	0.1	0.01	0.01	0.1	C45
Kaposi sarcoma	7	0	0	0	0	0	0	0.2	0.4	0	0	0	0.3	0.4	0	0	0	2.5	0.11	0.2	0.01	0.01	0.1	C46
Connective and soft tissue	58	0	0.3	0	0.3	0.3	0.4	0.7	0.6	1	1.7	1.8	2	2.5	5.2	1.1	0	6.2	0.89	1.5	0.08	0.09	1.1	C47,C49
Breast	12	0	0	0	0	0	0	0	0	0	0.6	0	1	0	0.7	2.2	2.9	2.5	0.18	0.3	0.01	0.04	0.3	C50
Penis	17	0	0	0	0	0	0	0	0.2	0.3	0.3	0.6	2	0.8	0.7	1.1	1.4	1.2	0.26	0.4	0.02	0.04	0.3	C60
Prostate	265	0	0	0	0	0	0	0	0.2	0	0.3	0	2	8	19	70.3	105	88.8	4.05	6.9	0.15	1.02	7.2	C61
Testis	42	0	0.8	0.1	0	0.7	0.7	1.2	1.9	1	0.6	0.3	0	0.4	0.7	0	0	0	0.64	1.1	0.04	0.04	0.6	C62
Other male genital organs	3	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	1.1	1.4	0	0.05	0.1	0	0.01	0.1	C63
Kidney	53	0	0	0	0	0	0.1	0.5	0.2	1	0.6	0	2.3	3.8	4.6	11.9	5.8	5	0.81	1.4	0.07	0.15	1.2	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0.02	0	0	0.01	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	97	0	0	0.1	0	0	0	0.2	0.6	0	1.4	0.3	2.7	5.5	9.8	15.1	23	25	1.48	2.5	0.1	0.29	2.3	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	19	0	2.3	0	0	0	0.1	0	0	0	0	0.3	0	0.4	0.7	0	0	0	0.29	0.5	0.02	0.02	0.3	C69
Brain, nervous system	65	0	1.7	1.4	0.6	0.7	0.1	1.2	0.6	1.3	0.9	0.9	1	1.3	0.7	3.2	2.9	1.2	0.99	1.7	0.06	0.09	1.1	C70-72
Thyroid	54	0	0	0	0.1	0.1	0.4	0.4	0.6	1	0.6	1.8	2.3	2.1	5.9	3.2	5.8	5	0.83	1.4	0.08	0.12	1.1	C73
Adrenal gland	5	0	0.3	0	0	0	0	0.2	0	0	0	0	0	0	0.7	0	0	1.2	0.08	0.1	0.01	0.01	0.1	C74
Other endocrine	8	0	0	0	0.4	0.4	0	0	0	0	0	0.3	0.3	0	0	0	0	0	0.12	0.2	0.01	0.01	0.1	C75
Hodgkin disease	48	0	0	0.1	0.3	0.6	1	0.9	0.6	1	0.9	0.9	1.7	0.4	1.3	2.2	0	7.5	0.73	1.2	0.05	0.06	0.8	C81
Non-Hodgkin lymphoma	297	0	1.4	1.1	1	1.2	1.3	1.6	2.2	2.9	5.2	6.7	12.7	13.4	21.6	32.4	34.5	33.8	4.54	7.7	0.36	0.7	6.1	C82-85,C96
Immunoproliferative diseases	18	0	0	0	0	0.1	0	0.2	0.2	0.3	0.3	0.6	0.3	0.8	2	1.1	2.9	2.5	0.28	0.5	0.02	0.04	0.4	C88
Multiple myeloma	48	0	0	0	0	0.1	0.1	0	0.4	0.3	0.3	2.8	1.3	3.8	4.6	6.5	4.3	5	0.73	1.2	0.07	0.12	1	C90
Lymphoid leukaemia	82	0	3.8	2.4	1.1	0.7	0.4	0.4	0.9	0.5	0.9	0.9	0.3	0.8	0.7	3.2	1.4	1.2	1.25	2.1	0.07	0.09	1.3	C91
Myeloid leukaemia	127	0	1.8	0.8	0.8	1.2	0.7	1.8	1.3	2.9	1.1	1.2	4	5	6.5	6.5	10.1	8.8	1.94	3.3	0.15	0.23	2.3	C92-94
Leukaemia unspecified	13	0	0.5	0.1	0	0.1	0	0.2	0	0.3	0.3	0.3	0.7	0	0.7	0	0	1.2	0.2	0.3	0.02	0.02	0.2	C95
Myeloproliferative disorders	8	0	0.2	0	0	0	0	0	0	0.3	0.6	0	0	0.4	1.3	1.1	0	0	0.12	0.2	0.01	0.02	0.2	MPD
Myelodysplastic syndromes	16	0	0	0	0	0	0	0.4	0	0	0	0.3	0	0	2.6	3.2	2.9	5	0.24	0.4	0.02	0.05	0.4	MDS
Other and unspecified	99	0	0.5	0.1	0	0.1	0.3	0.2	0.7	0.3	1.4	3.1	4.7	8.4	4.6	11.9	12.9	12.5	1.51	2.6	0.12	0.25	2.1	O&U
<b>All sites</b>	<b>4006</b>	<b>0</b>	<b>13.7</b>	<b>6.7</b>	<b>7.5</b>	<b>10.4</b>	<b>9.9</b>	<b>15.9</b>	<b>18.6</b>	<b>33.6</b>	<b>51.4</b>	<b>88.2</b>	<b>141.3</b>	<b>209.6</b>	<b>359.5</b>	<b>496.2</b>	<b>637.4</b>	<b>643.8</b>	<b>63.45</b>	<b>104.2</b>	<b>5.41</b>	<b>11.39</b>	<b>94.8</b>	<b>ALL</b>

**Appendix 34: Number of new cancer cases by site and age group, all residents, female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	16	0	0	0	0	0	0	0	1	1	1	3	2	4	7	5	7	3	6	0.3	C00
Tongue	42	0	0	0	0	0	0	1	1	1	3	3	4	7	5	7	3	7	0.9	C01-02	
Mouth	46	0	0	0	0	1	1	0	1	1	1	2	4	9	6	5	7	8	1	0.3	C03-06
Salivary glands	17	0	0	0	2	0	2	1	0	2	0	4	3	0	0	0	2	1	0.4	C07-08	
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	C09	
Other oropharynx	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0.1	C10	
Nasopharynx	140	0	0	0	5	1	3	3	9	9	17	16	25	16	13	10	4	9	3	C11	
Hypopharynx	7	0	0	0	0	0	0	1	0	0	0	2	2	1	1	0	0	0	0.2	C12-13	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C14	
Oesophagus	25	0	0	0	0	0	0	0	2	1	1	1	0	5	4	2	6	3	0.5	C15	
Stomach	145	0	0	0	0	1	0	1	4	5	3	9	11	20	21	14	20	36	3.1	C16	
Small intestine	9	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	3	3	0.2	C17	
Colon	223	0	0	0	0	0	2	3	5	15	12	11	36	30	29	19	26	35	4.8	C18	
Rectum	196	0	0	0	1	0	2	3	2	7	10	19	30	31	22	17	27	25	4.2	C19-20	
Anus	12	0	0	0	0	0	0	0	0	0	0	2	2	1	3	0	0	4	0.3	C21	
Liver	68	0	2	0	0	1	0	0	2	4	0	6	10	7	8	6	9	13	1.5	C22	
Gallbladder etc.	36	0	0	0	0	0	0	0	0	1	1	2	6	5	5	5	4	7	0.8	C23-24	
Pancreas	42	0	0	0	0	0	1	0	0	0	2	4	3	11	5	6	5	5	0.9	C25	
Nose, sinuses etc.	15	0	0	0	0	0	1	1	1	1	0	1	2	2	3	2	0	1	0.3	C30-31	
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	2	0	0.2	C32	
Trachea, bronchus and lung	291	0	0	0	0	0	1	5	5	7	11	16	33	37	44	43	43	46	6.3	C33-34	
Other thoracic organs	24	0	0	0	1	0	0	0	0	0	1	1	1	2	8	3	6	1	0.5	C37-38	
Bone	32	0	2	1	7	9	2	0	2	2	0	0	0	4	2	1	0	0	0.7	C40-41	
Melanoma of skin	22	0	0	0	0	0	2	1	0	1	0	3	3	2	4	2	4	0	0.5	C43	
Other skin	173	0	0	0	0	0	1	1	2	3	7	5	14	18	12	22	31	57	3.7	C44	
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45	
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46	
Connective and soft tissue	42	0	6	0	0	1	5	3	1	4	1	3	3	4	3	2	4	2	0.9	C47,C49	
Breast	1206	0	0	0	1	0	2	22	56	116	157	198	212	172	122	61	39	48	26	C50	
Vulva	13	0	0	0	0	0	0	1	0	2	0	1	3	0	1	3	0	2	0.3	C51	
Vagina	6	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	0.1	C52	
Cervix uteri	570	0	0	0	0	0	1	13	26	50	82	89	106	80	51	35	19	18	12.3	C53	
Corpus uteri	190	0	0	0	0	0	0	6	7	16	12	29	42	43	21	8	6	0	4.1	C54	
Uterus unspecified	74	0	0	0	0	0	0	2	3	9	4	11	8	20	10	3	2	2	1.6	C55	
Ovary	229	0	1	2	3	14	10	8	12	13	18	33	34	31	29	9	6	6	4.9	C56	
Other female genital organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	C57	
Placenta	4	0	0	0	0	2	1	0	0	1	0	0	0	0	0	0	0	0	0.1	C58	
Kidney	30	0	7	1	0	0	0	0	0	0	1	4	8	1	2	2	0	4	0.6	C64	
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	13	0	0	0	0	0	0	0	0	1	1	1	1	2	2	0	2	3	0.3	C67	
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	9	0	6	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0.2	C69	
Brain, nervous system	47	0	11	7	3	1	2	4	2	1	3	3	1	2	3	1	2	1	1	C70-72	
Thyroid	210	0	0	0	2	9	14	22	14	11	19	22	28	16	19	9	13	12	4.5	C73	
Adrenal gland	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74	
Other endocrine	3	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0.1	C75	
Hodgkin disease	34	0	0	0	0	6	4	7	5	0	4	4	0	1	0	0	2	1	0.7	C81	
Non-Hodgkin lymphoma	206	0	4	4	6	3	6	11	13	8	16	34	26	15	13	19	15	13	4.4	C82-85,C96	
Immunoproliferative diseases	11	0	0	0	0	0	0	0	0	1	2	1	4	1	0	0	2	0	0.2	C88	
Multiple myeloma	40	0	0	0	0	0	0	1	1	2	2	2	9	6	8	3	3	5	0.9	C90	
Lymphoid leukaemia	66	0	23	9	7	4	5	5	1	2	2	1	4	1	2	0	0	0	1.4	C91	
Myeloid leukaemia	110	0	8	5	5	5	8	6	1	9	7	9	5	12	8	9	6	7	2.4	C92-94	
Leukaemia unspecified	4	0	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C95	
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	0.1	MPD	
Myelodysplastic syndromes	11	0	0	0	0	0	0	1	0	1	1	1	1	0	2	1	1	2	0.2	MDS	
Other and unspecified	83	0	2	3	0	2	1	0	1	3	11	5	9	10	8	8	8	12	1.8	O&U	
<b>All sites</b>	<b>4812</b>	<b>0</b>	<b>75</b>	<b>33</b>	<b>44</b>	<b>60</b>	<b>77</b>	<b>133</b>	<b>180</b>	<b>311</b>	<b>414</b>	<b>562</b>	<b>701</b>	<b>633</b>	<b>504</b>	<b>342</b>	<b>335</b>	<b>408</b>	<b>103.7</b>	<b>ALL</b>	

### Appendix 35: Cancer Incidence by site and age group, all residents, female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	16	0	0	0	0	0	0	0	0	0	0	0.6	0.7	0.5	0	3.3	3	7.2	0.25	0.3	0.01	0.04	0.4	C00
Tongue	42	0	0	0	0	0	0	0.2	0.2	0.3	0.9	1	1.5	3.4	3.7	7.7	4.4	8.4	0.66	0.9	0.06	0.12	1	C01-02
Mouth	46	0	0	0	0	0.1	0.1	0	0.2	0.3	0.3	0.6	1.5	4.3	4.5	5.5	10.4	9.6	0.72	1	0.06	0.14	1.1	C03-06
Salivary glands	17	0	0	0	0.3	0	0.3	0.2	0	0.5	0	1.3	1.1	0	0	0	3	1.2	0.27	0.4	0.02	0.03	0.3	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	1.2	0.03	0	0	0	0	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0.3	0.3	0	0	0	0	0	1.2	0.05	0.1	0	0	0.1	C10
Nasopharynx	140	0	0	0	0.7	0.1	0.4	0.5	1.7	2.3	4.8	5.1	9.3	7.7	9.7	10.9	5.9	10.8	2.2	3	0.21	0.3	2.8	C11
Hypopharynx	7	0	0	0	0	0	0	0.2	0	0	0	0.6	0.7	0.5	0.7	0	0	0	0.11	0.2	0.01	0.01	0.1	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.02	0	0	0	0	C14
Oesophagus	25	0	0	0	0	0	0	0	0.4	0.3	0.3	0.3	0	2.4	3	2.2	8.9	3.6	0.39	0.5	0.03	0.09	0.6	C15
Stomach	145	0	0	0	0.1	0	0.2	0.7	1.3	0.9	2.9	4.1	9.6	15.7	15.3	29.6	43.4	4.4	2.27	3.1	0.18	0.4	3.5	C16
Small intestine	9	0	0	0	0	0	0	0	0	0	0.3	0	0	0.5	0	1.1	4.4	3.6	0.14	0.2	0	0.03	0.2	C17
Colon	223	0	0	0	0	0	0.3	0.5	0.9	3.9	3.4	3.5	13.4	14.4	21.7	20.8	38.5	42.2	3.5	4.8	0.31	0.61	5.1	C18
Rectum	196	0	0	0	0.1	0	0.3	0.5	0.4	1.8	2.8	6.1	11.2	14.9	16.5	18.6	40	30.1	3.07	4.2	0.27	0.57	4.5	C19-20
Anus	12	0	0	0	0	0	0	0	0	0	0	0.6	0.7	0.5	2.2	0	0	4.8	0.19	0.3	0.02	0.02	0.3	C21
Liver	68	0	0.3	0	0	0.1	0	0	0.4	1	0	1.9	3.7	3.4	6	6.6	13.3	15.7	1.07	1.5	0.08	0.18	1.6	C22
Gallbladder etc.	36	0	0	0	0	0	0	0	0	0.3	0.3	0.6	2.2	2.4	3.7	5.5	5.9	8.4	0.56	0.8	0.05	0.1	0.9	C23-24
Pancreas	42	0	0	0	0	0	0.1	0	0	0	0.6	1.3	1.1	5.3	3.7	6.6	7.4	6	0.66	0.9	0.06	0.13	1	C25
Nose, sinuses etc.	15	0	0	0	0	0	0.1	0.2	0.2	0.3	0	0.3	0.7	1	2.2	2.2	0	1.2	0.24	0.3	0.03	0.04	0.3	C30-31
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	0.4	1	1.5	0	3	0	0.11	0.2	0.01	0.03	0.2	C32
Trachea, bronchus and lung	291	0	0	0	0	0	0.1	0.8	0.9	1.8	3.1	5.1	12.3	17.8	33	47	63.7	55.4	4.56	6.3	0.38	0.93	7.2	C33-34
Other thoracic organs	24	0	0	0	0.1	0	0	0	0	0	0.3	0.3	0.4	1	6	3.3	8.9	1.2	0.38	0.5	0.04	0.1	0.6	C37-38
Bone	32	0	0.3	0.1	1	1.3	0.3	0	0.4	0.5	0	0	1.9	1.5	1.1	0	0	0	0.5	0.7	0.04	0.04	0.5	C40-41
Melanoma of skin	22	0	0	0	0	0	0.3	0.2	0	0.3	0	1	1.1	1	3	2.2	5.9	0	0.35	0.5	0.03	0.07	0.5	C43
Other skin	173	0	0	0	0	0	0.1	0.2	0.4	0.8	2	1.6	5.2	8.7	9	24	45.9	68.7	2.71	3.7	0.14	0.49	4.3	C44
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	42	0	1	0	0	0.1	0.7	0.5	0.2	1	0.3	1	1.1	1.9	2.2	2.2	5.9	2.4	0.66	0.9	0.05	0.09	0.8	C47,C49
Breast	1206	0	0	0	0.1	0	0.3	3.7	10.3	30.1	44.5	63.4	79.1	82.7	91.4	66.7	57.8	57.8	18.91	26	2.03	2.65	24.5	C50
Vulva	13	0	0	0	0	0	0	0.2	0	0.5	0	0.3	1.1	0	0.7	3.3	0	2.4	0.2	0.3	0.01	0.03	0.3	C51
Vagina	6	0	0	0	0	0	0	0	0	0.3	0	0	0.4	0.5	0.7	1.1	1.5	0	0.09	0.1	0.01	0.02	0.1	C52
Cervix uteri	570	0	0	0	0	0	0.1	2.2	4.8	13	23.3	28.5	39.6	38.5	38.2	38.3	28.1	21.7	8.94	12.3	0.94	1.27	11.5	C53
Corpus uteri	190	0	0	0	0	0	0	1	1.3	4.2	3.4	9.3	15.7	20.7	15.7	8.7	8.9	0	2.98	4.1	0.36	0.44	3.8	C54
Uterus unspecified	74	0	0	0	0	0	0	0.3	0.6	2.3	1.1	3.5	3	9.6	7.5	3.3	3	2.4	1.16	1.6	0.14	0.17	1.5	C55
Ovary	229	0	0.2	0.3	0.4	2.1	1.5	1.3	2.2	3.4	5.1	10.6	12.7	14.9	21.7	9.8	8.9	7.2	3.59	4.9	0.38	0.48	4.5	C56
Other female genital organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0.03	0	0.01	0.01	0.1	C57
Placenta	4	0	0	0	0	0.3	0.1	0	0	0.3	0	0	0	0	0	0	0	0	0.06	0.1	0	0	0.1	C58
Kidney	30	0	1.1	0.1	0	0	0	0	0	0	0.3	1.3	3	0.5	1.5	2.2	0	4.8	0.47	0.6	0.04	0.05	0.6	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	13	0	0	0	0	0	0	0	0	0.3	0.3	0.3	0.4	1	1.5	0	3	3.6	0.2	0.3	0.02	0.03	0.3	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	9	0	1	0	0	0	0	0	0.2	0.3	0	0	0	0	0	0	0	1.2	0.14	0.2	0.01	0.01	0.2	C69
Brain, nervous system	47	0	1.8	1	0.4	0.1	0.3	0.7	0.4	0.3	0.9	1	0.4	1	2.2	1.1	3	1.2	0.74	1	0.05	0.07	0.9	C70-72
Thyroid	210	0	0	0	0.3	1.3	2.1	3.7	2.6	2.9	5.4	7	10.4	7.7	14.2	9.8	19.3	14.5	3.29	4.5	0.29	0.43	4	C73
Adrenal gland	1	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.02	0	0	0	0	C74
Other endocrine	3	0	0	0	0.1	0	0	0.2	0	0	0	0	0.4	0	0	0	0	0	0.05	0.1	0	0	0	C75
Hodgkin disease	34	0	0	0	0	0.9	0.6	1.2	0.9	0	1.1	1.3	0	0.5	0	0	3	1.2	0.53	0.7	0.03	0.05	0.5	C81
Non-Hodgkin lymphoma	206	0	0.6	0.6	0.9	0.4	0.9	1.8	2.4	2.1	4.5	10.9	9.7	7.2	9.7	20.8	22.2	15.7	3.23	4.4	0.26	0.47	4.2	C82-85,C96
Immunoproliferative diseases	11	0	0	0	0	0	0	0	0	0.3	0.6	0.3	1.5	0.5	0	0	3	0	0.17	0.2	0.02	0.03	0.2	C88
Multiple myeloma	40	0	0	0	0	0	0	0	0.2	0.3	0.6	0.6	3.4	2.9	6	3.3	4.4	6	0.63	0.9	0.07	0.11	0.9	C90
Lymphoid leukaemia	66	0	3.7	1.3	1	0.6	0.7	0.8	0.2	0.5	0.6	0.3	1.5	0.5	1.5	0	0	0	1.04	1.4	0.07	0.07	1.1	C91
Myeloid leukaemia	110	0	1.3	0.7	0.7	0.7	1.2	1	0.2	2.3	2	2.9	1.9	5.8	6	9.8	8.9	8.4	1.73	2.4	0.13	0.23	2.2	C92-94
Leukaemia unspecified	4	0	0.5	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0.06	0.1	0	0	0.1	C95
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	0	0	0.3	0.4	1	0	0	0	0	0.06	0.1	0.01	0.01	0.1	MPD
Myelodysplastic syndromes	11	0	0	0	0	0	0	0.2	0	0.3	0.3	0.3	0.4	0	1.5	1.1	1.5	2.4	0.17	0.2	0.01	0.03	0.3	MDS
Other and unspecified	83	0	0.3	0.4	0	0.3	0.1	0	0.2	0.8	3.1	1.6	3.4	4.8	6	8.7	11.9	14.5	1.3	1.8	0.11	0.21	1.9	OU
<b>All sites</b>	<b>4812</b>	<b>0</b>	<b>12.1</b>	<b>4.8</b>	<b>6.4</b>	<b>8.9</b>	<b>11.4</b>	<b>22.2</b>	<b>33</b>	<b>80.7</b>	<b>117.4</b>	<b>179.8</b>	<b>261.6</b>	<b>304.3</b>	<b>377.5</b>	<b>373.8</b>	<b>496.3</b>	<b>491.6</b>	<b>78.47</b>	<b>103.7</b>	<b>7.86</b>	<b>12.48</b>	<b>111.1</b>	<b>ALL</b>



**Appendix 36: Number of new cancer cases by site and age group, Kadazan Dusun male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C00
Tongue	15	0	0	0	0	0	1	0	0	2	1	1	1	2	4	2	1	0	1.7	C01-02
Mouth	12	0	0	0	0	0	0	1	0	0	1	0	2	1	2	1	3	1	1.3	C03-06
Salivary glands	5	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0	1	0	0.6	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0.2	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0.3	C10
Nasopharynx	151	0	0	0	10	6	3	5	6	8	16	20	27	21	13	6	6	4	16.9	C11
Hypopharynx	6	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1	0.7	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C14
Oesophagus	15	0	0	0	0	0	0	0	0	0	0	1	2	1	2	2	4	3	1.7	C15
Stomach	89	0	0	0	0	0	1	2	0	1	3	7	8	8	17	12	7	23	10	C16
Small intestine	4	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	0.4	C17
Colon	104	0	0	0	0	0	0	1	1	4	6	7	12	14	17	14	10	18	11.6	C18
Rectum	41	0	0	1	0	0	0	0	0	1	2	3	5	5	8	5	2	9	4.6	C19-20
Anus	12	0	0	0	0	0	0	1	1	0	0	3	2	1	2	1	1	0	1.3	C21
Liver	10	0	0	0	0	0	0	0	1	1	1	1	0	2	0	1	3	1	1.1	C22
Gallbladder etc.	7	0	0	0	0	1	0	0	0	0	0	0	3	1	0	2	0	0	0.8	C23-24
Pancreas	15	0	0	0	0	0	0	0	0	0	0	2	2	0	1	3	3	4	1.7	C25
Nose, sinuses etc.	97	0	0	0	0	0	0	0	1	2	5	4	13	18	12	13	14	15	10.9	C30-31
Larynx	4	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	0	0	0.4	C32
Trachea, bronchus and lung	11	0	0	0	3	5	0	0	0	0	2	1	0	0	0	0	0	0	1.2	C33-34
Other thoracic organs	8	0	0	0	0	0	0	0	0	1	0	1	1	0	1	1	1	2	0.9	C37-38
Bone	34	0	0	0	0	0	0	0	0	0	1	2	3	4	6	2	9	7	3.8	C40-41
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C43
Other skin	2	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0.2	C44
Mesothelioma	9	0	0	0	0	0	1	0	0	1	1	1	3	1	1	0	0	0	1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	4	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	1	0.4	C47,C49
Breast	47	0	0	0	0	0	0	0	0	0	0	0	2	3	7	12	13	10	5.3	C50
Penis	8	0	2	0	0	2	0	1	1	1	0	0	0	1	0	0	0	0	0.9	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	9	0	0	0	0	0	0	2	1	0	1	0	1	1	0	2	0	1	1	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	13	0	0	0	0	0	0	0	0	0	1	0	2	3	1	2	2	2	1.5	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	4	0	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4	C67
Other urinary organs	6	0	1	1	0	1	0	0	0	0	0	0	0	0	1	2	0	0	0.7	C68
Eye	13	0	0	0	0	0	1	0	1	1	0	2	1	2	1	1	1	1	1.5	C69
Brain, nervous system	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C70-72
Thyroid	2	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0.2	C73
Adrenal gland	64	0	4	2	1	2	4	2	1	2	4	2	10	7	5	5	5	8	7.2	C74
Other endocrine	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0.3	C75
Hodgkin disease	17	0	0	0	0	0	1	0	0	1	0	3	1	3	2	3	0	3	1.9	C81
Non-Hodgkin lymphoma	56	0	13	5	4	5	0	2	3	3	2	2	4	5	4	1	1	2	6.3	C82-85,C96
Immunoproliferative diseases	21	0	0	0	0	0	1	1	0	0	0	3	4	2	2	1	3	4	2.4	C88
Multiple myeloma	927	0	24	9	19	23	13	19	18	30	47	69	117	111	115	97	93	123	103.8	C90
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C91
Myeloid leukaemia	15	0	0	0	0	0	1	0	0	2	1	1	1	2	4	2	1	0	1.7	C92-94
Leukaemia unspecified	12	0	0	0	0	0	1	0	0	1	0	1	0	2	1	3	1	1	1.3	C95
Myeloproliferative disorders	5	0	0	0	0	0	0	0	1	0	0	0	1	2	0	1	0	0	0.6	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0.2	MDS
Other and unspecified	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0.3	O&U
<b>All sites</b>	<b>151</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>10</b>	<b>6</b>	<b>3</b>	<b>5</b>	<b>6</b>	<b>8</b>	<b>16</b>	<b>20</b>	<b>27</b>	<b>21</b>	<b>13</b>	<b>6</b>	<b>6</b>	<b>4</b>	<b>16.9</b>	<b>ALL</b>

### Appendix 37: Cancer Incidence by site and age group, Kadazan Dusun male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.1	0	0.06	0.1	0	0.03	0.1	C00
Tongue	15	0	0	0	0	0	0.6	0	0	2.3	1.2	1.2	1.4	3.9	11.2	9.4	6.1	0	0.97	1.7	0.11	0.19	1.4	C01-02
Mouth	12	0	0	0	0	0	0	0.8	0	0	1.2	0	2.9	1.9	5.6	4.7	18.4	4.9	0.78	1.3	0.06	0.18	1.2	C03-06
Salivary glands	5	0	0	0	0	0	0	0	0.9	0	0	0	1.4	3.9	0	0	6.1	0	0.32	0.6	0.03	0.06	0.4	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	4.7	0	0	0.13	0.2	0.01	0.03	0.2	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	9.9	0	0.19	0.3	0.01	0.01	0.3	C10
Nasopharynx	151	0	0	0	6.1	3.5	1.8	3.8	5.1	9.2	19.4	25	38.6	40.8	36.4	28.3	36.8	19.7	9.8	16.9	0.95	1.27	11.8	C11
Hypopharynx	6	0	0	0	0	0	0	0	0	0	0	0	1.4	3.9	0	4.7	6.1	4.9	0.39	0.7	0.03	0.08	0.6	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0.06	0.1	0.01	0.01	0.1	C14
Oesophagus	15	0	0	0	0	0	0	0	0	0	1.2	2.9	1.9	5.6	9.4	24.5	14.8	0	0.97	1.7	0.06	0.23	1.6	C15
Stomach	89	0	0	0	0	0.6	1.5	0	1.2	3.6	8.8	11.4	15.5	47.6	56.6	42.9	113.3	0	5.78	10	0.45	0.95	8.9	C16
Small intestine	4	0	0	0	0	0	0	0	0	0	0	1.2	0	1.9	2.8	0	0	4.9	0.26	0.4	0.03	0.03	0.4	C17
Colon	104	0	0	0	0	0	0.8	0.9	4.6	7.3	8.8	17.2	27.2	47.6	66	61.3	88.7	0	6.75	11.6	0.57	1.21	10.2	C18
Rectum	41	0	0	0.6	0	0	0	0	1.2	2.4	3.8	7.2	9.7	22.4	23.6	12.3	44.3	0	2.66	4.6	0.24	0.42	4	C19-20
Anus	12	0	0	0	0	0	0.8	0.9	0	0	3.8	2.9	1.9	5.6	4.7	6.1	0	0	0.78	1.3	0.08	0.13	1	C21
Liver	10	0	0	0	0	0	0	0	1.2	1.2	1.2	0	3.9	0	4.7	18.4	4.9	0	0.65	1.1	0.04	0.15	1	C22
Gallbladder etc.	7	0	0	0	0	0.6	0	0	0	0	0	0	4.3	1.9	0	9.4	0	0	0.45	0.8	0.03	0.08	0.6	C23-24
Pancreas	15	0	0	0	0	0	0	0	0	0	2.5	2.9	0	2.8	14.2	18.4	19.7	0	0.97	1.7	0.04	0.2	1.6	C25
Nose, sinuses etc.	97	0	0	0	0	0	0	0.9	2.3	6.1	5	18.6	35	33.6	61.3	85.9	73.9	0	6.3	10.9	0.51	1.24	9.6	C30-31
Larynx	4	0	0	0	0	0.6	0	0	0	0	0	0	1.4	0	2.8	4.7	0	0	0.26	0.4	0.02	0.05	0.4	C32
Trachea, bronchus and lung	11	0	0	0	1.8	2.9	0	0	0	0	2.4	1.2	0	0	0	0	0	0	0.71	1.2	0.04	0.04	0.6	C33-34
Other thoracic organs	8	0	0	0	0	0	0	0	1.2	0	1.2	1.4	0	2.8	4.7	6.1	9.9	0	0.52	0.9	0.03	0.09	0.8	C37-38
Bone	34	0	0	0	0	0	0	0	0	1.2	2.5	4.3	7.8	16.8	9.4	55.2	34.5	0	2.21	3.8	0.16	0.49	3.5	C40-41
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0.06	0.1	0.01	0.01	0.1	C43
Other skin	2	0	0	0	0	0	0.8	0	0	0	0	0	1.9	0	0	0	0	0	0.13	0.2	0.01	0.01	0.1	C44
Mesothelioma	9	0	0	0	0	0.6	0	1.2	1.2	1.2	4.3	1.9	2.8	0	0	0	0	0	0.58	1	0.07	0.07	0.7	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	4	0	0	0	0	0	0	0.9	0	0	0	2.9	0	0	0	0	4.9	0	0.26	0.4	0.02	0.02	0.3	C47,C49
Breast	47	0	0	0	0	0	0	0	0	0	0	2.9	5.8	19.6	56.6	79.8	49.3	0	3.05	5.3	0.14	0.82	5.4	C50
Penis	8	0	1.2	0	1.2	0	0.8	0.9	1.2	0	0	0	1.9	0	0	0	0	0	0.52	0.9	0.04	0.04	0.5	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	9	0	0	0	0	0	1.5	0.9	0	1.2	0	1.4	1.9	0	9.4	0	4.9	0	0.58	1	0.03	0.08	0.8	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	13	0	0	0	0	0	0	0	1.2	0	2.9	5.8	2.8	9.4	12.3	9.9	0	0	0.84	1.5	0.06	0.17	1.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	4	0	1.8	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0.26	0.4	0.02	0.02	0.3	C67
Other urinary organs	6	0	0.6	0.6	0	0.6	0	0	0	0	0	0	2.8	9.4	0	0	0	0	0.39	0.7	0.02	0.07	0.6	C68
Eye	13	0	0	0	0	0.6	0	0.9	1.2	0	2.5	2.9	1.9	5.6	4.7	6.1	4.9	0	0.84	1.5	0.08	0.13	1.1	C69
Brain, nervous system	1	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.06	0.1	0	0	0	C70-72
Thyroid	2	0	0	0	0.6	0	0	0	0	0	1.2	0	0	0	0	0	0	0	0.13	0.2	0.01	0.01	0.1	C73
Adrenal gland	64	0	2.4	1.2	0.6	1.2	2.4	1.5	0.9	2.3	4.8	2.5	14.3	13.6	14	23.6	30.7	39.4	4.15	7.2	0.31	0.58	5.5	C74
Other endocrine	3	0	0	0	0	0	0	0	1.2	0	0	0	0	2.8	0	6.1	0	0	0.19	0.3	0.02	0.05	0.3	C75
Hodgkin disease	17	0	0	0	0	0.6	0	1.2	0	3.8	1.4	5.8	5.6	14.2	0	14.8	0	1.1	1.9	0.09	0.16	1.6	C81	
Non-Hodgkin lymphoma	56	0	8	3.1	2.4	2.9	0	1.5	2.6	3.5	2.4	2.5	5.7	9.7	11.2	4.7	6.1	9.9	3.64	6.3	0.28	0.33	4.1	C82-85,C96
Immunoproliferative diseases	21	0	0	0	0	0.6	0.8	0	0	0	3.8	5.7	3.9	5.6	4.7	18.4	19.7	0	1.36	2.4	0.1	0.22	1.9	C88
Multiple myeloma	927	0	14.7	5.5	11.5	13.4	7.9	14.3	15.4	34.5	57	86.2	167.4	215.5	322.1	457.5	570.6	605.9	60.18	103.8	4.83	9.97	85.1	C90
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.1	0	0	0.06	0.1	0	0.03	0.1	C91
Myeloid leukaemia	15	0	0	0	0	0.6	0	2.3	1.2	1.2	1.4	3.9	11.2	9.4	6.1	0	0	0.97	1.7	0.11	0.19	1.4	C92-94	
Leukaemia unspecified	12	0	0	0	0	0	0.8	0	1.2	0	1.2	0	2.9	1.9	5.6	4.7	18.4	4.9	0.78	1.3	0.06	0.18	1.2	C95
Myeloproliferative disorders	5	0	0	0	0	0	0	0.9	0	0	0	1.4	3.9	0	0	6.1	0	0	0.32	0.6	0.03	0.06	0.4	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	1.4	0	0	4.7	0	0	0	0.13	0.2	0.01	0.03	0.2	MDS
Other and unspecified	3	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	9.9	0	0.19	0.3	0.01	0.01	0.3	O&U
<b>All sites</b>	<b>151</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>6.1</b>	<b>3.5</b>	<b>1.8</b>	<b>3.8</b>	<b>5.1</b>	<b>9.2</b>	<b>19.4</b>	<b>25</b>	<b>38.6</b>	<b>40.8</b>	<b>36.4</b>	<b>28.3</b>	<b>36.8</b>	<b>19.7</b>	<b>9.8</b>	<b>16.9</b>	<b>0.95</b>	<b>1.27</b>	<b>11.8</b>	<b>ALL</b>

**Appendix 38: Number of new cancer cases by site and age group, Kadazan Dusun female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	8	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	0	4	0.8	C00
Tongue	13	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	5	1.2	C01-02
Mouth	17	0	0	0	0	0	1	0	0	0	1	0	3	3	3	1	2	3	1.6	C03-06
Salivary glands	6	0	0	0	1	0	2	1	0	0	0	0	1	0	0	0	1	0	0.6	C07-08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	53	0	0	0	2	0	2	2	3	3	4	4	9	7	6	4	3	4	5	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0.3	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	11	0	0	0	0	0	0	0	1	0	0	1	0	2	3	1	2	1	1	C15
Stomach	57	0	0	0	0	1	0	0	0	0	0	2	5	5	9	7	12	16	5.4	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.2	C17
Colon	83	0	0	0	1	0	1	1	3	4	5	9	11	3	11	6	13	15	7.8	C18
Rectum	15	0	0	0	0	1	0	0	0	0	0	0	2	0	2	3	4	3	1.4	C19-20
Anus	9	0	0	0	0	0	0	0	0	1	0	1	1	0	2	3	0	1	0.8	C21
Liver	8	0	0	0	0	0	0	0	0	0	0	3	0	2	0	1	1	1	0.8	C22
Gallbladder etc.	5	0	0	0	0	0	0	1	0	0	0	0	1	0	2	1	0	0	0.5	C23-24
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C25
Nose, sinuses etc.	69	0	0	0	0	0	1	2	1	1	2	4	7	7	12	9	16	7	6.5	C30-31
Larynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0	0.4	C32
Trachea, bronchus and lung	8	0	0	0	4	3	0	0	0	1	0	0	0	0	0	0	0	0	0.8	C33-34
Other thoracic organs	7	0	0	0	0	0	0	1	0	0	0	2	1	0	1	0	2	0	0.7	C37-38
Bone	61	0	0	0	0	0	0	0	0	1	1	2	4	6	3	9	7	28	5.8	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	12	0	2	0	0	0	3	1	1	1	0	1	0	1	1	0	1	0	1.1	C45
Kaposi sarcoma	226	0	0	0	0	0	1	4	13	21	30	36	35	41	16	12	9	8	21.3	C46
Connective and soft tissue	3	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0.3	C47,C49
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	140	0	0	0	0	0	1	2	7	8	21	21	28	21	11	12	4	4	13.2	C51
Vagina	33	0	0	0	0	0	0	2	2	5	2	3	8	9	1	1	0	0	3.1	C52
Cervix uteri	14	0	0	0	0	0	0	0	0	2	2	2	2	3	1	0	1	1	1.3	C53
Corpus uteri	46	0	0	0	0	3	2	2	1	3	3	3	11	10	4	3	0	1	4.3	C54
Uterus unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0.2	C55
Ovary	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	C56
Other female genital organs	5	0	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	0.5	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C67
Other urinary organs	11	0	5	0	1	0	0	0	0	0	1	1	0	2	0	1	0	0	1	C68
Eye	44	0	0	0	0	1	3	5	2	2	3	6	6	4	3	1	4	4	4.2	C69
Brain, nervous system	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C70-72
Thyroid	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C73
Adrenal gland	52	0	2	2	2	2	2	4	4	1	5	11	6	1	1	5	3	1	4.9	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C75
Hodgkin disease	14	0	0	0	0	0	0	0	1	0	1	0	3	0	4	2	2	1	1.3	C81
Non-Hodgkin lymphoma	46	0	12	3	2	5	4	6	0	1	1	2	1	1	3	1	1	3	4.3	C82-85,C96
Immunoproliferative diseases	23	0	1	1	0	0	0	0	0	0	2	1	1	1	4	1	4	7	2.2	C88
Multiple myeloma	1120	0	24	7	14	16	23	34	40	56	84	121	152	131	110	90	97	121	105.8	C90
Lymphoid leukaemia	8	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	0	4	0.8	C91
Myeloid leukaemia	13	0	0	0	0	0	0	0	0	0	0	1	1	1	3	1	5	1.2	C92-94	
Leukaemia unspecified	17	0	0	0	0	0	1	0	0	0	1	0	3	3	1	2	3	1.6	C95	
Myeloproliferative disorders	6	0	0	0	1	0	2	1	0	0	0	0	1	0	0	1	0	0	0.6	MPD
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>53</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>4</b>	<b>4</b>	<b>9</b>	<b>7</b>	<b>6</b>	<b>4</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>ALL</b>

### Appendix 39: Cancer Incidence by site and age group, Kadazan Dusun female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	8	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	13	0	16.4	0.53	0.8	0.01	0.07	0.8	C00
Tongue	13	0	0	0	0	0	0	0	0	0	0	1.3	1.5	2	3.1	13	5.2	20.5	0.86	1.2	0.04	0.13	1.3	C01-02
Mouth	17	0	0	0	0	0	0.6	0	0	1.2	0	4.4	6	9.2	4.3	10.5	12.3	1.13	1.6	0.11	0.18	1.5	C03-06	
Salivary glands	6	0	0	0	0.6	0	1.3	0.7	0	0	0	1.5	0	0	0	5.2	0	0.4	0.6	0.02	0.05	0.4	C07-08	
Tonsil	1	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	C09	
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	53	0	0	0	1.3	0	1.3	1.5	2.5	3.3	4.7	5.1	13.2	13.9	18.5	17.3	15.7	16.4	3.51	5	0.33	0.49	4.4	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	2.5	0	0	3.1	0	0	0	0.2	0.3	0.03	0.03	0.3	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	11	0	0	0	0	0	0	0	0.8	0	0	1.3	0	4	9.2	4.3	10.5	4.1	0.73	1	0.08	0.15	1.1	C15
Stomach	57	0	0	0	0.6	0	0	0	0	0	2.5	7.3	10	27.7	30.3	62.8	65.6	3.77	5.4	0.24	0.71	5.6	C16	
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	5.2	0	0.13	0.2	0.01	0.04	0.2	C17
Colon	83	0	0	0	0.6	0	0.6	0.7	2.5	4.4	5.9	11.4	16.1	6	33.8	26	68.1	61.5	5.5	7.8	0.41	0.88	7.4	C18
Rectum	15	0	0	0	0	0.6	0	0	0	0	0	2.9	0	6.2	13	20.9	12.3	0.99	1.4	0.05	0.22	1.5	C19-20	
Anus	9	0	0	0	0	0	0	0	0	1.1	0	1.3	1.5	0	6.2	13	0	0.6	0.8	0.05	0.11	0.9	C21	
Liver	8	0	0	0	0	0	0	0	0	0	0	3.8	0	4	0	4.3	5.2	4.1	0.53	0.8	0.04	0.09	0.7	C22
Gallbladder etc.	5	0	0	0	0	0	0	0.7	0	0	0	1.5	0	6.2	4.3	0	0	0.33	0.5	0.04	0.06	0.5	C23-24	
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0	0.07	0.1	0	0.03	0.1	C25	
Nose, sinuses etc.	69	0	0	0	0	0	0.6	1.5	0.8	1.1	2.4	5.1	10.2	13.9	36.9	39	83.8	28.7	4.57	6.5	0.36	0.98	6.7	C30-31
Larynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0	6.2	0	10.5	0	0.26	0.4	0.03	0.08	0.5	C32
Trachea, bronchus and lung	8	0	0	0	2.6	1.8	0	0	0	1.1	0	0	0	0	0	0	0	0.53	0.8	0.03	0.03	0.5	C33-34	
Other thoracic organs	7	0	0	0	0	0	0	0.7	0	0	0	2.5	1.5	0	3.1	0	10.5	0	0.46	0.7	0.04	0.09	0.6	C37-38
Bone	61	0	0	0	0	0	0	0	0	1.1	1.2	2.5	5.8	12	9.2	39	36.6	114.8	4.04	5.8	0.16	0.54	5.6	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	12	0	1.3	0	0	0	1.9	0.7	0.8	1.1	0	1.3	0	2	3.1	0	5.2	0	0.79	1.1	0.06	0.09	0.9	C45
Kaposi sarcoma	226	0	0	0	0	0	0.6	3	10.9	22.9	35.3	45.7	51.2	81.7	49.2	51.9	47.1	32.8	14.97	21.3	1.5	2	18.1	C46
Connective and soft tissue	3	0	0	0	0	0	0	0	0	0	0	0	2.9	0	3.1	0	0	0	0.2	0.3	0.03	0.03	0.3	C47,C49
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	140	0	0	0	0	0	0.6	1.5	5.9	8.7	24.7	26.7	40.9	41.8	33.8	51.9	20.9	16.4	9.27	13.2	0.92	1.29	11.5	C51
Vagina	33	0	0	0	0	0	0	1.5	1.7	5.4	2.4	3.8	11.7	17.9	3.1	4.3	0	0	2.19	3.1	0.24	0.26	2.5	C52
Cervix uteri	14	0	0	0	0	0	0	0	0	2.2	2.4	2.5	2.9	6	3.1	0	5.2	4.1	0.93	1.3	0.1	0.12	1.1	C53
Corpus uteri	46	0	0	0	0	1.8	1.3	1.5	0.8	3.3	3.5	3.8	16.1	19.9	12.3	13	0	4.1	3.05	4.3	0.32	0.39	3.6	C54
Uterus unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	6.2	0	0	0	0.13	0.2	0.03	0.03	0.2	C55
Ovary	1	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	C56
Other female genital organs	5	0	1.3	0	0	0	0	0	0	0	0	2.5	0	0	0	0	0	4.1	0.33	0.5	0.02	0.02	0.4	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	8.2	0.2	0.3	0.01	0.01	0.2	0.6	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	1	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	0.1	C67
Other urinary organs	11	0	3.3	0	0.6	0	0	0	0	1.2	1.3	0	4	0	4.3	0	0	0	0.73	1	0.05	0.07	0.9	C68
Eye	44	0	0	0	0	0.6	1.9	3.7	1.7	2.2	3.5	7.6	8.8	8	9.2	4.3	20.9	16.4	2.91	4.2	0.24	0.36	3.4	C69
Brain, nervous system	1	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	0.1	C70-72
Thyroid	1	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	0.1	C73
Adrenal gland	52	0	1.3	1.3	1.3	1.2	1.3	3	3.4	1.1	5.9	14	8.8	2	3.1	21.6	15.7	4.1	3.44	4.9	0.24	0.42	4	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	C75
Hodgkin disease	14	0	0	0	0	0	0	0	0.8	0	1.2	0	4.4	0	12.3	8.7	10.5	4.1	0.93	1.3	0.09	0.19	1.4	C81
Non-Hodgkin lymphoma	46	0	7.8	2	1.3	3	2.6	4.4	0	1.1	1.2	2.5	1.5	2	9.2	4.3	5.2	12.3	3.05	4.3	0.19	0.24	3.4	C82-85,C96
Immunoproliferative diseases	23	0	0.7	0.7	0	0	0	0	0	0	2.4	1.3	1.5	2	12.3	4.3	20.9	28.7	1.52	2.2	0.1	0.23	2.1	C88
Multiple myeloma	1120	0	15.7	4.6	9	9.7	14.7	25.2	33.7	61	98.8	153.7	222.2	261	338.5	389.6	507.9	495.9	74.17	105.8	6.24	10.73	94.9	C90
Lymphoid leukaemia	8	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	13	0	16.4	0.53	0.8	0.01	0.07	0.8	C91
Myeloid leukaemia	13	0	0	0	0	0	0	0	0	0	0	1.3	1.5	2	3.1	13	5.2	20.5	0.86	1.2	0.04	0.13	1.3	C92-94
Leukaemia unspecified	17	0	0	0	0	0	0.6	0	0	1.2	0	4.4	6	9.2	4.3	10.5	12.3	1.13	1.6	0.11	0.18	1.5	C95	
Myeloproliferative disorders	6	0	0	0	0.6	0	1.3	0.7	0	0	0	1.5	0	0	0	5.2	0	0.4	0.6	0.02	0.05	0.4	MPD	
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	MDS	
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>53</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.3</b>	<b>0</b>	<b>1.3</b>	<b>1.5</b>	<b>2.5</b>	<b>3.3</b>	<b>4.7</b>	<b>5.1</b>	<b>13.2</b>	<b>13.9</b>	<b>18.5</b>	<b>17.3</b>	<b>15.7</b>	<b>16.4</b>	<b>3.51</b>	<b>5</b>	<b>0.33</b>	<b>0.49</b>	<b>4.4</b>	<b>ALL</b>

**Appendix 40: Number of new cancer cases by site and age group, Chinese male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	12	0	0	0	0	0	0	0	0	1	0	0	4	1	1	3	1	1	1.3	C01-02	
Mouth	8	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	5	0.9	C03-06	
Salivary glands	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0.2	C07-08	
Tonsil	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.2	C09	
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	0.3	C10	
Nasopharynx	85	0	0	0	1	0	0	0	4	5	7	13	16	14	13	7	3	2	9.1	C11	
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C12-13	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C14	
Oesophagus	20	0	0	0	0	0	0	0	0	0	0	1	2	1	6	3	6	1	2.2	C15	
Stomach	51	0	0	0	0	0	0	0	0	0	2	4	3	2	9	7	8	16	5.5	C16	
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.2	C17	
Colon	192	0	0	0	0	0	0	0	4	5	7	16	24	37	27	32	40	20.7	C18		
Rectum	46	0	0	0	0	0	0	0	0	1	0	1	7	11	12	7	5	2	5	C19-20	
Anus	9	0	0	0	0	0	0	0	0	0	0	1	0	0	2	4	1	1	1	C21	
Liver	20	0	0	0	0	0	0	0	0	1	0	2	3	6	3	2	1	1	2.2	C22	
Gallbladder etc.	10	0	0	0	0	0	0	0	0	1	0	2	4	0	3	0	0	0	1.1	C23-24	
Pancreas	16	0	0	0	0	0	0	0	0	0	1	2	2	2	0	6	2	3	1.7	C25	
Nose, sinuses etc.	124	0	0	0	0	0	0	1	0	0	1	11	13	14	26	20	18	20	13.3	C30-31	
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0.2	C32	
Trachea, bronchus and lung	3	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0.3	C33-34	
Other thoracic organs	6	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	2	0.6	C37-38	
Bone	45	0	0	0	0	0	0	0	2	0	1	0	3	5	8	7	7	12	4.8	C40-41	
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C43	
Other skin	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.2	C44	
Mesothelioma	8	0	1	0	0	0	0	1	1	0	0	0	0	1	3	0	0	1	0.9	C45	
Kaposi sarcoma	7	0	0	0	0	0	0	0	0	0	1	0	2	0	1	1	1	1	0.8	C46	
Connective and soft tissue	4	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	0	0	0.4	C47,C49	
Breast	87	0	0	0	0	0	0	0	0	0	0	0	1	4	12	19	27	24	9.4	C50	
Penis	5	0	0	0	0	1	0	2	2	0	0	0	0	0	0	0	0	0	0.5	C60	
Prostate	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.2	C61	
Testis	17	0	0	0	0	0	0	0	0	1	1	0	1	3	2	7	1	1	1.8	C62	
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63	
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64	
Renal pelvis	28	0	0	0	0	0	0	0	0	0	0	0	2	3	9	5	2	7	3	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C67	
Other urinary organs	10	0	3	0	0	0	1	2	0	1	0	0	0	2	0	0	0	1	1.1	C68	
Eye	4	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0.4	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72	
Thyroid	2	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C73	
Adrenal gland	62	0	0	0	1	4	2	2	1	2	2	2	6	5	13	7	6	9	6.7	C74	
Other endocrine	7	0	0	0	0	1	0	0	0	0	1	0	1	1	1	1	1	0	0.8	C75	
Hodgkin disease	10	0	0	0	0	1	0	0	0	0	1	0	0	4	1	1	1	1	1.1	C81	
Non-Hodgkin lymphoma	35	0	1	0	4	2	3	1	3	1	0	3	1	2	3	5	3	3	3.8	C82-85,C96	
Immunoproliferative diseases	22	0	0	0	0	0	0	0	1	1	1	1	1	6	1	6	1	3	2.4	C88	
Multiple myeloma	974	0	5	0	7	10	8	9	15	20	24	57	90	113	173	150	130	163	104.8	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91	
Myeloid leukaemia	12	0	0	0	0	0	0	0	0	1	0	0	4	1	1	3	1	1	1.3	C92-94	
Leukaemia unspecified	8	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	5	0.9	C95	
Myeloproliferative disorders	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0.2	MPD	
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.2	MDS	
Other and unspecified	3	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	0.3	O&U	
<b>All sites</b>	<b>85</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>5</b>	<b>7</b>	<b>13</b>	<b>16</b>	<b>14</b>	<b>13</b>	<b>7</b>	<b>3</b>	<b>2</b>	<b>9.1</b>	<b>ALL</b>	

### Appendix 41: Cancer Incidence by site and age group, Chinese male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	12	0	0	0	0	0	0	0	0	1.7	0	0	7.5	2.1	2.8	12.2	6.4	5.8	1.53	1.3	0.07	0.16	1.3	C01-02
Mouth	8	0	0	0	0	0	0	0	0	0	0	2	0	2.1	0	0	6.4	29.1	1.02	0.9	0.02	0.05	0.9	C03-06
Salivary glands	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2.8	0	6.4	0	0.25	0.2	0.01	0.05	0.2	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	1.9	0	0	2.1	0	0	0	0	0.25	0.2	0.02	0.02	0.2	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0	3.9	0	0	0	0	5.8	0	0.38	0.3	0.02	0.02	0.4	C10
Nasopharynx	85	0	0	0	1.6	0	0	0	5.9	8.7	13.2	25.4	29.9	30	36.8	28.6	19.2	11.6	10.83	9.1	0.76	1	9	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.8	0	0.13	0.1	0	0	0.1	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.1	0	0	0.13	0.1	0	0.02	0.1	C14
Oesophagus	20	0	0	0	0	0	0	0	0	0	0	2	3.7	2.1	17	12.2	38.5	5.8	2.55	2.2	0.12	0.38	2.3	C15
Stomach	51	0	0	0	0	0	0	0	0	0	3.8	7.8	5.6	4.3	25.5	28.6	51.3	93	6.5	5.5	0.23	0.63	5.9	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0	0	5.8	0.25	0.2	0.01	0.01	0.2	C17
Colon	192	0	0	0	0	0	0	0	0	7	9.4	13.7	29.9	51.4	104.8	110.2	205.1	232.6	24.45	20.7	1.08	2.66	21.6	C18
Rectum	46	0	0	0	0	0	0	0	0	1.7	0	2	13.1	23.6	34	28.6	32.1	11.6	5.86	5	0.37	0.67	4.9	C19-20
Anus	9	0	0	0	0	0	0	0	0	0	0	2	0	0	5.7	16.3	6.4	5.8	1.15	1	0.04	0.15	1.1	C21
Liver	20	0	0	0	0	0	0	0	0	1.7	0	3.9	3.7	6.4	17	12.2	12.8	5.8	2.55	2.2	0.16	0.29	2.2	C22
Gallbladder etc.	10	0	0	0	0	0	0	0	0	1.7	0	3.9	7.5	0	8.5	0	0	0	1.27	1.1	0.11	0.11	1.1	C23-24
Pancreas	16	0	0	0	0	0	0	0	0	0	0	2	3.7	4.3	0	24.5	12.8	17.4	2.04	1.7	0.05	0.24	1.8	C25
Nose, sinuses etc.	124	0	0	0	0	0	0	1.5	0	0	1.9	21.5	24.3	30	73.7	81.6	115.4	116.3	15.79	13.3	0.76	1.75	14	C30-31
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	5.7	0	0	0	0.25	0.2	0.03	0.03	0.2	C32
Trachea, bronchus and lung	3	0	0	0	0	0	2.8	0	0	0	0	0	0	0	0	4.1	0	0	0.38	0.3	0.01	0.03	0.3	C33-34
Other thoracic organs	6	0	0	0	0	0	0	0	0	0	0	2	1.9	2.1	2.8	0	0	11.6	0.76	0.6	0.04	0.04	0.6	C37-38
Bone	45	0	0	0	0	0	0	0	3	0	1.9	0	5.6	10.7	22.7	28.6	44.9	69.8	5.73	4.8	0.22	0.59	5.1	C40-41
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.8	0.13	0.1	0	0	0.1	C43
Other skin	2	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0	0	5.8	0.25	0.2	0.01	0.01	0.2	C44
Mesothelioma	8	0	2.6	0	0	0	0	1.5	1.5	0	0	0	0	2.1	8.5	0	0	5.8	1.02	0.9	0.08	0.08	1.1	C45
Kaposi sarcoma	7	0	0	0	0	0	0	0	0	0	1.9	0	3.7	0	2.8	4.1	6.4	5.8	0.89	0.8	0.04	0.09	0.8	C46
Connective and soft tissue	4	0	0	0	0	0	0	0	0	0	0	3.9	0	2.1	0	4.1	0	0	0.51	0.4	0.03	0.05	0.4	C47,C49
Breast	87	0	0	0	0	0	0	0	0	0	0	0	1.9	8.6	34	77.6	173.1	139.5	11.08	9.4	0.22	1.48	10.4	C50
Penis	5	0	0	0	0	1.5	0	3	3	0	0	0	0	0	0	0	0	0	0.64	0.5	0.04	0.04	0.5	C60
Prostate	2	0	0	0	0	0	0	0	0	0	0	2	0	0	0	4.1	0	0	0.25	0.2	0.01	0.03	0.2	C61
Testis	17	0	0	0	0	0	0	0	0	1.7	1.9	0	1.9	6.4	5.7	28.6	6.4	5.8	2.17	1.8	0.09	0.26	1.9	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	28	0	0	0	0	0	0	0	0	0	0	0	3.7	6.4	25.5	20.4	12.8	40.7	3.57	3	0.18	0.34	3.1	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0.13	0.1	0.01	0.01	0.1	C67
Other urinary organs	10	0	7.7	0	0	0	1.4	3	0	1.7	0	0	0	4.3	0	0	0	5.8	1.27	1.1	0.09	0.09	1.7	C68
Eye	4	0	0	0	0	0	0	1.5	1.7	0	0	0	2.1	0	0	0	0	5.8	0.51	0.4	0.03	0.03	0.4	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	2	0	0	0	1.6	1.5	0	0	0	0	0	0	0	0	0	0	0	0	0.25	0.2	0.02	0.02	0.3	C73
Adrenal gland	62	0	0	0	1.6	5.9	2.8	3	1.5	3.5	3.8	3.9	11.2	10.7	36.8	28.6	38.5	52.3	7.9	6.7	0.42	0.76	7	C74
Other endocrine	7	0	0	0	0	1.5	0	0	0	0	1.9	0	1.9	2.1	2.8	4.1	6.4	0	0.89	0.8	0.05	0.1	0.8	C75
Hodgkin disease	10	0	0	0	0	1.5	0	0	0	0	1.9	0	0	8.6	2.8	4.1	6.4	5.8	1.27	1.1	0.07	0.13	1.1	C81
Non-Hodgkin lymphoma	35	0	2.6	0	6.5	2.9	4.2	1.5	4.4	1.7	0	5.9	1.9	4.3	8.5	20.4	19.2	17.4	4.46	3.8	0.22	0.42	4.3	C82-85,C96
Immunoproliferative diseases	22	0	0	0	0	0	0	0	1.5	1.7	1.9	2	1.9	12.8	2.8	24.5	6.4	17.4	2.8	2.4	0.12	0.28	2.4	C88
Multiple myeloma	974	0	12.8	0	11.4	14.7	11.2	13.4	22.2	35	45.3	111.3	168.2	242	490.1	612.2	833.3	947.7	124.04	104.8	5.89	13.12	110.4	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	12	0	0	0	0	0	0	0	0	1.7	0	0	7.5	2.1	2.8	12.2	6.4	5.8	1.53	1.3	0.07	0.16	1.3	C92-94
Leukaemia unspecified	8	0	0	0	0	0	0	0	0	0	0	2	0	2.1	0	0	6.4	29.1	1.02	0.9	0.02	0.05	0.9	C95
Myeloproliferative disorders	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2.8	0	6.4	0	0.25	0.2	0.01	0.05	0.2	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	1.9	0	0	2.1	0	0	0	0	0.25	0.2	0.02	0.02	0.2	MDS
Other and unspecified	3	0	0	0	0	0	0	0	0	0	0	3.9	0	0	0	0	0	5.8	0.38	0.3	0.02	0.02	0.4	O&U
<b>All sites</b>	<b>85</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.6</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>5.9</b>	<b>8.7</b>	<b>13.2</b>	<b>25.4</b>	<b>29.9</b>	<b>30</b>	<b>36.8</b>	<b>28.6</b>	<b>19.2</b>	<b>11.6</b>	<b>10.83</b>	<b>9.1</b>	<b>0.76</b>	<b>1</b>	<b>9</b>	<b>ALL</b>

**Appendix 42: Number of new cancer cases by site and age group, Chinese female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C00	
Tongue	9	0	0	0	0	0	0	0	0	1	0	1	0	1	2	2	1	0	1	0.9	C01-02
Mouth	4	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	1	0.4	C03-06
Salivary glands	3	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0.3	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09	
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10	
Nasopharynx	33	0	0	0	0	0	0	0	1	2	7	6	6	2	1	5	1	2	3.4	C11	
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C12-13	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C14	
Oesophagus	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0.2	C15	
Stomach	31	0	0	0	0	0	0	1	1	2	2	0	1	3	5	1	3	12	3.2	C16	
Small intestine	4	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0	0.4	C17	
Colon	129	0	0	0	0	0	0	1	2	4	7	16	22	12	17	17	31	13.2	C18		
Rectum	21	0	0	0	0	0	0	0	0	2	0	2	2	3	1	1	3	7	2.1	C19-20	
Anus	11	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	2	3	1.1	C21	
Liver	14	0	0	0	0	0	0	0	0	0	0	0	1	2	3	3	2	3	1.4	C22	
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C23-24	
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C25	
Nose, sinuses etc.	93	0	0	0	0	0	0	0	1	2	2	5	6	16	14	15	9	23	9.5	C30-31	
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	1	1	0.7	C32	
Trachea, bronchus and lung	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0.3	C33-34	
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C37-38	
Bone	30	0	0	0	0	0	1	0	0	0	0	0	3	0	1	3	11	11	3.1	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43	
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44	
Mesothelioma	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.1	C45	
Kaposi sarcoma	287	0	0	0	0	0	0	1	6	15	21	42	38	50	42	28	18	26	29.3	C46	
Connective and soft tissue	6	0	0	0	0	0	0	0	0	1	0	1	0	0	0	3	0	1	0.6	C47,C49	
Breast	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.2	C50	
Vulva	70	0	0	0	0	0	0	1	2	4	2	8	14	11	13	7	6	2	7.2	C51	
Vagina	52	0	0	0	0	0	0	1	1	1	2	12	12	11	6	4	2	0	5.3	C52	
Cervix uteri	18	0	0	0	0	0	0	0	0	0	0	3	2	6	4	1	1	1	1.8	C53	
Corpus uteri	45	0	0	1	1	1	1	1	0	1	0	2	5	9	3	13	4	3	4.6	C54	
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55	
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56	
Other female genital organs	7	0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	0	2	0.7	C57	
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58	
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64	
Renal pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0.2	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67	
Other urinary organs	8	0	1	1	0	0	0	2	0	0	0	1	0	0	2	0	1	0	0.8	C68	
Eye	21	0	0	0	0	0	0	0	3	2	1	1	0	2	1	3	5	3	2.1	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72	
Thyroid	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.1	C73	
Adrenal gland	36	0	0	0	0	0	0	0	3	1	2	0	9	1	2	5	6	5	3.7	C74	
Other endocrine	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	0	0.4	C75	
Hodgkin disease	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	0.5	C81	
Non-Hodgkin lymphoma	23	0	1	2	1	0	1	2	0	1	0	1	3	1	3	3	1	3	2.3	C82-85,C96	
Immunoproliferative diseases	21	0	0	0	0	0	1	0	0	0	2	2	3	3	1	3	0	6	2.1	C88	
Multiple myeloma	1009	0	2	4	2	1	5	12	19	38	49	109	123	149	135	114	100	147	103.1	C90	
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C91	
Myeloid leukaemia	9	0	0	0	0	0	0	0	1	0	1	0	1	2	2	1	0	1	0.9	C92-94	
Leukaemia unspecified	4	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	1	0.4	C95	
Myeloproliferative disorders	3	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0.3	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS	
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U	
<b>All sites</b>	<b>33</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>7</b>	<b>6</b>	<b>6</b>	<b>2</b>	<b>1</b>	<b>5</b>	<b>1</b>	<b>2</b>	<b>3.4</b>	<b>ALL</b>	

### Appendix 43: Cancer Incidence by site and age group, Chinese female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C00
Tongue	9	0	0	0	0	0	0	0	1.5	0	2.1	0	2.2	5.1	6.7	4.8	0	5.6	1.23	0.9	0.09	0.11	1.1	C01-02
Mouth	4	0	0	0	0	0	0	0	0	0	0	2.1	0	5.1	0	0	0	5.6	0.55	0.4	0.04	0.04	0.4	C03-06
Salivary glands	3	0	0	0	0	0	0	0	0	1.9	0	2.1	2.2	0	0	0	0	0	0.41	0.3	0.03	0.03	0.4	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	33	0	0	0	0	0	0	0	1.5	3.7	14.6	12.7	13.4	5.1	3.4	24.2	7.1	11.2	4.51	3.4	0.27	0.43	4	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C14
Oesophagus	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.1	5.6	0.27	0.2	0	0.04	0.3	C15
Stomach	31	0	0	0	0	0	0	1.4	1.5	3.7	4.2	0	2.2	7.7	16.8	4.8	21.4	67	4.24	3.2	0.19	0.32	3.7	C16
Small intestine	4	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	4.8	14.3	0	0.55	0.4	0.01	0.11	0.6	C17
Colon	129	0	0	0	0	0	0	1.5	3.7	8.3	14.8	35.7	56.4	40.3	82.1	121.4	173.2	17.63	13.2	0.8	1.82	15.7	C18	
Rectum	21	0	0	0	0	0	0	0	0	3.7	0	4.2	4.5	7.7	3.4	4.8	21.4	39.1	2.87	2.1	0.12	0.25	2.5	C19-20
Anus	11	0	0	0	0	0	0	0	0	0	0	0	4.5	5.1	6.7	0	14.3	16.8	1.5	1.1	0.08	0.15	1.3	C21
Liver	14	0	0	0	0	0	0	0	0	0	0	0	2.2	5.1	10.1	14.5	14.3	16.8	1.91	1.4	0.09	0.23	1.8	C22
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	3.4	0	0	0	0.14	0.1	0.02	0.02	0.1	C23-24
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.1	0	0.14	0.1	0	0.04	0.1	C25
Nose, sinuses etc.	93	0	0	0	0	0	0	0	1.5	3.7	4.2	10.6	13.4	41	47	72.5	64.3	128.5	12.71	9.5	0.61	1.29	11.4	C30-31
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	0	2.6	6.7	9.7	7.1	5.6	0.96	0.7	0.05	0.13	0.9	C32
Trachea, bronchus and lung	3	0	0	0	0	0	0	0	0	0	0	0	0	5.1	0	4.8	0	0	0.41	0.3	0.03	0.05	0.4	C33-34
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	3.4	0	0	0	0.14	0.1	0.02	0.02	0.1	C37-38
Bone	30	0	0	0	0	0	1.4	0	0	0	0	0	6.7	0	3.4	14.5	78.6	61.5	4.1	3.1	0.06	0.52	3.8	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	1	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C45
Kaposi sarcoma	287	0	0	0	0	0	0	1.4	8.9	27.8	43.7	89	84.8	128.2	140.9	135.3	128.6	145.3	39.23	29.3	2.62	3.94	34.8	C46
Connective and soft tissue	6	0	0	0	0	0	0	0	0	1.9	0	2.1	0	0	0	14.5	0	5.6	0.82	0.6	0.02	0.09	0.8	C47,C49
Breast	2	0	0	0	0	0	0	0	0	0	0	0	0	0	3.4	4.8	0	0	0.27	0.2	0.02	0.04	0.3	C50
Vulva	70	0	0	0	0	0	0	1.4	3	7.4	4.2	16.9	31.2	28.2	43.6	33.8	42.9	11.2	9.57	7.2	0.68	1.06	8.5	C51
Vagina	52	0	0	0	0	0	0	1.4	1.5	1.9	4.2	25.4	26.8	28.2	20.1	19.3	14.3	0	7.11	5.3	0.55	0.72	6.2	C52
Cervix uteri	18	0	0	0	0	0	0	0	0	0	0	6.4	4.5	15.4	13.4	4.8	7.1	5.6	2.46	1.8	0.2	0.26	2.2	C53
Corpus uteri	45	0	0	2	1.8	1.5	1.4	0	1.5	0	4.2	10.6	20.1	7.7	43.6	19.3	21.4	5.6	6.15	4.6	0.47	0.68	5.8	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56
Other female genital organs	7	0	0	0	0	0	0	0	0	0	2.1	2.1	0	2.6	3.4	4.8	0	11.2	0.96	0.7	0.05	0.07	0.9	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	3.4	0	7.1	0	0.27	0.2	0.02	0.05	0.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67
Other urinary organs	8	0	2.7	2	0	0	0	2.8	0	0	0	2.1	0	0	6.7	0	7.1	0	1.09	0.8	0.08	0.12	1.3	C68
Eye	21	0	0	0	0	0	0	0	4.5	3.7	2.1	2.1	0	5.1	3.4	14.5	35.7	16.8	2.87	2.1	0.1	0.36	2.6	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	1	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C73
Adrenal gland	36	0	0	0	0	0	0	4.3	1.5	3.7	0	19.1	2.2	5.1	6.7	24.2	42.9	27.9	4.92	3.7	0.21	0.55	4.5	C74
Other endocrine	4	0	0	0	0	0	0	0	0	1.9	0	0	2.2	0	0	0	14.3	0	0.55	0.4	0.02	0.09	0.5	C75
Hodgkin disease	5	0	0	0	0	0	0	0	0	0	2.1	0	0	2.6	0	4.8	7.1	5.6	0.68	0.5	0.02	0.08	0.6	C81
Non-Hodgkin lymphoma	23	0	2.7	4	1.8	0	1.4	2.8	0	1.9	0	2.1	6.7	2.6	10.1	14.5	7.1	16.8	3.14	2.3	0.18	0.29	3.2	C82-85,C96
Immunoproliferative diseases	21	0	0	0	0	0	1.4	0	0	0	4.2	4.2	6.7	7.7	3.4	14.5	0	33.5	2.87	2.1	0.14	0.21	2.5	C88
Multiple myeloma	1009	0	5.5	8	3.6	1.5	7.1	17	28.2	70.5	101.9	230.9	274.6	382.1	453	550.7	714.3	821.2	137.94	103.1	7.92	14.24	124.1	C90
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0	0.14	0.1	0.01	0.01	0.1	C91
Myeloid leukaemia	9	0	0	0	0	0	0	0	1.5	0	2.1	0	2.2	5.1	6.7	4.8	0	5.6	1.23	0.9	0.09	0.11	1.1	C92-94
Leukaemia unspecified	4	0	0	0	0	0	0	0	0	0	0	2.1	0	5.1	0	0	0	5.6	0.55	0.4	0.04	0.04	0.4	C95
Myeloproliferative disorders	3	0	0	0	0	0	0	0	0	1.9	0	2.1	2.2	0	0	0	0	0	0.41	0.3	0.03	0.03	0.4	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>33</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.5</b>	<b>3.7</b>	<b>14.6</b>	<b>12.7</b>	<b>13.4</b>	<b>5.1</b>	<b>3.4</b>	<b>24.2</b>	<b>7.1</b>	<b>11.2</b>	<b>4.51</b>	<b>3.4</b>	<b>0.27</b>	<b>0.43</b>	<b>4</b>	<b>ALL</b>



**Appendix 44: Number of new cancer cases by site and age group, Bajau male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	4	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	1	0	0.8	C01-02	
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0.6	C03-06	
Salivary glands	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0.4	C07-08	
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.4	C09	
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0.4	C10	
Nasopharynx	20	0	0	0	0	1	0	0	0	1	4	4	3	4	0	0	1	2	4.2	C11	
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14	
Oesophagus	5	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0	1	1.1	C15	
Stomach	19	0	0	0	0	0	0	1	1	0	3	4	0	2	2	1	2	3	4	C16	
Small intestine	4	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	0.8	C17	
Colon	96	0	0	0	0	0	2	0	6	6	1	15	8	19	9	6	11	13	20.4	C18	
Rectum	33	0	1	0	0	0	0	0	1	2	1	0	4	5	4	8	3	4	7	C19-20	
Anus	6	0	0	0	0	0	0	0	0	0	0	1	1	3	0	0	1	0	1.3	C21	
Liver	10	0	0	0	0	0	0	0	0	0	0	2	2	2	1	1	1	1	2.1	C22	
Gallbladder etc.	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0.4	C23-24	
Pancreas	9	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1	1	2	1.9	C25	
Nose, sinuses etc.	68	0	0	0	0	0	1	0	2	3	4	6	6	11	15	8	10	2	14.4	C30-31	
Larynx	5	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	1	0	1.1	C32	
Trachea, bronchus and lung	5	0	0	0	0	1	2	0	0	0	1	0	0	0	0	0	1	0	1.1	C33-34	
Other thoracic organs	5	0	0	0	0	0	0	0	0	0	1	0	1	2	1	0	0	0	1.1	C37-38	
Bone	18	0	0	0	0	0	0	1	1	0	1	2	1	1	2	4	1	4	3.8	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43	
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44	
Mesothelioma	5	0	0	0	0	0	1	0	1	0	1	1	0	0	0	0	0	1	1.1	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.2	C46	
Connective and soft tissue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C47,C49	
Breast	17	0	0	0	0	0	0	0	0	0	1	0	0	2	3	4	4	3	3.6	C50	
Penis	7	0	2	1	0	1	0	0	0	0	1	1	0	0	1	0	0	0	1.5	C60	
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61	
Testis	7	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	1	0	1.5	C62	
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63	
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64	
Renal pelvis	13	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	6	3	2.8	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	3	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	C67	
Other urinary organs	6	0	3	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	1.3	C68	
Eye	9	0	0	0	0	0	0	2	1	1	1	1	1	0	2	0	0	0	1.9	C69	
Brain, nervous system	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.2	C70-72	
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73	
Adrenal gland	44	0	2	3	2	0	2	0	2	4	3	5	5	3	4	3	6	9.3	C74		
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.2	C75	
Hodgkin disease	6	0	0	0	0	0	0	0	1	0	0	2	1	1	1	0	0	0	1.3	C81	
Non-Hodgkin lymphoma	40	0	7	5	2	1	1	6	3	3	1	0	3	2	2	1	2	1	8.5	C82-85,C96	
Immunoproliferative diseases	11	0	1	0	0	0	0	0	0	0	1	0	2	2	2	1	0	2	2.3	C88	
Multiple myeloma	489	0	19	10	4	5	8	13	17	20	31	45	46	68	56	44	52	51	103.8	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91	
Myeloid leukaemia	4	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	1	0	0.8	C92-94	
Leukaemia unspecified	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0.6	C95	
Myeloproliferative disorders	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0.4	MPD	
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.4	MDS	
Other and unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0.4	O&U	
<b>All sites</b>	<b>20</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>4.2</b>	<b>ALL</b>	

### Appendix 45: Cancer Incidence by site and age group, Bajau male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	4	0	0	0	0	0	0	0.9	0	1.5	0	0	0	2.5	0	0	9.6	0	0.33	0.8	0.02	0.07	0.5	C01-02
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	2.5	4.4	0	0	8.9	0.25	0.6	0.03	0.03	0.5	C03-06
Salivary glands	2	0	0	0	0	0.7	0.7	0	0	0	0	0	0	0	0	0	0	0	0.16	0.4	0.01	0.01	0.1	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	8.9	0.16	0.4	0.01	0.01	0.3	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14.1	0	0	0.16	0.4	0	0.07	0.4	C10
Nasopharynx	20	0	0	0	0	0.7	0	0	0	1.5	6.6	6.8	5.4	9.9	0	0	9.6	17.9	1.63	4.2	0.15	0.2	2.2	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	5	0	0	0	0	0	0	0	0	0	0	1.7	1.8	0	8.8	0	0	8.9	0.41	1.1	0.06	0.06	0.7	C15
Stomach	19	0	0	0	0	0	0	0.9	1.1	0	5	6.8	0	4.9	8.8	7	19.2	26.8	1.55	4	0.14	0.27	2.5	C16
Small intestine	4	0	0	0	0	0	0	0	0	0	3.3	1.7	1.8	0	0	0	0	0	0.33	0.8	0.03	0.03	0.4	C17
Colon	96	0	0	0	0	0	1.5	0	6.5	8.8	1.7	25.6	14.3	46.9	39.5	42.3	105.8	116.1	7.85	20.4	0.72	1.46	12.5	C18
Rectum	33	0	0.8	0	0	0	0	0	1.1	2.9	1.7	0	7.1	12.3	17.5	56.3	28.8	35.7	2.7	7	0.22	0.64	5	C19-20
Anus	6	0	0	0	0	0	0	0	0	0	0	0	1.7	1.8	7.4	0	0	9.6	0.49	1.3	0.05	0.1	0.7	C21
Liver	10	0	0	0	0	0	0	0	0	0	0	0	3.4	3.6	4.9	4.4	7	9.6	0.82	2.1	0.08	0.16	1.3	C22
Gallbladder etc.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9.6	0.16	0.4	0.01	0.06	0.3	C23-24
Pancreas	9	0	0	0	0	0	0	0	0	0	1.7	0	1.8	0	13.2	7	9.6	17.9	0.74	1.9	0.08	0.17	1.5	C25
Nose, sinuses etc.	68	0	0	0	0	0	0.7	0	2.2	4.4	6.6	10.2	10.7	27.2	65.8	56.3	96.2	17.9	5.56	14.4	0.64	1.4	9.7	C30-31
Larynx	5	0	0	0	0	0	0	0	0	0	1.7	0	1.8	0	0	14.1	9.6	0	0.41	1.1	0.02	0.14	0.8	C32
Trachea, bronchus and lung	5	0	0	0	0	0.7	1.5	0	0	0	1.7	0	0	0	0	0	9.6	0	0.41	1.1	0.02	0.07	0.5	C33-34
Other thoracic organs	5	0	0	0	0	0	0	0	0	0	1.7	0	1.8	4.9	4.4	0	0	0	0.41	1.1	0.06	0.06	0.6	C37-38
Bone	18	0	0	0	0	0	0	0.9	1.1	0	1.7	3.4	1.8	2.5	8.8	28.2	9.6	35.7	1.47	3.8	0.1	0.29	2.7	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	5	0	0	0	0	0	0.7	0	1.1	0	1.7	1.7	0	0	0	0	0	8.9	0.41	1.1	0.03	0.03	0.5	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9.6	0	0.08	0.2	0	0.05	0.2	C46
Connective and soft tissue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C47,C49
Breast	17	0	0	0	0	0	0	0	0	0	1.7	0	0	4.9	13.2	28.2	38.5	26.8	1.39	3.6	0.1	0.43	3	C50
Penis	7	0	1.6	0.7	0	0.7	0	0	0	0	1.7	1.7	0	0	4.4	0	0	0	0.57	1.5	0.05	0.05	0.7	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	7	0	0	0	0	0	0	0	0	0	0	0	3.6	4.9	8.8	0	9.6	0	0.57	1.5	0.09	0.13	0.9	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	13	0	0	0	0	0	0	0	0	0	0	0	1.8	4.9	0	7	57.7	26.8	1.06	2.8	0.03	0.36	2.2	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	3	0	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.25	0.6	0.01	0.01	0.3	C67
Other urinary organs	6	0	2.4	0.7	0	0	0	0	0	1.5	0	0	1.8	0	0	0	0	0	0.49	1.3	0.03	0.03	0.5	C68
Eye	9	0	0	0	0	0	0	1.9	1.1	1.5	1.7	1.7	1.8	0	8.8	0	0	0	0.74	1.9	0.09	0.09	0.9	C69
Brain, nervous system	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.9	0	0.08	0.2	0	0	0.2	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	44	0	1.6	2.2	1.4	0	0	1.9	0	2.9	6.6	5.1	8.9	12.3	13.2	28.2	28.8	53.6	3.6	9.3	0.28	0.57	5.5	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	0.08	0.2	0.01	0.01	0.1	C75
Hodgkin disease	6	0	0	0	0	0	0	0	1.1	0	0	3.4	1.8	2.5	4.4	0	0	0	0.49	1.3	0.07	0.07	0.6	C81
Non-Hodgkin lymphoma	40	0	5.5	3.7	1.4	0.7	0.7	5.6	3.3	4.4	1.7	0	5.4	4.9	8.8	7	19.2	8.9	3.27	8.5	0.23	0.36	3.9	C82-85,C96
Immunoproliferative diseases	11	0	0.8	0	0	0	0	0	0	0	1.7	0	3.6	4.9	8.8	7	0	17.9	0.9	2.3	0.1	0.13	1.5	C88
Multiple myeloma	489	0	15.1	7.3	2.8	3.5	5.9	12.2	18.5	29.2	51.3	76.8	82.1	167.9	245.6	309.9	500	455.4	39.96	103.8	3.59	7.64	64.2	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	4	0	0	0	0	0	0	0.9	0	1.5	0	0	0	2.5	0	0	9.6	0	0.33	0.8	0.02	0.07	0.5	C92-94
Leukaemia unspecified	3	0	0	0	0	0	0	0	0	0	0	0	0	2.5	4.4	0	0	8.9	0.25	0.6	0.03	0.03	0.5	C95
Myeloproliferative disorders	2	0	0	0	0	0.7	0.7	0	0	0	0	0	0	0	0	0	0	0	0.16	0.4	0.01	0.01	0.1	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	8.9	0.16	0.4	0.01	0.01	0.3	MDS
Other and unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14.1	0	0	0.16	0.4	0	0.07	0.4	O&U
<b>All sites</b>	<b>20</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0.7</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.5</b>	<b>6.6</b>	<b>6.8</b>	<b>5.4</b>	<b>9.9</b>	<b>0</b>	<b>0</b>	<b>9.6</b>	<b>17.9</b>	<b>1.63</b>	<b>4.2</b>	<b>0.15</b>	<b>0.2</b>	<b>2.2</b>	<b>ALL</b>

**Appendix 46: Number of new cancer cases by site and age group, Bajau female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.3	C00
Tongue	9	0	0	0	0	0	0	0	0	0	2	1	1	4	0	0	1	0	1.3	C01-02
Mouth	13	0	0	0	0	0	0	0	0	0	0	0	1	3	1	3	2	1.9	C03-06	
Salivary glands	4	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	1	0.6	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	10	0	0	0	2	0	0	0	1	1	0	1	2	2	0	1	0	1.5	C11	
Hypopharynx	2	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0.3	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	6	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	2	1	0.9	C15
Stomach	13	0	0	0	0	0	0	0	1	2	0	2	1	2	2	2	1	0	1.9	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C17
Colon	66	0	0	0	0	1	3	2	7	7	4	11	9	10	5	2	5	9.9	C18	
Rectum	9	0	0	0	0	0	0	0	1	1	0	3	1	1	1	0	1	1.3	C19-20	
Anus	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0.4	C21	
Liver	4	0	0	0	0	0	0	0	0	0	2	0	0	1	1	0	0	0.6	C22	
Gallbladder etc.	3	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0.4	C23-24	
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C25	
Nose, sinuses etc.	39	0	0	0	0	0	0	0	1	2	2	1	8	3	7	6	5	4	5.8	C30-31
Larynx	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C32
Trachea, bronchus and lung	6	0	0	1	1	2	0	0	0	0	0	0	0	2	0	0	0	0	0.9	C33-34
Other thoracic organs	4	0	0	0	0	0	1	0	0	1	0	0	1	0	1	0	0	0.6	C37-38	
Bone	16	0	0	0	0	0	0	0	2	0	1	2	1	1	0	0	3	6	2.4	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	7	0	3	0	0	0	0	2	0	0	0	0	0	0	1	0	1	0	1	C45
Kaposi sarcoma	134	0	0	0	0	0	0	1	8	19	18	20	31	14	13	3	2	5	20.1	C46
Connective and soft tissue	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.1	C47,C49
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	101	0	0	0	0	0	0	2	3	12	18	17	16	17	7	4	2	3	15.1	C51
Vagina	26	0	0	0	0	0	0	0	2	4	1	3	6	6	3	0	1	0	3.9	C52
Cervix uteri	13	0	0	0	0	0	0	0	0	2	1	4	0	5	0	1	0	0	1.9	C53
Corpus uteri	45	0	0	0	0	2	4	1	4	5	5	11	2	7	2	0	1	1	6.7	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C56
Other female genital organs	4	0	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.6	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0.4	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.3	C67
Other urinary organs	7	0	2	0	0	1	0	2	1	0	1	0	1	0	0	0	0	0	1	C68
Eye	46	0	0	0	2	5	1	4	2	4	2	3	6	3	8	3	1	2	6.9	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	34	0	0	0	1	2	2	2	4	1	4	1	7	2	3	1	3	1	5.1	C74
Other endocrine	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.3	C75
Hodgkin disease	3	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0.4	C81
Non-Hodgkin lymphoma	27	0	9	1	3	1	1	1	0	4	2	1	0	3	0	0	1	0	4	C82-85,C96
Immunoproliferative diseases	16	0	0	1	0	1	0	0	0	2	0	1	3	4	1	2	1	0	2.4	C88
Multiple myeloma	684	0	17	3	9	14	12	18	34	72	66	79	105	95	62	32	33	33	102.4	C90
Lymphoid leukaemia	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.3	C91
Myeloid leukaemia	9	0	0	0	0	0	0	0	0	0	2	1	1	4	0	1	0	1.3	C92-94	
Leukaemia unspecified	13	0	0	0	0	0	0	0	0	0	0	0	1	3	1	3	2	1.9	C95	
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0.6	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1.5</b>	<b>ALL</b>

## Appendix 47: Cancer Incidence by site and age group, Bajau female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	8	0.17	0.3	0.01	0.01	0.3	C00
Tongue	9	0	0	0	0	0	0	0	0	0	3.1	1.8	2.2	11.3	0	0	10	0	0.75	1.3	0.09	0.14	1.1	C01-02
Mouth	13	0	0	0	0	0	0	0	0	0	0	0	2.2	8.5	4.8	20.4	30	16	1.09	1.9	0.08	0.33	2.2	C03-06
Salivary glands	4	0	0	0	0	0	0	0	0	1.4	0	1.8	2.2	0	0	0	10	0	0.33	0.6	0.03	0.08	0.5	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	10	0	0	0	1.5	0	0	0	1	1.4	0	1.8	4.5	5.6	0	6.8	0	0	0.84	1.5	0.08	0.11	1	C11
Hypopharynx	2	0	0	0	0	0	0	0.9	0	0	0	0	2.2	0	0	0	0	0	0.17	0.3	0.02	0.02	0.2	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	6	0	0	0	0	0	0	0	1	1.4	0	0	0	0	4.8	0	20	8	0.5	0.9	0.04	0.14	0.9	C15
Stomach	13	0	0	0	0	0	0	0	1	2.8	0	3.6	2.2	5.6	9.5	13.6	10	0	1.09	1.9	0.12	0.24	1.8	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	0.08	0.1	0	0	0.2	C17
Colon	66	0	0	0	0	0	0.7	2.7	2.1	9.9	10.8	7.2	24.6	25.4	47.6	34	20	40	5.51	9.9	0.66	0.93	8.4	C18
Rectum	9	0	0	0	0	0	0	0	1	1.4	0	5.4	2.2	2.8	4.8	0	10	0	0.75	1.3	0.09	0.14	1.1	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	0	0	2.8	4.8	0	10	0	0.25	0.4	0.04	0.09	0.5	C21
Liver	4	0	0	0	0	0	0	0	0	0	3.1	0	0	2.8	4.8	0	0	0	0.33	0.6	0.05	0.05	0.5	C22
Gallbladder etc.	3	0	0	0	0	0	0.7	0	0	0	0	0	2.2	2.8	0	0	0	0	0.25	0.4	0.03	0.03	0.3	C23-24
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C25
Nose, sinuses etc.	39	0	0	0	0	0	0	0	1	2.8	3.1	1.8	17.9	8.5	33.3	40.8	50	32	3.26	5.8	0.34	0.8	6	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C32
Trachea, bronchus and lung	6	0	0	0.8	0.7	1.4	0	0	0	0	0	0	0	5.6	0	0	0	0	0.5	0.9	0.04	0.04	0.5	C33-34
Other thoracic organs	4	0	0	0	0	0	0.7	0	0	1.4	0	0	0	2.8	0	6.8	0	0	0.33	0.6	0.02	0.06	0.5	C37-38
Bone	16	0	0	0	0	0	0	0	2.1	0	1.5	3.6	2.2	2.8	0	0	30	48	1.34	2.4	0.06	0.21	2.2	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	7	0	2.6	0	0	0	0	1.8	0	0	0	0	0	0	4.8	0	10	0	0.58	1	0.05	0.1	0.8	C45
Kaposi sarcoma	134	0	0	0	0	0	0	0.9	8.2	26.9	27.7	36.2	69.2	39.5	61.9	20.4	20	40	11.19	20.1	1.35	1.56	15.3	C46
Connective and soft tissue	1	0	0	0	0	0	0	0.9	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C47,C49
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	101	0	0	0	0	0	0	1.8	3.1	17	27.7	30.8	35.7	48	33.3	27.2	20	24	8.44	15.1	0.99	1.22	11.6	C51
Vagina	26	0	0	0	0	0	0	0	2.1	5.7	1.5	5.4	13.4	16.9	14.3	0	10	0	2.17	3.9	0.3	0.35	3	C52
Cervix uteri	13	0	0	0	0	0	0	0	0	2.8	1.5	7.2	0	14.1	0	6.8	0	0	1.09	1.9	0.13	0.16	1.5	C53
Corpus uteri	45	0	0	0	0	1.4	3	0.9	4.1	7.1	7.7	19.9	4.5	19.8	9.5	0	10	8	3.76	6.7	0.39	0.44	4.5	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C56
Other female genital organs	4	0	1.7	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	8	0.33	0.6	0.02	0.02	0.5	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	1.4	1.5	0	0	2.8	0	0	0	0	0.25	0.4	0.03	0.03	0.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	0.9	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0.17	0.3	0.01	0.01	0.2	C67
Other urinary organs	7	0	1.7	0	0	0	0.7	0	2.1	1.4	0	1.8	0	0	0	0	0	0	0.58	1	0.04	0.04	0.6	C68
Eye	46	0	0	0	1.5	3.6	0.7	3.5	2.1	5.7	3.1	5.4	13.4	8.5	38.1	20.4	10	16	3.84	6.9	0.43	0.58	5.4	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	34	0	0	0	0.7	1.4	1.5	1.8	4.1	1.4	6.2	1.8	15.6	5.6	14.3	6.8	30	8	2.84	5.1	0.27	0.46	3.8	C74
Other endocrine	2	0	0	0	0	0	0	0	0	0	0	0	1.8	2.2	0	0	0	0	0.17	0.3	0.02	0.02	0.2	C75
Hodgkin disease	3	0	0	0	0	0	0	0	0	0	0	1.8	2.2	2.8	0	0	0	0	0.25	0.4	0.03	0.03	0.3	C81
Non-Hodgkin lymphoma	27	0	7.7	0.8	2.2	0.7	0.7	0.9	0	5.7	3.1	1.8	0	8.5	0	0	10	0	2.26	4	0.16	0.21	2.6	C82-85,C96
Immunoproliferative diseases	16	0	0	0.8	0	0.7	0	0	0	2.8	0	1.8	6.7	11.3	4.8	13.6	10	0	1.34	2.4	0.14	0.26	2	C88
Multiple myeloma	684	0	14.5	2.3	6.6	10.1	8.9	16	34.9	102	101.7	143.1	234.4	268.4	295.2	217.7	330	264	57.14	102.4	6.19	8.93	81	C90
Lymphoid leukaemia	2	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	8	0.17	0.3	0.01	0.01	0.3	C91
Myeloid leukaemia	9	0	0	0	0	0	0	0	0	0	3.1	1.8	2.2	11.3	0	0	10	0	0.75	1.3	0.09	0.14	1.1	C92-94
Leukaemia unspecified	13	0	0	0	0	0	0	0	0	0	0	0	2.2	8.5	4.8	20.4	30	16	1.09	1.9	0.08	0.33	2.2	C95
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	1.4	0	1.8	2.2	0	0	0	10	0	0.33	0.6	0.03	0.08	0.5	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.5</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1.4</b>	<b>0</b>	<b>1.8</b>	<b>4.5</b>	<b>5.6</b>	<b>0</b>	<b>6.8</b>	<b>0</b>	<b>0</b>	<b>0.84</b>	<b>1.5</b>	<b>0.08</b>	<b>0.11</b>	<b>1</b>	<b>ALL</b>

**Appendix 48: Number of new cancer cases by site and age group, Malay male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1.9	C01-02	
Mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-06
Salivary glands	2	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1.3	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	14	0	0	0	1	0	0	2	0	1	0	4	2	1	1	2	0	0	9	0	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.6	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1.3	C15	
Stomach	3	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	1.9	C16	
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	17	0	0	0	0	0	0	0	1	1	3	1	0	7	2	1	1	1	11	0	C18
Rectum	4	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	2.6	C19-20	
Anus	4	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	1	2.6	C21	
Liver	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	1.9	C22	
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1.3	C25	
Nose, sinuses etc.	20	0	0	0	0	0	0	0	0	1	1	3	1	3	4	2	4	1	12.9	C30-31	
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.6	C32	
Trachea, bronchus and lung	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1.3	C33-34	
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.6	C37-38	
Bone	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.3	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	6	0	0	0	0	0	0	0	1	0	1	1	0	2	1	0	0	0	3.9	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.6	C46	
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.6	C47,C49	
Breast	7	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	2	1	4.5	C50	
Penis	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1.3	C60	
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.6	C62	
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	6	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	2	0	3.9	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67
Other urinary organs	4	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	1	0	2.6	C68	
Eye	2	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	1.3	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	25	0	0	1	0	2	0	3	1	1	3	3	2	2	2	1	1	3	16.1	C74	
Other endocrine	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	1.9	C75	
Hodgkin disease	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.6	C81	
Non-Hodgkin lymphoma	14	0	4	1	0	1	0	1	1	0	2	2	0	1	0	0	0	1	9	0	C82-85,C96
Immunoproliferative diseases	3	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	1.9	C88	
Multiple myeloma	157	0	4	4	1	4	3	6	5	7	11	21	11	19	21	14	13	101.3	0	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1.9	C92-94	
Leukaemia unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Myeloproliferative disorders	2	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1.3	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>4</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>9</b>	<b>0</b>	<b>ALL</b>

### Appendix 49: Cancer Incidence by site and age group, Malay male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	4.5	0	10.9	0	0	50	0.45	1.9	0.08	0.08	1.7	C01-02
Mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-06
Salivary glands	2	0	0	1	0	0	0	0	0	0	0	3.9	0	0	0	0	0	0	0.3	1.3	0.02	0.02	0.3	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	14	0	0	0	1.1	0	0	3.7	0	2.8	0	15.7	9.1	6.4	10.9	38.5	0	0	2.1	9	0.25	0.44	3.8	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10.9	0	0	0	0.15	0.6	0.05	0.05	0.4	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	2	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0	0	31.2	0	0.3	1.3	0.01	0.17	0.8	C15
Stomach	3	0	0	0	0	0	0	0	0	0	0	3.9	0	12.7	0	0	0	0	0.45	1.9	0.08	0.08	0.7	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	17	0	0	0	0	0	0	0	0	2.8	3.4	11.8	4.5	0	76.1	38.5	31.2	50	2.56	11	0.49	0.84	7.1	C18
Rectum	4	0	0	0	0	0	0	0	0	0	0	0	0	6.4	21.7	19.2	0	0	0.6	2.6	0.14	0.24	1.7	C19-20
Anus	4	0	0	0	0	0	0	0	0	0	3.4	3.9	0	6.4	0	0	0	50	0.6	2.6	0.07	0.07	1.7	C21
Liver	3	0	0	0	0	0	0	0	0	0	0	0	0	0	10.9	19.2	0	50	0.45	1.9	0.05	0.15	2	C22
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	2	0	0	0	0	0	0	0	0	0	0	0	4.5	0	0	19.2	0	0	0.3	1.3	0.02	0.12	0.8	C25
Nose, sinuses etc.	20	0	0	0	0	0	0	0	0	2.8	3.4	11.8	4.5	19.1	43.5	38.5	125	50	3.01	12.9	0.43	1.24	8.5	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19.2	0	0	0.15	0.6	0	0.1	0.6	C32
Trachea, bronchus and lung	2	0	0	0	0	0	0	0	0	0	3.4	0	0	6.4	0	0	0	0	0.3	1.3	0.05	0.05	0.5	C33-34
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10.9	0	0	0	0.15	0.6	0.05	0.05	0.4	C37-38
Bone	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	50	0	0.3	1.3	0.01	0.01	1.1	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	6	0	0	0	0	0	0	0	2	0	3.4	3.9	0	12.7	10.9	0	0	0	0.9	3.9	0.16	0.16	1.5	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	50	0	0.15	0.6	0	0	1	C46
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	31.2	0	0.15	0.6	0	0.16	0.6	C47,C49
Breast	7	0	0	0	0	0	0	0	0	0	0	0	4.5	6.4	0	38.5	62.5	50	1.05	4.5	0.05	0.56	3.9	C50
Penis	2	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0.3	1.3	0.02	0.02	0.3	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	1	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0	0	0	0	0.15	0.6	0.01	0.01	0.2	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	6	0	0	0	0	0	0	0	2	0	0	0	4.5	6.4	0	19.2	62.5	0	0.9	3.9	0.06	0.47	2.4	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67
Other urinary organs	4	0	0	1	0	0	0	0	0	2.8	3.4	0	0	0	0	0	31.2	0	0.6	2.6	0.04	0.19	1.1	C68
Eye	2	0	0	0	0	0	2	0	0	0	0	3.9	0	0	0	0	0	0	0.3	1.3	0.03	0.03	0.4	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	25	0	0	1	0	4	0	5.6	2	2.8	10.1	11.8	9.1	12.7	21.7	19.2	31.2	150	3.76	16.1	0.4	0.66	8.5	C74
Other endocrine	3	0	0	0	0	0	0	0	0	0	0	3.9	0	6.4	0	0	0	50	0.45	1.9	0.05	0.05	1.5	C75
Hodgkin disease	1	0	0	0	0	0	0	0	0	0	0	0	0	6.4	0	0	0	0	0.15	0.6	0.03	0.03	0.3	C81
Non-Hodgkin lymphoma	14	0	3.3	1	0	2	0	1.9	2	0	6.7	7.8	0	6.4	0	0	0	50	2.1	9	0.16	0.16	3.1	C82-85,C96
Immunoproliferative diseases	3	0	0	0	0	0	2	0	0	0	0	0	4.5	6.4	0	0	0	0	0.45	1.9	0.06	0.06	0.6	C88
Multiple myeloma	157	0	3.3	3.9	1.1	8.1	6.1	11.2	10.1	19.3	36.9	82.4	50	121	228.3	269.2	406.2	650	23.6	101.3	2.91	6.29	57.6	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	3	0	0	0	0	0	0	0	0	0	0	0	4.5	0	10.9	0	0	50	0.45	1.9	0.08	0.08	1.7	C92-94
Leukaemia unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Myeloproliferative disorders	2	0	0	1	0	0	0	0	0	0	0	3.9	0	0	0	0	0	0	0.3	1.3	0.02	0.02	0.3	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.1</b>	<b>0</b>	<b>0</b>	<b>3.7</b>	<b>0</b>	<b>2.8</b>	<b>0</b>	<b>15.7</b>	<b>9.1</b>	<b>6.4</b>	<b>10.9</b>	<b>38.5</b>	<b>0</b>	<b>0</b>	<b>2.1</b>	<b>9</b>	<b>0.25</b>	<b>0.44</b>	<b>3.8</b>	<b>ALL</b>

**Appendix 50: Number of new cancer cases by site and age group, Malay female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.5	C03-06
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.5	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.5	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1.5	1.5	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	16	0	0	0	0	0	0	0	1	2	0	4	1	5	1	2	0	0	8.2	8.2	C18
Rectum	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C22
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	9	0	0	0	0	0	0	1	0	0	1	0	2	1	1	1	1	1	4.6	4.6	C30-31
Larynx	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0.5	C32
Trachea, bronchus and lung	5	0	1	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0	2.6	2.6	C33-34
Other thoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C37-38
Bone	5	0	0	0	0	0	0	0	0	1	0	0	1	0	2	1	0	0	2.6	2.6	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	1	C45
Kaposi sarcoma	62	0	0	0	0	0	0	2	5	7	6	15	11	6	5	4	1	0	31.8	31.8	C46
Connective and soft tissue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C47,C49
Breast	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	C50
Vulva	10	0	0	0	0	0	0	0	1	1	2	2	1	1	0	0	0	2	5.1	5.1	C51
Vagina	9	0	0	0	0	0	0	1	0	0	1	2	2	1	2	0	0	0	4.6	4.6	C52
Cervix uteri	3	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	0	1.5	1.5	C53
Corpus uteri	7	0	1	0	0	0	1	0	1	1	0	2	1	0	0	0	0	0	3.6	3.6	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56
Other female genital organs	3	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1.5	1.5	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.5	0.5	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	C67
Other urinary organs	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	C68
Eye	8	0	0	0	0	1	3	0	1	0	0	0	2	1	0	0	0	0	4.1	4.1	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	24	0	0	1	1	1	0	3	5	0	1	4	7	1	0	0	0	0	12.3	12.3	C74
Other endocrine	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	1	C75
Hodgkin disease	3	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	1.5	1.5	C81
Non-Hodgkin lymphoma	16	0	4	1	1	1	2	0	0	1	0	1	3	1	1	0	0	0	8.2	8.2	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	200	0	10	3	3	3	7	8	15	15	15	31	35	17	17	8	7	6	102.6	102.6	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.5	0.5	C95
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.5	0.5	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0.5</b>	<b>0.5</b>	<b>ALL</b>

## Appendix 51: Cancer Incidence by site and age group, Malay female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.15	0.5	0.02	0.02	0.3	C03-06
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.15	0.5	0.02	0.02	0.3	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	7.5	0	0	0	0	0.15	0.5	0.04	0.04	0.3	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	26.3	64.5	0.46	1.5	0	0.13	1.8	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	16	0	0	0	0	0	0	0	2.9	7.1	0	20.7	7.5	55.6	18.9	52.6	0	2.48	8.2	0.47	0.83	5.8	C18	
Rectum	2	0	0	0	0	0	0	0	0	0	0	0	7.5	0	0	0	32.3	0.31	1	0.04	0.04	0.9	C19-20	
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C22
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	9	0	0	0	0	0	0	1.7	0	0	3.6	0	10.4	7.5	11.1	18.9	26.3	32.3	1.39	4.6	0.17	0.4	3.3	C30-31
Larynx	1	0	0	0	1.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.15	0.5	0.01	0.01	0.1	C32
Trachea, bronchus and lung	5	0	0.9	0	0	0	0	0	4	0	0	0	0	0	22.2	0	0	0	0.77	2.6	0.14	0.14	1.2	C33-34
Other thoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C37-38
Bone	5	0	0	0	0	0	0	0	0	0	3.6	0	0	7.5	0	37.7	26.3	0	0.77	2.6	0.06	0.38	2.2	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	2	0	0	0	0	0	0	0	2.9	0	4.4	0	0	0	0	0	0	0	0.31	1	0.04	0.04	0.4	C45
Kaposi sarcoma	62	0	0	0	0	0	0	3.3	10	20.1	21.4	65.8	57	45.1	55.6	75.5	26.3	0	9.6	31.8	1.39	1.9	17	C46
Connective and soft tissue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C47,C49
Breast	2	0	0	0	0	0	0	0	0	2.9	0	0	0	0	0	0	26.3	0	0.31	1	0.01	0.15	0.7	C50
Vulva	10	0	0	0	0	0	0	0	2	2.9	7.1	8.8	5.2	7.5	0	0	0	64.5	1.55	5.1	0.17	0.17	3.1	C51
Vagina	9	0	0	0	0	0	0	1.7	0	0	3.6	8.8	10.4	7.5	22.2	0	0	0	1.39	4.6	0.27	0.27	2.6	C52
Cervix uteri	3	0	0	0	0	0	0	1.7	0	2.9	0	0	5.2	0	0	0	0	0	0.46	1.5	0.05	0.05	0.6	C53
Corpus uteri	7	0	0.9	0	0	0	2	0	2	2.9	0	8.8	5.2	0	0	0	0	0	1.08	3.6	0.11	0.11	1.3	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56
Other female genital organs	3	0	1.8	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.46	1.5	0.03	0.03	0.5	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.15	0.5	0.02	0.02	0.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.31	1	0.01	0.01	0.2	C67
Other urinary organs	2	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0.31	1	0.01	0.01	0.3	C68
Eye	8	0	0	0	0	2.1	5.9	0	2	0	0	0	10.4	7.5	0	0	0	0	1.24	4.1	0.14	0.14	1.6	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	24	0	0	1	1.2	2.1	0	5	10	0	3.6	17.5	36.3	7.5	0	0	0	0	3.72	12.3	0.42	0.42	4.8	C74
Other endocrine	2	0	0	0	0	0	0	0	0	0	3.6	0	0	7.5	0	0	0	0	0.31	1	0.06	0.06	0.5	C75
Hodgkin disease	3	0	0	0	0	0	0	0	0	2.9	0	0	5.2	0	11.1	0	0	0	0.46	1.5	0.1	0.1	0.9	C81
Non-Hodgkin lymphoma	16	0	3.5	1	1.2	2.1	3.9	0	0	2.9	0	4.4	15.5	7.5	11.1	0	0	0	2.48	8.2	0.27	0.27	3.1	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	200	0	8.9	3	3.5	6.4	13.7	13.3	30.1	43	53.4	136	181.3	127.8	188.9	150.9	184.2	193.5	30.96	102.6	4.05	5.72	54	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.15	0.5	0.02	0.02	0.3	C95
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0	0	0.15	0.5	0.02	0.02	0.3	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>7.5</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0.15</b>	<b>0.5</b>	<b>0.04</b>	<b>0.04</b>	<b>0.3</b>	<b>ALL</b>



**Appendix 52: Number of new cancer cases by site and age group, Murut male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1.9	C01-02	
Mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-06
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	10	0	0	0	0	1	1	0	0	0	1	0	2	2	1	1	1	0	9.4	C11	
Hypopharynx	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9	C12-13	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.9	C14	
Oesophagus	3	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	2.8	C15	
Stomach	12	0	0	0	0	0	0	0	0	0	1	0	2	2	1	2	4	0	11.3	C16	
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	12	0	0	0	0	0	0	0	0	1	2	0	5	0	2	0	0	2	11.3	C18	
Rectum	9	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	2	8.5	C19-20	
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.9	C22	
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	10	0	0	0	0	0	0	0	0	0	1	1	1	2	0	1	2	2	9.4	C30-31	
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.9	C32	
Trachea, bronchus and lung	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9	C33-34	
Other thoracic organs	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	2.8	C37-38	
Bone	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1.9	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.9	C44	
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.9	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.9	C46	
Connective and soft tissue	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1.9	C47,C49	
Breast	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	3	2	6.6	C50	
Penis	2	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1.9	C60	
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1.9	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.9	C67	
Other urinary organs	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.9	C68	
Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain, nervous system	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9	C70-72	
Thyroid	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.9	C73	
Adrenal gland	7	0	0	0	0	0	0	0	0	2	2	0	1	1	0	1	0	0	6.6	C74	
Other endocrine	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9	C75	
Hodgkin disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C81
Non-Hodgkin lymphoma	5	0	2	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	4.7	C82-85,C96	
Immunoproliferative diseases	5	0	0	1	0	0	0	1	0	0	0	0	0	2	1	0	0	0	4.7	C88	
Multiple myeloma	108	0	7	2	1	2	1	4	2	7	7	2	16	16	7	12	13	9	101.9	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1.9	C92-94	
Leukaemia unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>9.4</b>	<b>ALL</b>	

### Appendix 53: Cancer Incidence by site and age group, Murut male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	2	0	0	0	0	0	0	0	0	5.6	0	0	0	0	27.8	0	0	0	0.71	1.9	0.17	0.17	1.5	C01-02
Mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-06
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	10	0	0	0	0	3	3.5	0	0	0	6.4	0	16.9	25	27.8	40	40	0	3.56	9.4	0.41	0.81	5.9	C11
Hypopharynx	1	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0.36	0.9	0.02	0.02	0.3	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	12.5	0	0	0	0	0	0.36	0.9	0.06	0.06	0.5	C14
Oesophagus	3	0	0	0	0	0	0	0	0	5.6	0	0	0	25	0	0	0	0	1.07	2.8	0.15	0.15	1.3	C15
Stomach	12	0	0	0	0	0	0	0	0	0	6.4	0	16.9	25	27.8	80	160	0	4.28	11.3	0.38	1.58	8.9	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	12	0	0	0	0	0	0	0	0	5.6	12.7	0	42.4	0	55.6	0	48.8	0	4.28	11.3	0.58	0.58	6.4	C18
Rectum	9	0	0	0	0	0	0	0	0	5.6	0	7.9	8.5	12.5	27.8	40	40	48.8	3.21	8.5	0.31	0.71	5.8	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	1	0	0	0	0	0	0	0	0	0	0	0	8.5	0	0	0	0	0	0.36	0.9	0.04	0.04	0.4	C22
Gallbladder etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	10	0	0	0	0	0	0	0	0	0	6.4	7.9	8.5	25	0	40	80	48.8	3.56	9.4	0.24	0.84	6.1	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	12.5	0	0	0	0	0	0.36	0.9	0.06	0.06	0.5	C32
Trachea, bronchus and lung	1	0	0	0	3.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.36	0.9	0.02	0.02	0.3	C33-34
Other thoracic organs	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	80	40	0	1.07	2.8	0	0.6	3.2	C37-38
Bone	2	0	0	0	0	0	0	0	0	0	0	0	12.5	0	40	0	0	0.71	1.9	0.06	0.26	1.7	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	24.4	0	0.36	0.9	0	0	0.5	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	12.5	0	0	0	0	0	0.36	0.9	0.06	0.06	0.5	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	8.5	0	0	0	0	0	0.36	0.9	0.04	0.04	0.4	C46
Connective and soft tissue	2	0	0	0	0	0	0	0	0	0	0	0	16.9	0	0	0	0	0.71	1.9	0.08	0.08	0.8	0.4	C47,C49
Breast	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	80	120	48.8	2.49	6.6	0	1	5.8	C50
Penis	2	0	0	0	0	0	0	4	4.5	0	0	0	0	0	0	0	0	0.71	1.9	0.04	0.04	0.6	0.6	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	40	0	0.71	1.9	0	0.4	2	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	6.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.71	1.9	0.03	0.03	0.8	C67
Other urinary organs	2	0	6.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.71	1.9	0.03	0.03	0.8	C68
Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain, nervous system	1	0	3.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.36	0.9	0.02	0.02	0.4	C70-72
Thyroid	1	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0.36	0.9	0.01	0.01	0.3	C73
Adrenal gland	7	0	0	0	0	0	0	0	0	11.3	12.7	0	8.5	12.5	0	40	0	0	2.49	6.6	0.23	0.43	3.6	C74
Other endocrine	1	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0.36	0.9	0.02	0.02	0.3	C75
Hodgkin disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C81
Non-Hodgkin lymphoma	5	0	6.5	3.3	0	0	0	0	4.5	5.6	0	0	0	0	0	0	0	0	1.78	4.7	0.1	0.1	1.7	C82-85,C96
Immunoproliferative diseases	5	0	0	3.3	0	0	0	4	0	0	0	0	25	27.8	0	0	0	0	1.78	4.7	0.3	0.3	2.8	C88
Multiple myeloma	108	0	22.7	6.6	3.1	6	3.5	16.2	8.9	39.5	44.6	15.9	135.6	200	194.4	480	520	219.5	38.48	101.9	3.49	8.49	64.1	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	2	0	0	0	0	0	0	0	0	5.6	0	0	0	0	27.8	0	0	0	0.71	1.9	0.17	0.17	1.5	C92-94
Leukaemia unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>3.5</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>6.4</b>	<b>0</b>	<b>16.9</b>	<b>25</b>	<b>27.8</b>	<b>40</b>	<b>40</b>	<b>0</b>	<b>3.56</b>	<b>9.4</b>	<b>0.41</b>	<b>0.81</b>	<b>5.9</b>	<b>ALL</b>

**Appendix 54: Number of new cancer cases by site and age group, Murut female, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1.4	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C03-06
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	4	0	0	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	2.9	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	2.1	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	18	0	0	0	0	0	1	0	2	0	2	1	4	4	2	0	3	1	12.9	C18
Rectum	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1.4	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	2.1	C21
Liver	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C22
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	6	0	0	0	0	0	0	0	0	0	2	1	0	0	2	1	0	0	4.3	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.7	C32
Trachea, bronchus and lung	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C33-34
Other thoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C37-38
Bone	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1.4	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.7	C45
Kaposi sarcoma	22	0	0	0	0	0	0	1	0	4	3	7	1	3	2	1	0	0	15.7	C46
Connective and soft tissue	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.7	C47,C49
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	33	0	0	0	0	0	0	0	1	7	4	4	7	4	2	2	1	1	23.6	C51
Vagina	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.7	C52
Cervix uteri	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.7	C53
Corpus uteri	11	0	0	1	1	0	0	1	0	1	2	3	0	1	1	0	0	0	7.9	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.7	C56
Other female genital organs	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.7	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	C67
Other urinary organs	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	C68
Eye	6	0	0	0	0	0	0	0	1	0	0	1	2	0	1	0	1	0	4.3	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	7	0	0	0	0	0	1	1	1	1	1	0	0	1	0	0	0	1	5	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C81
Non-Hodgkin lymphoma	5	0	1	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	3.6	C82-85,C96
Immunoproliferative diseases	4	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	1	0	2.9	C88
Multiple myeloma	142	0	3	3	2	3	3	4	4	16	13	21	17	21	11	8	8	5	101.4	C90
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1.4	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2.9</b>	<b>ALL</b>

## Appendix 55: Cancer Incidence by site and age group, Murut female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0	18.5	0.72	1.4	0	0.2	1.6	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	13.9	0	0	0	0	0.36	0.7	0.07	0.07	0.6	C03-06
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	4	0	0	0	0	3.1	0	0	0	0	0	15.9	9.3	0	0	0	0	0	1.45	2.9	0.14	0.14	1.7	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	3	0	0	0	0	0	0	0	4.6	0	0	0	0	0	0	40	40	0	1.09	2.1	0.02	0.42	2.3	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	18	0	0	0	0	0	3.8	0	13	0	7.9	37	55.6	46.5	0	120	18.5	6.52	12.9	0.82	1.42	10.3	C18	
Rectum	2	0	0	0	0	0	0	0	0	0	0	0	0	27.8	0	0	0	0	0.72	1.4	0.14	0.14	1.1	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	0	9.3	0	0	40	0	1.09	2.1	0.05	0.25	2	C21	
Liver	1	0	0	0	0	0	0	0	0	0	0	0	0	13.9	0	0	0	0	0.36	0.7	0.07	0.07	0.6	C22
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	13.9	0	0	0	0	0.36	0.7	0.07	0.07	0.6	C23-24
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	6	0	0	0	0	0	0	0	0	13.6	7.9	0	0	0	46.5	40	0	2.17	4.3	0.34	0.54	4.4	C30-31	
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	23.3	0	0	0.36	0.7	0.12	0.12	0.9	C32	
Trachea, bronchus and lung	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C33-34
Other thoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C37-38
Bone	2	0	0	0	0	0	0	0	0	0	0	0	0	27.8	0	0	0	0	0.72	1.4	0.14	0.14	1.1	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	1	0	0	0	0	3.1	0	0	0	0	0	0	0	0	0	0	0	0	0.36	0.7	0.02	0.02	0.3	C45
Kaposi sarcoma	22	0	0	0	0	0	3.8	0	26	20.4	55.6	9.3	41.7	46.5	40	0	0	7.97	15.7	1.02	1.22	11.6	C46	
Connective and soft tissue	1	0	0	0	0	0	0	0	6.5	0	0	0	0	0	0	0	0	0.36	0.7	0.03	0.03	0.4	C47,C49	
Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C50
Vulva	33	0	0	0	0	0	0	4.6	45.5	27.2	31.7	64.8	55.6	46.5	80	40	18.5	11.95	23.6	1.38	1.98	17.4	C51	
Vagina	1	0	0	0	0	0	0	0	6.8	0	0	0	0	0	0	0	0	0.36	0.7	0.03	0.03	0.4	C52	
Cervix uteri	1	0	0	0	0	0	0	0	0	0	7.9	0	0	0	0	0	0	0.36	0.7	0.04	0.04	0.5	C53	
Corpus uteri	11	0	3.3	3.2	0	0	3.8	0	6.5	13.6	23.8	0	13.9	23.3	0	0	0	3.98	7.9	0.46	0.46	5	C54	
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	3.4	0	0	0	0	0	0	0	0	0	0	0	0.36	0.7	0.02	0.02	0.3	C56	
Other female genital organs	1	0	0	0	0	0	0	0	0	0	0	0	9.3	0	0	0	0	0.36	0.7	0.05	0.05	0.5	C57	
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	6.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.72	1.4	0.03	0.03	0.8	C67	
Other urinary organs	1	0	0	3.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.36	0.7	0.02	0.02	0.3	C68	
Eye	6	0	0	0	0	0	0	4.6	0	0	7.9	18.5	0	23.3	0	40	0	2.17	4.3	0.27	0.47	3.4	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	7	0	0	0	0	3.4	3.8	4.6	6.5	6.8	0	0	13.9	0	0	0	18.5	2.54	5	0.19	0.19	2.6	C74	
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1	0	0	0	0	0	0	0	0	0	0	0	0	13.9	0	0	0	0.36	0.7	0.07	0.07	0.6	C81	
Non-Hodgkin lymphoma	5	0	3.4	3.2	3.1	3.4	0	0	0	0	0	0	0	0	0	40	0	1.81	3.6	0.07	0.27	2	C82-85,C96	
Immunoproliferative diseases	4	0	0	3.3	0	0	0	0	0	0	7.9	0	0	0	0	40	40	1.45	2.9	0.06	0.46	2.8	C88	
Multiple myeloma	142	0	10.2	10	6.3	9.3	10.1	15.3	18.3	103.9	88.4	166.7	157.4	291.7	255.8	320	320	51.43	101.4	5.72	8.92	75.9	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0	0.72	1.4	0	0.2	1.6	C92-94	
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	13.9	0	0	0	0.36	0.7	0.07	0.07	0.6	C95	
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
<b>All sites</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3.1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>15.9</b>	<b>9.3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.45</b>	<b>2.9</b>	<b>0.14</b>	<b>0.14</b>	<b>1.7</b>	<b>ALL</b>	

**Appendix 56: Number of new cancer cases by site and age group, Other Bumiputra male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C00
Tongue	12	0	0	0	0	0	0	1	0	1	2	1	2	1	1	0	1	2	1.2	C01-02
Mouth	5	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0.5	C03-06
Salivary glands	8	0	0	0	0	1	1	0	0	1	1	1	1	0	1	1	1	0	0.8	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0.2	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.2	C10
Nasopharynx	60	0	0	0	2	2	0	2	1	0	6	6	12	8	6	7	4	4	5.9	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0.3	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C14
Oesophagus	12	0	0	0	0	0	0	0	0	0	0	1	2	1	4	1	2	1	1.2	C15
Stomach	41	0	0	0	0	0	1	2	0	1	1	2	3	7	5	3	9	7	4	C16
Small intestine	5	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	1	0	0.5	C17
Colon	153	0	0	0	0	0	2	2	1	5	7	12	22	27	29	17	14	15	15	C18
Rectum	47	0	1	0	0	0	1	1	2	0	2	5	5	9	8	5	3	5	4.6	C19-20
Anus	7	0	0	0	0	0	0	0	0	1	0	1	2	1	1	0	0	1	0.7	C21
Liver	17	0	0	0	0	0	0	0	1	0	0	0	3	2	4	5	2	0	1.7	C22
Gallbladder etc.	9	0	0	0	0	0	0	0	1	0	1	0	2	1	2	1	0	1	0.9	C23-24
Pancreas	15	0	0	0	0	0	0	0	0	1	0	1	1	3	2	1	4	2	1.5	C25
Nose, sinuses etc.	136	0	0	0	0	0	0	0	2	3	6	10	12	24	28	19	15	17	13.3	C30-31
Larynx	6	0	0	0	0	1	1	0	0	0	0	0	0	2	1	0	1	0	0.6	C32
Trachea, bronchus and lung	10	0	0	0	2	2	2	1	1	0	0	0	2	0	0	0	0	0	1	C33-34
Other thoracic organs	10	0	0	0	0	0	0	0	0	1	1	1	0	1	1	0	1	4	1	C37-38
Bone	44	0	0	0	0	1	1	0	1	2	0	4	5	2	7	6	7	8	4.3	C40-41
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C43
Other skin	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0.2	C44
Mesothelioma	19	0	1	0	1	0	1	2	0	2	2	3	3	0	2	1	0	1	1.9	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1	C46
Connective and soft tissue	5	0	0	0	0	0	0	0	0	0	1	0	2	1	1	0	0	0	0.5	C47,C49
Breast	79	0	0	0	0	0	0	0	0	0	0	0	2	8	5	21	19	24	7.7	C50
Penis	14	0	0	0	0	0	4	3	3	3	1	0	0	0	0	0	0	0	1.4	C60
Prostate	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C61
Testis	16	0	0	0	0	0	1	0	1	0	0	0	2	3	3	2	2	1	1.6	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	28	0	0	0	0	0	0	1	1	0	4	0	2	3	4	4	3	6	2.7	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	7	0	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.7	C67
Other urinary organs	24	0	2	5	2	1	0	3	3	0	1	3	2	0	0	1	1	0	2.3	C68
Eye	21	0	0	0	1	1	1	0	0	0	1	2	3	2	5	2	1	2	2.1	C69
Brain, nervous system	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0.2	C70-72
Thyroid	2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0.2	C73
Adrenal gland	113	0	2	3	4	4	8	4	10	5	4	10	15	12	8	10	7	7	11.1	C74
Other endocrine	3	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0.3	C75
Hodgkin disease	12	0	0	0	0	0	0	0	1	0	0	4	2	0	2	2	1	0	1.2	C81
Non-Hodgkin lymphoma	58	0	10	9	3	4	4	2	1	5	2	1	4	4	3	2	2	2	5.7	C82-85,C96
Immunoproliferative diseases	52	0	3	0	0	1	0	1	3	0	4	4	5	7	7	7	6	4	5.1	C88
Multiple myeloma	1066	0	25	17	16	18	28	27	35	31	50	73	120	131	148	120	110	117	104.3	C90
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C91
Myeloid leukaemia	12	0	0	0	0	0	0	1	0	1	2	1	2	1	1	0	1	2	1.2	C92-94
Leukaemia unspecified	5	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0.5	C95
Myeloproliferative disorders	8	0	0	0	0	1	1	0	0	0	1	1	1	0	1	1	1	0	0.8	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0.2	MDS
Other and unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.2	O&U
<b>All sites</b>	<b>60</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>6</b>	<b>6</b>	<b>12</b>	<b>8</b>	<b>6</b>	<b>7</b>	<b>4</b>	<b>4</b>	<b>5.9</b>	<b>ALL</b>

### Appendix 57: Cancer Incidence by site and age group, Other Bumiputra male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	0.06	0.1	0.01	0.01	0.1	C00
Tongue	12	0	0	0	0	0	0	0.6	0	0.9	2.1	1.2	2.8	1.6	2.5	0	5.6	9.2	0.7	1.2	0.06	0.09	0.9	C01-02
Mouth	5	0	0	0	0	0	0	0	0	0	1.2	1.4	1.6	2.5	4.2	0	0	0	0.29	0.5	0.03	0.05	0.4	C03-06
Salivary glands	8	0	0	0	0	0.5	0.5	0	0	0	1.1	1.2	1.4	0	2.5	4.2	5.6	0	0.46	0.8	0.04	0.09	0.6	C07-08
Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	5.6	0	0.12	0.2	0.01	0.03	0.2	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	0	4.6	0	0.12	0.2	0	0.02	0.2	C10
Nasopharynx	60	0	0	0	1	1	0	1.3	0.7	0	6.4	7.1	16.7	12.9	15	29.7	22.3	18.3	3.48	5.9	0.31	0.57	4.8	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	1.1	0	0	0	2.5	0	5.6	0	0.17	0.3	0.02	0.05	0.3	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.6	0	0.06	0.1	0	0	0.1	C14
Oesophagus	12	0	0	0	0	0	0	0	0	0	1.2	2.8	1.6	10	4.2	11.2	4.6	0	0.7	1.2	0.08	0.15	1.1	C15
Stomach	41	0	0	0	0	0	0.5	1.3	0	0.9	1.1	2.4	4.2	11.3	12.5	12.7	50.3	32.1	2.37	4	0.17	0.49	3.6	C16
Small intestine	5	0	0	0	0	0	0	0	0	0	1.1	0	1.4	0	5	0	5.6	0	0.29	0.5	0.04	0.07	0.4	C17
Colon	153	0	0	0	0	0	1.1	1.3	0.7	4.7	7.5	14.2	30.6	43.4	72.5	72	78.2	68.8	8.86	15	0.88	1.63	13.1	C18
Rectum	47	0	0.7	0	0	0	0.5	0.6	1.3	0	2.1	5.9	7	14.5	20	21.2	16.8	22.9	2.72	4.6	0.26	0.45	3.9	C19-20
Anus	7	0	0	0	0	0	0	0	0	0.9	0	1.2	2.8	1.6	2.5	0	4.6	0	0.41	0.7	0.05	0.05	0.5	C21
Liver	17	0	0	0	0	0	0	0	0.7	0	0	0	4.2	3.2	10	21.2	11.2	0	0.98	1.7	0.09	0.25	1.6	C22
Gallbladder etc.	9	0	0	0	0	0	0	0	0.7	0	1.1	0	2.8	1.6	5	4.2	0	4.6	0.52	0.9	0.06	0.08	0.7	C23-24
Pancreas	15	0	0	0	0	0	0	0	0	0.9	0	1.2	1.4	4.8	5	4.2	22.3	9.2	0.87	1.5	0.07	0.2	1.3	C25
Nose, sinuses etc.	136	0	0	0	0	0	0	0	1.3	2.8	6.4	11.8	16.7	38.6	70	80.5	83.8	78	7.88	13.3	0.74	1.56	12.2	C30-31
Larynx	6	0	0	0	0	0.5	0.5	0	0	0	0	0	0	3.2	2.5	0	5.6	0	0.35	0.6	0.03	0.06	0.4	C32
Trachea, bronchus and lung	10	0	0	0	1	1	1.1	0.6	0.7	0	0	0	2.8	0	0	0	0	0	0.58	1	0.04	0.04	0.5	C33-34
Other thoracic organs	10	0	0	0	0	0	0	0	0	0.9	1.1	1.2	0	1.6	2.5	0	5.6	18.3	0.58	1	0.04	0.06	0.8	C37-38
Bone	44	0	0	0	0	0.5	0.5	0	0.7	1.9	0	4.7	7	3.2	17.5	25.4	39.1	36.7	2.55	4.3	0.18	0.5	4	C40-41
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	0.06	0.1	0.01	0.01	0.1	C43
Other skin	2	0	0	0	0	0	0	0	1.3	0	0	0	0	0	0	0	0	0	0.12	0.2	0.01	0.01	0.1	C44
Mesothelioma	19	0	0.7	0	0.5	0	0.5	1.3	0	1.9	2.1	3.6	4.2	0	5	4.2	0	4.6	1.1	1.9	0.1	0.12	1.4	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	0	0	0.06	0.1	0.01	0.01	0.1	C46
Connective and soft tissue	5	0	0	0	0	0	0	0	0	0	1.1	0	2.8	1.6	2.5	0	0	0	0.29	0.5	0.04	0.04	0.4	C47,C49
Breast	79	0	0	0	0	0	0	0	0	0	0	0	2.8	12.9	12.5	89	106.1	110.1	4.58	7.7	0.14	1.12	8.1	C50
Penis	14	0	0	0	0	0	2.2	1.9	2	2.8	1.1	0	0	0	0	0	0	0	0.81	1.4	0.05	0.05	0.7	C60
Prostate	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0	0.06	0.1	0	0.03	0.1	C61
Testis	16	0	0	0	0	0	0.5	0.6	0	0.9	0	0	2.8	4.8	7.5	8.5	11.2	4.6	0.93	1.6	0.09	0.18	1.4	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	28	0	0	0	0	0	0	0.6	0.7	0	4.3	0	2.8	4.8	10	16.9	16.8	27.5	1.62	2.7	0.12	0.28	2.5	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	7	0	4.2	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0.41	0.7	0.03	0.03	0.6	C67
Other urinary organs	24	0	1.4	2.7	1	0.5	0	1.9	2	0	1.1	3.6	2.8	0	0	4.2	5.6	0	1.39	2.3	0.08	0.13	1.5	C68
Eye	21	0	0	0	0.5	0.5	0.5	0	0	0	1.1	2.4	4.2	3.2	12.5	8.5	5.6	9.2	1.22	2.1	0.12	0.19	1.7	C69
Brain, nervous system	2	0	0	0	0	0	0	0.6	0	0	0	0	0	0	2.5	0	0	0	0.12	0.2	0.02	0.02	0.2	C70-72
Thyroid	2	0	0	0	0.5	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0.12	0.2	0.01	0.01	0.1	C73
Adrenal gland	113	0	1.4	1.6	2.1	2.1	4.3	2.5	6.6	4.7	4.3	11.8	20.9	19.3	20	42.4	39.1	32.1	6.55	11.1	0.51	0.92	8.2	C74
Other endocrine	3	0	0	0	0	0	0	0	0.7	0	0	0	0	0	2.5	0	0	4.6	0.17	0.3	0.02	0.02	0.2	C75
Hodgkin disease	12	0	0	0	0	0	0	0	0.7	0	0	4.7	2.8	0	5	8.5	5.6	0	0.7	1.2	0.07	0.14	1	C81
Non-Hodgkin lymphoma	58	0	7.1	4.9	1.6	2.1	2.2	1.3	0.7	4.7	2.1	1.2	5.6	6.4	7.5	8.5	11.2	9.2	3.36	5.7	0.24	0.33	4	C82-85,C96
Immunoproliferative diseases	52	0	2.1	0	0	0.5	0	0.6	2	0	4.3	4.7	7	11.3	17.5	29.7	33.5	18.3	3.01	5.1	0.25	0.57	4.4	C88
Multiple myeloma	1066	0	17.7	9.3	8.3	9.4	15.2	16.9	23.2	29	53.3	86.5	167.1	210.6	370	508.5	614.5	536.7	61.75	104.3	5.08	10.7	88.6	C90
Lymphoid leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	0.06	0.1	0.01	0.01	0.1	C91
Myeloid leukaemia	12	0	0	0	0	0	0	0.6	0	0.9	2.1	1.2	2.8	1.6	2.5	0	5.6	9.2	0.7	1.2	0.06	0.09	0.9	C92-94
Leukaemia unspecified	5	0	0	0	0	0	0	0	0	0	0	1.2	1.4	1.6	2.5	4.2	0	0	0.29	0.5	0.03	0.05	0.4	C95
Myeloproliferative disorders	8	0	0	0	0	0.5	0.5	0	0	0	1.1	1.2	1.4	0	2.5	4.2	5.6	0	0.46	0.8	0.04	0.09	0.6	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	5.6	0	0.12	0.2	0.01	0.03	0.2	MDS
Other and unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	0	4.6	0	0.12	0.2	0	0.02	0.2	O&U
<b>All sites</b>	<b>60</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>1.3</b>	<b>0.7</b>	<b>0</b>	<b>6.4</b>	<b>7.1</b>	<b>16.7</b>	<b>12.9</b>	<b>15</b>	<b>29.7</b>	<b>22.3</b>	<b>18.3</b>	<b>3.48</b>	<b>5.9</b>	<b>0.31</b>	<b>0.57</b>	<b>4.8</b>	<b>ALL</b>

Appendix 58: Number of new cancer cases by site and age group, Other Bumiputra female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	5	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	1	0.4	C00
Tongue	9	0	0	0	0	0	0	1	0	1	0	1	1	0	2	2	1	0	0.7	C01-02
Mouth	9	0	0	0	0	1	0	0	1	1	0	0	0	0	2	0	2	2	0.7	C03-06
Salivary glands	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.2	C07-08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0.2	C10
Nasopharynx	33	0	0	0	0	0	1	1	3	3	5	3	6	4	5	0	0	2	2.6	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	6	0	0	0	0	0	0	0	0	0	1	0	0	3	0	1	1	0	0.5	C15
Stomach	30	0	0	0	0	0	0	0	1	1	1	4	2	8	5	1	2	5	2.3	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C17
Colon	100	0	0	0	0	0	2	1	1	5	3	11	19	19	11	6	13	9	7.8	C18
Rectum	17	0	2	0	0	0	0	0	0	1	0	1	5	0	4	2	1	1	1.3	C19-20
Anus	9	0	0	0	0	0	0	0	0	0	1	1	1	2	0	1	1	2	0.7	C21
Liver	14	0	0	0	0	0	1	0	0	0	0	1	2	5	0	2	2	1	1.1	C22
Gallbladder etc.	4	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	1	0.3	C23-24
Pancreas	4	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0.3	C25
Nose, sinuses etc.	66	0	0	0	0	0	0	2	2	2	1	5	6	9	7	10	11	11	5.1	C30-31
Larynx	9	0	0	0	0	0	0	0	0	0	1	1	0	1	2	1	3	0	0.7	C32
Trachea, bronchus and lung	7	0	0	0	2	2	2	0	0	1	0	0	0	0	0	0	0	0	0.5	C33-34
Other thoracic organs	8	0	0	0	0	0	1	0	0	0	0	1	2	0	2	1	1	0	0.6	C37-38
Bone	38	0	0	0	0	0	0	1	0	1	3	1	2	5	5	5	6	9	3	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	15	0	1	0	0	0	1	0	0	1	0	1	3	3	1	2	1	1	1.2	C45
Kaposi sarcoma	374	0	0	0	1	0	1	9	19	37	64	61	82	45	36	9	4	6	29	C46
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C47,C49
Breast	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C50
Vulva	182	0	0	0	0	0	0	8	9	17	30	32	34	20	16	8	4	4	14.1	C51
Vagina	57	0	0	0	0	0	0	1	0	6	4	8	13	13	6	3	3	0	4.4	C52
Cervix uteri	21	0	0	0	0	0	0	1	3	3	1	0	3	5	4	1	0	0	1.6	C53
Corpus uteri	59	0	0	0	0	7	2	2	3	3	5	8	9	8	7	2	2	1	4.6	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C56
Other female genital organs	6	0	1	1	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0.5	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.2	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67
Other urinary organs	15	0	1	3	2	1	0	2	0	2	0	1	0	1	0	1	1	1	1.2	C68
Eye	64	0	0	0	0	2	5	10	2	2	9	7	11	5	6	2	1	2	5	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	68	0	2	1	1	3	4	5	1	2	6	10	4	8	4	8	5	4	5.3	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C75
Hodgkin disease	8	0	0	0	0	0	0	0	0	0	0	1	3	2	0	0	0	2	0.6	C81
Non-Hodgkin lymphoma	48	0	6	7	4	1	2	1	2	3	3	1	2	7	3	4	1	1	3.7	C82-85,C96
Immunoproliferative diseases	26	0	1	0	0	1	0	0	1	1	6	2	2	4	3	1	3	1	2	C88
Multiple myeloma	1326	0	14	12	10	19	22	45	49	92	147	164	221	180	134	72	72	73	103	C90
Lymphoid leukaemia	5	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	1	0.4	C91
Myeloid leukaemia	9	0	0	0	0	0	0	1	0	1	0	1	1	0	2	2	1	0	0.7	C92-94
Leukaemia unspecified	9	0	0	0	0	1	0	0	1	1	0	0	0	0	2	0	2	2	0.7	C95
Myeloproliferative disorders	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.2	MPD
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	MDS
Other and unspecified	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0.2	O&U
All sites	33	0	0	0	0	0	1	1	3	3	5	3	6	4	5	0	0	2	2.6	ALL

## Appendix 59: Cancer Incidence by site and age group, Other Bumiputra female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	5	0	0	0	0	0	0	0	0	0	0	0	1.5	1.9	0	0	12.4	5.3	0.29	0.4	0.02	0.08	0.5	C00
Tongue	9	0	0	0	0	0	0	0.6	0	0.9	0	1.2	1.5	0	6	9	6.2	0	0.53	0.7	0.05	0.13	0.9	C01-02
Mouth	9	0	0	0	0	0.5	0	0	0.7	0.9	0	0	0	0	6	0	12.4	10.7	0.53	0.7	0.04	0.1	0.8	C03-06
Salivary glands	2	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	5.3	0.12	0.2	0.01	0.01	0.2	C07-08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.3	0.06	0.1	0	0	0.1	C09
Other oropharynx	3	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	5.3	0.18	0.2	0.01	0.01	0.2	C10
Nasopharynx	33	0	0	0	0	0	0.5	0.6	2	2.7	5.1	3.6	8.7	7.5	14.9	0	10.7	1.93	2.6	0.23	0.23	2.4	C11	
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0	0.06	0.1	0.01	0.01	0.1	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	6	0	0	0	0	0	0	0	0	0	1	0	0	5.6	0	4.5	6.2	0	0.35	0.5	0.03	0.09	0.5	C15
Stomach	30	0	0	0	0	0	0	0	0.7	0.9	1	4.8	2.9	15	14.9	4.5	12.4	26.7	1.76	2.3	0.2	0.29	2.7	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.3	0.06	0.1	0	0	0.1	C17
Colon	100	0	0	0	0	0	1	0.6	0.7	4.5	3.1	13.3	27.7	35.6	32.7	26.9	80.7	48.1	5.86	7.8	0.6	1.13	8.9	C18
Rectum	17	0	1.4	0	0	0	0	0	0	0.9	0	1.2	7.3	0	11.9	9	6.2	5.3	1	1.3	0.11	0.19	1.6	C19-20
Anus	9	0	0	0	0	0	0	0	0	0	1	1.2	1.5	3.7	0	4.5	6.2	10.7	0.53	0.7	0.04	0.09	0.8	C21
Liver	14	0	0	0	0	0	0.5	0	0	0	0	1.2	2.9	9.4	0	9	12.4	5.3	0.82	1.1	0.07	0.18	1.3	C22
Gallbladder etc.	4	0	0	0	0	0	0	0	0.7	0.9	0	1.2	0	0	0	0	0	5.3	0.23	0.3	0.01	0.01	0.3	C23-24
Pancreas	4	0	0	0	0	0	0	0	0	0	0	0	1.5	1.9	6	0	0	0	0.23	0.3	0.05	0.05	0.4	C25
Nose, sinuses etc.	66	0	0	0	0	0	0	1.2	1.3	1.8	1	6	8.7	16.9	20.8	44.8	68.3	58.8	3.87	5.1	0.29	0.85	6.5	C30-31
Larynx	9	0	0	0	0	0	0	0	0	0	1	1.2	0	1.9	6	4.5	18.6	0	0.53	0.7	0.05	0.17	1	C32
Trachea, bronchus and lung	7	0	0	0	1.1	1	1	0	0	0.9	0	0	0	0	0	0	0	0	0.41	0.5	0.02	0.02	0.3	C33-34
Other thoracic organs	8	0	0	0	0	0	0.5	0	0	0	0	1.2	2.9	0	6	4.5	6.2	0	0.47	0.6	0.05	0.11	0.8	C37-38
Bone	38	0	0	0	0	0	0	0.6	0	0.9	3.1	1.2	2.9	9.4	14.9	22.4	37.3	48.1	2.23	3	0.16	0.46	3.9	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	15	0	0.7	0	0	0	0.5	0	0	0.9	0	1.2	4.4	5.6	3	9	6.2	5.3	0.88	1.2	0.08	0.16	1.3	C45
Kaposi sarcoma	374	0	0	0	0.5	0	0.5	5.2	12.4	33.7	65.6	73.7	119.5	84.3	107.1	40.4	24.8	32.1	21.91	29	2.51	2.84	27.6	C46
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.06	0.1	0	0	0.1	C47,C49
Breast	1	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	0	0.06	0.1	0.01	0.01	0.1	C50
Vulva	182	0	0	0	0	0	0	4.7	5.9	15.5	30.7	38.6	49.6	37.5	47.6	35.9	24.8	21.4	10.66	14.1	1.15	1.45	13.7	C51
Vagina	57	0	0	0	0	0	0	0.6	0	5.5	4.1	9.7	19	24.3	17.9	13.5	18.6	0	3.34	4.4	0.4	0.57	4.6	C52
Cervix uteri	21	0	0	0	0	0	0	0.6	2	2.7	1	0	4.4	9.4	11.9	4.5	0	0	1.23	1.6	0.16	0.18	1.6	C53
Corpus uteri	59	0	0	0	0	3.7	1	1.2	2	2.7	5.1	9.7	13.1	15	20.8	9	12.4	5.3	3.46	4.6	0.37	0.48	4.4	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	1	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0.06	0.1	0	0	0	C56
Other female genital organs	6	0	0.7	0.6	0	0	0	0	0	0	0	0	5.8	0	0	0	0	0	0.35	0.5	0.04	0.04	0.4	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	3	0	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	6.2	5.3	0.18	0.2	0.01	0.04	0.3	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C67
Other urinary organs	15	0	0.7	1.7	1.1	0.5	0	1.2	0	0	2	0	1.5	0	3	0	6.2	5.3	0.88	1.2	0.06	0.09	1	C68
Eye	64	0	0	0	0	1	2.6	5.8	1.3	1.8	9.2	8.5	16	9.4	17.9	9	6.2	10.7	3.75	5	0.37	0.44	4.5	C69
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C73
Adrenal gland	68	0	1.4	0.6	0.5	1.6	2.1	2.9	0.7	1.8	6.1	12.1	5.8	15	11.9	35.9	31.1	21.4	3.98	5.3	0.31	0.65	5.6	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	0	0	0.06	0.1	0.01	0.01	0.1	C75
Hodgkin disease	8	0	0	0	0	0	0	0	0	0	0	1.2	4.4	3.7	0	0	10.7	0.47	0.6	0.05	0.05	0.7	C81	
Non-Hodgkin lymphoma	48	0	4.3	4	2.2	0.5	1	0.6	1.3	2.7	3.1	1.2	2.9	13.1	8.9	17.9	6.2	5.3	2.81	3.7	0.23	0.35	3.6	C82-85,C96
Immunoproliferative diseases	26	0	0.7	0	0	0.5	0	0	0.7	0.9	6.1	2.4	2.9	7.5	8.9	4.5	18.6	5.3	1.52	2	0.15	0.27	2.2	C88
Multiple myeloma	1326	0	10.1	6.8	5.5	9.9	11.5	26.2	31.9	83.7	150.6	198.1	322.2	337.1	398.8	322.9	447.2	390.4	77.68	103	7.96	11.81	106.1	C90
Lymphoid leukaemia	5	0	0	0	0	0	0	0	0	0	0	0	1.5	1.9	0	0	12.4	5.3	0.29	0.4	0.02	0.08	0.5	C91
Myeloid leukaemia	9	0	0	0	0	0	0	0.6	0	0.9	0	1.2	1.5	0	6	9	6.2	0	0.53	0.7	0.05	0.13	0.9	C92-94
Leukaemia unspecified	9	0	0	0	0	0.5	0	0	0.7	0.9	0	0	0	0	6	0	12.4	10.7	0.53	0.7	0.04	0.1	0.8	C95
Myeloproliferative disorders	2	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	5.3	0.12	0.2	0.01	0.01	0.2	MPD
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.3	0.06	0.1	0	0	0.1	MDS
Other and unspecified	3	0	0	0	0	0	0	0	0	0	1	1.2	0	0	0	0	0	5.3	0.18	0.2	0.01	0.01	0.2	O&U
All sites	33	0	0	0	0	0	0.5	0.6	2	2.7	5.1	3.6	8.7	7.5	14.9	0	10.7	1.93	2.6	0.23	0.23	2.4	ALL	



**Appendix 60: Number of new cancer cases by site and age group, Others male, Sabah, 2012-2016**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	1.1	C03-06	
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.4	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.4	C10	
Nasopharynx	13	0	0	0	0	2	0	1	0	1	0	2	2	4	0	0	1	0	4.9	C11	
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	3	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	1.1	C15	
Stomach	17	0	0	0	0	0	0	0	0	1	0	0	1	2	2	2	4	5	6.4	C16	
Small intestine	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.7	C17	
Colon	48	0	0	0	0	0	1	1	0	2	0	3	4	10	11	3	5	8	18	C18	
Rectum	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	1.1	C19-20	
Anus	6	0	0	0	0	0	0	0	0	0	0	1	3	1	0	0	1	0	2.2	C21	
Liver	6	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	2.2	C22		
Gallbladder etc.	2	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0.7	C23-24		
Pancreas	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1.1	C25		
Nose, sinuses etc.	28	0	0	0	0	0	0	0	0	1	2	2	1	9	4	3	4	2	10.5	C30-31	
Larynx	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	1.1	C32	
Trachea, bronchus and lung	3	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	1	1.1	C33-34	
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4	C37-38		
Bone	18	0	0	0	1	0	1	2	0	0	2	1	2	2	0	2	5	6.7	C40-41		
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	10	0	0	0	1	2	0	1	0	1	1	0	0	1	1	0	0	2	3.7	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.4	C46		
Connective and soft tissue	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.4	C47,C49		
Breast	21	0	0	0	0	0	0	0	1	0	0	0	0	1	2	5	5	7.9	C50		
Penis	4	0	1	0	0	0	0	0	3	0	0	0	0	0	0	0	0	1.5	C60		
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	1.1	C62	
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.4	C63		
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	7	0	0	1	0	0	0	0	1	0	0	1	0	1	1	0	0	2	2.6	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.7	C67		
Other urinary organs	13	0	0	2	2	3	0	2	0	2	1	0	0	1	0	0	0	4.9	C68		
Eye	5	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	2	1.9	C69		
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4	C73		
Adrenal gland	30	0	1	0	1	0	2	1	2	1	2	5	4	1	4	4	2	11.2	C74		
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.7	C81		
Non-Hodgkin lymphoma	14	0	3	3	1	1	0	1	0	1	1	0	3	0	0	0	0	5.2	C82-85,C96		
Immunoproliferative diseases	9	0	0	0	0	0	0	0	0	1	1	3	1	1	0	0	1	3.4	C88		
Multiple myeloma	285	0	6	6	10	6	11	7	14	9	21	24	42	30	22	32	39	106.7	C90		
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1.1	C95		
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.4	MPD		
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.4	O&U		
All sites	13	0	0	0	0	2	0	1	0	1	0	2	2	4	0	0	1	0	4.9	ALL	

## Appendix 61: Cancer Incidence by site and age group, Others male, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	8.7	14.5	26.3	0	0	0	0.93	1.1	0.12	0.25	1.7	C03-06
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0	0.31	0.4	0	0.2	0.8	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0	0.31	0.4	0	0.2	0.8	C10
Nasopharynx	13	0	0	0	0	5.6	0	3.9	0	5.7	0	13.6	15.2	34.8	0	0	40	0	4.01	4.9	0.39	0.59	4.9	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	3	0	0	0	0	0	0	3.9	0	0	0	0	8.7	0	26.3	0	0	0	0.93	1.1	0.06	0.19	1.4	C15
Stomach	17	0	0	0	0	0	0	0	0	5.7	0	7.6	17.4	29	52.6	160	111.1	5.25	6.4	0.3	1.36	9.6	C16	
Small intestine	2	0	0	0	0	0	0	0	0	0	6.6	0	0	8.7	0	0	0	0	0.62	0.7	0.08	0.08	0.7	C17
Colon	48	0	0	0	0	0	3.1	3.9	0	11.4	0	20.4	30.3	87	159.4	78.9	200	177.8	14.82	18	1.58	2.97	23.8	C18
Rectum	3	0	0	0	0	0	0	0	0	0	0	6.8	0	0	0	0	44.4	0.93	1.1	0.03	0.03	1.3	C19-20	
Anus	6	0	0	0	0	0	0	0	0	0	0	6.8	22.7	8.7	0	0	40	1.85	2.2	0.19	0.39	2.7	C21	
Liver	6	0	0	0	0	0	0	0	0	0	0	6.8	0	0	14.5	52.6	0	1.85	2.2	0.11	0.37	3.5	C22	
Gallbladder etc.	2	0	0	0	0	0	3.1	0	0	0	0	0	7.6	0	0	0	0	0.62	0.7	0.05	0.05	0.6	C23-24	
Pancreas	3	0	0	0	0	0	0	0	0	0	0	0	0	8.7	0	0	40	0.93	1.1	0.04	0.24	1.6	C25	
Nose, sinuses etc.	28	0	0	0	0	0	0	0	0	5.7	13.2	13.6	7.6	78.3	58	78.9	160	8.65	10.5	0.88	2.08	14.2	C30-31	
Larynx	3	0	0	0	0	0	0	0	0	0	0	0	17.4	0	0	0	22.2	0.93	1.1	0.09	0.09	1.1	C32	
Trachea, bronchus and lung	3	0	0	0	0	2.8	0	3.9	0	0	0	0	7.6	0	0	0	0	0.93	1.1	0.07	0.07	0.9	C33-34	
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	8.7	0	0	0	0	0.31	0.4	0.04	0.04	0.3	C37-38	
Bone	18	0	0	0	2.7	0	3.1	7.7	0	0	0	13.6	7.6	17.4	29	0	80	111.1	5.56	6.7	0.41	0.81	8	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	10	0	0	0	2.7	5.6	0	3.9	0	5.7	6.6	0	0	8.7	14.5	0	0	44.4	3.09	3.7	0.24	0.24	3.6	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	26.3	0	0.31	0.4	0	0.13	0.8	C46	
Connective and soft tissue	1	0	0	0	0	0	0	0	0	5.7	0	0	0	0	0	0	0	0.31	0.4	0.03	0.03	0.3	C47,C49	
Breast	21	0	0	0	0	0	0	0	4.3	0	0	0	0	8.7	29	131.6	200	6.49	7.9	0.21	1.87	12.8	C50	
Penis	4	0	2.4	0	0	0	0	0	13	0	0	0	0	0	0	0	0	1.24	1.5	0.08	0.08	1.1	C60	
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C61
Testis	3	0	0	0	0	0	0	0	0	5.7	0	0	7.6	0	0	0	0	0.93	1.1	0.07	0.07	1.2	C62	
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0.31	0.4	0	0.2	0.8	C63	
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	7	0	0	2.5	0	0	0	0	4.3	0	0	6.8	0	8.7	14.5	0	0	2.16	2.6	0.18	0.18	2.7	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	2.4	0	0	0	3.1	0	0	0	0	0	0	0	0	0	0	0.62	0.7	0.03	0.03	0.5	C67	
Other urinary organs	13	0	0	5.1	5.5	8.5	0	7.7	0	11.4	6.6	0	0	8.7	0	0	0	4.01	4.9	0.27	0.27	3.8	C68	
Eye	5	0	0	0	0	0	0	0	0	5.7	0	0	7.6	8.7	0	0	80	1.54	1.9	0.11	0.51	2.7	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	1	0	0	0	0	2.8	0	0	0	0	0	0	0	0	0	0	0	0.31	0.4	0.01	0.01	0.3	C73	
Adrenal gland	30	0	2.4	0	2.7	0	6.2	3.9	8.7	5.7	13.2	34	30.3	8.7	58	105.3	80	9.26	11.2	0.87	1.8	14	C74	
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	2	0	0	0	0	0	0	0	0	0	0	0	0	0	14.5	0	40	0.62	0.7	0.07	0.27	1.4	C81	
Non-Hodgkin lymphoma	14	0	7.2	7.6	2.7	2.8	0	3.9	0	5.7	6.6	0	22.7	0	0	0	0	4.32	5.2	0.3	0.3	4.3	C82-85,C96	
Immunoproliferative diseases	9	0	0	0	0	0	0	0	0	5.7	6.6	20.4	7.6	8.7	0	0	40	2.78	3.4	0.24	0.44	3.9	C88	
Multiple myeloma	285	0	14.4	15.2	16.5	28.2	18.8	42.5	30.4	80	59.2	142.9	181.8	365.2	434.8	578.9	1280	88.02	106.7	7.15	16.44	132.3	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	3	0	0	0	0	0	0	0	0	0	0	0	8.7	14.5	26.3	0	0	0.93	1.1	0.12	0.25	1.7	C95	
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0.31	0.4	0	0.2	0.8	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	0.31	0.4	0	0.2	0.8	O&U	
All sites	13	0	0	0	0	5.6	0	3.9	0	5.7	0	13.6	15.2	34.8	0	0	40	4.01	4.9	0.39	0.59	4.9	ALL	

Appendix 62: Number of new cancer cases by site and age group, Others female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.3	C03-06	
Salivary glands	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	6	0	0	0	1	0	0	0	1	0	1	0	1	0	1	0	0	1	1.9	C11	
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	8	0	0	0	0	0	0	0	0	0	0	1	2	2	2	2	0	1	2.6	C16	
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.3	C17	
Colon	19	0	0	0	0	0	0	0	1	1	0	3	4	3	1	3	3	6.1	C18		
Rectum	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.6	C19-20		
Anus	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.3	C21		
Liver	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.3	C22		
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.3	C23-24		
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	9	0	0	0	0	0	0	0	0	0	1	0	4	1	1	1	1	2.9	C30-31		
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.3	C32		
Trachea, bronchus and lung	3	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	1	0.3	C33-34	
Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.6	C37-38		
Bone	21	0	0	0	0	0	0	0	0	1	1	0	4	3	3	3	3	6.8	C40-41		
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	4	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1.3	C45		
Kaposi sarcoma	101	0	0	0	0	0	0	4	5	13	15	17	14	13	8	4	5	32.6	C46		
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.3	C47,C49		
Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.3	C50		
Vulva	34	0	0	0	0	0	0	0	3	1	5	5	6	6	2	2	2	11	C51		
Vagina	12	0	0	0	0	0	0	1	2	0	1	1	1	3	3	0	0	3.9	C52		
Cervix uteri	4	0	0	0	0	0	0	0	1	0	1	0	1	1	1	0	0	1.3	C53		
Corpus uteri	16	0	0	0	1	1	0	2	2	0	1	1	2	2	2	0	2	5.2	C54		
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56
Other female genital organs	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	1.3	C57		
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.3	C65		
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	C67		
Other urinary organs	3	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.6	C68	
Eye	21	0	0	0	0	2	3	3	1	4	4	1	1	0	0	1	1	6.8	C69		
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.3	C73		
Adrenal gland	19	0	0	0	1	1	1	0	2	1	3	3	1	1	3	0	2	6.1	C74		
Other endocrine	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.3	C75		
Hodgkin disease	6	0	0	0	0	0	0	0	0	0	0	0	1	1	3	0	1	1.9	C81		
Non-Hodgkin lymphoma	15	0	1	0	0	2	1	0	1	3	4	1	0	0	1	1	1	4.8	C82-85,C96		
Immunoproliferative diseases	8	0	0	0	0	0	1	0	1	2	0	2	0	1	1	0	0	2.6	C88		
Multiple myeloma	331	0	5	1	4	4	5	12	19	22	40	37	48	40	35	18	23	106.8	C90		
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.3	C95		
Myeloproliferative disorders	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	MPD		
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
All sites	6	0	0	0	1	0	0	0	1	0	1	0	1	0	1	0	0	1.9	ALL		

### Appendix 63: Cancer Incidence by site and age group, Others female, Sabah, 2012-2016

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C01-02
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	37	0	0	0.33	0.3	0	0.19	1.1	C03-06
Salivary glands	1	0	0	0	2.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0.33	0.3	0.01	0.01	0.2	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	6	0	0	0	2.8	0	0	0	4.1	0	7.2	0	9.9	0	20	0	0	90.9	1.97	1.9	0.22	0.22	4	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C15
Stomach	8	0	0	0	0	0	0	0	0	0	0	8.5	19.8	25.6	0	74.1	0	90.9	2.63	2.6	0.27	0.64	6.6	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	90.9	0.33	0.3	0	0	1.8	C17
Colon	19	0	0	0	0	0	0	0	5.7	7.2	0	29.7	51.3	60	37	120	272.7	6.25	6.1	0.77	1.55	15.7	C18	
Rectum	2	0	0	0	0	0	0	0	4.1	0	0	0	0	0	0	0	90.9	0.66	0.6	0.02	0.02	2.1	C19-20	
Anus	1	0	0	0	0	0	0	0	0	0	0	0	9.9	0	0	0	0	0.33	0.3	0.05	0.05	0.5	C21	
Liver	1	0	0	0	0	0	0	0	0	0	0	0	0	0	20	0	0	0.33	0.3	0.1	0.1	0.8	C22	
Gallbladder etc.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	37	0	0.33	0.3	0	0.19	1.1	C23-24	
Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C25
Nose, sinuses etc.	9	0	0	0	0	0	0	0	0	0	7.2	0	39.6	12.8	20	37	40	0	2.96	2.9	0.4	0.78	5.6	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	20	0	0	0.33	0.3	0.1	0.1	0.8	C32	
Trachea, bronchus and lung	3	0	2.5	0	0	6.1	0	0	0	0	0	0	0	0	0	0	0	0.99	1	0.04	0.04	0.9	C33-34	
Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	0	0	12.8	0	40	0	0.66	0.6	0.06	0.26	1.3	C37-38	
Bone	21	0	0	0	0	0	0	0	5.7	7.2	0	39.6	38.5	60	111.1	120	272.7	6.91	6.8	0.76	1.91	17.9	C40-41	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43
Other skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C44
Mesothelioma	4	0	0	0	0	0	0	0	5.7	7.2	0	0	0	0	0	40	90.9	1.32	1.3	0.06	0.26	3.4	C45	
Kaposi sarcoma	101	0	0	0	0	0	14.4	20.7	74.3	108.7	144.1	138.6	166.7	160	148.1	200	272.7	33.25	32.6	4.14	5.88	55.9	C46	
Connective and soft tissue	1	0	0	0	0	0	0	0	0	0	0	0	9.9	0	0	0	0	0.33	0.3	0.05	0.05	0.5	C47,C49	
Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	12.8	0	0	0	0.33	0.3	0.06	0.06	0.5	C50	
Vulva	34	0	0	0	0	0	0	12.4	5.7	36.2	42.4	59.4	76.9	40	74.1	80	181.8	11.19	11	1.37	2.14	20.9	C51	
Vagina	12	0	0	0	0	0	3.6	8.3	0	7.2	8.5	9.9	38.5	60	0	0	0	3.95	3.9	0.68	0.68	6.2	C52	
Cervix uteri	4	0	0	0	0	0	0	0	5.7	0	8.5	0	12.8	20	0	0	0	1.32	1.3	0.24	0.24	2.2	C53	
Corpus uteri	16	0	0	0	2.8	3.1	0	7.2	8.3	0	7.2	8.5	19.8	25.6	40	0	181.8	5.27	5.2	0.61	0.61	9.8	C54	
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C56
Other female genital organs	4	0	0	0	0	0	0	0	0	0	0	0	19.8	0	20	37	0	1.32	1.3	0.2	0.38	2.9	C57	
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	20	0	0	0.33	0.3	0.1	0.1	0.8	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	2	0	2.5	0	0	0	0	0	0	0	0	0	0	0	0	0	90.9	0.66	0.6	0.01	0.01	2.1	C67	
Other urinary organs	3	0	5.1	2.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.99	1	0.04	0.04	0.9	C68	
Eye	21	0	0	0	0	0	6.4	10.8	12.4	5.7	29	33.9	9.9	12.8	0	40	90.9	6.91	6.8	0.6	0.8	9.9	C69	
Brain, nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C70-72
Thyroid	1	0	0	0	0	0	0	0	0	0	0	0	9.9	0	0	0	0	0.33	0.3	0.05	0.05	0.5	C73	
Adrenal gland	19	0	0	0	2.8	3.1	3.2	0	8.3	5.7	21.7	25.4	9.9	12.8	60	0	181.8	6.25	6.1	0.76	0.76	11.5	C74	
Other endocrine	1	0	0	0	0	0	0	0	0	0	7.2	0	0	0	0	0	0	0.33	0.3	0.04	0.04	0.4	0.4	C75
Hodgkin disease	6	0	0	0	0	0	0	0	0	0	0	0	9.9	12.8	60	0	90.9	1.97	1.9	0.41	0.41	5.2	C81	
Non-Hodgkin lymphoma	15	0	2.5	0	0	0	6.4	3.6	0	5.7	21.7	33.9	9.9	0	37	40	0	4.94	4.8	0.42	0.8	7.2	C82-85,C96	
Immunoproliferative diseases	8	0	0	0	0	0	0	3.6	0	5.7	14.5	0	19.8	0	20	37	0	2.63	2.6	0.32	0.5	4.4	C88	
Multiple myeloma	331	0	12.7	2.5	11	12.3	16	43.2	78.8	125.7	289.9	313.6	475.2	512.8	700	666.7	720	108.95	106.8	12.97	19.9	205.6	C90	
Lymphoid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C91
Myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	37	0	0.33	0.3	0	0.19	1.1	C95	
Myeloproliferative disorders	1	0	0	0	2.8	0	0	0	0	0	0	0	0	0	0	0	0	0.33	0.3	0.01	0.01	0.2	0.2	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O&U
All sites	6	0	0	0	2.8	0	0	0	4.1	0	7.2	0	9.9	0	20	0	0	90.9	1.97	1.9	0.22	0.22	4	ALL

**Appendix 64: Number of new cancer cases by site and age group, all residents, Male, Sabah, 2011**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0.4	C01-02
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0.4	C03-06	
Salivary glands	6	0	0	0	0	0	1	0	1	1	0	0	0	0	1	1	1	0	0.8	C07-08	
Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0.4	C09	
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C10	
Nasopharynx	76	0	0	0	1	3	2	3	4	2	6	12	16	10	7	8	1	1	10.1	C11	
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0.4	C12-13	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C14	
Oesophagus	13	0	0	0	0	0	0	0	0	0	0	1	3	1	0	1	2	5	1.7	C15	
Stomach	55	0	0	0	0	0	0	1	0	0	1	5	6	7	8	8	8	11	7.3	C16	
Small intestine	4	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0.5	C17	
Colon	57	0	0	0	0	0	1	0	2	1	2	2	5	10	10	5	8	11	7.6	C18	
Rectum	58	0	0	0	0	0	0	1	0	1	2	5	9	7	6	12	6	9	7.7	C19-20	
Anus	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0.4	C21	
Liver	45	0	0	0	0	0	0	0	1	0	3	4	6	9	6	8	4	4	6	C22	
Gallbladder etc.	4	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	2	0	0.5	C23-24	
Pancreas	13	0	0	0	0	0	0	0	0	1	2	2	0	1	1	3	2	1	1.7	C25	
Nose, sinuses etc.	5	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	1	0	0.7	C30-31	
Larynx	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0.7	C32	
Trachea, bronchus and lung	119	0	0	0	0	0	0	1	1	2	4	16	9	10	23	30	11	12	15.8	C33-34	
Other thoracic organs	4	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	1	0	0.5	C37-38	
Bone	7	0	0	0	0	3	1	0	0	0	0	1	0	1	0	0	1	0	0.9	C40-41	
Melanoma of skin	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0.4	C43	
Other skin	21	0	0	0	0	0	0	0	0	0	0	1	4	1	1	6	5	3	2.8	C44	
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C46	
Connective and soft tissue	8	0	0	2	0	0	0	0	0	0	0	0	0	2	0	3	0	1	1.1	C47,C49	
Breast	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0.4	C50	
Penis	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C60	
Prostate	57	0	0	0	0	0	0	0	0	0	0	0	3	8	7	10	13	16	7.6	C61	
Testis	6	0	2	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0.8	C62	
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C63	
Kidney	15	0	1	0	0	0	1	0	0	0	1	1	3	3	3	0	2	0	2	C64	
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	9	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1	2	1.2	C67	
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69	
Brain, nervous system	21	0	2	0	1	1	1	2	2	0	1	0	3	1	3	1	0	3	2.8	C70-72	
Thyroid	13	0	0	0	0	0	0	0	0	1	0	2	2	1	2	3	2	0	1.7	C73	
Adrenal gland	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C74	
Other endocrine	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C75	
Hodgkin disease	5	0	0	0	1	0	1	0	1	0	0	1	0	1	0	0	0	0	0.7	C81	
Non-Hodgkin lymphoma	46	0	0	2	1	1	1	1	1	3	5	0	6	3	8	3	4	7	6.1	C82-85,C96	
Immunoproliferative diseases	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0.4	C88	
Multiple myeloma	6	0	0	0	0	0	0	0	0	0	0	2	2	1	0	0	0	1	0.8	C90	
Lymphoid leukaemia	20	0	6	3	2	5	1	1	0	1	0	0	0	1	0	0	0	0	2.7	C91	
Myeloid leukaemia	17	0	1	1	1	1	0	1	0	1	2	0	1	3	1	1	2	1	2.3	C92-94	
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C95	
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	MPD	
Myelodysplastic syndromes	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0.4	MDS	
Other and unspecified	22	0	2	0	1	0	1	0	0	1	0	1	1	6	2	4	1	2	2.9	O&U	
<b>All sites</b>	<b>774</b>	<b>0</b>	<b>16</b>	<b>8</b>	<b>10</b>	<b>15</b>	<b>14</b>	<b>11</b>	<b>16</b>	<b>17</b>	<b>31</b>	<b>58</b>	<b>86</b>	<b>95</b>	<b>95</b>	<b>118</b>	<b>88</b>	<b>96</b>	<b>102.8</b>	<b>ALL</b>	

## Appendix 65: Cancer Incidence by site and age group, all residents, male, Sabah, 2011

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	1.8	5.2	0	0	0	0	0.24	0.4	0.04	0.04	0.3	C01-02
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	0	8.2	7	0.24	0.4	0.02	0.06	0.5	C03-06
Salivary glands	6	0	0	0	0	0	0.8	0	1.2	1.4	0	0	0	0	4.2	5.6	8.2	0	0.48	0.8	0.04	0.11	0.7	C07-08
Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	1.8	0	0	5.6	8.2	0	0.24	0.4	0.01	0.08	0.4	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	0	0	0	0.08	0.1	0.02	0.02	0.2	C10
Nasopharynx	76	0	0	0	0.7	2.1	1.7	2.7	4.7	2.8	8.9	18.9	29.1	26	29.4	45.2	8.2	7	6.12	10.1	0.64	0.9	8.1	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	5.6	0	7	0.24	0.4	0.02	0.05	0.5	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	1.8	0	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C14
Oesophagus	13	0	0	0	0	0	0	0	0	0	0	1.6	5.5	2.6	0	5.6	16.4	35.2	1.05	1.7	0.05	0.16	1.7	C15
Stomach	55	0	0	0	0	0	0	0.9	0	0	1.5	7.9	10.9	18.2	33.6	45.2	65.6	77.5	4.43	7.3	0.36	0.92	7.5	C16
Small intestine	4	0	0	0	0	0	0	0	0	0	1.5	0	1.8	2.6	0	0	8.2	0	0.32	0.5	0.03	0.07	0.4	C17
Colon	57	0	0	0	0	0	0.8	0	2.3	1.4	3	3.2	9.1	26	42	28.2	65.6	77.5	4.59	7.6	0.44	0.91	7.5	C18
Rectum	58	0	0	0	0	0	0	0.9	0	1.4	3	7.9	16.4	18.2	25.2	67.8	49.2	63.4	4.67	7.7	0.36	0.95	7.6	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16.4	7	0.24	0.4	0	0.08	0.5	C21
Liver	45	0	0	0	0	0	0	0	1.2	0	4.5	6.3	10.9	23.4	25.2	45.2	32.8	28.2	3.62	6	0.36	0.75	5.8	C22
Gallbladder etc.	4	0	0	0	0	0	0.8	0	0	0	0	0	0	0	4.2	0	16.4	0	0.32	0.5	0.03	0.11	0.6	C23-24
Pancreas	13	0	0	0	0	0	0	0	1.4	3	3.2	0	0	2.6	4.2	16.9	16.4	7	1.05	1.7	0.07	0.24	1.7	C25
Nose, sinuses etc.	5	0	0	0	0.7	0	0	0	0	0	0	0	1.8	0	4.2	5.6	8.2	0	0.4	0.7	0.03	0.1	0.7	C30-31
Larynx	5	0	0	0	0	0	0	0	0	0	0	1.6	1.8	0	0	0	16.4	7	0.4	0.7	0.02	0.1	0.7	C32
Trachea, bronchus and lung	119	0	0	0	0	0	0	0.9	1.2	2.8	6	25.2	16.4	26	96.6	169.5	90.2	84.5	9.58	15.8	0.88	2.17	16.5	C33-34
Other thoracic organs	4	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	11.3	8.2	0	0.32	0.5	0.01	0.1	0.6	C37-38
Bone	7	0	0	0	0	2.1	0.8	0	0	0	0	1.6	0	2.6	0	0	8.2	0	0.56	0.9	0.04	0.08	0.6	C40-41
Melanoma of skin	3	0	0	0	0	0	0	0	0	1.4	0	0	0	2.6	0	0	0	7	0.24	0.4	0.02	0.02	0.3	C43
Other skin	21	0	0	0	0	0	0	0	0	0	0	1.6	7.3	2.6	4.2	33.9	41	21.1	1.69	2.8	0.08	0.45	3	C44
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0.08	0.1	0.01	0.01	0.1	C46
Connective and soft tissue	8	0	0	1.4	0	0	0	0	0	0	0	0	0	0	5.2	0	16.9	0	0.64	1.1	0.03	0.12	1	C47,C49
Breast	3	0	0	0	0	0	0	0	0	0	1.5	0	0	2.6	0	0	8.2	0	0.24	0.4	0.02	0.06	0.4	C50
Penis	1	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C60
Prostate	57	0	0	0	0	0	0	0	0	0	0	0	0	5.5	20.8	29.4	56.5	106.6	4.59	7.6	0.28	1.09	8.4	C61
Testis	6	0	1.4	0	0	0.7	0.8	0.9	1.2	0	0	0	0	0	0	0	0	0	0.48	0.8	0.03	0.03	0.4	C62
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0	0	0.08	0.1	0	0.03	0.2	C63
Kidney	15	0	0.7	0	0	0	0.8	0	0	0	1.5	1.6	5.5	7.8	12.6	0	16.4	0	1.21	2	0.15	0.23	1.8	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	9	0	0	0	0	0	0	0	0	0	0	1.6	1.8	2.6	0	16.9	8.2	14.1	0.72	1.2	0.03	0.16	1.2	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	1	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C69
Brain, nervous system	21	0	1.4	0	0.7	0.7	0.8	1.8	2.3	0	1.5	0	5.5	2.6	12.6	5.6	0	21.1	1.69	2.8	0.15	0.18	2.2	C70-72
Thyroid	13	0	0	0	0	0	0	0	0	1.4	0	3.2	3.6	2.6	8.4	16.9	16.4	0	1.05	1.7	0.1	0.26	1.7	C73
Adrenal gland	1	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C74
Other endocrine	1	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0.08	0.1	0	0	0.1	C75
Hodgkin disease	5	0	0	0	0.7	0	0.8	0	1.2	0	0	1.6	0	2.6	0	0	0	0	0.4	0.7	0.03	0.03	0.4	C81
Non-Hodgkin lymphoma	46	0	0	1.4	0.7	0.7	0.8	0.9	1.2	4.2	7.4	0	10.9	7.8	33.6	16.9	32.8	49.3	3.7	6.1	0.35	0.6	5.5	C82-85,C96
Immunoproliferative diseases	3	0	0	0	0	0	0	0	1.2	0	0	0	0	0	0	5.6	8.2	0	0.24	0.4	0.01	0.08	0.4	C88
Multiple myeloma	6	0	0	0	0	0	0	0	0	0	0	3.2	3.6	2.6	0	0	7	0	0.48	0.8	0.05	0.05	0.6	C90
Lymphoid leukaemia	20	0	4.3	2.1	1.4	3.6	0.8	0.9	0	1.4	0	0	0	2.6	0	0	0	0	1.61	2.7	0.09	0.09	1.5	C91
Myeloid leukaemia	17	0	0.7	0.7	0.7	0	0.8	0	1.2	1.4	3	0	1.8	7.8	4.2	5.6	16.4	7	1.37	2.3	0.11	0.22	1.8	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C95
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0	0	0.08	0.1	0	0.03	0.2	MPD
Myelodysplastic syndromes	3	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	0	8.2	7	0.24	0.4	0.02	0.06	0.5	MDS
Other and unspecified	22	0	1.4	0	0.7	0	0.8	0	0	1.4	0	1.6	1.8	15.6	8.4	22.6	8.2	14.1	1.77	2.9	0.16	0.31	2.7	O&U
<b>All sites</b>	<b>774</b>	<b>0</b>	<b>11.5</b>	<b>5.5</b>	<b>7.2</b>	<b>10.7</b>	<b>11.8</b>	<b>9.7</b>	<b>18.8</b>	<b>23.7</b>	<b>46.1</b>	<b>91.5</b>	<b>156.6</b>	<b>246.8</b>	<b>399.2</b>	<b>666.7</b>	<b>721.3</b>	<b>676.1</b>	<b>62.28</b>	<b>102.8</b>	<b>5.2</b>	<b>12.14</b>	<b>97.7</b>	<b>ALL</b>

**Appendix 66: Number of new cancer cases by site and age group, all residents, female, Sabah, 2011**

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.2	C00
Tongue	6	0	0	0	1	1	0	0	0	0	0	0	3	1	0	0	0	0	0.7	C01-02
Mouth	7	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3	2	0	0.8	C03-06
Salivary glands	8	0	0	1	0	0	2	0	1	0	0	0	0	2	0	0	2	0	0.9	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C10
Nasopharynx	33	0	0	0	2	1	1	2	0	2	2	4	6	3	2	0	5	3	3.7	C11
Hypopharynx	3	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0.3	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	0	0.5	C15
Stomach	38	0	0	0	0	0	1	0	0	1	3	2	6	4	5	3	7	6	4.3	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0.2	C17
Colon	39	0	0	0	0	0	0	1	0	1	0	3	7	7	4	5	4	7	4.4	C18
Rectum	32	0	0	0	0	0	0	1	0	3	1	1	5	4	3	2	3	9	3.6	C19-20
Anus	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0.5	C21
Liver	20	0	1	0	0	0	0	0	0	2	0	0	1	3	5	1	4	3	2.3	C22
Gallbladder etc.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.2	C23-24
Pancreas	9	0	0	0	0	0	1	0	0	0	2	0	1	2	1	1	0	1	1	C25
Nose, sinuses etc.	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0.3	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	1	1	1	1	3	7	8	6	13	9	7	6.4	C33-34
Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0.2	C37-38
Bone	7	0	0	1	2	1	0	0	0	0	1	0	1	0	1	0	0	1	0.8	C40-41
Melanoma of skin	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0.2	C43
Other skin	35	0	0	0	0	0	0	1	0	0	1	1	3	2	2	10	1	14	3.9	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	13	0	4	1	1	0	0	1	0	1	0	0	2	0	0	1	2	0	1.5	C47,C49
Breast	185	0	0	0	0	0	3	4	7	13	27	33	34	20	20	8	10	6	20.9	C50
Vulva	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.2	C51
Vagina	5	0	0	0	0	0	0	0	0	1	1	0	0	1	0	1	1	0	0.6	C52
Cervix uteri	106	0	0	0	0	0	1	4	3	9	15	19	14	14	12	3	9	3	12	C53
Corpus uteri	27	0	0	0	0	0	0	1	2	3	3	1	2	7	4	1	2	1	3	C54
Uterus unspecified	35	0	0	0	0	0	1	1	0	3	5	7	6	6	3	1	2	0	3.9	C55
Ovary	65	0	0	1	1	3	1	6	2	5	5	12	6	9	5	4	3	2	7.3	C56
Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	3	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0.3	C58
Kidney	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.2	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0.3	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain, nervous system	20	0	1	3	4	0	1	1	0	0	0	3	2	1	1	1	1	1	2.3	C70-72
Thyroid	34	0	0	1	0	1	1	2	2	3	4	6	3	3	0	3	3	2	3.8	C73
Adrenal gland	3	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0.3	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C75
Hodgkin disease	3	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	0.3	C81
Non-Hodgkin lymphoma	34	0	3	0	1	1	2	2	1	2	3	4	2	2	3	2	2	4	3.8	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C88
Multiple myeloma	13	0	0	0	0	0	0	0	0	1	2	0	2	2	2	2	2	0	1.5	C90
Lymphoid leukaemia	7	0	2	0	1	0	0	1	0	0	0	0	0	0	0	0	0	3	0.8	C91
Myeloid leukaemia	21	0	2	2	0	1	1	0	0	0	1	1	5	0	5	0	1	2	2.4	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	MDS
Other and unspecified	19	0	0	1	1	2	2	0	0	1	1	1	3	1	2	2	1	1	2.1	O&U
<b>All sites</b>	<b>922</b>	<b>0</b>	<b>13</b>	<b>12</b>	<b>14</b>	<b>12</b>	<b>20</b>	<b>29</b>	<b>21</b>	<b>55</b>	<b>79</b>	<b>108</b>	<b>124</b>	<b>108</b>	<b>90</b>	<b>72</b>	<b>80</b>	<b>85</b>	<b>103.9</b>	<b>ALL</b>

## Appendix 67: Cancer Incidence by site and age group, all residents, female, Sabah, 2011

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	2.1	0	0	0	8.2	0	0.17	0.2	0.01	0.05	0.3	C00
Tongue	6	0	0	0	0.7	0.7	0	0	0	0	0	0	6.3	3.1	0	0	0	0	0.5	0.7	0.05	0.05	0.6	C01-02
Mouth	7	0	0	0	0	0	0	0	0	1.4	1.5	0	0	0	0	18	16.4	0	0.58	0.8	0.01	0.19	1	C03-06
Salivary glands	8	0	0	0.7	0	0	1.6	0	1.2	0	0	0	0	6.1	0	0	16.4	0	0.66	0.9	0.05	0.13	0.8	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.1	0	0.08	0.1	0	0	0.1	C10
Nasopharynx	33	0	0	0	1.5	0.7	0.8	1.7	0	2.8	3	6.9	12.6	9.2	9.2	0	41	21.3	2.74	3.7	0.24	0.45	3.8	C11
Hypopharynx	3	0	0	0	0	0	0.8	0	0	0	0	0	0	3.1	4.6	0	0	0	0.25	0.3	0.04	0.04	0.4	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	4	0	0	0	0	0	0	0	0	0	0	1.7	0	0	4.6	0	16.4	0	0.33	0.5	0.03	0.11	0.6	C15
Stomach	38	0	0	0	0	0	0.8	0	0	1.4	4.6	3.5	12.6	12.2	22.9	18	57.4	42.6	3.16	4.3	0.29	0.67	5.2	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	0	3.1	4.6	0	0	0	0.17	0.2	0.04	0.04	0.3	C17
Colon	39	0	0	0	0	0	0	0.9	0	1.4	0	5.2	14.7	21.4	18.3	29.9	32.8	49.6	3.24	4.4	0.31	0.62	5.3	C18
Rectum	32	0	0	0	0	0	0	0.9	0	4.1	1.5	1.7	10.5	12.2	13.8	12	24.6	63.8	2.66	3.6	0.22	0.41	4.2	C19-20
Anus	4	0	0	0	0	0	0	0	0	0	0	1.7	2.1	0	0	0	8.2	7.1	0.33	0.5	0.02	0.06	0.5	C21
Liver	20	0	0.8	0	0	0	0	0	0	2.8	0	0	2.1	9.2	22.9	6	32.8	21.3	1.66	2.3	0.19	0.38	2.9	C22
Gallbladder etc.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	7.1	0.17	0.2	0	0.03	0.3	C23-24
Pancreas	9	0	0	0	0	0	0.8	0	0	0	3	0	2.1	6.1	4.6	6	0	7.1	0.75	1	0.08	0.11	1.1	C25
Nose, sinuses etc.	3	0	0	0	0	0	0	0	0	0	1.5	1.7	0	0	0	0	0	7.1	0.25	0.3	0.02	0.02	0.3	C30-31
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	0.9	1.2	1.4	1.5	5.2	14.7	24.5	27.5	77.8	73.8	49.6	4.73	6.4	0.38	1.14	8.2	C33-34
Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	0	0	2.1	3.1	0	0	0	0.17	0.2	0.03	0.03	0.2	C37-38
Bone	7	0	0	0.7	1.5	0.7	0	0	0	0	0	1.7	0	3.1	0	0	0	7.1	0.58	0.8	0.04	0.04	0.6	C40-41
Melanoma of skin	2	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	6	0	0	0.17	0.2	0.01	0.04	0.3	C43
Other skin	35	0	0	0	0	0	0	0.9	0	0	1.5	1.7	6.3	6.1	9.2	59.9	8.2	99.3	2.91	3.9	0.13	0.47	5.1	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	3.1	0	0	0	0	0.08	0.1	0.02	0.02	0.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	13	0	3	0.7	0.7	0	0	0.9	0	1.4	0	0	4.2	0	0	6	16.4	0	1.08	1.5	0.05	0.17	1.4	C47,C49
Breast	185	0	0	0	0	0	2.5	3.4	8.2	17.9	41	57.1	71.3	61.2	91.7	47.9	82	42.6	15.36	20.9	1.77	2.42	21.5	C50
Vulva	2	0	0	0	0	0	0	0	0	0	0	1.7	0	0	4.6	0	0	0	0.17	0.2	0.03	0.03	0.3	C51
Vagina	5	0	0	0	0	0	0	0	0	1.4	1.5	0	0	3.1	0	6	8.2	0	0.42	0.6	0.03	0.1	0.6	C52
Cervix uteri	106	0	0	0	0	0	0.8	3.4	3.5	12.4	22.8	32.9	29.4	42.8	55	18	73.8	21.3	8.8	12	1.01	1.47	12.5	C53
Corpus uteri	27	0	0	0	0	0	0	0.9	2.3	4.1	4.6	1.7	4.2	21.4	18.3	6	16.4	7.1	2.24	3	0.29	0.4	3.3	C54
Uterus unspecified	35	0	0	0	0	0	0.8	0.9	0	4.1	7.6	12.1	12.6	18.3	13.8	6	16.4	0	2.91	3.9	0.35	0.46	4	C55
Ovary	65	0	0	0.7	0.7	2.2	0.8	5.1	2.3	6.9	7.6	20.8	12.6	27.5	22.9	24	24.6	14.2	5.4	7.3	0.55	0.79	7.2	C56
Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	3	0	0	0	0	0	0.8	0	1.2	1.4	0	0	0	0	0	0	0	0	0.25	0.3	0.02	0.02	0.2	C58
Kidney	2	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	7.1	0.17	0.2	0.01	0.01	0.2	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	21.3	0.25	0.3	0	0	0.4	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain, nervous system	20	0	0.8	2.2	3	0	0.8	0.9	0	0	0	5.2	4.2	3.1	4.6	6	8.2	7.1	1.66	2.3	0.12	0.19	2	C70-72
Thyroid	34	0	0	0.7	0	0.7	0.8	1.7	2.3	4.1	6.1	10.4	6.3	9.2	0	18	24.6	14.2	2.82	3.8	0.21	0.42	3.7	C73
Adrenal gland	3	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	12	0	0	0.25	0.3	0	0.06	0.4	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	3.1	0	0	0	0	0.08	0.1	0.02	0.02	0.1	C75
Hodgkin disease	3	0	0	0	0	0.7	0	0	0	0	0	0	0	0	4.6	6	0	0	0.25	0.3	0.03	0.06	0.4	C81
Non-Hodgkin lymphoma	34	0	2.3	0	0.7	0.7	1.6	1.7	1.2	2.8	4.6	6.9	4.2	6.1	13.8	12	16.4	28.4	2.82	3.8	0.23	0.37	3.9	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C88
Multiple myeloma	13	0	0	0	0	0	0	0	0	1.4	3	0	4.2	6.1	9.2	12	16.4	0	1.08	1.5	0.12	0.26	1.8	C90
Lymphoid leukaemia	7	0	1.5	0	0.7	0	0	0.9	0	0	0	0	0	0	0	0	0	21.3	0.58	0.8	0.02	0.02	0.7	C91
Myeloid leukaemia	21	0	1.5	1.5	0	0.7	0.8	0	0	0	1.5	1.7	10.5	0	22.9	0	8.2	14.2	1.74	2.4	0.21	0.25	2.5	C92-94
Leukaemia unspecified	1	0	0	0	0	0	0	0	1.2	0	0	0	0	0	0	0	0	0	0.08	0.1	0.01	0.01	0.1	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.1	0	0.08	0.1	0	0	0.1	MDS
Other and unspecified	19	0	0	0.7	0.7	1.5	1.6	0	0	1.4	1.5	1.7	6.3	3.1	9.2	12	8.2	7.1	1.58	2.1	0.14	0.24	2.2	OU
<b>All sites</b>	<b>922</b>	<b>0</b>	<b>9.8</b>	<b>8.8</b>	<b>10.5</b>	<b>8.8</b>	<b>16.4</b>	<b>24.9</b>	<b>24.5</b>	<b>75.7</b>	<b>119.9</b>	<b>186.9</b>	<b>260</b>	<b>330.3</b>	<b>412.8</b>	<b>431.1</b>	<b>655.7</b>	<b>602.8</b>	<b>76.57</b>	<b>103.9</b>	<b>7.45</b>	<b>12.88</b>	<b>112.3</b>	<b>ALL</b>



Appendix 68: Cancer notification form

<p><b>CANCER NOTIFICATION FORM</b> (Explanatory notes overleaf) Unit Epidemiologi Jabatan Kesihatan Negeri Sabah Tingkat 1, Rumah Persekutuan Peti Surat 11290 88814 Kota Kinabalu, Sabah Tel: 088-265960 Fax: 088-217740</p>	<p><b>NCR 02</b> <b>CONFIDENTIAL</b></p>	<p>FOR REGISTRY USE Case No. CR4: _____ <input type="checkbox"/> Pending    <input type="checkbox"/> Confirmed Mode of notification 1. Spontaneous    3. Other 2. On request</p>
<p><b>1. PATIENT</b></p> <p>Identification No: <input style="width: 100px; height: 15px; border: 1px solid black;" type="text"/> Old I.C. No: <input style="width: 100px; height: 15px; border: 1px solid black;" type="text"/>          [Malaysian New I.C.] [Malaysia Old I.C./Police/Arm Force/Passport]</p> <p>Name: _____</p> <p>Usual Residential Address: _____</p> <p>Postcode: <input style="width: 40px; height: 15px; border: 1px solid black;" type="text"/> State: _____ District: _____</p> <p>Date of birth: <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/>          D D / M M / Y Y      Ethnic group:      Sex:      Citizenship:</p> <p>Age <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> Years</p> <p>1 <input type="checkbox"/> Malay      5 <input type="checkbox"/> Others...          2 <input type="checkbox"/> Chinese      [Please specify]      1 <input type="checkbox"/> Male      1 <input type="checkbox"/> Malaysian          3 <input type="checkbox"/> Indian           2 <input type="checkbox"/> Female      2 <input type="checkbox"/> Permanent Resident          4 <input type="checkbox"/> Other Indig .....          [Please specify]           3 <input type="checkbox"/> Others .....          [Please specify]</p>		
<p><b>2. SOURCE INFORMATION</b></p> <p>1 <input type="checkbox"/> Hospital/Clinic      _____ Reg. No: _____</p> <p>2 <input type="checkbox"/> Pathology lab      _____ Reg. No: _____</p> <p>3 <input type="checkbox"/> Other sources      _____</p>	<p><b>6. STAGE OF DIAGNOSIS [at time of diagnosis]</b></p> <p><input type="checkbox"/> Stage I      <input type="checkbox"/> Stage IV  <input type="checkbox"/> Stage II      <input type="checkbox"/> Unknown  <input type="checkbox"/> Stage III</p> <p>Lymph node involvement      1 <input type="checkbox"/> Yes      2 <input type="checkbox"/> No          Remote metastasis      1 <input type="checkbox"/> Yes      2 <input type="checkbox"/> No</p>	
<p><b>3. DIAGNOSIS</b>      [Specify primary organ/site cancer/ exact location/laterality if possible]</p> <p>Topography (Site)      _____ Morphology (Histology)      _____</p>	<p><b>7. TYPE OF TREATMENT [Date started treatment]</b></p> <p><input type="checkbox"/> None      <input type="checkbox"/> Surgery ( / / )  <input type="checkbox"/> Chemotherapy ( / / )      <input type="checkbox"/> Radiotherapy ( / / )  <input type="checkbox"/> Hormonal ( / / )      <input type="checkbox"/> Unknown  <input type="checkbox"/> Others ..... ( / / ) Please specify</p>	
<p><b>4. DATE OF DIAGNOSIS</b>      <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/>          D D / M M / Y Y</p>	<p><b>8. PRESENT STATUS</b></p> <p>1 <input type="checkbox"/> Alive    2 <input type="checkbox"/> Dead</p> <p>Date last seen      <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/>          D D / M M / Y Y</p> <p>If dead, date of death      <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/>          D D / M M / Y Y</p> <p>Cause of death: _____</p>	
<p><b>5. BASIS OF DIAGNOSIS</b></p> <p><input type="checkbox"/> Death certificate only      <input type="checkbox"/> 6 Histology of metastasis  <input type="checkbox"/> 1 Clinical      <input type="checkbox"/> 7 Histology of primary tumor  <input type="checkbox"/> 2 Clinical investigation      <input type="checkbox"/> 9 Unknown  <input type="checkbox"/> 4 Specific tumor markers  <input type="checkbox"/> 5 Cytology</p>		
<p><b>9. REMARKS [if any]</b></p> <p>DATE OF NOTIFICATION      <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> / <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/>          D D / M M / Y Y</p> <p>Notified by: _____          [Name and designation of reporting Officer]          Clinic/Hospital name: _____</p> <p>Tel. No: <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/> <input style="width: 20px; height: 15px; border: 1px solid black;" type="text"/></p> <p style="text-align: center;"><b>PLEASE FILL THIS FORM WITH ANY INFORMATION AVAILABLE WITH YOU AND SEND IT AS SOON AS POSSIBLE</b>  <b>PLEASE MAINTAIN CONFIDENTIALITY AT ALL TIME</b>  <b>THANK YOU FOR YOUR COOPERATION</b></p>		

## Appendix 69: Explanatory notes for completing cancer notification form

### Please Notify

- a) All case of cancers (i.e. carcinomas, sarcomas, leukaemias and all other malignant tumours) diagnosed or treated in your hospital, clinic or practice.
- b) Confirmed cases of cancer as well as cases of 'probable cancer' in which the diagnosis is based only on clinical finding (i.e. without histological, radiological or other methods of confirmation).
- c) All cases diagnosed in Malaysia regardless of citizenships or place of domicile of the patient.
- d) Cancer cases referred to your hospital/clinic/practice which may have already been notified by the previous attending doctor.
- e) Follow up cases; please use the same form (Fill in name, I/C number, source of information and any other information that is different from the original previous notification form). You may choose to notify only once.

### PROCEDURE

1. Patient
  - Identification No.
    - For Malaysian patient with new I/C No. fill up all the 12 digits and the old I/C No. if available.
    - For patient with only old I/C No. fill up his/her I/C No. in the Identification No. boxes.
    - Children below 12 years without NRIC, insert patient's I/C No. with additional M or F in the appropriate boxes indicating mother or father NRIC was used (e.g. A 1234567M).
    - Passport No. Police/ Arm Forces Identification Card Number to be used for foreigners/ police/ arms personnel. (Please indicate).
  - Name – Full name in block letters as in NRIC/ passport.
  - Usual Resident Address: Address where the patient usually resides at least for 6 months [Note: The address NRIC may not be the same].
  - Date of birth: Insert date of birth of patient into boxes. [If not available insert year of birth].
  - Sex, Ethnic Group, Citizenship: Tick appropriate box.
2. Source of Information (refers to Hospital/ Clinic the notifying doctor is working in).
3. Diagnosis (If insufficient space, write the information on a piece of paper and attach as appendix).  
Diagnosis (Site for topography): Please write in words with as much detail as possible.  
Pathological Diagnosis (Morphology): Please write in words with as much detail as possible.
4. Date of Diagnosis: Insert date of diagnosis made (Date that can be verified from records) and follow IARC definition\*.
5. Basis of diagnosis: Tick appropriate box(es).
6. Stage of Disease at the time of diagnosis: Fill in and tick appropriate box(es).
7. Type of treatment: Tick appropriate box(es) and fill in date of first treatment.
8. Present status: Tick the appropriate box and fill in relevant details.
9. Date of notification: Insert the date into the appropriate box.
10. Notified by: Fill in the relevant details. Please give the accessible contact number of the ward, clinic or hospital.

- ❖ If patient is being followed up frequently: for example when undergoing treatment, the attending practitioner may choose to notify only once

#### *\*Definition of Incidence Date*

1. Date of first histological or cytological confirmation
  - a) Date when the specimen was taken (biopsy or operation).
  - b) Date of receipt by the pathologist.
  - c) Date of the pathology report.
2. Date of admission to the hospital because of this malignancy.
3. Date of first consultation at the outpatient clinic (only).
4. Date of diagnosis, other than 1, 2 or 3.
5. Date of death, if no information than that the patient has died because of a malignancy.
6. Date of death, if the malignancy is discovered at autopsy.